

# Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

January 29, 2008

Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC)

## How to Cite the Adult and Adolescent Guidelines:

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed (insert date) [insert page number, table number, etc. if applicable]

It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the **AIDSinfo** Web site (<http://AIDSinfo.nih.gov>).

## ***What's New in the Document?***

The following changes have been made to several sections of the December 1, 2007 version of the guidelines.

### **What to Start: Initial Combination Regimens for the Antiretroviral-Naïve Patient?**

The Panel revised its recommendations for several “preferred” and “alternative” antiretroviral components for treatment-naïve patients:

- “Abacavir + lamivudine” has been changed from “alternative” to “preferred” 2-NRTI component in patients who have tested negative for HLA-B\*5701 (**AI**).
- “Zidovudine + lamivudine” has been changed from “preferred” to “alternative” 2-NRTI component (**BII**).
- “Ritonavir-boosted saquinavir” has been changed from a PI-option that was considered as “Acceptable as initial antiretroviral components but inferior to preferred or alternative components” to an “alternative” PI component (**BII**).
- The following options are no longer recommended as components for initial therapy in treatment-naïve patients:
  - Nelfinavir as PI component
  - Stavudine + lamivudine as 2-NRTI components
  - Abacavir + zidovudine + lamivudine as a triple-NRTI combination regimen

A new topic entitled “Other Treatment Options Under Investigation: Insufficient Data to Recommend” has been added, which includes a review of recent clinical trial data in treatment-naïve patients for ritonavir-boosted darunavir-based regimens, maraviroc-based regimens, and raltegravir-based regimens.

### **Treatment Interruption**

This section has been updated with recent data on short-term and long-term treatment interruption. The Panel reaffirms our recommendation that aside from unplanned or planned short-term interruption due to illnesses precluding oral therapy or toxicities, long-term treatment interruption is not recommended unless in the context of a clinical trial (**DI**).

### **Acute HIV Infection**

- A new table on “Identifying, diagnosing, and managing acute HIV-1 infection” has replaced the table on “Associated signs and symptoms of acute retroviral syndrome and percentage of expected frequency”.
- The Panel also recommends that since clinically significant resistance to PIs is less common than resistance to NNRTIs in antiretroviral-naïve persons who harbor drug resistant virus, if therapy is initiated before drug resistance test results are available, consideration should be given to using a PI-based regimen (**BIII**).

### **Mycobacterium Tuberculosis Disease or Latent Tuberculosis Infection with HIV Coinfection**

This section has been updated with the following information:

- Discussions and recommendations on the timing of initiation of antiretroviral therapy in patients with active tuberculosis (TB), with emphasis on the risks and benefits of concomitant therapy related to overlapping toxicities, drug interactions, CD4 cell counts, and potential for immune reconstitution inflammatory syndrome.
- Recommendation for repeat testing to detect latent TB infection in persons who had CD4 count <200 cells/mm<sup>3</sup> and have tested negative prior to antiretroviral therapy and have improved CD4 count to >200 cells/mm<sup>3</sup> (**BII**).

### **Table Updates:**

- Various tables have been updated to include information regarding etravirine, updates on various antiretroviral drugs, as well as new atazanavir dosing recommendations when used in combination with proton pump inhibitors or H2 receptor antagonists.
- The following tables have been removed from the document:
  - “Antiretroviral components that are acceptable as initial antiretroviral components but are inferior to preferred or alternative components”; and
  - “Treatment outcome of selected clinical trials of combination antiretroviral regimens in treatment-naïve patients with 48-week follow-up data”.

**January 29, 2008**

# Table of Contents

---

Guidelines Panel Roster .....	v
INTRODUCTION .....	1
Key Clinical Questions Addressed by Guidelines .....	1
Guidelines Process .....	1
BASELINE EVALUATION .....	3
LABORATORY TESTING FOR INITIAL ASSESSMENT AND MONITORING FOR THERAPEUTIC RESPONSE .....	4
CD4 T-Cell Count .....	4
Viral Load Testing .....	4
Drug Resistance Testing .....	5
Genotypic and Phenotypic Resistance Assays .....	5
Use of Resistance Assays in Clinical Practice .....	6
HLA-B*5701 Screening .....	7
Coreceptor Tropism Assays .....	8
TREATMENT GOALS .....	10
Strategies to Achieve Treatment Goals .....	10
WHEN TO START: Indications for Initiation of Antiretroviral Therapy .....	12
<b>WHAT TO START: Initial Combination Regimens for the Antiretroviral-Naïve Patient</b> .....	16
Considerations When Selecting a First Antiretroviral Regimen for Treatment-Naïve Patients .....	16
NNRTI-Based Regimens (1 NNRTI + 2 NRTIs) .....	17
Summary: NNRTI-Based Regimens .....	17
PI-Based Regimens (1 or 2 PIs + 2 NRTIs) .....	19
Summary: PI-Based Regimens .....	19
Dual-Nucleoside Options as Part of Initial Combination Therapy .....	22
All-NRTI Regimens .....	24
<b>Other Treatment Options Under Investigation: Insufficient Data to Recommend</b> .....	24
<b>WHAT NOT TO USE</b> .....	26
Antiretroviral Regimens Not Recommended .....	26
Antiretroviral Components Not Recommended .....	26
LIMITATIONS TO TREATMENT SAFETY AND EFFICACY .....	28
Adherence to Antiretroviral Therapy .....	28
Adverse Effects of Antiretroviral Agents .....	28
Drug Interactions .....	29

MANAGEMENT OF THE TREATMENT–EXPERIENCED PATIENT .....	32
The Treatment-Experienced Patient .....	32
Definitions and Causes of Antiretroviral Treatment Failure .....	32
Assessment of Antiretroviral Treatment Failure and Changing Therapy .....	33
Therapeutic Drug Monitoring for Antiretroviral Agents .....	37
Discontinuation or Interruption of Antiretroviral Therapy .....	39
CONSIDERATIONS FOR ANTIRETROVIRAL USE IN SPECIAL PATIENT POPULATIONS .....	42
Acute HIV Infection .....	42
HIV-Infected Adolescents .....	43
Injection Drug Users .....	45
HIV-Infected Women of Reproductive Age and Pregnant Women .....	47
ANTIRETROVIRAL CONSIDERATIONS IN PATIENTS WITH COINFECTIONS .....	50
Hepatitis B (HBV)/HIV Coinfection .....	50
Hepatitis C (HCV)/HIV Coinfection .....	51
Mycobacterium Tuberculosis Disease or Latent Tuberculosis Infection with HIV Coinfection .....	52
PREVENTION COUNSELING FOR THE HIV-INFECTED PATIENT .....	55
CONCLUSION .....	56
Tables and Figure .....	57-106
References .....	107
Appendix A: Financial Disclosure for Members of the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (A Working Group of OARAC) – February 2007 .....	125

## List of Tables and Figure

---

Table 1. Rating Scheme for Clinical Practice Recommendations .....	57
Table 2. Indications for Plasma HIV RNA Testing .....	58
Table 3. Recommendations for Using Drug Resistance Assays .....	59
Table 4a. Probability of Progressing to AIDS or Death According to CD4 Cell Count, Viral Load, and Sociodemographic Factors .....	60
Table 4b. Predicted 6-Month Risk of AIDS According to Age and Current CD4 Cell Count and Viral Load, Based on a Poisson Regression Model .....	61
Table 5. Indications for Initiating Antiretroviral Therapy for the Chronically HIV-1 Infected Patient .....	62
Table 6. Antiretroviral Components Recommended for Treatment of HIV-1 Infection in Treatment-Naïve Patients .....	63
Table 7. Antiretroviral Drugs and Components Not Recommended as Initial Therapy .....	64
Table 8. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time .....	65

<b>Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy</b> .....	66
Table 10. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs).....	68
<b>Table 11. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</b> .....	70
Table 12. Characteristics of Protease Inhibitors (PIs).....	71
Table 13. Characteristics of <b>Fusion</b> Inhibitors.....	74
<b>Table 14. Characteristics of CCR5 Antagonists</b> .....	74
Table 15. Characteristics of Integrase Inhibitors.....	74
Table 16. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency.....	75
Table 17. Strategies to Improve Adherence to Antiretroviral Therapy.....	77
Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations.....	78
<b>Table 18a. Potentially Life-Threatening and Serious Adverse Events</b> .....	78
Table 18b. Adverse Events With Potential Long-Term Complications.....	82
Table 18c. Adverse Effects Compromising Quality of Life and/or With Potential Impact on Medication Adherence.....	83
Table 19. HIV-Related Drugs With Overlapping Toxicities.....	84
Table 20. Adverse Drug Reactions and Related “Black Box Warnings” in Product Labeling for Antiretroviral Agents.....	85
Table 21. Drugs That Should Not Be Used With PI, NNRTI, or CCR5 Antagonist Antiretrovirals.....	87
Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc.....	88
<b>Table 22b. Drug Interactions Among Antiretrovirals and Other Drugs: NNRTIs</b> .....	94
Table 22c. Drug Interactions Among Antiretrovirals and Other Drugs: NRTIs.....	96
Table 23a. Drug Effects on Concentration of PIs.....	97
<b>Table 23b. Drug Effects on Concentration of NNRTIs and Maraviroc</b> .....	98
Table 24. Suggested Minimum Target Trough Concentrations for Persons with Wild-Type HIV-1.....	99
<b>Table 25. Identifying, Diagnosing, and Managing Acute HIV-1 Infection</b> .....	100
Table 26. Preclinical and Clinical Data Relevant to the Use of Antiretrovirals in Pregnancy.....	101
Table 27. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy.....	102
Figure A. Prognosis According to CD4 Cell Count and Viral Load in the Pre-HAART and HAART Eras.....	106

## DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Roster

*These Guidelines were developed by the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council).*

### **Panel Co-Chairs:**

John G. Bartlett, Johns Hopkins University, Baltimore, MD  
H. Clifford Lane, National Institutes of Health, Bethesda, MD

### **Executive Secretary:**

Alice K. Pau, National Institutes of Health, Bethesda, MD

### **Members of the Panel:**

Jean Anderson	Johns Hopkins University, Baltimore, MD
A. Cornelius Baker	National Black Gay Men's Advocacy Coalition & Academy for Educational Development, Washington, DC
Charles Carpenter	Brown Medical School, Providence, RI
Judith Currier	University of California–Los Angeles, Los Angeles, CA
Paul Dalton	Project Inform, San Francisco, CA
Steven G. Deeks	University of California–San Francisco, San Francisco, CA
Carlos del Rio	Emory University, Atlanta, GA
Wafaa El-Sadr	Harlem Hospital Center & Columbia University, New York, NY
Courtney V. Fletcher	University of Nebraska Medical Center, Omaha, Nebraska
Joel Gallant	Johns Hopkins University, Baltimore, MD
Eric P. Goosby	Pangaea Global AIDS Foundation and University of California, San Francisco, CA
Roy M. Gulick	Weill Medical College of Cornell University, New York, NY
Mark Harrington	Treatment Action Group, New York, NY
W. Keith Henry	University of Minnesota, Minneapolis, MN
Martin S. Hirsch	Massachusetts General Hospital and Harvard University, Boston, MA
Morris Jackson	Center for Health Justice, Los Angeles, CA
Wilbert Jordan	OASIS HIV Clinic & Charles R. Drew University of Medicine & Science, Los Angeles, CA
John W. Mellors	University of Pittsburgh, Pittsburgh, PA
James Neaton	University of Minnesota, Minneapolis, MN
Heidi Nass	University of Wisconsin, Madison, WI
James Oleske	University of Medicine and Dentistry of New Jersey, Newark, NJ
Michael Saag	University of Alabama, Birmingham, AL
Renslow Sherer	University of Chicago, Chicago, IL
Paul Volberding	University of California, San Francisco & VA Medical Center, San Francisco, CA
Suzanne Willard	Elizabeth Glazer Pediatric AIDS Foundation, Washington DC

### **Participants from the Department of Health and Human Services:**

Victoria Cargill-Swiren	National Institutes of Health
Laura Cheever	Health Resources and Services Administration
Jonathan Kaplan	Centers for Disease Control and Prevention
Henry Masur	National Institutes of Health
Lynne Mofenson	National Institutes of Health
Jeffrey Murray	Food and Drug Administration
Kimberly Struble	Food and Drug Administration

### **Guidelines Acknowledgement List**

The Panel would like to extend our appreciation to Gerald Friedland, M.D., for being an invited writer for the section, "Injection Drug Users."

The Panel would also like to acknowledge the following individuals for their assistance in the review and the preparation of this document: *Eric Daar, M.D., Kenneth Sherman, M.D., Mark Sulkowski, M.D., and Chloe Thio, M.D.*

Updated January 2008

# Introduction (Updated December 1, 2007)

---

Antiretroviral therapy (ART) for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy in 1996. More recently, new drugs have been approved that offer new mechanisms of action, added potency, dosing convenience, and improved safety profiles, whereas some previously popular drugs are being used less often as their drawbacks become better defined. Resistance testing is used more commonly in clinical practice, and interactions among antiretroviral agents and other drugs have become more complex.

The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel), a working group of the Office of AIDS Research Advisory Council, develops these guidelines, which outline current understanding of how clinicians should use antiretroviral drugs to treat adults and adolescents with HIV infection in the United States. The Panel considers new evidence and adjusts recommendations accordingly. The primary areas of attention and revision have included when to initiate therapy, which drug combinations are preferred and which drugs or combinations should be avoided, and means to continue clinical benefit in the face of antiretroviral drug resistance. In contrast, some aspects of therapy, such as medication adherence, although important, have seen less rapid data evolution and thus fewer changes. Yet other topics, such as the treatment of HIV during pregnancy, have warranted more in-depth attention by separate guidelines groups.

## KEY CLINICAL QUESTIONS ADDRESSED BY GUIDELINES

For ease of use, these guidelines are organized so as to answer the following series of clinical questions clinicians are most likely to face in making treatment decisions:

- ***What are some key clinical and laboratory parameters to assess and monitor before and after initiation of antiretroviral therapy?***
- ***What is the role of resistance testing in guiding therapy decisions?***
- ***When should therapy be started in patients with established HIV infection?***

- ***Which drugs are preferred for initial therapy? What are some alternative options? What drugs or drug combinations should not be used?***
- ***What are some limitations to the safety and efficacy of antiretroviral therapy?***
- ***What are the goals and how should therapy be optimized in treatment-experienced patients with virologic failure?***
- ***What are specific considerations when using antiretroviral therapy in certain special patient populations (e.g., acute HIV infection, HIV-infected adolescents, illicit drug users, HIV-infected females [including pregnant women], and patients with coinfections such as hepatitis B or C or tuberculosis)?***

## GUIDELINES PROCESS

These guidelines outline the current understanding of how clinicians should use antiretroviral agents to treat adults and adolescents infected with HIV-1.

### ***Basis for Recommendations***

Recommendations are based upon expert opinion and scientific evidence. Each recommendation has a letter/Roman numeral rating ([Table 1](#)). The letter indicates the strength of the recommendation based on the expert opinion of the Panel. The Roman numeral indicates the quality of the scientific evidence to support the recommendation. When appropriate data are unavailable, inconclusive, or contradictory, the recommendation is based on expert opinion. These recommendations are not intended to supersede the judgment of clinicians who are knowledgeable in the care of HIV infection.

### ***Updating of Guidelines***

These guidelines generally represent the state of knowledge regarding the use of antiretroviral agents. However, as the science rapidly evolves, the availability of new agents and new clinical data may rapidly change therapeutic options and preferences. The guidelines are therefore updated frequently by the Panel, which meets monthly by teleconferencing to make ongoing revisions as necessary. All revisions are

summarized and highlighted on the AIDSinfo Web site. Proposed revisions are posted for a public comment period, generally for 2 weeks, after which comments are reviewed by the Panel prior to finalization. Comments can be sent to [aidsinfowebmaster@aidsinfo.nih.gov](mailto:aidsinfowebmaster@aidsinfo.nih.gov).

### **Other Guidelines**

These guidelines focus on treatment for adults and adolescents. Separate guidelines outline how to use antiretroviral therapy for such populations as pregnant women, pediatric patients and health care workers with possible occupational exposure to HIV. (See <http://aidsinfo.nih.gov/guidelines>.) There is a brief discussion of the management of women of reproductive age and pregnant women in this document. However, for more detailed and up-to-date discussion on this and other special populations, the Panel defers to the designated expertise outlined by panels that have developed these guidelines.

### **Importance of HIV Expertise in Clinical Care**

Multiple studies have demonstrated that better outcomes are achieved in patients cared for by a clinician with expertise [1-6]. This has been shown in terms of mortality, rate of hospitalizations, compliance with guidelines, cost of care, and adherence to medications. The definition of expertise in these studies has varied, but most rely on the number of patients actively managed. Based on this observation, the Panel recommends HIV primary care by a clinician with at least 20, and preferably at least 50, HIV-infected patients. Many authoritative groups have combined the recommendation based on active patients, along with fulfilling ongoing continuing medical education (CME) requirements on HIV-related topics.



# Baseline Evaluation (Updated December 1, 2007)

---

Each patient initially entering care should have a complete medical history, physical examination, and laboratory evaluation. The purpose is to confirm the presence of HIV infection, determine if HIV infection is acute (see [Acute HIV Infection](#)), determine the presence of coinfections, and assess overall health condition as recommended by the primary care guidelines for the management of HIV-infected patients [7].

The following laboratory tests should be performed for each new patient during initial patient visits:

- HIV antibody testing (if laboratory confirmation not available) **(AI)**;
- CD4 T-cell count **(AI)**;
- Plasma HIV RNA **(AI)**;
- Complete blood count, chemistry profile, transaminase levels, BUN and creatinine, urinalysis, RPR or VDRL, tuberculin skin test (TST) or **interferon- $\gamma$  release assay (IGRA)** (unless a history of prior tuberculosis or positive TST or IGRA), *Toxoplasma gondii* IgG, Hepatitis A, B, and C serologies, and PAP smear in women **(AIII)**;
- Fasting blood glucose and serum lipids if considered at risk for cardiovascular disease and for baseline evaluation prior to initiation of combination antiretroviral therapy **(AIII)**; and
- For patients with pretreatment HIV RNA >1,000 copies/mL, genotypic resistance testing is recommended when the patients enter into care, regardless of whether therapy will be initiated immediately **(AIII)**. If therapy is to be deferred, repeat testing at the time of antiretroviral initiation should be considered **(CIII)**. (See [Drug Resistance Testing](#) section.)

In addition:

1. An optional test for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in order to identify high-risk behavior and the need for sexually transmitted disease (STD) therapy **(BII)**; and
2. Chest x-ray if clinically indicated **(BIII)**.

Patients living with HIV infection must often cope with multiple social, psychiatric, and medical issues. Thus, the evaluation should also include assessment of substance abuse, economic factors, social support, mental illness, comorbidities, and other factors that are known to impair the ability to adhere to treatment and to alter outcomes. Once evaluated, these factors should be managed accordingly.

# Laboratory Testing for Initial Assessment and Monitoring for Therapeutic Response

---

Two surrogate markers are routinely used to determine indications for treatment and to monitor the efficacy of therapy: CD4 T-cell count and plasma HIV RNA (viral load). In addition, resistance testing should be used to guide selection of antiretroviral regimen in both treatment-naïve and -experienced patients; viral tropism assay should be performed prior to initiation of a CCR5 antagonist; and HLA-B\*5701 testing should be performed prior to initiation of abacavir. The rationale and utility of these laboratory tests are discussed below.

## CD4 T-CELL COUNT (Updated October 29, 2004)

The CD4 T-cell count (or CD4 count) serves as the major clinical indicator of immunocompetence in patients with HIV infection. It is usually the most important consideration in decisions to initiate antiretroviral therapy. The most recent CD4 cell count is the strongest predictor of subsequent disease progression and survival, according to clinical trials and cohort studies data on patients receiving antiretroviral therapy. A significant change between two tests (2 standard deviations) is defined as approximately 30% change of the absolute count and 3 digit change in CD4 percentage.

- **Use of CD4 T-Cell Count for Initial Assessment.** The CD4 T-cell count is usually the most important consideration in decisions to initiate antiretroviral therapy. All patients should have a baseline CD4 cell count at entry into care (**AI**); many authorities recommend two baseline measurements before decisions are made to initiate antiretroviral therapy because of wide variations in results (**CIII**). The test should be repeated yet a third time if discordant results are seen (**AI**). Recommendations for initiation of antiretroviral therapy based on CD4 T-cell count are found in the [When to Start: Indications for Initiation of Antiretroviral Therapy](#) section.
- **Use of CD4 T-Cell Count for Monitoring Therapeutic Response.** Adequate viral suppression for most patients on therapy is defined as an increase in CD4 cell count that averages 100–150 cells/mm<sup>3</sup> per year with an accelerated response in the first 3 months. This is largely because of redistribution. Subsequent increases with good virologic control

show an average increase of approximately 100 cells/mm<sup>3</sup> per year for the subsequent few years until a threshold is reached [8].

- **Frequency of CD4 T-Cell Count Monitoring.** In general, CD4 count should be determined every 3 to 6 months to (1) determine when to start antiretroviral therapy in patients who do not meet the criteria for initiation; (2) assess immunologic response to antiretroviral therapy; and (3) assess the need for initiating chemoprophylaxis for opportunistic infections.

## VIRAL LOAD TESTING (Updated October 29, 2004)

Plasma HIV RNA (viral load) may be a consideration in the decision to initiate therapy. In addition, viral load is critical for evaluating response to therapy (**AI**). Three HIV viral load assays have been approved by the Food and Drug Administration (FDA) for clinical use:

- HIV-1 reverse transcriptase polymerase chain reaction (PCR) assay (Amplicor HIV-1 Monitor Test, version 1.5, Roche Diagnostic);
- Nucleic acid amplification test for HIV RNA (NucliSens HIV-1 QT, bioMerieux); and
- Signal amplification nucleic acid probe assay (VERSANT HIV-1RNA 3.0 assay, Bayer).

Analysis of 18 trials including more than 5,000 participants with viral load monitoring showed a significant association between a decrease in plasma viremia and improved clinical outcome. Thus, viral load testing serves as a surrogate marker for treatment response and may be useful in predicting clinical progression. The minimal change in viral load considered to be statistically significant (2 standard deviations) is a threefold or a 0.5 log<sub>10</sub> copies/mL change. One key goal of therapy is a viral load below the limits of detection (at <50 copies/mL for the Amplicor assay, <75 copies/mL for the VERSANT assay, and <80 copies/mL for the NucliSens assay). This goal should be achieved by 16–24 weeks (**AI**). Recommendations for the frequency of viral load monitoring are summarized below and in [Table 2](#).

- **At Initiation or Change in Therapy.** Plasma viral load should be measured immediately before treatment and at 2–8 weeks after treatment initiation

or treatment changes because of suboptimal viral suppression. In the latter measure, there should be a decrease of at least a 1.0 log<sub>10</sub> copies/mL (BI).

- **In Patients With Viral Suppression Where Changes are Motivated by Drug Toxicity or Regimen Simplification.** Some experts also recommend repeating viral load measurement within 2–8 weeks after changing therapy. The purpose of viral load monitoring at this point is to confirm potency of the new regimen (BII).
- **In Patients on a Stable Antiretroviral Regimen**  
The viral load testing should be repeated every 3–4 months thereafter or if clinically indicated (BII).  
The testing should be repeated every 3–4 months thereafter or if clinically indicated ([Table 2](#)).

**Monitoring in Patients With Suboptimal Response.** In addition to viral load monitoring, a number of additional factors should be assessed, such as nonadherence, altered pharmacology, or drug interactions. Resistance testing may be helpful in identifying the presence of resistance mutations that may necessitate a change in therapy (AII).

## DRUG RESISTANCE TESTING

(Updated December 1, 2007)

### *Panel's Recommendations:*

- *HIV drug resistance testing is recommended for persons with HIV infection when they enter into care regardless of whether therapy will be initiated immediately (AIII). If therapy is deferred, repeat testing at the time of antiretroviral therapy initiation should be considered (CIII).*
- *A genotypic assay is generally preferred for antiretroviral-naïve persons (AIII).*
- *HIV drug resistance testing should be performed to assist in selecting active drugs when changing antiretroviral regimens in cases of virologic failure (AII).*
- *Drug resistance testing should also be performed when managing suboptimal viral load reduction (AII).*
- *Drug resistance testing in the setting of virologic failure should be performed while the patient is taking his/her antiretroviral drugs, or immediately (i.e., within 4 weeks) after discontinuing therapy (AII).*
- *Genotypic resistance testing is recommended for all pregnant women prior to initiation of therapy (AIII) and for those entering pregnancy with detectable HIV RNA levels while on therapy (AII).*

- ***Drug resistance testing is not advised for persons with HIV RNA <1,000 copies/mL, because amplification of the virus is unreliable (DIII).***

## Genotypic and Phenotypic Resistance Assays

Two types of resistance assays are used to assess viral strains and select treatment strategies: genotypic and phenotypic assays.

### Genotypic Assays

Genotypic assays detect drug resistance mutations present in relevant viral genes. Certain genotypic assays involve sequencing of the entire reverse transcriptase and protease genes, whereas others use probes to detect selected mutations that are known to confer drug resistance. Genotypic assays can be performed rapidly, and results can be reported within 1–2 weeks of sample collection. Interpretation of test results requires knowledge of the mutations that different antiretroviral drugs select for and of the potential for cross resistance to other drugs conferred by certain mutations. The International AIDS Society-USA (IAS-USA) maintains a list of significant resistance-associated mutations in the reverse transcriptase, protease, and envelope genes. (See [http://www.iasusa.org/resistance\\_mutations](http://www.iasusa.org/resistance_mutations).)

Various techniques are now available to assist the provider in interpreting genotypic test results [9-12]. Clinical trials have demonstrated the benefit of consultation with specialists in HIV drug resistance in improving virologic outcomes [13]. Clinicians are thus encouraged to consult a specialist to facilitate interpretation of genotypic results and design of an optimal new regimen.

### Phenotypic Assays

Phenotypic assays measure the ability of a virus to grow in different concentrations of antiretroviral drugs. Reverse transcriptase and protease gene sequences derived from patient plasma HIV RNA are inserted into the backbone of a laboratory clone of HIV, either by cloning or by *in vitro* recombination. Replication of the recombinant virus at different drug concentrations is monitored by expression of a reporter gene and is compared with replication of a reference HIV strain. The drug concentration that inhibits 50% of viral replication (i.e., the median inhibitory concentration [IC]<sub>50</sub>) is calculated, and the ratio of the IC<sub>50</sub> of test and reference viruses is reported as the fold increase in IC<sub>50</sub> (i.e., fold resistance).

Automated, recombinant phenotypic assays are commercially available with results available in 2–3 weeks. However, phenotypic assays cost more to perform than genotypic assays. In addition, interpretation of phenotypic assay results is complicated by incomplete information regarding the specific resistance level (i.e., fold increase in  $IC_{50}$ ) that is associated with drug failure, although clinically significant fold increase cutoffs are now available for some drugs [14-18]. Again, consultation with a specialist can be helpful for interpreting test results.

Further limitations of both genotypic and phenotypic assays include lack of uniform quality assurance for all available assays, relatively high cost, and insensitivity for minor viral species. If drug-resistant viruses are present but constitute <10%–20% of the circulating virus population, they probably will not be detected by available assays. This limitation is important because, after drugs exerting selective pressure on drug-resistant populations are discontinued, a re-emergence of wild-type virus as the predominant plasma population often occurs, resulting in a decrease of the proportion of virus with resistance mutations to below these thresholds [19-21]. This reversion to predominantly wild-type virus often occurs in the first 4–6 weeks after drugs are stopped. Prospective clinical studies have shown that, despite this plasma reversion, reinstitution of the same antiretroviral agents (or those sharing similar resistance pathways) is usually associated with early drug failure, and the virus present at failure is derived from previously archived resistant virus [22]. Therefore, resistance testing is of greatest value when performed before or within 4 weeks after drugs are discontinued (AII). Because detectable resistant virus may persist in the plasma of some patients for longer periods of time, resistance testing beyond 4 to 6 weeks after discontinuation may still reveal mutations. Yet, the absence of detectable resistance in such patients must be interpreted with caution in designing subsequent antiretroviral regimens.

### **Use of Resistance Assays in Clinical Practice (Table 3)**

No definitive prospective data exist to support using one type of resistance assay over another (i.e., genotypic versus phenotypic) in different clinical situations. Therefore, one type of assay is recommended per sample. However, for patients with a complex treatment history, results derived from both assays might provide critical and complementary information to guide regimen changes.

Drug resistance testing is not advised for persons with viral load <1,000 copies/mL, because amplification of the virus is unreliable, and unnecessary charges may be incurred for testing (DIII).

### **Use of Resistance Assays in Determining Initial Treatment**

Transmission of drug-resistant HIV strains has been well documented and has been associated with suboptimal virologic response to initial antiretroviral therapy [23-26]. The likelihood that a patient will acquire drug-resistant virus is related to the prevalence of drug resistance in persons engaging in high-risk behaviors in the community. In the United States and Europe, recent studies suggest the risk that transmitted virus will be resistant to at least one antiretroviral drug is in the range of 6%–16% [27-32], with 3%–5% of transmitted viruses exhibiting reduced susceptibility to drugs from more than one class [23, 31]. If the decision is made to initiate therapy in a person with acute HIV infection, resistance testing at baseline will likely optimize virologic response. Therefore, resistance testing in this situation is recommended (AIII), and a genotypic assay is generally preferred because of its more rapid turnaround time (AIII). In the absence of therapy, resistant viruses may decline over time to less than the detection limit of standard resistance tests but may still increase the risk of treatment failure when therapy is eventually initiated. Therefore, if the decision is made to defer therapy, resistance testing during acute HIV infection should still be performed (AIII). In this situation, the genotypic resistance test result might be kept on record for several years before it becomes clinically useful. Because of the possibility of acquisition of drug-resistant virus during this period of time, repeat resistance testing at the time ART is initiated should be considered (CIII).

Performing drug resistance testing before initiation of antiretroviral therapy in patients with chronic HIV infection is less straightforward. The rate at which transmitted resistance-associated mutations revert to wild-type virus has not been completely delineated, but mutations present at the time of HIV transmission are more stable than those selected under drug pressure, and it is often possible to detect resistance-associated mutations in viruses that were transmitted several years earlier [33, 34]. No prospective trial has addressed whether drug resistance testing prior to initiation of therapy confers benefit in this population. However, limited data from several, but not all, studies suggest suboptimal virologic responses in persons with baseline mutations [23-26, 35-37]. In



addition, a cost-effectiveness analysis of early genotypic resistance testing suggests that baseline testing in this population should be performed [38]. Therefore, resistance testing in chronically infected persons at the time of entry into HIV care is recommended (AIII). Genotypic testing is generally preferred in this situation (AIII). Repeat testing at the time ART is initiated should be considered because of the possibility that the patient may have acquired drug-resistant virus (CIII).

### Use of Resistance Assays in the Event of Virologic Failure

Resistance assays are useful in guiding decisions for patients experiencing virologic failure while on antiretroviral therapy. Prospective data supporting drug-resistance testing in clinical practice at this time are derived from trials in which test utility was assessed for cases of virologic failure. These studies involved genotypic assays, phenotypic assays, or both [13, 39-45]. In general, these studies indicated that early virologic response to salvage regimens was improved when results of resistance testing were available to guide changes in therapy, compared with responses observed when changes in therapy were guided only by clinical judgment. Thus, resistance testing appears to be a useful tool in selecting active drugs when changing antiretroviral regimens in cases of virologic failure (AII). (See [Management of the Treatment-Experienced Patient](#).)

Resistance testing also can help guide treatment decisions for patients with suboptimal viral load reduction (AII). Virologic failure in the setting of combination antiretroviral therapy is, for certain patients, associated with resistance to only one component of the regimen [46-48]. In that situation, substituting individual drugs in a failing regimen might be possible, although this concept will require clinical validation. (See [Management of the Treatment-Experienced Patient](#).)

### Use of Resistance Assays in Pregnant Patients

In pregnant women, the goal of antiretroviral therapy is to maximally reduce plasma HIV RNA to provide appropriate maternal therapy and to prevent mother-to-child transmission of HIV. Genotypic resistance testing is recommended for all pregnant women prior to initiation of therapy (AIII) and for those entering pregnancy with detectable HIV RNA levels while on therapy (AII). Optimal prevention of perinatal transmission may require initiation of antiretroviral

therapy before results of resistance testing are available.

## HLA-B\*5701 SCREENING

(Updated December 1, 2007)

### *Panel's Recommendations:*

- *The Panel recommends screening for HLA-B\*5701 before starting patients on an abacavir-containing regimen, to reduce the risk of hypersensitivity reaction (AI).*
- *HLA-B\*5701-positive patients should not be prescribed abacavir (AI).*
- *The positive status should be recorded as an abacavir allergy in the patient's medical record (AII).*
- *When HLA-B\*5701 screening is not readily available, it remains reasonable to initiate abacavir with appropriate clinical counseling and monitoring for any signs of hypersensitivity reaction (CIII).*

The abacavir hypersensitivity reaction (ABC HSR) is a multiorgan clinical syndrome typically seen within the initial 6 weeks of abacavir treatment. This reaction has been reported in 5%–8% of patients participating in clinical trials when using clinical criteria for the diagnosis, and it is the major reason for early discontinuation of abacavir. (See [Table 18a](#).) Discontinuing abacavir usually promptly reverses HSR, whereas subsequent rechallenge can cause a rapid, severe, and even life-threatening recurrence.

Studies that evaluated demographic risk factors for ABC HSR have shown racial background as a risk factor, with white patients generally having a higher risk (5%–8%) than black patients (2%–3%). Several groups reported a highly significant association between ABC HSR and the presence of the MHC class I allele HLA-B\*5701 [49, 50]. An abacavir skin patch test (ABC SPT) was developed as a research tool to immunologically confirm ABC HSR, because the clinical criteria used for ABC HSR are overly sensitive and may lead to false-positive ABC HSR diagnoses [51]. A positive ABC SPT is an abacavir-specific delayed hypersensitivity reaction that results in redness and swelling at the skin site. All ABC SPT positive patients studied were also positive for the HLA-B\*5701 allele [52]. The ABC SPT could be falsely negative for some patients with ABC HSR. It is not recommended as a clinical tool at this point. The PREDICT-1 study randomized patients before starting abacavir either to be prospectively screened for HLA-B\*5701 (in which HLA-B\*5701-positive patients were not offered abacavir) or to standard of care (no screening, with all patients receiving

abacavir) [53]. The overall HLA-B\*5701 prevalence in this predominately white population was 5.6%. In this cohort, screening for HLA-B\*5701 eliminated immunologic ABC HSR (defined as ABC SPT positive) compared with standard of care (0% vs. 2.7%), yielding a 100% negative predictive value with respect to SPT as well as significantly decreasing the rate of clinically suspected ABC HSR (3.4% vs. 7.8%). The SHAPE study corroborated the low rate of immunologically validated ABC HSR in black patients and confirmed the utility of HLA-B\*5701 screening for the risk for ABC HSR (100% sensitivity in black and white populations) [54].

On the basis of the results of these studies, the Panel recommends screening for HLA-B\*5701 before starting patients on an abacavir-containing regimen (AI). HLA-B\*5701–positive patients should not be prescribed abacavir (AI), and the positive status should be recorded as an abacavir allergy in the patient’s medical record (AII). HLA-B\*5701 testing needs to be performed only once in a patient’s lifetime, so efforts to carefully record and maintain the result and to educate the patient about its implications are important. The specificity of the HLA-B\*5701 test is lower than the sensitivity (i.e., 33%–50% of HLA-B\*5701 positive patients would likely not develop confirmed ABC HSR if exposed to ABC). HLA-B\*5701 should not be used as a substitute for clinical judgment or pharmacovigilance, because a negative HLA-B\*5701 result does not absolutely rule out the possibility of some form of ABC HSR. When HLA-B\*5701 screening is not readily available, it remains reasonable to initiate ABC with appropriate clinical counseling and monitoring for any signs of ABC HSR (CIII).

## CORECEPTOR TROPISM ASSAYS

(Updated December 1, 2007)

### ***Panel’s Recommendations:***

- ***Coreceptor tropism assay should be performed whenever the use of a CCR5 inhibitor is being considered (AII).***
- ***Coreceptor tropism testing might also be considered for patients who exhibit virologic failure on a CCR5 inhibitor (BIII).***

HIV enters cells by a complex process that involves the sequential attachment to the CD4 receptor, followed by binding to either the CCR5 or CXCR4 molecules and fusion of the viral and cellular membranes [55]. The CCR5 inhibitors (i.e., maraviroc, vicriviroc) prevent HIV entry into target cells by binding to the CCR5

receptor [56]. Phenotypic and, to a lesser degree, genotypic assays have been developed that can determine the coreceptor tropism (CCR5, CXCR4, or both) of the patient’s dominant virus population. One assay (*Trofile*, Monogram Biosciences, Inc., South San Francisco, CA) was used to screen patients who were participating in studies that formed the basis of approval for maraviroc, the only CCR5 inhibitor currently available. Other assays are under development and are currently used primarily for research purposes or in clinical situations in which the *Trofile* assay is not readily available.

## **Background**

The vast majority of patients harbor a CCR5-utilizing virus (R5 virus) during acute/recent infection, suggesting that the R5 variant is preferentially transmitted compared with CXCR4 (X4) variants. Viruses in the majority of untreated patients eventually exhibit a shift in coreceptor tropism from CCR5 to either CXCR4 or both CCR5 and CXCR4 (dual- or mixed-tropic; D/M-tropic). This shift is temporally associated with a more rapid decline in CD4 T-cell counts [57, 58], although whether this shift is a cause or a consequence of progressive immunodeficiency remains undetermined [55]. Antiretroviral-treated patients with extensive drug-resistance are more likely to harbor detectable X4- or D/M-tropic variants than untreated patients with comparable CD4 T-cell counts [59]. The prevalence of X4- or D/M-tropic variants increases to more than 50% in treated patients with CD4 T-cell counts less than 100 cells/mm<sup>3</sup> [60, 61].

## **Phenotypic Assays**

There are now at least two high-throughput phenotypic assays that can quantify the coreceptor characteristics of plasma-derived virus. Both involve the generation of laboratory viruses that express patient-derived envelope proteins (gp120 and gp41). These pseudoviruses are either replication-competent (*Phenoscript* assay, VIRalliance, Paris, France) or replication-defective (*Trofile* assay, Monogram Biosciences, Inc.) [62, 63]. These pseudoviruses can then be used to infect target cell lines that express CD4 and either CCR5 or CXCR4. In the *Trofile* assay, the coreceptor tropism of the patient-derived virus is confirmed by testing the susceptibility of the virus to specific CCR5 or CXCR4 inhibitors *in vitro*. The *Trofile* assay takes about 2 weeks to perform and requires a plasma viral load  $\geq 1,000$  copies/mL. *In vitro* mixing experiments of R5 and X4 variants indicate that the assay can detect a minor variant with 100% sensitivity when that variant is present at a frequency of 10%, whereas the assay has 83%

sensitivity when the variant is present at a frequency of 5% [62]. This sensitivity may not be sufficient to rule out the presence of clinically meaningful levels of X4- or D/M-tropic virus in patients who are initiating a CCR5 inhibitor-based regimen [64]. For unclear reasons, a minority of samples cannot be successfully phenotyped with this assay. A more sensitive assay that has improved detection of minor viral populations is under development [65].

### **Genotypic Assays**

These assays are under investigation [66-68] but are not commercially available.

### **Use of Coreceptor Tropism Assays in Clinical Practice**

Coreceptor tropism assays should be used whenever the use of a CCR5 inhibitor is being considered **(AII)**. Coreceptor tropism testing might also be considered for patients who exhibit virologic failure on maraviroc (or any CCR5 inhibitor) **(BIII)**.

Other potential clinical uses for the tropism assay are for prognostic purposes [57, 58, 69] or for assessment of tropism prior to starting ART, in case a CCR5 inhibitor is required later (e.g., in a regimen change for toxicity). Currently, there are not sufficient data to support these uses.

# Treatment Goals (Updated December 1, 2007)

---

Eradication of HIV infection cannot be achieved with available antiretroviral regimens. This is chiefly because the pool of latently infected CD4 T-cells is established during the earliest stages of acute HIV infection [70] and persists with a long half-life, even with prolonged suppression of plasma viremia [71-74]. The primary goals driving the decision to initiate antiretroviral therapy therefore are to:

- reduce HIV-related morbidity and prolong survival,
- improve quality of life,
- restore and preserve immunologic function,
- maximally and durably suppress viral load, and
- prevent vertical HIV transmission.

Adoption of treatment strategies recommended in these guidelines has resulted in substantial reductions in HIV-related morbidity and mortality [75-77] and has reduced vertical transmission [78, 79].

Higher plasma HIV RNA levels (viral load) are associated with more rapid disease progression [80], although other factors likely contribute as well to the rate of CD4 T-cell decline [81]. Maximal suppression of plasma viremia for as long as possible to delay the selection of drug resistance mutations, to preserve CD4 T-cell numbers, and to confer substantial clinical benefits are the most important goals of antiretroviral therapy [82]. (See [Baseline Evaluation](#).)

The goal of maximal viral suppression in initial therapy may be difficult in some cases of HIV with pre-existing resistance mutations. To be successful, antiretroviral regimens need to contain at least two, and preferably three, active drugs from multiple drug classes. When maximal initial suppression is not achieved or is lost, changing to a new regimen with at least two active drugs is required for this goal. If this is not possible in a clinically and immunologically stable patient, an interval of persisting viremia may be acceptable while waiting for arrival of potent new therapies.

Viral load reduction to below limits of assay detection in a treatment-naïve patient usually occurs within the first 12–24 weeks of therapy. Predictors of virologic success include:

- high potency of antiretroviral regimen,
- excellent adherence to treatment regimen [83, 84],
- low baseline viremia,

- higher baseline CD4 T-cell count [83, 84], and
- rapid (i.e.,  $\geq 1 \log_{10}$  in 1 to 4 months) reduction of viremia in response to treatment [84].

Successful outcomes are not always observed. Viral suppression rates in clinical practice may be lower than the 80%–90% seen in clinical trials, although the use of current compact, potent, and well-tolerated regimens has probably decreased this difference in outcomes between clinical trials and clinical practice [85]. (See also [Management of the Treatment-Experienced Patient: Assessment of Antiretroviral Treatment Failure and Changing Therapy](#).)

## STRATEGIES TO ACHIEVE TREATMENT GOALS

Achieving treatment goals requires a balance of sometimes competing considerations, outlined below. Providers and patients must work together to define priorities and determine treatment goals and options.

### ***Selection of Initial Combination Regimen***

Several preferred and alternative antiretroviral regimens are recommended for use. (See [What to Start: Initial Combination Regimens for the Antiretroviral-Naïve Patient](#).) They vary in efficacy, pill burden, and potential side effects. A regimen tailored to the patient may be more successful in fully suppressing the virus by allowing more complete medication adherence. Individual tailoring is based on such considerations as expected side effects, convenience, comorbidities, interactions with other required medications, and results of pretreatment genotypic drug resistance testing.

### ***Pretreatment Drug Resistance Testing***

Current studies suggest a prevalence of HIV drug resistance of 6%–16% in antiretroviral treatment-naïve patients, and some studies suggest that the presence of transmitted drug-resistant viruses, particularly those with non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations, may lead to suboptimal virologic responses. Therefore,



pretreatment genotypic resistance testing should be used in guiding selection of the most optimal initial antiretroviral regimen. (See [Drug Resistance Testing](#) section.)

### ***Improving Adherence***

Suboptimal adherence may result in reduced treatment response. Incomplete adherence can result from complex medication regimens; patient factors, such as active substance abuse and depression; and health system issues, including interruptions in medication access and inadequate treatment education and support. Conditions that promote adherence should be maximized prior to initiating antiretroviral therapy.

# When to Start: Indications for Initiation of Antiretroviral Therapy ([Table 5](#)) (Updated December 1, 2007)

## *Panel's Recommendations:*

- ***Antiretroviral therapy should be initiated in patients with a history of an AIDS-defining illness or with a CD4 T-cell count <350 cells/mm<sup>3</sup>. The data supporting this recommendation are stronger for those with a CD4 T-cell count <200 cells/mm<sup>3</sup> and with a history of AIDS (AI) than for those with CD4 T-cell counts between 200 and 350 cells/mm<sup>3</sup> (AII).***
- ***Antiretroviral therapy should also be initiated in the following groups of patients regardless of CD4 T-cell count:***
  - a. *Pregnant women (AI);*
  - b. *Patients with HIV-associated nephropathy (AI); and*
  - c. *Patients coinfectd with HBV when treatment is indicated (BIII).*
- ***Antiretroviral therapy may be considered in some patients with CD4 T-cell counts >350 cells/mm<sup>3</sup>. (See text for further discussion.)***
- ***The necessity for patient adherence to a long-term drug regimen should be discussed in depth by the patient and clinician (AIII). Barriers to adherence should be addressed before therapy is initiated.***

The primary goals of antiretroviral therapy are to improve and/or preserve immune function and reduce HIV-associated morbidity and mortality. A potential secondary benefit is the theoretical likelihood of reducing HIV transmission because of continued high-risk behaviors [86].

Large observational cohort studies and prognostic models provide some guidance based on the prognosis for disease-free survival as determined by baseline CD4 T-cell count ([Figure A](#) and [Tables 4a, 4b](#)) [87-89]. Potent combination antiretroviral therapy can increase and potentially normalize CD4 T-cell count in the majority of patients with maximal viral suppression regardless of baseline CD4 T-cell count [90, 91].

Currently recommended antiretroviral regimens can achieve sustained viral suppression for many years. However, immediate virologic rebound followed by CD4 T-cell count decline is seen with most patients upon therapy interruption. Thus, once the decision is made to initiate antiretroviral therapy with currently

available drugs, treatment should be continued without interruption, except for serious toxicities or concurrent conditions that preclude oral therapy. (See [Treatment Interruption](#) section.)

Before initiating therapy, patient counseling and education should be conducted. The patient should understand the potential benefits and risks of antiretroviral therapy, including short- and long-term adverse drug effects and the need for long-term commitment and adherence to the prescribed treatment regimen.

**The Panel recommends initiation of antiretroviral therapy in patients with a history of AIDS-defining illness or with a CD4 T-cell count of <350 cells/mm<sup>3</sup>. The following sections discuss the evidence used to support this recommendation.**

***For patients with a history of an AIDS-defining illness or a CD4 T-cell count <200 cells/mm<sup>3</sup>, antiretroviral therapy should be initiated (AI).*** HIV-infected patients with CD4 T-cell counts <200 cells/mm<sup>3</sup> are at higher risk for development of opportunistic diseases. The role of antiretroviral therapy is best defined in this population.

Randomized controlled trials strongly support initiation of therapy in patients with CD4 T-cell count <200 cells/mm<sup>3</sup>. A prospective, controlled study provided strong evidence that treating symptomatic patients and patients with CD4 T-cell counts <200 cells/mm<sup>3</sup> improved survival and reduced disease progression [92].

Subsequent long-term data from multiple observational cohort studies have provided strong support for the recommendation that therapy should always be initiated before the CD4 T-cell counts decline to <200 cells/mm<sup>3</sup> ([Figure A](#) and [Table 4a](#)) [75, 76, 88, 89, 93-95].

***For patients with CD4 T-cell counts between 200 and 350 cells/mm<sup>3</sup>, antiretroviral therapy is also recommended (AII).*** No randomized trial definitively addresses the optimal time to initiate antiretroviral therapy in chronically infected patients with CD4 T-cell counts >200 cells/mm<sup>3</sup>. The Panel's recommendation for initiating antiretroviral therapy in

these patients is based on several large, long-term observational cohort studies assessing immunological responses as defined by CD4 T-cell count increases and progression of HIV disease in patients with various baseline CD4 T-cell counts.

Data from the ART Cohort Collaboration, which included 61,798 patient-years of follow-up, showed that, at 3 to 5 years after starting therapy, the risk for AIDS/death was significantly less in those who started therapy with a CD4 T-cell count between 200 and 350 compared with those who initiated ART at a CD4 threshold of 200 cells/mm<sup>3</sup> [96]. This study also demonstrated that baseline viral load was not significantly associated with risk of AIDS or death. However, patients with high viral loads 6-months posttreatment were found to have higher rates of disease progression, which indicates that virologic response to antiretroviral therapy remains a critical factor in monitoring ART.

In the era of combination antiretroviral therapy, several large observational studies have indicated that the risk of several non-AIDS-defining conditions, including cardiovascular diseases, liver-related events, renal disease, and certain non-AIDS malignancies [97-102] is greater than the risk for AIDS in persons with CD4 T-cell counts >200 cells/mm<sup>3</sup>; the risk for these events increases progressively as the CD4 T-cell count decreases from 350 to 200 cells/mm<sup>3</sup>.

The SMART study, a prospective, randomized, multicenter, cohort study, compared treatment involving CD4 count-guided treatment interruption (i.e., therapy was discontinued when the CD4 T-cell count exceeded 350 cells/mm<sup>3</sup> and reinitiated when the CD4 T-cell count declined to <250 cells/mm<sup>3</sup>) with continuous antiretroviral therapy. The risks for all-cause mortality, which was largely attributed to causes other than AIDS, and several non-AIDS defining conditions (including hepatic failure, renal disease, cardiovascular disease, and non-AIDS malignancy) were greater in participants randomized to CD4 count-guided treatment interruption than in those who received continuous therapy [103, 104].

In a subgroup analysis of the SMART study, in which treatment-naïve patients with CD4 T-cell counts >350 cells/mm<sup>3</sup> were randomized to receive antiretroviral therapy either immediately or after the CD4 T-cell count dropped to <250 cells/mm<sup>3</sup>, the risk of opportunistic diseases and serious non-AIDS events was higher in the deferred-therapy arm than in the treatment arm (absolute risk of 4.9% vs. 1.0%, respectively). These data for this small subgroup suggest that delaying therapy until the CD4 T-cell

count decreases to <250 cells/mm<sup>3</sup> should be avoided [105].

Collectively, the studies cited above support the use of antiretroviral therapy in all individuals with a CD4 T-cell count <350 cells/mm<sup>3</sup>.

### **Antiretroviral Therapy should be initiated in the following patients regardless of CD4 T-cell count:**

*Pregnant Women* – All HIV-infected pregnant women should be started on antiretroviral therapy to manage maternal HIV infection and to maximize viral suppression, in order to reduce the risk for perinatal HIV transmission (**AI**). For women who do not require antiretroviral therapy for their own health, postpartum discontinuation of antiretroviral drugs can be considered. For more detailed discussion, please refer to the [Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women and Interventions to Reduce Perinatal HIV Transmission in the United States](#) [106] and the [HIV-Infected Women of Reproductive Age and Pregnant Women](#) section.

*HIV-Associated Nephropathy (HIVAN)* – HIVAN is the most frequent cause of chronic renal failure in persons living with HIV infection. This entity, which is more common in black than in white patients, is not clearly related to CD4 T-cell depletion. Ongoing viral replication appears to be directly involved in renal injury. Antiretroviral therapy for individuals with HIVAN has been associated with both preserved renal function and prolonged survival, and therefore should be initiated for patients with a diagnosis of HIVAN regardless of CD4 T-cell count (**AI**) [107, 108]. When prescribing antiretroviral drugs, clinicians should note that most nucleoside reverse transcriptase inhibitors (NRTIs), except for abacavir, are renally excreted. Dosage adjustment for these agents may be necessary based on renal function; prescribers can refer to [Table 16](#) for dosing recommendations based on calculated creatinine clearance.

*Hepatitis B virus (HBV) coinfection requiring treatment of HBV* – HIV-infected patients may also be coinfecting with HBV. The two-NRTI combination of tenofovir plus either lamivudine or emtricitabine is a component of many recommended first-line antiretroviral regimens and is also an effective treatment for HBV infection. In the HIV-infected patients, if therapy for either HIV or HBV infection is indicated, initiation of a fully suppressive antiretroviral regimen that includes tenofovir and either lamivudine or emtricitabine is recommended in order to prevent development of antiretroviral drug resistance (**BIII**). If antiretroviral therapy is not initiated, HBV

therapy should include only agent(s) with the least potential of selecting HIV resistance mutations. (See [Hepatitis B Coinfection](#) section.)

**Antiretroviral therapy may be considered in some patients with CD4 T-cell count greater than 350 cells/mm<sup>3</sup>.**

Existing data are inadequate to recommend initiation of antiretroviral therapy in all patients with CD4 T-cell counts >350 cells/mm<sup>3</sup>. Any theoretical potential benefits could be outweighed by unknown risks or by patient-specific preferences. The clinician should refer to [Table 5](#) for a list of potential risks and benefits of initiating therapy in these patients.

The short-term risk for AIDS or death at CD4 T-cell counts 350 cells/mm<sup>3</sup> is low ([Table 4b](#)). Thus, the potential absolute risk reductions associated with treatment in such patients are small ([Table 4a](#)). Within the ART Cohort Collaboration, the absolute 3-year risk differences between those with CD4 T-cell counts 200 to 349 cells/mm<sup>3</sup> and those with CD4 T-cell counts ≥350 cells/mm<sup>3</sup> were only 1.3% (for those with HIV-RNA <100,000 copies/mL) and 1.7% (for those with HIV-RNA ≥100,000 copies/mL) [88]. These differences were similar through 5 years of observation [96]. The cost-effectiveness of early initiation of antiretroviral therapy in these patients is unknown.

Data from the AIDS Therapy Evaluation Project, Netherlands (ATHENA), have demonstrated that patients who started therapy at CD4 T-cell counts >350 cells/mm<sup>3</sup> were significantly more likely to achieve CD4 T-cell counts >800 cells/mm<sup>3</sup> after 7 years of therapy than those who initiated therapy at lower CD4 T-cell counts [91]. A long-term study based on the Johns Hopkins Clinical Cohort demonstrated that patients who initiated ART with a CD4 T-cell count <350 cells/mm<sup>3</sup> were significantly less likely to achieve a CD4 T-cell count >500 cells/mm<sup>3</sup> after 6 years of highly active antiretroviral therapy (HAART) compared with those who started therapy at CD4 T-cell counts >350 cells/mm<sup>3</sup> [109].

Earlier treatment of HIV infection may also have positive public health implications, as it may reduce HIV transmission [86]. This may have significant implication in individuals in discordant relationships (i.e., HIV-infected individuals with HIV-negative sexual partners) or in individuals who continue to engage in risky behaviors.

Despite possible benefits of treatment of persons with CD4 T-cell counts >350 cells/mm<sup>3</sup>, there are also considerations that argue against therapy. First, the potential absolute reduction in risk of non-AIDS events/morbidity resulting from antiretroviral responses in CD4 T-cell count increase and viral load suppression is not large. Second, although there are now several reasonably safe and well-tolerated options for first-line regimens, the long-term toxicities remain unknown. Third, antiretroviral treatment requires life-long adherence to therapy. Some patients may find that the need to take daily medications decreases quality of life, even without side effects. Lastly, nonadherence to the regimen may promote the development of drug resistance.

The level of HIV RNA in a patient with a higher CD4 T-cell count is not strongly associated with short-term risk of AIDS/death and is a less important criterion for initiation of therapy than the CD4 T-cell count. Nevertheless, a high viral load is a predictor of more rapid progression to AIDS overall. Some experts may take viral load into consideration when deciding whether or not to start therapy in patients with CD4 T-cell counts >350 cells/mm<sup>3</sup> [87, 110].

Clinical scenarios, the presence of comorbidities, age, patient readiness, potential impact on quality of life, and adherence should be considered in the decision of when and if to initiate therapy in patients with a CD4 T-cell count >350 cells/mm<sup>3</sup>. Some experts suggest that antiretroviral therapy should be initiated in the subset of persons who have evidence of a rapid decline in CD4 T-cells (e.g., a decrease of >120 cells/mm<sup>3</sup> per annum) before it drops to a CD4 T-cell count of 350 cells/mm<sup>3</sup> in order to avoid rapid immunologic deterioration and subsequent clinical progression.

**Special considerations in patients presenting with an opportunistic disease.** The timing of when to start therapy in patients presenting with an opportunistic disease is controversial and is covered in detail in the **Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Patients [in preparation]**. The optimal time to start therapy varies, depending on the clinical scenarios. In patients with conditions for which there is no effective therapy except for improvement of immune function as a result of antiretroviral therapy (e.g., cryptosporidiosis, microsporidiosis, progressive multifocal leukoencephalopathy, and HIV-associated dementia), the early benefits of potent antiretroviral therapy outweigh any increased risk, and therefore therapy should be started as soon as possible (**AIII**). In the setting of *Mycobacterium avium* complex infection, *Pneumocystis jirovecii* pneumonia (PCP), and

cryptococcal meningitis, in which immediate therapy may increase the risk of immune reconstitution inflammatory syndrome (IRIS), a short delay may be warranted before initiating antiretroviral treatment **(CIII)**. With concomitant *M.tuberculosis* infection, delay of ART for 2 to 8 weeks after initiation of tuberculosis (TB) treatment is recommended in order to avoid confusion in the event of adverse drug reactions and to prevent or minimize IRIS **(BIII)**. (See [TB/HIV Coinfection](#) section.)

**Adherence Considerations.** Concern about adherence to therapy is a major determinant for timing of initiation of therapy, with patient readiness to start treatment being a key factor in future adherence [111]. Depression and substance abuse may negatively affect adherence and response to therapy and should therefore be addressed, whenever possible, before therapy is initiated. However, no patient should automatically be excluded from consideration for antiretroviral therapy simply because the clinician judges that the patient exhibits behaviors or characteristics affecting adherence. Instead, the necessity for patient adherence to a long-term drug regimen should be discussed in detail by the patient and clinician before therapy is initiated. To achieve the level of adherence necessary for effective therapy, providers are encouraged to use strategies for assessing and assisting adherence. (See [Adherence](#) section.)



# What to Start: Initial Combination Regimens for the Antiretroviral-Naïve Patient (Updated January 29, 2008)

There are more than 20 approved antiretroviral drugs across six mechanistic classes, with which to design combination regimens. These six classes include the nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), fusion inhibitors, CCR5 antagonists, and integrase inhibitors.

## Summary of Recommended Regimens

The most extensively studied combination antiretroviral regimens for treatment-naïve patients generally consist of one NNRTI with two NRTIs, or a PI (with or without ritonavir-boosting) with two NRTIs. A list of Panel-recommended components for initial therapy in treatment-naïve patients can be found in [Table 6](#). Column A lists the preferred and alternative NNRTI and PI components, and Column B lists the preferred and alternative dual-NRTI components. To construct a complete three- or four-drug antiretroviral regimen, the clinician should select one component from Column A and one from Column B. A list of agents or components not recommended for initial treatment can be found in [Table 7](#). Some agents or components not generally recommended for use because of lack of potency or potential serious safety concerns are listed in [Table 8](#). Potential advantages and disadvantages of the components recommended as initial therapy for treatment-naïve patients are listed in [Table 9](#) to guide prescribers in choosing the regimen best suited for an individual patient.

## CONSIDERATIONS WHEN SELECTING A FIRST ANTIRETROVIRAL REGIMEN FOR TREATMENT-NAÏVE PATIENTS

### Data Used for Making Recommendations

In its deliberations, the Panel reviews clinical trial data published in peer-reviewed journals and data prepared by manufacturers for FDA review. In selected cases, data presented in abstract format in major scientific meetings are also reviewed. The first criteria for selection are data from a randomized, prospective clinical trial with an adequate sample size, demonstrating durable viral suppression and immunologic enhancement (as evidenced by increased

CD4 T-cell count). Few of these trials include clinical end points, such as development of AIDS-defining illness or death. Thus, assessment of regimen efficacy and potency is primarily based on surrogate marker endpoints (i.e., viral load and CD4 responses). The Panel reviewed data from randomized clinical trials in arriving at preferred versus alternative ratings in [Table 6](#). Components are designated as preferred for use in treatment-naïve patients when clinical trial data have demonstrated optimal efficacy and durability with acceptable tolerability and ease of use.

Alternative components refer to those for which clinical trial data show efficacy but also show disadvantages compared with preferred components. On the basis of individual patient characteristics and needs, a regimen listed as an alternative regimen may actually be the preferred regimen.

With the improved choices available for more effective and convenient regimens, some of the agents or combinations previously recommended by the Panel as alternative regimens have been removed from the list.

### Factors to Consider When Selecting an Initial Regimen

Regimen selection should be individualized, and should consider a number of factors including:

- comorbidity (e.g., cardiovascular disease, chemical dependency, liver disease, psychiatric disease, pregnancy, renal diseases, or tuberculosis);
- patient adherence potential;
- convenience (e.g., pill burden, dosing frequency, and food and fluid considerations);
- potential adverse drug effects;
- potential drug interactions with other medications;
- pregnancy potential;
- results of genotypic drug resistance testing;
- gender and pretreatment CD4 T-cell count if considering nevirapine; and
- HLA B\*5701 testing if considering abacavir.

## Considerations for Therapies

A listing of characteristics (dosing, pharmacokinetics, and common adverse effects) of individual antiretroviral agents can be found in [Tables 9](#) and [Tables 10–15](#). Additionally, [Table 16](#) provides clinicians with dosing recommendations of these agents for patients with renal or hepatic insufficiency.

### NNRTI- versus PI-Based Regimens

Currently preferred regimens use combinations of two NRTIs and either an NNRTI or a ritonavir-boosted PI. Both NNRTI- and PI-based regimens result in suppression of HIV RNA levels and CD4 T-cell increases in a large majority of patients [112-116]. Some comparative data are available (see below).

Efavirenz-based regimens were superior to older PI-based regimens in comparative studies [114, 117]. The A1424-034 study demonstrated comparable virologic and immunologic responses with atazanavir- and efavirenz-based regimens [116]. The ACTG A5142 study, however, showed better virologic responses with an efavirenz-based regimen compared with a lopinavir/ritonavir-based regimen, but better CD4 cell responses and less resistance following virologic failure with lopinavir/ritonavir plus two NRTIs [115]. In addition, potent PI-based regimens reduced HIV-related morbidity and mortality [92, 118], whereas there are no clinical end point data available for potent NNRTI-based regimens because they were developed after such endpoints were no longer widely employed in antiretroviral clinical trials.

The side effect profiles of the two-class-based regimens differ, with PI-based regimens generally associated with more gastrointestinal symptoms and lipid abnormalities, and NNRTI-based regimens associated with more rash and central nervous system side effects (efavirenz). Both kinds of regimens may cause hepatic transaminase elevations. Surprisingly, the A5142 study showed significantly more lipoatrophy (>20% loss of limb fat by DEXA scan) in the efavirenz group than in the lopinavir/ritonavir groups; higher rates of lipoatrophy were seen when stavudine and, to a lesser degree, zidovudine were part of the regimens [119].

Drug resistance to most PIs requires multiple mutations in the HIV protease, and it seldom develops following early virologic failure [120], especially when ritonavir boosting is used. Resistance to efavirenz or nevirapine, however, is conferred by a single mutation in reverse transcriptase, and develops rapidly following virologic

failure [120]. An estimated 7% of U.S. patients are infected with NNRTI-resistant viruses [31]. Because of the concern of primary resistance in the treatment-naïve population, genotypic testing results should be used to guide the selection of the initial antiretroviral regimen. (See [Drug Resistance Testing](#) section). In terms of convenience, NNRTI-based regimens are among the simplest to take, particularly with the coformulated tablet containing tenofovir, emtricitabine, and efavirenz, which allows for once daily dosing with a single pill. PI-based regimens are usually used with ritonavir, may be dosed once- or twice daily, and generally require more pills in the regimen, although the pill burden associated with PI-based regimens has decreased over the years. Drug-drug interactions are important with both kinds of regimens, but more clinically significant interactions are seen with ritonavir-boosted regimens.

In summary, either PI- (preferably with ritonavir boosting) or NNRTI-based regimens are recommended as first-line therapy and the choice should be individualized.

### NNRTI-BASED REGIMENS (1 NNRTI + 2 NRTIs)

#### *Panel's Recommendations:*

#### *Preferred NNRTI (AII):*

- *Efavirenz (except during first trimester of pregnancy or in women with high pregnancy potential\*)*

#### *Alternative NNRTI (BII):*

- *Nevirapine may be used as an alternative in adult females with CD4 T-cell counts <250 cells/mm<sup>3</sup> and in adult males with CD4 T-cell counts <400 cells/mm<sup>3</sup>.*

*\* Women of child bearing age with high pregnancy potential are those who are trying to conceive or who are sexually active with men and not using effective and consistent contraception.*

#### **Summary: NNRTI-Based Regimens**

Four NNRTIs (namely, delavirdine, efavirenz, etravirine, and nevirapine) are currently marketed for use.

Use of NNRTI-based regimens as initial therapy can preserve PIs for later use, thus reducing or delaying patient exposure to some of the adverse effects more commonly associated with PIs. The major disadvantages of currently available NNRTIs involve prevalence of NNRTI-resistant viral strains in treatment-naïve patients [27, 28, 34] and the low genetic barrier of NNRTIs for development of resistance. Resistance testing is now recommended for treatment-naïve patients prior to starting therapy. (See

### **Utilization of Drug Resistance Testing in Clinical Practice** section.)

The first three approved NNRTIs (efavirenz, nevirapine, or delavirdine) only require a single mutation to confer resistance, and cross resistance affecting these three NNRTIs is common.

Etravirine, an NNRTI recently approved for treatment-experienced patients, has in vitro activity against some viruses with mutations that confer resistance to delavirdine, efavirenz, and nevirapine [121].

On the basis of clinical trial results and safety data, the Panel recommends the use of efavirenz as the preferred NNRTI as part of initial antiretroviral therapy (**AII**). Efavirenz should not be used in pregnant women (especially during the first trimester) or in women of child-bearing potential who are planning to conceive or are sexually active with men and not using effective and consistent contraception.

Nevirapine may be used as an alternative to efavirenz for the initial NNRTI-based regimen in women with pretreatment CD4 counts  $\leq 250$  cells/mm<sup>3</sup> or in men with pretreatment CD4 counts  $\leq 400$  cells/mm<sup>3</sup> (**BII**).

Symptomatic and sometimes serious or life-threatening hepatic events have been observed with much greater frequency in women with pretreatment CD4 counts  $>250$ /mm<sup>3</sup> and in men with pretreatment CD4 counts  $>400$ /mm<sup>3</sup>. Nevirapine thus should be initiated in these patients only if the benefit clearly outweighs the risk. Close monitoring for elevated liver enzymes and skin rash should be undertaken for all patients during the first 18 weeks of nevirapine therapy.

Among these four agents, delavirdine is dosed three times daily, has the least supportive data, and appears to have the least antiviral activity. As such, it is not recommended as part of an initial regimen (**DII**).

Etravirine has not been studied in large, randomized trials in treatment-naïve subjects. Thus, it cannot currently be recommended as part of initial therapy.

Following is a more detailed discussion of recommendations for preferred and alternate NNRTI-based regimens for initial therapy.

### **Efavirenz as Preferred NNRTI (AII)**

Large randomized, controlled trials and cohort studies of treatment-naïve patients have demonstrated potent viral suppression in efavirenz-treated patients with a substantial proportion having HIV RNA  $<50$  copies/mL during up to 3 years of follow-up [112, 113]. Studies comparing efavirenz-based regimens with other regimens have demonstrated that regimens containing efavirenz with two NRTIs were superior

virologically to some PI-based regimens, including indinavir [114], lopinavir/ritonavir [115], and nelfinavir [117] and to triple-NRTI-based regimens [122, 123]. Efavirenz-based regimens also had comparable activities to nevirapine- [124, 125] and atazanavir-based regimens [116].

The ACTG 5142 study randomized patients to receive two NRTIs together with either efavirenz or lopinavir/ritonavir (or an NRTI-sparing regimen of efavirenz and lopinavir/ritonavir) [115]. The dual-NRTI and efavirenz regimen was associated with a significantly better virologic response than the dual-NRTI and lopinavir/ritonavir regimen at 96 weeks, whereas the dual-NRTI with lopinavir/ritonavir regimen was associated with a significantly better CD4 cell response and less drug resistance following virologic failure.

The 2NN trial compared efavirenz and nevirapine, both given with stavudine and lamivudine, in treatment-naïve patients. Virologic responses were similar for both drugs, although nevirapine was associated with greater toxicity (see below) and did not meet criteria for non-inferiority compared with efavirenz (see below) [124].

Two major limitations of efavirenz are its central nervous system side effects, which usually resolve over a few weeks, and its potential teratogenic effects. In animal reproductive studies, efavirenz caused major central nervous system congenital anomalies in nonhuman primates at drug exposure levels similar to those achieved in humans [126]. Several cases of neural tube defects in human newborns, when mothers were exposed to efavirenz during first trimester of pregnancy, have been reported [127, 128].

Studies using efavirenz and two-NRTI combinations (abacavir, didanosine, stavudine, tenofovir, or zidovudine together with emtricitabine or lamivudine) show durable virologic activity. A single pill of coformulated tenofovir, emtricitabine, and efavirenz now allows one-pill, once-daily dosing.

### **Nevirapine as Alternative NNRTI (BII)**

In the 2NN trial, 70% of subjects in the efavirenz arm and 65.4% in the twice-daily nevirapine arm had virologic suppression (defined as HIV RNA  $<50$  copies/mL) at 48 weeks. This difference did not reach criteria necessary to demonstrate non-inferiority of nevirapine [124]. Two deaths were attributed to nevirapine use. One resulted from fulminant hepatitis



and one from staphylococcal sepsis as a complication of Stevens-Johnson syndrome.

Serious hepatic events have been observed when nevirapine was initiated in treatment-naïve patients. These events generally occur within the first few weeks of treatment. In addition to experiencing elevated serum transaminases, approximately half of the patients also develop skin rash, with or without fever or flu-like symptoms. Women with higher CD4 counts appear to be at highest risk [129, 130]. A 12-fold higher incidence of symptomatic hepatic events was seen in women (including pregnant women) with CD4 counts  $>250$  cells/mm<sup>3</sup> at the time of nevirapine initiation when compared with women with CD4 counts  $\leq 250$  cells/mm<sup>3</sup> (11.0% vs. 0.9%). An increased risk was also seen in men with pretreatment CD4 counts  $>400$  cells/mm<sup>3</sup> when compared with men with pretreatment CD4 counts  $\leq 400$  cells/mm<sup>3</sup> (6.3% vs. 1.2%). Most of these patients had no identifiable underlying hepatic abnormalities. In some cases, hepatic injuries continued to progress despite discontinuation of nevirapine [129, 131]. Symptomatic hepatic events have not been reported with single doses of nevirapine given to mothers or infants for prevention of perinatal HIV infection.

On the basis of the safety data described, the Panel recommends that nevirapine may be used as an alternative to efavirenz for treatment-naïve women with pretreatment CD4 counts  $\leq 250$  cells/mm<sup>3</sup> or in men with CD4 counts  $\leq 400$  cells/mm<sup>3</sup> (BII). Patients experiencing CD4 count increases to levels above these thresholds as a result of nevirapine-containing therapy can safely continue therapy without an increased risk of adverse hepatic events.

At the initiation of nevirapine, a 14-day lead-in period at a dosage of 200mg once daily should be instituted before increasing to the maintenance dosage of 200mg twice daily. Serum transaminases should be obtained at baseline, prior to and 2 weeks after dose escalation, then monthly for the first 18 weeks. Clinical and laboratory parameters should be assessed at each visit. More detailed recommendations on the management of nevirapine-associated hepatic events can be found in [Table 18a](#).

## PI-BASED REGIMENS (RITONAVIR-BOOSTED OR UNBOOSTED PIs + 2 NRTIs)

### *Panel's Recommendations:*

#### *Preferred PIs (in alphabetical order):*

- *atazanavir + ritonavir (AIII)*
- *fosamprenavir + ritonavir twice daily (AII)*
- *lopinavir/ritonavir (coformulated) twice daily (AII)*

#### *Alternative PIs (BII) (in alphabetical order):*

- *atazanavir\**
- *fosamprenavir*
- *fosamprenavir + ritonavir once daily*
- *lopinavir/ritonavir (coformulated) once daily*
- *saquinavir + ritonavir*

\* Ritonavir 100mg per day must be given when tenofovir or efavirenz is used with atazanavir.

### **Summary: PI-Based Regimens**

Each PI has its own virologic potency, adverse effect profile, and pharmacokinetic properties. The characteristics, advantages, and disadvantages of each PI can be found in [Tables 9](#) and [12](#). In selecting a PI-based regimen for a treatment-naïve patient, clinicians should consider factors such as dosing frequency, food and fluid requirements, pill burden, drug interaction potential, baseline hepatic function, and toxicity profile. A number of metabolic abnormalities, including dyslipidemia, fat maldistribution, and insulin resistance, have been associated with PI use. PIs differ in their propensity to cause these metabolic complications. The extent to which these complications may result in adverse long-term consequences, such as increased cardiac events, is unknown.

The potent inhibitory effect of ritonavir on the cytochrome P450 3A4 isoenzyme has allowed the addition of low-dose ritonavir to other PIs (with the exception of nelfinavir) as a pharmacokinetic booster to increase drug exposure and prolong plasma half-lives of the active PIs. This allows for reduced dosing frequency and/or pill burden, which may improve overall adherence to the regimen. The increased trough concentration ( $C_{min}$ ) may improve the antiretroviral activity of the active PIs, which can be beneficial when the patient harbors HIV strains with reduced susceptibility to the PI [132-134]. The major drawbacks associated with this strategy are the potential for increased risk of hyperlipidemia and a greater potential of drug-drug interactions from the addition of ritonavir.

The list of Panel-recommended PIs can be found in [Table 6](#). The Panel considers atazanavir + ritonavir (**AIII**), fosamprenavir + ritonavir (given twice daily) (**AII**), and lopinavir/ritonavir (coformulated, given twice daily) (**AII**) as preferred PIs for the treatment-naïve patient. This recommendation is based on clinical trial efficacy, the barrier for virologic resistance, convenience, and tolerability. Alternative PIs include atazanavir (**BII**), fosamprenavir (**BII**), once-daily fosamprenavir + ritonavir (**BII**), once-daily lopinavir/ritonavir (**BII**), or **twice daily saquinavir + ritonavir (BII)**. PIs not recommended in initial treatment regimens include indinavir (with or without ritonavir), **nelfinavir**, ritonavir alone, saquinavir (without ritonavir), or tipranavir + ritonavir. There are insufficient data to recommend darunavir + ritonavir at this time (See [Other Treatment Options Under Investigation: Insufficient Data to Recommend](#) section).

### Preferred PI Components (in alphabetical order)

**Ritonavir-boosted Atazanavir (AIII).** Atazanavir is an azapeptide PI with the advantages of once-daily dosing. Ritonavir-boosting of atazanavir enhances the concentrations of atazanavir. **In a comparison of boosted and unboosted atazanavir, overall efficacy results were comparable [135].** However, the study was not powered to demonstrate non-inferiority of unboosted atazanavir, and there were numerically fewer virologic failures and less emergence of PI resistance in patients in the boosted atazanavir arm. The suggestion of improved virologic activity compared with unboosted atazanavir in treatment-naïve patients, the improved pharmacokinetics with ritonavir-boosting, and the data on use of boosted atazanavir in treatment-experienced patients [136] support its designation as a preferred regimen. The main adverse effect associated with atazanavir + ritonavir use is indirect hyperbilirubinemia, with or without jaundice or scleral icterus, but without concomitant hepatic transaminase elevations. **Several cases of nephrolithiasis have been reported to the U.S. FDA in patients who received ritonavir-boosted or unboosted atazanavir. The causal relationship is still uncertain [137].** Lipid elevations (total, LDL, and HDL cholesterol) were slightly greater in patients treated with ritonavir-boosted atazanavir [135]. Patients who receive concomitant therapy with tenofovir or efavirenz should use ritonavir-boosted atazanavir to overcome the pharmacokinetic interactions between unboosted atazanavir and these two agents. Atazanavir + ritonavir requires acidic gastric pH for dissolution. Thus, concomitant use of drugs that raise gastric pH, such as antacids, H<sub>2</sub> antagonists, and particularly

proton pump inhibitors, may impair absorption of atazanavir + ritonavir. **Proton pump inhibitors in a dose not exceeding an equivalence of omeprazole 20mg per day taken at least 12 hours prior to the PIs may be used in treatment-naïve patients receiving ritonavir-boosted atazanavir. H<sub>2</sub> antagonists and antacids should be used with caution and with careful dose separation.** (See [Tables 21 and 22a.](#))

**Ritonavir-boosted Fosamprenavir (twice daily) (AII).** Fosamprenavir is a prodrug of the PI amprenavir. A randomized trial (KLEAN) compared twice-daily ritonavir-boosted fosamprenavir with lopinavir/ritonavir, each in combination with abacavir and lamivudine in antiretroviral-naïve patients. At week 48, 73% of the patients in the ritonavir-boosted fosamprenavir arm and 71% of those in the lopinavir/ritonavir arm achieved viral loads of <400 copies/mL (95% confidence interval [CI] around treatment difference: -4.84 to 7.05) [138]. **Similar virologic responses were seen at 96 weeks [139].** Clinical and laboratory adverse events did not differ between the regimens. In this study of treatment-naïve subjects, twice-daily ritonavir-boosted fosamprenavir was non-inferior to twice-daily lopinavir/ritonavir, which supports the recommendation of twice-daily ritonavir-boosted fosamprenavir as a preferred PI component [140]. **As with lopinavir/ritonavir, atazanavir + ritonavir, and possibly other ritonavir-boosted PIs, resistance is uncommon in previously PI-naïve patients who fail boosted fosamprenavir. Metabolic side effects occurred at similar frequencies with boosted fosamprenavir as with lopinavir/ritonavir in the KLEAN study.**

**Lopinavir/ritonavir (coformulated; twice daily) (AII).** In several clinical trials, regimens containing twice-daily lopinavir/ritonavir with two NRTIs have shown potent virologic activity in treatment-naïve patients. In a randomized, placebo-controlled trial comparing lopinavir/ritonavir with nelfinavir (each with stavudine and lamivudine) in 653 subjects, lopinavir/ritonavir was superior to nelfinavir in maintaining a viral load <400 copies/mL through 48 weeks (84% versus 66% with persistent virologic response through 48 weeks; hazard ratio = 2.0; 95% CI: 1.5 to 2.7) [141]. Overall adverse event rates and study discontinuation rates due to adverse events were similar in the two groups. No evidence of genotypic or phenotypic resistance to PIs was detected in the 51 lopinavir/ritonavir-treated patients with HIV RNA >400 copies/mL at up to 48 weeks follow-up. In contrast, D30N and/or L90M mutations were detected in 43 of 96 (45%) of nelfinavir-treated patients [142]. A 7-year follow-up study of lopinavir/ritonavir and two

NRTIs showed sustained virologic suppression in patients who were maintained on the originally assigned regimen [142]. As mentioned above, ACTG 5142 demonstrated that in combination with two NRTIs, lopinavir/ritonavir was associated with lower virologic efficacy compared with efavirenz, but the CD4 T-cell count response was greater, and there was less drug resistance with virologic failure [115]. Major adverse effects of lopinavir/ritonavir include insulin resistance and hyperlipidemia, especially hypertriglyceridemia, necessitating pharmacologic management in some patients. Fat accumulation also has been attributed to lopinavir/ritonavir and other PIs, although the causal relationship is not clearly established. Gastrointestinal intolerance, especially diarrhea, also has been observed, although it may occur less frequently with the newer tablet formulation than it did with the original soft-gel capsules.

Lopinavir/ritonavir given twice daily is the preferred PI for use in pregnant women [106]. For more detailed information regarding antiretroviral drug choice and related issues in pregnancy, see [“Recommendations for the Use of Antiretroviral Drugs in HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States”](#) available at <http://aidsinfo.nih.gov>.

#### Alternative PI-based regimens (in alphabetical order)

**Atazanavir (BII).** Unboosted atazanavir is given once daily and has fewer adverse effects on lipid profiles than other available PIs. Three studies compared atazanavir-based combination regimens to either nelfinavir- or efavirenz-based regimens. These studies established similar virologic efficacy among atazanavir 400mg once daily and both comparator treatment groups in antiretroviral-naïve patients after 48 weeks of therapy [116, 143, 144]. Unboosted atazanavir has also been compared against boosted atazanavir (see [Ritonavir-boosted Atazanavir](#)). Atazanavir may be chosen as initial therapy for patients when a once-daily regimen without ritonavir is desired and in patients with underlying risk factors when hyperlipidemia may be particularly undesirable. However, ritonavir-boosting is recommended in PI-experienced patients. Patients who receive concomitant therapy with tenofovir or efavirenz should use ritonavir-boosted atazanavir to overcome the adverse pharmacokinetic interactions between unboosted atazanavir and these two agents. Atazanavir requires acidic gastric pH for dissolution. Thus, concomitant use of drugs that raise gastric pH, such as antacids, H<sub>2</sub> antagonists, and proton pump inhibitors, may significantly impair its absorption. **Proton pump**

inhibitors should not be used in patients taking unboosted atazanavir. H<sub>2</sub> antagonists and antacids should be used with caution and with careful dose separation. (See [Tables 21 and 22a](#).)

**Fosamprenavir (BII) and Ritonavir-Boosted Fosamprenavir (once daily) (BII).** Fosamprenavir can be recommended as an alternative PI when given without ritonavir (1400mg twice daily) or as a once-daily ritonavir-boosted regimen (1400/200 or 1400/100 mg once daily). Two studies compared twice-daily fosamprenavir and once-daily ritonavir-boosted fosamprenavir with nelfinavir [145, 146]. In the first trial, more subjects randomized to fosamprenavir achieved viral suppression at 48 weeks than those assigned to nelfinavir, with greater differences seen in those with pretreatment viral load >100,000 copies/mL [145]. Once-daily ritonavir-boosted fosamprenavir had similar virologic activity to nelfinavir in the second trial [146]. The 1400/100mg once daily dose was recently approved by the FDA based primarily on pharmacokinetic data demonstrating higher amprenavir concentrations than with unboosted fosamprenavir [147].

#### Lopinavir/ritonavir (once daily) (BII).

Lopinavir/ritonavir can be given once daily in treatment-naïve patients. When compared with the traditional twice-daily dosing, giving the same total dose once daily results in a similar mean area under the concentration-time curve but a lower mean C<sub>min</sub>. In two randomized trials comparing once-daily and twice-daily lopinavir/ritonavir in combination with tenofovir and emtricitabine, a similar proportion of subjects achieved viral suppression to <50 copies/mL [148, 149]. However, a greater incidence of moderate to severe diarrhea was reported in the patients randomized to the once-daily arms in both trials, using the soft gel capsule formulation. In ACTG 5073, the overall efficacy of once- and twice-daily lopinavir/ritonavir (soft-gel capsule formulation) was similar [150]. However, in two studies, subjects with baseline viral loads above 100,000 copies/mL were more likely to experience virologic failure [150, 151]. A lower C<sub>min</sub> is expected with the once-daily dosing [152], so this dosing strategy is not recommended in PI-experienced patients, especially in those who may have HIV strains with reduced susceptibility to lopinavir. **Once-daily dosing also should not be used in pregnant women, especially during the third trimester, when lopinavir levels are expected to be lower.**

**Ritonavir-boosted Saquinavir (BII).** The addition of low-dose ritonavir (an inhibitor of CYP 3A4 isoenzyme in both the intestine and the liver) to

saquinavir results in a significant increase in oral bioavailability and a delay in saquinavir clearance. This leads to a higher peak saquinavir concentration, a longer elimination half-life, and a higher pre-dose concentration. The GEMINI study compared saquinavir/ritonavir (1,000mg/100mg twice daily) with lopinavir/ritonavir, both given twice daily, in combination with tenofovir/emtricitabine given once daily, in 337 treatment-naïve patients monitored over 48 weeks. Similar levels of viral suppression and increases in CD4 counts were seen in both arms [153].

## DUAL-NUCLEOSIDE OPTIONS AS PART OF INITIAL COMBINATION THERAPY

### *Panel's Recommendations:*

#### ***Preferred dual-NRTI (AII) (in alphabetical order):***

- ***abacavir/lamivudine\*(coformulated)***
- ***tenofovir/emtricitabine\*(coformulated)***

#### ***Alternative dual-NRTI (BII) (in order of preference):***

- ***zidovudine/lamivudine\*(coformulated)***
- ***didanosine + (lamivudine or emtricitabine)***

\* Emtricitabine may be used in place of lamivudine or vice versa.

Dual-NRTI combinations are commonly utilized components of combination antiretroviral regimens with the addition of an NNRTI or a PI (usually boosted with ritonavir). Most dual-NRTI combinations used in clinical practice consist of a primary NRTI in combination with lamivudine or emtricitabine. Both lamivudine and emtricitabine have few side effects, and each selects for the M184V resistance mutation that confers high-level resistance to both drugs; a modest decrease in susceptibility to didanosine and abacavir; and improved susceptibility to zidovudine, stavudine, and tenofovir [154].

All NRTIs except didanosine can be taken without food restrictions. Adherence may be further improved with once-daily dosing (currently possible with all NRTIs except stavudine and zidovudine) and with fixed-dosage combination products, such as abacavir/lamivudine, tenofovir/emtricitabine (with or without efavirenz), or zidovudine/lamivudine.

The Panel's recommendations on specific dual-NRTI options are made on the basis of virologic potency and durability, short- and long-term toxicities, the propensity to select for resistance mutations, dosing convenience, and drug-drug interaction potential.

The following sections list the recommended dual-NRTI combinations and discuss the rationale behind each recommendation.

### **Preferred Dual-NRTI Components (in alphabetical order)**

**Abacavir/lamivudine (coformulated) for patients who test negative for HLA B\*5701 (AII).** In a comparative trial of abacavir/lamivudine and zidovudine/lamivudine (both given twice daily and combined with efavirenz), subjects from both arms achieved similar virologic responses. The abacavir-treated subjects experienced a greater CD4 cell increase at 48 weeks [155]. The fixed-dose combination of abacavir/lamivudine allows for one-pill, once-daily dosing. The biggest drawback to the use of abacavir has been the potential for hypersensitivity reactions (HSR). Clinically suspected HSRs have been observed in 5%–8% of patients starting this drug. The risk for this reaction can be substantially decreased with pretreatment HLA B\*5701 testing, see [HLA-B\\*5701 Screening](#) section [53, 54]. Whenever possible, HLA-B\*5701 testing should precede the use of abacavir. Abacavir should not be given to patients who test positive for HLA-B\*5701, and abacavir hypersensitivity should be noted on the patient's allergy list based on these results. Those who test negative are unlikely to experience HSR, but should be counseled about the symptoms of the reaction. Because of the high sensitivity and negative predictive value of the HLA B\*5701 test in identifying patients at high and low risk for HSR, abacavir/lamivudine is now recommended as a preferred NRTI combination for patients who have tested negative for HLA-B\*5701 (AII).

### **Tenofovir/emtricitabine (coformulated) (AII).**

Tenofovir is a nucleotide analog with potent activity against HIV and HBV and with a long intracellular half-life that allows for once-daily dosing. The fixed-dose combinations of tenofovir/emtricitabine and tenofovir/emtricitabine/efavirenz are both administered as one pill once daily and are designed to improve adherence.

Tenofovir, when used with either lamivudine or emtricitabine as part of an efavirenz-based regimen in treatment-naïve patients, demonstrated potent virologic suppression through 144 weeks [113] and was superior to zidovudine/lamivudine in virologic efficacy at up to 144 weeks [25, 156]. In the Gilead 934 study, more subjects in the zidovudine/lamivudine arm developed loss of limb fat as assessed by DEXA scans and anemia at 96 and 144 weeks compared with the



tenofovir/emtricitabine arm [156, 157]. Emergence of the M184V mutation was less frequent than with zidovudine/lamivudine, and no subject has developed the K65R mutation after 144 weeks of therapy, in contrast to the Gilead 903 study and other studies in which tenofovir was combined with lamivudine. A tenofovir-based dual-NRTI combination has not been compared head-to-head with another dual-NRTI combination in a PI-based regimen. In a study comparing once- and twice-daily lopinavir/ritonavir using tenofovir/emtricitabine as the dual-NRTI backbone, the 48-week virologic efficacy was similar to that seen in other trials in treatment-naïve subjects [148].

Renal impairment, manifested by increases in serum creatinine, glycosuria, hypophosphatemia, and acute tubular necrosis, has been reported with tenofovir use [158, 159]. The extent of this toxicity is not completely defined. Risk factors may include advanced HIV disease, greater treatment experience and pre-existing renal impairment [160, 161]. Renal function, urinalysis, and electrolytes should be monitored in patients while on tenofovir. The calculated creatinine clearance, using either the Cockcroft-Gault equation or the MDRD equation, is a more sensitive indicator of impaired or declining renal function than the serum creatinine. In patients with some degree of pre-existing renal insufficiency (creatinine clearance or CrCl <50 mL/min, see [Table 16](#) for dosage recommendations), tenofovir dosage adjustment is required. However, because no safety and efficacy data using the dosage-adjustment guidelines for renal dysfunction are available, the use of alternative NRTIs (especially abacavir) may be preferred over dose-adjusted tenofovir in this setting.

There is a larger body of data on the renal safety of tenofovir when combined with efavirenz than with PIs. Tenofovir levels can be increased by some PIs, and some studies have suggested a greater risk for renal dysfunction when tenofovir is used in PI-based regimens [162, 163], but others have not found this association [160]. Tenofovir has been used in combination with PIs in several clinical trials involving patients with CrCl above 50-60 mL/min, without renal toxicity.

Tenofovir plus either emtricitabine or lamivudine is the preferred NRTI combination for patients coinfecting with both HIV and HBV, as these drugs have activity against both viruses. The use of a single HBV-active NRTI (such as lamivudine or emtricitabine) can lead to HBV resistance and is not recommended.

## Alternative Dual-NRTI Components (in order of preference)

**Zidovudine/lamivudine (coformulated) (BII).** The dual-NRTI combination of zidovudine/lamivudine has been the main dual-NRTI component in multiple clinical trials examining the potency of various NNRTI- and PI-based regimens [114, 116, 117, 122, 164-166]. This combination has extensive durability, safety, and tolerability experience. A fixed-dose combination of zidovudine/lamivudine is available for one-tablet, twice-daily dosing. Selection of the lamivudine-associated M184V mutation has been associated with increased susceptibility to zidovudine. In a comparative trial of abacavir/lamivudine vs. zidovudine/lamivudine (both given twice daily and combined with efavirenz), even though virologic responses were similar in both arms, the CD4 T cell count increase was greater in the abacavir/lamivudine treated patients than in the zidovudine/lamivudine treated patients [155].

Bone marrow suppression, manifested by macrocytic anemia and/or neutropenia, is seen in some patients. Zidovudine is also associated with gastrointestinal toxicity, fatigue, and possibly mitochondrial toxicity, including lactic acidosis/hepatic steatosis and lipoatrophy. In the Gilead 934 study, subjects taking zidovudine had significantly less limb fat at 96 and 144 weeks than those on tenofovir, and there was a significant loss of fat among zidovudine recipients between 48, 96, and 144 weeks [157]. In ACTG 5142, limb fat was lowest in patients treated with stavudine, but those on zidovudine had significantly less limb fat than those taking tenofovir [119].

Primarily because of its greater toxicity compared with preferred regimens, the combination of zidovudine + lamivudine is now considered to be an alternative rather than a preferred dual-NRTI option (BII).

**Didanosine + (emtricitabine or lamivudine) (BII).** To date, the clinical trial experience with didanosine + emtricitabine or lamivudine is limited. The FTC-301A trial tested didanosine + emtricitabine with efavirenz and demonstrated potent virologic suppression (78% of patients achieved HIV RNA <50 copies/mL at 48 weeks) [35]. Because of the limited data and the risk for pancreatitis, peripheral neuropathy, and possibly other mitochondria-associated toxicities, didanosine together with either emtricitabine or lamivudine can only be recommended as an alternative dual-NRTI component.

**NRTIs and Hepatitis B.** Three of the current NRTIs, emtricitabine, lamivudine, and tenofovir, have activity against HBV. Most coinfecting patients should use coformulated tenofovir/emtricitabine (or tenofovir plus lamivudine) as their nucleoside backbone to provide additional activity against HBV and to avoid lamivudine/emtricitabine resistance. It is important to note that patients with HBV/HIV coinfection may be at risk of acute exacerbation of hepatitis after initiation or upon discontinuation of these drugs [167-169]. Thus, these patients should be monitored closely for clinical or chemical hepatitis if these drugs are to be initiated or discontinued. (See [Hepatitis B \(HBV\)/HIV Coinfection](#) and [When to Start](#) sections.)

## ALL-NRTI REGIMENS

A triple-NRTI combination regimen has multiple advantages: fewer drug-drug interactions (e.g., none with rifampin), low pill burden, availability of a fixed-dose combination (zidovudine/lamivudine/abacavir), and the ability to spare patients from potential side effects seen with PIs and NNRTIs. However, several clinical trials that studied triple-NRTI regimens have shown suboptimal virologic activity [122, 123, 138, 170-173], and current PI- and NNRTI-based regimens have improved convenience and tolerability compared with older regimens [112, 113, 116].

### Abacavir/lamivudine/zidovudine (coformulated)

**(DII).** Abacavir/lamivudine/zidovudine is the only triple-NRTI combination for which randomized, controlled trials are available.

Abacavir/lamivudine/zidovudine demonstrated comparable antiretroviral activity to indinavir [164, 165] and nelfinavir [174] but was inferior virologically to an efavirenz-based regimen [122]. This combination is generally not recommended and should be used only when a preferred or an alternative NNRTI-based or a PI-based regimen is less desirable because of concerns about toxicities, drug interactions, or regimen complexity **(DII)**.

**Zidovudine/lamivudine + tenofovir (DII).** The DART study demonstrated that the combination of zidovudine/lamivudine + tenofovir had antiviral activity [175]; however, comparative data with standard regimens are not available.

A quadruple-NRTI regimen with zidovudine, lamivudine, abacavir, and tenofovir showed comparable virologic responses to an efavirenz-based regimen in a small pilot study [176], but definitive data are lacking. Thus, this regimen cannot be recommended at this time **(DII)**.

## OTHER TREATMENT OPTIONS UNDER INVESTIGATION: INSUFFICIENT DATA TO RECOMMEND

Several novel treatment regimens using agents approved for treatment-experienced patients are currently in Phase II or III clinical trials, evaluating their safety and efficacy in treatment-naïve patients. Preliminary data from these trials are summarized below.

**Ritonavir-boosted darunavir-based regimen** The ARTEMIS study compared darunavir/ritonavir (800/100mg once daily) with lopinavir/ritonavir (once or twice daily), both in combination with tenofovir/emtricitabine, in a randomized, open-label, non-inferiority trial. The study enrolled 689 treatment-naïve subjects with a median CD4 count of 228 cells/mm<sup>3</sup>, and a median plasma HIV RNA level of 60,000-70,000 copies/mL. At 48 weeks, plasma HIV RNA was <50 copies/mL in 84% of darunavir/ritonavir recipients and 78% of lopinavir/ritonavir recipients (p <0.001). Grade 2 to 4 adverse events, primarily diarrhea, were seen in 7% of darunavir/ritonavir recipients and 14% of lopinavir/ritonavir recipients (p <0.01). However, because these are preliminary data, and because of the lack of availability of a 400 or 800mg formulation, the panel cannot recommend this regimen as initial therapy at the present time [177].

**Raltegravir-based regimen** The integrase inhibitor, raltegravir has been studied in a Phase II trial, initially involving monotherapy in 35 treatment-naïve subjects, and then expanded into a larger trial comparing different doses of raltegravir with efavirenz, both in combination with tenofovir and lamivudine [178, 179]. At a 24 week analysis, similar numbers of patients achieved plasma HIV RNA <50 copies/mL with efavirenz-based regimens or with any of 4 doses of raltegravir in raltegravir-based regimens (n=197). CD4 cell increases were also comparable across arms. Adverse events were comparable except that headache, dizziness and abnormal dreams occurred more frequently on efavirenz. Durable antiviral activity was subsequently observed during a 48-week analysis of the same study [179]. Phase III trials of raltegravir-based regimens in treatment-naïve subjects are underway.

**Maraviroc-based regimen** The MERIT study compared the CCR5 antagonist, maraviroc, with efavirenz, both in combination with zidovudine/lamivudine, in a randomized, double-blind trial in treatment-naïve subjects [180]. Only subjects

with R5 virus and no evidence of resistance to any drugs used in the study were enrolled (n=633). At 48 weeks, virologic suppression (defined as HIV RNA <400 copies/mL) was seen in 75.3% of maraviroc and 78.9% of efavirenz recipients, and HIV RNA <50 copies/mL was observed in 65.2% of maraviroc and 69.2% of efavirenz recipients. The HIV RNA <50 copies/mL results did not meet the criteria set by the investigators to demonstrate non-inferiority for maraviroc in this study. CD4 counts increased an average of 170 cells/mm<sup>3</sup> in the maraviroc arm vs 143 cells/mm<sup>3</sup> in the efavirenz arm. Through 48 weeks, more subjects discontinued maraviroc because of lack of efficacy (11.9% vs 4.2%), whereas fewer subjects discontinued maraviroc because of toxicity (4.2% vs 13.6%).

# What Not To Use ([Table 8](#)) (Updated **January 29, 2008**)

Some antiretroviral regimens or components are not generally recommended because of suboptimal antiviral potency, unacceptable toxicities, or pharmacologic concerns. These are summarized below.

## ANTIRETROVIRAL REGIMENS NOT RECOMMENDED

**Monotherapy with NRTI (EII).** Single NRTI therapy does not demonstrate potent and sustained antiviral activity and should not be used. For prevention of mother to child transmission, zidovudine monotherapy might be considered in certain unusual circumstances. See “[Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States](#)” available at <http://aidsinfo.nih.gov>.

Single-drug treatment regimens with a ritonavir-boosted PI, either lopinavir [181] or atazanavir [182], are under investigation but cannot be recommended outside of a clinical trial at this time.

**Dual-nucleoside regimens (EII).** These regimens are not recommended because they have not demonstrated potent and sustained antiviral activity as compared with three-drug combination regimens [183].

**Triple-NRTI regimens (EII).** Except for abacavir/lamivudine/zidovudine (DII) and possibly zidovudine/lamivudine + tenofovir (DII), triple-NRTI regimens should NOT be used routinely, because of suboptimal virologic activity [158, 184-187] or lack of data.

## ANTIRETROVIRAL COMPONENTS NOT RECOMMENDED (in alphabetical order)

**Atazanavir + indinavir (EIII).** Both of these PIs can cause grade 3 to 4 hyperbilirubinemia and jaundice. Additive or worsening of these adverse effects may be possible when these agents are used concomitantly.

**Didanosine + stavudine (EII).** The combined use of didanosine and stavudine as a dual-NRTI backbone can result in a high incidence of toxicities, particularly peripheral neuropathy, pancreatitis, and lactic acidosis [117, 188, 189]. This combination has been implicated in several deaths of HIV-infected pregnant women

secondary to severe lactic acidosis with or without hepatic steatosis and pancreatitis [190].

**Two-NNRTI (EII).** In the 2NN trial, treatment naïve subjects were randomized to receive once or twice daily nevirapine vs. efavirenz vs. efavirenz plus nevirapine, all combined with stavudine and lamivudine [124]. A higher frequency of clinical adverse events leading to treatment discontinuation was reported in subjects randomized to the two NNRTIs. Both efavirenz and nevirapine may induce metabolism of etravirine leading to reductions in etravirine drug exposure [191]. Based on these findings, the Panel does not recommend using 2-NNRTI in combination in any regimen.

**Efavirenz in first trimester of pregnancy and in women with significant childbearing potential (EIII).** Efavirenz use was associated with significant teratogenic effects in primates at drug exposures similar to those representing human exposure. Several cases of congenital anomalies have been reported after early human gestational exposure to efavirenz [127, 128]. Efavirenz should be avoided in pregnancy, particularly during the first trimester, and in women of child-bearing potential who are trying to conceive or who are not using effective and consistent contraception. If no other antiretroviral options are available in the woman who is pregnant or at risk for becoming pregnant, consultation should be obtained with a clinician who has expertise in both HIV infection and pregnancy. See “[Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States](#)” available at <http://aidsinfo.nih.gov>.

**Emtricitabine + lamivudine (EIII).** Both of these drugs have similar resistance profiles and have minimal additive antiviral activity. Inhibition of intracellular phosphorylation may occur *in vivo* as seen with other dual-cytidine-analog combinations [192].

**Nevirapine initiated in treatment-naïve women with CD4 counts >250 cells/mm<sup>3</sup> or in treatment-naïve men with CD4 counts >400 cells/mm<sup>3</sup> (DI).** Greater risk of symptomatic, including serious and life-threatening, hepatic events have been observed in these patient groups. Nevirapine should be initiated only if the benefit clearly outweighs the risk [129-131].



**Unboosted darunavir, saquinavir, or tipranavir (EII).** The virologic efficacies of these PIs were demonstrated only if they were used with concomitant ritonavir. Therefore, use of these agents as part of a combination regimen without ritonavir is not recommended.

**Stavudine + zidovudine (EII).** These two NRTIs should not be used in combination because of the demonstration of antagonism *in vitro* [193] and *in vivo* [194].

# Limitations to Treatment Safety and Efficacy

---

A number of factors may influence the safety and efficacy of antiretroviral therapy in individual patients. Examples include but are not limited to nonadherence to therapy, adverse drug reactions, drug-drug interactions, and development of drug resistance. Each is discussed below. Drug resistance, which has become a major reason for treatment failure, is discussed in greater detail in the section, [Management of the Treatment-Experienced Patient](#).

## ADHERENCE TO ANTIRETROVIRAL THERAPY (Updated October 29, 2004)

HIV viral suppression, reduced rates of resistance [195, 196], and improved survival [197] have been correlated with high rates of adherence to antiretroviral therapy. According to recommendations in these guidelines, many patients will be initiating, or have initiated, therapy when asymptomatic. This treatment must be maintained for a lifetime, which is an even greater challenge given that the efficacy of therapy has increased life expectancy for people living with HIV. A commitment to lifelong therapy requires a commitment of both the patient and the health care team.

Measurement of adherence is imperfect and currently lacks established standards. Although patient self-reporting of complete adherence has been an unreliable predictor of adherence, a patient's estimate of suboptimal adherence is a strong predictor and should be taken seriously [198, 199]. The clinician's estimate of the likelihood of a patient's adherence has also been proven to be an unreliable predictor of patient adherence [200].

Regimen complexity and pill burden were the most common reasons for nonadherence when combination therapy was first introduced. A number of advances over the past several years have dramatically simplified many of the regimens. These guidelines note regimen simplicity as well as potency in their recommendations.

Adherence to HIV medications has been well studied. However, the determinants, measurements, and interventions to improve adherence to antiretroviral therapies are insufficiently characterized and understood. Additional research on this topic continues to be needed. Various strategies can be used and have

been associated with improvements in adherence. These strategies are listed in [Table 17](#).

Clinicians seeking additional information are referred to the [http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL\\_AdherenceSup.pdf](http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL_AdherenceSup.pdf) Web site.

## Assessing and Monitoring Adherence

The first principle to success is to negotiate an understandable treatment plan to which the patient can commit [201, 202]. Trusting relationships among the patient, clinician, and health care team (including case managers, social workers, pharmacists, and others) are essential for optimal adherence. Therefore, establishing a trusting relationship over time is critical to good communication that will facilitate quality treatment outcomes. This often requires several office visits and the patience of clinicians, before therapy can be started.

Prior to writing the first prescriptions, clinicians need to assess the patient's readiness to take medication.

Patients need to understand that the first regimen is the best chance for long-term success [203]. Resources need to be identified to assist in success. Interventions can also assist with identifying adherence education needs and strategies for each patient. Examples include adherence support groups, adherence counselors, behavioral interventions [204], and using community-based case managers and peer educators.

Lastly, and most importantly, adherence counseling and assessment should be done at each clinical encounter. Early detection of nonadherence and prompt intervention can greatly reduce the chance of virologic failure and development of viral resistance.

## ADVERSE EFFECTS OF ANTIRETROVIRAL AGENTS (Updated October 29, 2004)

Adverse effects have been reported with virtually all antiretroviral drugs and are among the most common reasons for switching or discontinuation of therapy and for medication nonadherence [205]. In a review of more than 1,000 patients in a Swiss HIV cohort that

received combination antiretroviral therapy, 47% and 27% of the patients were reported to have clinical and laboratory adverse events, respectively [206]. Whereas some common adverse effects were identified during pre-marketing clinical trials, some less frequent toxicities (such as lactic acidosis with hepatic steatosis and progressive ascending neuromuscular weakness syndrome) and some long-term complications (such as dyslipidemia and fat maldistribution) were not recognized until after the drugs had been used in a larger population for a longer duration. In rare cases, some events may result in significant morbidity and even mortality.

Several factors may predispose individuals to certain antiretroviral-associated adverse events. For example, female patients seem to have a higher propensity of developing Stevens-Johnson syndrome and symptomatic hepatic events from nevirapine [129, 207, 208] or lactic acidosis from NRTIs [209]. Other factors may also contribute to the development of adverse events, such as use of concomitant medications with overlapping and additive toxicities; comorbid conditions that may increase risk of or exacerbate adverse effects (e.g., alcoholism [184] or coinfection with hepatitis B or C may increase risk of hepatotoxicity [185, 186, 210]); or drug-drug interactions that may lead to an increase in dose-related toxicities (e.g., concomitant use of hydroxyurea [187, 211] or ribavirin [212-214] with didanosine may increase didanosine-associated toxicities).

Although the therapeutic goals of antiretroviral therapy include achieving and maintaining viral suppression and improving patient immune function, one of the secondary goals should be to select a safe and effective regimen, taking into account individual patient underlying conditions, concomitant medications, and history of drug intolerance.

Information on adverse events is outlined in multiple tables in the guidelines:

- [Tables 10–15](#) summarize common adverse effects of individual antiretroviral agents;
- [Tables 18a–c](#) provide clinicians with a list of antiretroviral-associated adverse events, along with their common causative agents, estimated frequency of occurrence, symptom onset and clinical manifestations, potential preventive measures, and suggested management strategies. Adverse events of antiretroviral drugs are classified in these tables in the following categories, based on the acuity and severity of the presenting signs and symptoms:

- Potentially life-threatening and serious toxicities;
  - Adverse effects that may lead to long-term consequences; and
  - Adverse effects presenting as clinical symptoms that may affect overall quality of life or may impact overall medication adherence.
- [Table 19](#) includes a list of overlapping toxicities of antiretroviral agents and other drugs commonly used in HIV patients.
  - [Table 20](#) lists Black Box Warnings found in the product labeling of antiretroviral drugs.

## Drug Interactions

(Updated December 1, 2007)

Potential drug-drug and/or drug-food interactions should be taken into consideration when selecting an antiretroviral regimen. A thorough review of current medications can help in designing a regimen that minimizes undesirable interactions. Moreover, review of drug interaction potential should be undertaken when any new drug, including over-the-counter agents, is added to an existing antiretroviral combination. [Tables 21–23b](#) list significant drug interactions with different antiretroviral agents and suggested recommendations on contraindication, dose modification, and alternative agents.

### PI and NNRTI Drug Interactions

Most drug interactions with antiretrovirals are mediated through inhibition or induction of hepatic drug metabolism [215]. All PIs and NNRTIs are metabolized in the liver by the CYP system, particularly by the CYP3A4 isoenzyme. The list of drugs that may have significant interactions with PIs or NNRTIs is extensive and continuously expanding. Some examples of these drugs include medications that are commonly prescribed in HIV patients for non-HIV medical conditions, such as lipid-lowering agents (statins), benzodiazepines, calcium channel blockers, immunosuppressants (such as cyclosporine and tacrolimus), anticonvulsants, rifamycins, erectile dysfunction agents (such as sildenafil), ergot derivatives, azole antifungals, macrolides, oral contraceptives, and methadone. Unapproved therapies, such as St. John's Wort, can also cause negative interactions.

All PIs are substrates of CYP3A4, so their metabolic rate may be altered in the presence of CYP inducers or inhibitors. Some PIs may also be inducers or inhibitors of other CYP isoenzymes and of P-glycoprotein.

Tipranavir, for example, is a potent inducer of P-glycoprotein. The net effect of tipranavir/ritonavir on CYP3A *in vivo* appears to be enzyme inhibition. Thus, concentrations of drugs that are substrates for only CYP3A are likely to be increased if given with tipranavir/ritonavir. The net effect of tipranavir/ritonavir on a drug that is a substrate for both CYP3A and P-glycoprotein cannot be confidently predicted; significant decreases in saquinavir, amprenavir, and lopinavir concentrations have been observed *in vivo* when given with tipranavir/ritonavir.

The NNRTIs are also substrates of CYP3A4 and can act as an inducer (nevirapine), an inhibitor (delavirdine), or a mixed inducer and inhibitor (efavirenz). Etravirine is a substrate of CYP 3A4, 2C9 and 2C19. It is also an inducer of CYP3A4, but inhibitor of 2C9 and 2C19. Thus, these antiretroviral agents can interact with each other in multiple ways and with other drugs commonly prescribed for other concomitant diseases.

For example, the use of a CYP3A4 substrate that has a narrow margin of safety in the presence of a potent CYP3A4 inhibitor may lead to markedly prolonged elimination half-life ( $t_{1/2}$ ) and toxic drug accumulation. Avoidance of concomitant use or dose reduction of the affected drug, with close monitoring for dose-related toxicities, may be warranted.

The inhibitory effect of ritonavir (or delavirdine), however, can be beneficial when added to a PI, such as amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, or saquinavir [216]. Lower than therapeutic doses of ritonavir are commonly used in clinical practice as a pharmacokinetic enhancer to increase the trough concentration ( $C_{min}$ ) and prolong the half-life of the active PIs [217]. The higher  $C_{min}$  allows for a greater  $C_{min}$ :  $IC_{50}$  ratio, reducing the chance for development of drug resistance as a result of suboptimal drug exposure; the longer half-life allows for less frequent dosing, which may enhance medication adherence.

Coadministration of PIs or NNRTIs with a potent CYP3A4 inducer, on the other hand, may lead to suboptimal drug concentrations and reduced therapeutic effects of the antiretroviral agents. These drug combinations should be avoided. If this is not possible, close monitoring of plasma HIV RNA, with or without antiretroviral dosage adjustment and therapeutic drug monitoring (TDM), may be warranted. For example, the rifamycins (rifampin, and, to a lesser extent, rifabutin) are CYP3A4 inducers that can significantly reduce plasma concentrations of most PIs

and NNRTIs [218, 219]. As rifabutin is a less potent inducer, it is generally considered a reasonable alternative to rifampin for the treatment of TB when it is used with a PI- or NNRTI-based regimen, despite wider experience with rifampin use [220]. [Table 22](#) lists dosage recommendations for concomitant use of rifamycins and other CYP3A4 inducers and PIs and NNRTIs.

### **NRTI Drug Interactions**

Unlike PIs and NNRTIs, NRTIs do not undergo hepatic transformation through the CYP metabolic pathway. Some, however, do have other routes of hepatic metabolism. Significant pharmacodynamic interactions of NRTIs and other drugs have been reported. They include increases in intracellular drug levels and toxicities when didanosine is used in combination with hydroxyurea [221, 222] or ribavirin [214]; additive bone marrow suppressive effects of zidovudine and ganciclovir [223]; and antagonism of intracellular phosphorylation with the combination of zidovudine and stavudine [193]. Pharmacokinetic interactions have also been reported. However, the mechanisms of some of these interactions are still unclear. Some such interactions include increases of didanosine concentrations in the presence of oral ganciclovir or tenofovir [224, 225] and decreases in atazanavir concentration when it is coadministered with tenofovir [226, 227]. [Table 22c](#) lists significant interactions with NRTIs.

### **CCR5 Antagonist Drug Interaction**

Maraviroc, the first FDA-approved CCR5 antagonist, is a substrate of CYP3A enzymes. As a consequence, the concentrations of maraviroc can be significantly increased in the presence of strong CYP3A inhibitors (such as ritonavir and other PIs, except for ritonavir-boosted tipranavir) and are reduced when used with CYP3A inducers, such as efavirenz or rifampin. Dose adjustment is necessary when used in combination with these agents. (See [Table 14](#) for dosage recommendations) Maraviroc is neither an inducer nor an inhibitor of CYP3A system. It does not alter the pharmacokinetics of the drugs evaluated in interaction studies to date.

### **Fusion Inhibitor Drug Interaction**

The fusion inhibitor enfuvirtide is a 36 amino-acid peptide that does not enter human cells. It is expected to undergo catabolism to its constituent amino acids with subsequent recycling of the amino acids in the

body pool. No clinically significant drug-drug interaction has been identified with enfuvirtide to date.

### ***Integrase Inhibitor Drug Interaction***

Raltegravir, an HIV integrase strand transfer inhibitor, is primarily eliminated by glucuronidation mediated by the enzyme UDP-glucuronosyltransferases (UGT1A1). Strong inducers of UGT1A1 enzymes (such as rifampin) can significantly reduce the concentration of raltegravir. The significance of this interaction is unknown; thus this combination should be used with caution or an alternative therapy should be considered. Other inducers of UGT1A1, such as efavirenz, tipranavir/ritonavir, or rifabutin, can also reduce raltegravir concentration. A pharmacokinetic interaction should be considered if optimal virologic response is not achieved when these drugs are used in combination.

# Management of the Treatment-Experienced Patient

## **Panel's Recommendations:**

- ***In treatment-experienced patients with suppressed viremia, assess adherence frequently and simplify the regimen as much as possible. Change individual antiretroviral drugs to reduce or manage toxicity, as needed.***
- ***Evaluation of antiretroviral treatment failure in a patient should include an assessment of the severity of HIV disease of the patient; the antiretroviral treatment history, including the duration, drugs used, antiretroviral potency, adherence history, and drug intolerance/toxicity; HIV RNA and CD4 T-cell count trends over time; and the results of prior drug resistance testing.***
- ***Virologic failure on treatment can be defined as a confirmed HIV RNA level >400 copies/mL after 24 weeks, >50 copies/mL after 48 weeks, or a repeated detectable HIV RNA level after prior suppression of viremia.***
- ***Drug resistance testing should be obtained while the patient is taking the failing antiretroviral regimen (or within 4 weeks of treatment discontinuation) (AI).***
- ***The goal of treatment for patients with prior drug exposure and drug resistance is to re-establish maximal virologic suppression, HIV RNA <50 copies/mL (AI).***
- ***Use the treatment history and the past and current resistance test results to identify fully active agents to design a new regimen (AII). A fully active agent is one that is likely to have antiretroviral activity on the basis of both the treatment history and susceptibility on drug resistance testing. Adding at least 2 (preferably 3) fully active agents to an optimized background antiretroviral regimen can provide significant antiretroviral activity (BII).***
- ***Immunologic failure can be defined as a failure to achieve and maintain an adequate CD4 response despite virologic suppression.***
- ***For immunologic failure, current medications, untreated coinfection, and serious medical conditions should be assessed.***
- ***There is no consensus for when and how to treat immunologic failure.***
- ***Assessing and managing a patient who has antiretroviral experience, who exhibits drug***

***resistance, and who is experiencing treatment failure is complex and expert advice is critical.***

## **THE TREATMENT-EXPERIENCED PATIENT**

(Updated December 1, 2007)

Most patients benefit from antiretroviral therapy regimens. In clinical trials of effective combination regimens, a majority of study participants maintained virologic suppression for 3–7 years [113, 142, 228, 229].

In a patient on antiretroviral therapy with virologic suppression, adherence to antiretroviral drugs should be assessed on an ongoing basis (See [Adherence](#) section.) In such patients, antiretroviral regimens should be simplified as much as possible to ensure maximal adherence. The use of newer formulations or coformulations of antiretroviral drugs will reduce dosing frequency and pill counts. Changing antiretroviral drugs to reduce or manage toxicity also is reasonable.

Antiretroviral treatment failure is not uncommon, and it increases the risk for HIV disease progression; therefore, it should be addressed aggressively.

## **DEFINITIONS AND CAUSES OF ANTIRETROVIRAL TREATMENT FAILURE** (Updated December 1, 2007)

Antiretroviral treatment failure can be defined as a suboptimal response to therapy. Treatment failure is often associated with virologic failure, immunologic failure, and/or clinical progression.

Many factors are associated with an increased risk of treatment failure, including:

- Baseline patient factors, such as:
  - earlier calendar year of starting therapy, in which less potent regimens or less well-tolerated antiretroviral drugs were used,
  - higher pretreatment or baseline HIV RNA level (depending on the specific regimen used),
  - lower pretreatment or nadir CD4 T-cell count,



- prior AIDS diagnosis,
- comorbidities (e.g., depression, active substance use),
- presence of drug-resistant virus, and
- prior treatment failure, with development of drug resistance or cross resistance;
- incomplete medication adherence and missed clinic appointments;
- drug side effects and toxicity;
- suboptimal pharmacokinetics (variable absorption, metabolism, and/or penetration into reservoirs, food/fasting requirements, adverse drug-drug interactions with concomitant medications);
- suboptimal potency of the antiretroviral regimen; and/or
- other, unknown reasons.

Data from some patient cohorts suggest that suboptimal adherence and toxicity accounted for 28%–40% of treatment failure and regimen discontinuations [230, 231]. Multiple reasons for treatment failure can occur in one patient. Some factors that have not been associated with treatment failure include gender, pregnancy, and history of past substance use.

## ASSESSMENT OF ANTIRETROVIRAL TREATMENT FAILURE AND CHANGING THERAPY (Updated December 1, 2007)

In general, the cause of treatment failure should be explored by:

- Reviewing the medical history, including:
  - change in HIV RNA and CD4 T-cell count over time;
  - occurrence of HIV-related clinical events;
  - antiretroviral treatment history;
  - results of prior resistance testing (if any);
  - medication-taking behavior, including adherence to recommended drug doses, dosing frequency, and food/fasting requirements;
  - tolerability of the medications;
  - concomitant medications (with consideration of adverse drug-drug interactions); and
  - comorbidities (including substance use) and
- Performing a physical examination to assess for signs of clinical progression.

In many cases the cause(s) of treatment failure will be readily apparent. In some cases, no obvious cause may be identified.

**Initial Assessment of Treatment Failure.** In conducting the assessment of treatment failure, it is important to distinguish among the reasons for treatment failure, because the approaches to subsequent therapy will differ. The following assessments should be undertaken initially:

- **Adherence.** Assess the patient's adherence to the regimen. For incomplete adherence, identify and address the underlying cause(s) of nonadherence (e.g., access to medications, depression, active substance use), and simplify the regimen if possible (e.g., decrease pill count or dosing frequency) (AIII). (See [Adherence](#) section.)
- **Medication Intolerance.** Assess the patient's side effects. Address and review the likely duration of side effects (e.g., the limited duration of gastrointestinal symptoms with some regimens). Management strategies for intolerance may include:
  - using symptomatic treatment (e.g., antiemetics, antidiarrheals);
  - changing one drug to another within the same drug class, if needed (e.g., change to tenofovir or abacavir for zidovudine-related gastrointestinal symptoms or anemia; change to nevirapine for efavirenz-related central nervous system symptoms) (AII);
  - changing drug classes (e.g., from an NNRTI to a PI, from an injectable drug to an oral agent), if necessary (AII).
- **Pharmacokinetic Issues.** Review food/fasting requirements for each medication. Review recent history of gastrointestinal symptoms (such as vomiting or diarrhea) to assess the likelihood of short-term malabsorption. Review concomitant medications and dietary supplements for possible adverse drug-drug interactions, and make appropriate substitutions for antiretroviral agents and/or concomitant medications, if possible (AIII). (See also [Therapeutic Drug Monitoring](#).)
- **Suspected Drug Resistance.** Obtain resistance testing while the patient is taking the failing regimen or within 4 weeks after regimen discontinuation (AII). (See [Drug Resistance Testing](#).)

**Further Assessment of Treatment Failure.** When adherence, tolerability, and pharmacokinetic causes of treatment failure have been considered and addressed, make further assessments for virologic failure, immunologic failure, and clinical progression.

**Virologic suppression** can be defined as a sustained reduction in HIV RNA level below the assay limit of detection (e.g., 50 copies/mL). Virologic failure is best

understood in the context of virologic success; that is, virologic failure is defined as the inability to achieve or maintain suppression of viral replication to levels below the limit of detection (<50 copies/mL) and may manifest as any of the following:

- **Incomplete virologic response:** Two consecutive HIV RNA >400 copies/mL after 24 weeks or >50 copies/mL by 48 weeks in a treatment-naïve patient who is initiating therapy. Baseline HIV RNA may affect the time course of response, and some patients will take longer than others to suppress HIV RNA levels. The timing, pattern, and/or slope of HIV RNA decrease may predict ultimate virologic response [232]. For example, most patients with an adequate virologic response at 24 weeks had at least a 1 log<sub>10</sub> decrease in HIV RNA copies/mL at 1–4 weeks after starting therapy [233–235].
- **Virologic rebound:** After virologic suppression, repeated detection of HIV RNA above the assay limit of detection (e.g., 50 copies/mL).

**Assessment of Virologic Failure.** There is no consensus on the optimal time to change therapy for virologic failure. The most aggressive approach would be to change for any repeated, detectable viremia (e.g., two consecutive HIV RNA >50 copies/mL after suppression to <50 copies/mL in a patient taking the regimen). Other approaches allow detectable viremia up to an arbitrary level (e.g., 1,000–5,000 copies/mL). However, ongoing viral replication in the presence of antiretroviral drugs promotes the selection of drug resistance mutations [236] and may limit future treatment options. Isolated episodes of viremia ("blips," e.g., single levels of 51–1,000 copies/mL) may simply represent laboratory variation [237] and usually are not associated with subsequent virologic failure, but rebound to higher viral load levels or more frequent episodes of viremia increase the risk of failure [238, 239].

When assessing virologic failure, one should assess the degree of drug resistance and should take into account prior treatment history and prior resistance test results (**AII**). Drug resistance tends to be cumulative for a given individual; thus, all prior treatment history and resistance test results should be taken into account.

#### **Management of Virologic Failure:**

**General Approach.** Ideally, one should design a regimen with at least two, and preferably three, fully active drugs on the basis of drug history, resistance testing, or new mechanistic class (**BII**) [41, 240–247]. Some antiretroviral drugs (e.g., NRTIs) may contribute partial antiretroviral activity to an antiretroviral regimen, despite drug resistance. Because of the

potential for drug-class cross resistance that reduces drug activity, using a "new" drug that a patient has not yet taken may not mean that the drug is fully active. Drug potency and viral susceptibility are more important than the number of drugs prescribed.

Several clinical trials illustrate effective therapeutic strategies for treatment-experienced patients [241–243, 246–248]. In these studies, patients received an antiretroviral regimen optimized based on drug treatment history and resistance testing and then were randomized to receive a new active antiretroviral agent or placebo. Patients who received more active drugs (e.g., a ritonavir-boosted PI and a drug with activity against resistance viral strains with or without a new mechanism of action) had a better and more prolonged virologic response than those with fewer active drugs in the regimen. These studies illustrate and support the strategy of conducting resistance testing while a treatment-experienced patient is taking a failing regimen, designing a new regimen based on the treatment history and resistance testing results, and selecting active antiretroviral drugs for the new treatment regimen.

Early studies of treatment-experienced patients identified factors associated with better virologic responses to subsequent regimens [249, 250]. They included lower HIV RNA at the time of therapy change, using a new (i.e., not yet taken) class of drugs (e.g., NNRTI, EI, integrase inhibitor), and using ritonavir-boosted PIs in PI-experienced patients. More recent studies show that higher CD4 T-cell counts and higher genotypic and/or phenotypic susceptibility scores (indicating a greater number of active agents) are associated with better virologic responses [243–247].

In general, adding a single, fully active antiretroviral drug in a new regimen is not recommended because of the risk of development of rapid resistance (**DII**). However, in patients with a high likelihood of clinical progression (e.g., CD4 T-cell count <100/mm<sup>3</sup>) and limited drug options, adding a single drug may reduce the risk of immediate clinical progression, because even transient decreases in HIV RNA and or transient increases in CD4 T-cell counts have been associated with clinical benefits (**CI**) [251]. Weighing the risks (e.g., selection of drug resistance) and benefits (e.g., antiretroviral activity) of using a single active drug in the heavily treatment experienced patient is complicated, and consultation with an expert is advised.

Discontinuing or briefly interrupting therapy (even with ongoing viremia) may lead to a rapid increase in



HIV RNA and a decrease in the CD4 T-cell count, and it increases the risk for clinical progression [252, 253]. Therefore, it is not recommended (**DIII**).

**Sequencing and Cross Resistance.** The order of use of some antiretroviral agents may be important. Cross resistance among NRTIs is common but varies by drug. Most, if not all, mutations associated with efavirenz resistance cause cross resistance to nevirapine, and vice versa. Etravirine demonstrates activity against some NNRTI-resistant viruses both *in vitro* and in clinical trials. The K103N substitution does not affect the activity of etravirine, while the presence of other NNRTI-associated resistance mutations (e.g., Y181C, G190A), particularly when there are three or more, are associated with decreased activity of etravirine. Novel early mutations to some PIs (e.g., unboosted fosamprenavir, atazanavir, nelfinavir, saquinavir) that do not confer cross resistance to other PIs may occur initially, but subsequent accumulation of additional mutations confers broad cross resistance to the entire PI class. Pharmacologic boosting of PIs with ritonavir markedly reduces the likelihood of PI resistance with failure in patients without pre-existing PI mutations.

Tipranavir and darunavir are the two newest PIs approved for patients who are highly treatment-experienced or have HIV-1 strains resistant to multiple PIs based on demonstrated activity against PI-resistant viruses [243, 248]. However, with ongoing viremia and the accumulation of additional mutations, antiretroviral activity is time limited unless the regimen contains other active drugs (e.g., enfuvirtide, a CCR5 inhibitor, or an integrase inhibitor).

#### Newer Agents.

**Maraviroc**, the first approved CCR5 inhibitor, is an antiretroviral drug that specifically binds to the CCR5 receptor of the CD4 T-cell, thereby inhibiting HIV strains that use this coreceptor for cellular entry. Phase III clinical studies enrolled triple-class, treatment-experienced patients who experienced failure on their current antiretroviral regimens with detectable viremia with only CCR5-tropic (R5) viral strains (documented using a tropism assay). In these studies, maraviroc resulted in significantly better virologic responses over 24 weeks compared with placebo when added to an antiretroviral regimen that was optimized based on treatment history and drug resistance testing [244, 245]. In another study, maraviroc did not demonstrate significant virologic activity in treatment-experienced patients with viremia with only X4 virus, a dual/mixed population of X4 and R5 viruses, or an indeterminate tropism result, although CD4 increases were seen

[254]. Maraviroc was generally safe and well tolerated, although theoretical concerns about the longer-term safety of CCR5 inhibitors require additional assessment. With a unique mechanism of action and documented short-term efficacy and safety, maraviroc should be considered a fully active antiretroviral agent in treatment-experienced patients who have only R5 virus and who are naïve to CCR5 inhibitors.

**Raltegravir**, the first approved HIV integrase inhibitor, specifically inhibits the final step in integration, strand transfer of viral DNA to host cell DNA. Phase III clinical studies enrolled triple-class, treatment-experienced patients who experienced failure on their current antiretroviral regimens with detectable viremia. In these studies, raltegravir resulted in significantly better virologic responses over 24 weeks compared with placebo when added to an antiretroviral regimen that was optimized based on treatment history and drug resistance testing [246, 247]. Raltegravir was generally safe and well tolerated. With a unique mechanism of action and documented short-term efficacy and safety, raltegravir should be considered a fully active antiretroviral agent in treatment-experienced patients who are naïve to HIV integrase inhibitors.

**Etravirine**, an NNRTI, has activity *in vitro* against viral strains with mutations that confer resistance to efavirenz and nevirapine [121]. Phase III studies enrolled triple-class, treatment-experienced patients who had at least one NNRTI-associated drug resistance mutation and who had detectable viremia on their current antiretroviral regimen. All subjects also received darunavir/ritonavir as part of the optimized background regimen. In these studies, subjects in the etravirine arm experienced significantly better virologic responses over 24 weeks compared with placebo [255, 256]. In a phase II clinical study, patients who had failed a regimen containing NRTIs and an NNRTI (and who had NNRTI resistance) were randomized to receive either etravirine or an investigator selected PI in combination with 2 NRTIs. A lower virologic response was seen in patients randomized to etravirine arm [191]. Based on these results, etravirine should not be used with 2-NRTIs without additional active agents, especially in patients with pre-treatment NNRTI resistance mutations. Etravirine is a substrate and inducer of CYP 3A4, as well as being a substrate and inhibitor of 2C9, and 2C19, with complex drug interaction potential. Based on pharmacokinetic studies, either etravirine or the coadministered antiretroviral's drug exposure may be significantly affected when used in combination. As a result, etravirine is not recommended to be used with any unboosted PI, ritonavir-boosted atazanavir, fosamprenavir, or tipranavir (see [Table 21](#) and [23b](#)).

With activity against some NNRTI-resistant viral strains, etravirine may provide increased virologic activity in treatment-experienced patients, depending on the amount of NNRTI-resistance.

Other investigational drugs with newer mechanisms of action demonstrate short-term antiretroviral activity in patients with resistance to reverse transcriptase inhibitors and PIs [257-259] and are also under investigation in clinical trials.

Specific clinical scenarios follow:

- **Prior treatment with no resistance identified.** Consider the timing of the drug resistance test (e.g., Was the patient off antiretroviral medications?) and/or nonadherence. Consider resuming the same regimen or starting a new regimen and then repeating genotypic testing early (e.g., in 2–4 weeks) to determine whether a resistant viral strain emerges (**CIII**). Consider intensifying with one drug (e.g., tenofovir) (**BII**) [260] or pharmacokinetic enhancement (use of ritonavir boosting of an unboosted PI, e.g. atazanavir, fosamprenavir) (**BII**) [132].
- **Prior treatment and drug resistance.** The goals in this situation are to resuppress HIV RNA levels maximally (e.g., to <50 copies/mL) and to prevent further selection of resistance mutations. With virologic failure, consider changing the treatment regimen sooner, rather than later, to minimize continued selection of resistance mutations. Discontinuing an NNRTI in a patient with ongoing viremia and evidence of NNRTI resistance in order to decrease the risk of selecting additional NNRTI-resistance mutations is particularly important, because newer NNRTIs with activity against some NNRTI-resistant strains are available. A new regimen should include at least two, and preferably three, fully active agents (**BII**).
- **Extensive prior treatment and drug resistance.** The goal is to resuppress the HIV RNA levels maximally (e.g., to <50 copies/mL). With the availability of multiple new antiretroviral drugs, including some with new mechanisms of action, this goal is now possible in many patients, including those with extensive treatment experience and drug resistance. In some cases, however, viral suppression may be difficult to achieve. If maximal virologic suppression cannot be achieved, the goals are to preserve immunologic function and to prevent clinical progression (even with ongoing viremia). Even partial virologic suppression of HIV RNA >0.5 log<sub>10</sub> copies/mL from baseline correlates with

clinical benefits [251]; however, this must be balanced with the ongoing risk for accumulating additional resistance mutations.

- **New regimen that contains at least two fully active agents cannot be identified.** It is reasonable to observe a patient on the same regimen, rather than changing the regimen, depending on the stage of HIV disease (**BII**). There is evidence from cohort studies that continuing therapy, even in the presence of viremia and the absence of CD4 T-cell count increases, decreases the risk of disease progression [20]. Other cohort studies suggest continued immunologic and clinical benefits if the HIV RNA level is maintained <10,000–20,000 copies/mL [261, 262].

**Immunologic Failure** can be defined as a failure to achieve and maintain an adequate CD4 T-cell response despite virologic suppression. There is no specific definition for immunologic failure, although some studies have focused on patients who fail to increase CD4 T-cell counts above a specific threshold (e.g. >350 or 500 cells/mm<sup>3</sup>) over a specific period of time (e.g. 4–7 years). Others have focused on an inability to increase CD4 T-cell counts above pre-therapy levels by a certain threshold (e.g. >50 or 100 cells/mm<sup>3</sup>) over a given time period. The former approach may be preferable because of recent data linking these thresholds with the risk of non-AIDS clinical events [101].

The proportion of patients experiencing immunologic failure depends on how failure is defined, the observation period, and the CD4 T-cell count when treatment was started. In the longest study conducted to date, the percentage of patients with suppressed viremia who reached a CD4 T-cell count >500 cells/mm<sup>3</sup> through 6 years of treatment was 42% (starting treatment with a CD4 <200 cells/mm<sup>3</sup>), 66% (starting with CD4 200–350 cells/mm<sup>3</sup>), and 85% (starting with CD4 >350 cells/mm<sup>3</sup>) [109]; increases in CD4 T-cell counts in treatment-naïve patients with initial antiretroviral regimens are approximately 150 cells/mm<sup>3</sup> over the first year [263]. A CD4 T-cell count plateau may occur after 4–6 years of treatment with suppressed viremia [8, 109, 264-266].

A persistently low CD4 T-cell count while on suppressive antiretroviral therapy is associated with a small, but appreciable, risk of AIDS- and non-AIDS-related morbidity and mortality [267, 268]. For example, in the FIRST study [269], a low CD4 T-cell count on therapy was associated with an increased risk for AIDS-related complications (adjusted hazard ratio of 0.57 for CD4 T-cell count 100 cells/mm<sup>3</sup> higher).

Similarly, a low CD4 T-cell count was associated with an increased risk for non-AIDS events, including cardiovascular, hepatic, renal, and cancer events. Other studies support these associations [97, 102, 103].

#### **Factors associated with immunologic failure:**

- CD4 count  $<200/\text{mm}^3$  when starting ART;
- Older age;
- Coinfection (e.g., HCV);
- Medications, both antiretrovirals (ZDV [270], TDF + ddI [271-273]) and other medications;
- Persistent immune activation; and
- Loss of regenerative potential of the immune system.

**Assessment of Immunologic Failure:** CD4 T-cell count should be confirmed by repeat testing. Concomitant medications should be reviewed carefully, with a focus on those known to decrease white blood cells or, specifically, CD4 T-cells (e.g., interferon, cancer chemotherapy, prednisone, zidovudine, combination of tenofovir and didanosine). Untreated coinfections (e.g., HIV-2, HTLV-1, HTLV-2) and serious medical conditions (e.g., malignancy) also should be considered. In many cases, no obvious cause for immunologic failure can be identified.

**Management of Immunologic Failure:** There is no consensus on when or how to treat immunologic failure. Given the risk of clinical events, it is reasonable to focus on patients with CD4 T-cell counts  $<200/\text{mm}^3$ . Patients with higher CD4 T-cell counts have a low risk of clinical events. It is not clear that immunologic failure in the setting of virologic suppression should prompt a change in the antiretroviral drug regimen. Because ongoing viral replication occurs in some patients with suppressed HIV RNA levels, some have suggested adding a drug to an existing regimen. However, this strategy does not result in clear virologic or immunologic benefit [274]. Others suggest changing the regimen (e.g., to a more suppressive regimen or from an NNRTI-based regimen to a PI-based regimen, based on some evidence that suggests improved CD4 T-cell count responses); however, these strategies have not been formally tested.

Immune-based therapies, such as interleukin-2, demonstrated robust and sustained CD4 T-cell count increases in some studies [275, 276]. However, controversy persists as to how much enhancement of immune function occurs. With this controversy, drug-associated side effects, and the need for parenteral administration, this strategy cannot be recommended

unless with enrollment into a clinical trial (**DII**). Other investigational immune-based therapies (e.g., growth hormone, cyclosporine, interleukin-7) have associated toxicity and costs and cannot be recommended routinely. Currently, immune-based therapies should only be used in the context of a clinical trial (**DII**).

**Clinical Progression** can be defined as the occurrence or recurrence of HIV-related events (after at least 3 months on an antiretroviral regimen), excluding immune reconstitution syndromes [277, 278]. In one study, clinical progression (a new AIDS event or death) occurred in 7% of treated patients with virologic suppression, 9% of treated patients with virologic rebound, and 20% of treated patients who never achieved virologic suppression in 2.5 years [279].

**Management of Clinical Progression.** Consider the possibility of immune reconstitution syndrome [277, 278], which typically occurs within the first 3 months after starting effective antiretroviral therapy and which may respond to anti-inflammatory treatment(s) rather than changing antiretroviral therapy. Clinical progression may not warrant a change in therapy in the setting of suppressed viremia and adequate immunologic response (**BIII**).

#### **Relationship Among Virologic Failure, Immunologic Failure, and Clinical Progression:**

Some patients demonstrate discordant responses in virologic, immunologic, and clinical parameters [280]. In addition, virologic failure, immunologic failure, and clinical progression have distinct time courses and may occur independently or simultaneously. In general, virologic failure occurs first, followed by immunologic failure, and finally by clinical progression. These events may be separated by months to years [281].

### **THERAPEUTIC DRUG MONITORING (TDM) FOR ANTIRETROVIRAL AGENTS (Updated October 29, 2004)**

TDM is a strategy applied to certain antiarrhythmics, anticonvulsants, and antibiotics to utilize drug concentrations to design regimens that are safe and will achieve a desired therapeutic outcome. The key characteristic of a drug that is a candidate for TDM is knowledge of a therapeutic range of concentrations. The therapeutic range is a probabilistic concept. It is a range of concentrations established through clinical investigations that are associated with achieving the desired therapeutic response and reducing the frequency of drug-associated adverse reactions.

Current antiretroviral agents meet most of the characteristics of agents that can be considered candidates for a TDM strategy [282]. The rationale for TDM in managing antiretroviral therapy arises because of:

- data showing that considerable interpatient variability in drug concentrations among patients who take the same dose, and
- data indicating relationships between the concentration of drug in the body and anti-HIV effect—and, in some cases, toxicities.

**TDM with PIs and NNRTIs.** Data describing relationships between antiretroviral agents and treatment response have been reviewed in various publications [283-286]. Although there are limitations and unanswered questions in these data, the consensus of U.S. and European clinical pharmacologists is that the data provide a framework for the potential implementation of TDM for PIs and NNRTIs. This is because concentration-response data exist for PIs and NNRTIs. Information on relationships between concentrations and drug-associated toxicities is sparse. Clinicians using TDM as a strategy to manage these toxicities should consult the most current literature for specific concentration recommendations.

**TDM with NRTIs.** Relationships between plasma concentrations of NRTIs and their intracellular pharmacologically active moieties have not yet been established. Therefore, monitoring of plasma NRTI concentrations largely remains a research tool.

**Scenarios for Use of TDM.** There are multiple scenarios in which both data and expert opinion indicate that information on the concentration of an antiretroviral agent may be useful in patient management. Consultation with an expert clinical pharmacologist may be advisable. These scenarios include:

- **clinically significant drug-drug or drug-food interactions** that may result in reduced efficacy or increased dose-related toxicities;
- **changes in pathophysiologic states** that may impair gastrointestinal, hepatic, or renal function, thereby potentially altering drug absorption, distribution, metabolism, or elimination;
- **in persons such as pregnant women** who may be at risk for virologic failure as a result of their pharmacokinetic characteristics that result in plasma concentrations lower than those achieved in the typical patient;

- **in treatment-experienced persons** who may have viral isolates with reduced susceptibility to antiretroviral agents;
- **use of alternative dosing regimens** in which safety and efficacy have not been established in clinical trials;
- **concentration-dependent toxicities**; and
- **lack of expected virologic response** in a treatment-naïve person.

#### **Use of TDM to Monitor Drug Concentrations.**

There are several challenges and scientific gaps to the implementation of TDM in the clinical setting. (See [Limitations to Using TDM in Patient Management](#).) Use of TDM to monitor drug concentration in a patient requires multiple steps:

- quantification of the concentration of the drug, usually in plasma or serum;
- determination of the patient's pharmacokinetic characteristics;
- interpretation of the concentrations; and
- adjustment of the drug dose to achieve concentrations within the therapeutic range if necessary.

Guidelines for the collection of blood samples and other practical suggestions can be found in a position paper by the Adult AIDS Clinical Trials Group Pharmacology Committee [283]. (See <http://www.hivpharmacology.com> [287].)

#### **Limitations to Using TDM in Patient Management.**

There are multiple factors that limit the use of TDM in the clinical setting. They include the following:

- lack of prospective studies demonstrating that TDM improves clinical outcome. This is the most important limiting factor for the implementation of TDM at present;
- lack of established therapeutic range of concentrations associated with achieving the desired therapeutic response and/or reducing the frequency of drug-associated adverse reactions; and
- lack of widespread availability of laboratories that perform quantitation of antiretroviral drug concentrations under rigorous quality assurance/quality control standards and the lack of experts in the interpretation of antiretroviral concentration data and application of such data to revise patients' dosing regimens.

#### **TDM in Different Patient Populations.**

- **Patients with wild-type virus.** [Table 24](#) presents a synthesis of recommendations [283-285, 287] for

minimum target trough PI and NNRTI concentrations in persons with wild-type virus.

- **Treatment-experienced patients.** Fewer data are available to formulate suggestions for minimum target trough concentration in treatment-experienced patients who have viral isolates with reduced susceptibility to these agents. It is likely that use of these agents in the setting of reduced viral susceptibility may require higher trough concentrations than those for wild-type virus.

A final caveat to the use of measured drug concentration in patient management is a general one: drug concentration information cannot be used alone; it must be integrated with other clinical and patient information. In addition, as knowledge of associations between antiretroviral concentrations and virologic response continues to accumulate, clinicians employing a TDM strategy for patient management should consult the most current literature.

## DISCONTINUATION OR INTERRUPTION OF ANTIRETROVIRAL THERAPY

(Updated **January 29, 2008**)

Discontinuation of antiretroviral therapy may result in viral rebound, immune decompensation, and clinical progression. Unplanned interruption of antiretroviral therapy may become necessary because of severe drug toxicity, intervening illness, surgery that precludes oral therapy, or antiretroviral medication nonavailability. Planned treatment discontinuations have been proposed by some in situations such as: in patients who achieve viral suppression aiming to enhance adherence; reduce inconvenience, long-term toxicities, and costs for patients; or in extensively-treated patients who experience treatment failure due to resistant HIV, to allow reversion to wild-type virus. Potential risks and benefits of interruption vary according to a number of factors, including the clinical and immunologic status of the patient, the reason for the interruption, the type and duration of the interruption, and the presence or absence of resistant HIV at the time of interruption. Below are brief discussions on what is currently known about the risks and benefits of treatment interruption in some of these circumstances.

### Short-term therapy interruptions

Reasons for short-term interruption (**days to weeks**) of antiretroviral therapy vary and may include drug toxicity; intercurrent illnesses that preclude oral intake, such as gastroenteritis or pancreatitis; surgical procedures; or nonavailability of drugs. **Stopping antiretroviral drugs for a short time (i.e., <1 to 2 days)**

due to medical/surgical procedures can usually be done by holding all drugs in the regimen. Recommendations for some other scenarios are listed below:

#### Unanticipated Need for Short-Term Interruption:

- **When a patient experiences a severe or life-threatening toxicity or unexpected inability to take oral medications** – all components of the drug regimen should be stopped simultaneously, regardless of drug half-life.

#### Planned Short Term Interruption (>2–3 days):

- **When all regimen components have similar half-lives and do not require food for proper absorption** – all drugs should be stopped simultaneously or may be given with a sip of water, if allowed. All discontinued regimen components should be restarted simultaneously.
- **When all regimen components have similar half-lives and require food for adequate absorption, and the patient is required not to take anything by mouth for a sustained period of time** – temporary discontinuation of all drug components is indicated. The regimen should be restarted as soon as the patient can resume oral intake.
- **When the antiretroviral regimen contains drugs with differing half-lives** – stopping all drugs simultaneously may result in functional monotherapy with the drug with the longest half-life (typically an NNRTI). Options in this circumstance are discussed below. (See [Discontinuation of efavirenz, etravirine, or nevirapine.](#))

### Interruption of therapy after pregnancy

During pregnancy, HIV-infected pregnant women who otherwise do not meet current CD4 count or clinical criteria for starting treatment may initiate antiretroviral therapy primarily for the purpose of preventing mother-to-child HIV transmission. After delivery, these women may desire to stop therapy. Discontinuation recommendations are in the current guidelines for pregnant women [141]. (See [HIV-Infected Women of Reproductive Age and Pregnant Women.](#))

### Planned long-term therapy interruptions

Planned therapy interruptions have been contemplated in various scenarios, listed below. Research is ongoing in several of the scenarios. None of the therapy interruptions can be recommended at this time outside of controlled clinical trials.

- **In patients who initiated therapy during acute HIV infection and achieved virologic suppression**—the optimal duration of treatment and the consequences of



treatment interruption are not known at this time. (See [Acute HIV Infection](#) section.)

- **In patients who have had exposure to multiple antiretroviral agents, have experienced antiretroviral treatment failure, and have few treatment options available because of extensive resistance mutations**—interruption is not recommended unless it is done in a clinical trial setting. Several clinical trials largely yielding negative results, but some with conflicting results, have been conducted to better understand the role of treatment interruption in these patients [253, 288-290]. The largest of these studies showed negative clinical impact of treatment interruption in these patients [253]. The Panel notes that partial virologic suppression from combination therapy has been associated with clinical benefit [291]; therefore, interruption of therapy is not recommended.
- **In patients on antiretroviral therapy who have maintained a CD4 count above the level currently recommended for treatment initiation and irrespective of whether their baseline CD4 count was either above or below that recommended threshold**—interruption is also not recommended unless it is done in a clinical trial setting. (See discussion below highlighting potential adverse outcomes seen in some treatment interruption trials.)

Temporary treatment interruption to reduce inconvenience, potential long-term toxicity, and/or overall treatment cost has been considered as a strategy for patients on antiretroviral therapy who have maintained CD4 counts above those currently recommended for initiating therapy. Several clinical trials have been designed to determine the safety of such interruptions, in which reinitiation is triggered by predetermined CD4 count thresholds. In these trials, various CD4 count levels have been set to guide both treatment interruption and reinitiation. Two separate, randomized clinical trials of CD4 count-guided treatment interruption have been reported. In the SMART study, the largest of such trials, interrupting treatment with CD4 counts  $>350$  cells/mm<sup>3</sup> and reinitiating when  $<250$  cells/mm<sup>3</sup> was associated with an increased risk of disease progression and death compared with the trial arm of continuous antiretroviral therapy [103]. In the TRIVACAN study, the same CD4 count thresholds were used for stopping and restarting treatment [292]. This study also showed that interruption was an inferior strategy; the interventions in both trials were stopped early because of these findings. **Data from the DART trial reported a two-fold increase in rates of WHO stage 4 events/deaths in the 12-week ART cycling group among African patients achieving a CD4 count**

**$>300$ /mm<sup>3</sup> compared to the continuous ART group [293].** Observational data from the EuroSIDA cohort noted a 2-fold increase in risk of death after a treatment interruption of  $\geq 3$  months. Factors linked to increased risk of death or progression included lower CD4 counts, higher viral loads, and a prior history of AIDS [294]. Other studies have reported no major safety concerns [295-297], but these studies had smaller sample sizes. Results have been reported from several small observational studies evaluating treatment interruption in patients doing well with nadir CD4 counts  $>350$ /mm<sup>3</sup>, but further studies are needed to determine the safety of treatment interruption in this population [298, 299]. There is concern that CD4 counts  $<500$  cells/mm<sup>3</sup> are associated with a range of non-AIDS clinical events (e.g., cancer, heart, liver, and kidney disease) [103, 269, 300].

**Planned long-term therapy interruption strategies cannot be recommended at this time outside of controlled clinical trials (DI) based on available data and a range of ongoing concerns (see below).**

If therapy has to be discontinued, patients should be counseled about the need for close clinical and laboratory monitoring. They should also be aware of the risks of viral rebound, acute retroviral syndrome, increased risk for HIV transmission, decline of CD4 count, HIV disease progression or death, development of minor HIV-associated manifestations such as oral thrush, development of serious non-AIDS complications, development of drug resistance, and the need for chemoprophylaxis against opportunistic infections depending on the CD4 count. Treatment interruptions often result in rapid reductions in CD4 counts.

Prior to any planned treatment interruption, a number of antiretroviral-specific issues should be taken into consideration. These include:

- **Discontinuation of efavirenz, **etravirine**, or nevirapine.** The optimal interval between stopping efavirenz, **etravirine**, or nevirapine and other antiretroviral drugs is not known. The duration of detectable levels of these drugs after discontinuation ranges from less than 1 week to more than 3 weeks [301, 302]. Simultaneously stopping all drugs in a regimen containing these agents may result in functional monotherapy with the NNRTIs, because their half-lives are longer than other agents. This may increase the risk of selection of NNRTI-resistant mutations. It is further complicated by evidence that certain host genetic polymorphisms may result in slower rates of clearance. Such polymorphisms may be more common among specific ethnic groups, such



as African Americans and Hispanics [303, 304]. Some experts recommend stopping the NNRTI but continuing the other antiretroviral drugs for a period of time. The optimal time sequence for staggered component discontinuation has not been determined. A study in South Africa demonstrated that giving four or seven days of zidovudine + lamivudine after a single dose of nevirapine reduced the risk of postnatal nevirapine resistance from 60% to 10%–12% [305]. Use of nucleosides with a longer half-life such as tenofovir plus emtricitabine has also been shown to decrease nevirapine resistance after single dose treatment [306, 307]. The findings may however differ in patients on chronic nevirapine treatment. An alternative strategy used by some experts is to substitute a PI for the NNRTI and to continue the PI with dual NRTIs for a period of time; however, no efficacy data supporting this have been reported. The optimal duration needed to continue the PI-based regimen after stopping the NNRTI is not known. Given the potential of prolonged detectable NNRTI concentrations for more than 3 weeks, some suggest that the PI-based regimen may need to be continued for up to 4 weeks. Further research to determine the best approach to discontinuing NNRTIs is needed. Clinical data on etravirine and treatment interruption is lacking but its long half-life of approximately 40 hours suggests that stopping etravirine needs to be done carefully using the same suggestions for nevirapine and efavirenz for the time being.

- **Discontinuation and reintroduction of nevirapine.** Because nevirapine is an inducer of the drug-metabolizing hepatic enzymes, administration of full therapeutic doses of nevirapine without a 2-week, low-dose escalation phase will result in excess plasma drug levels and potentially increase the risk for toxicity. Therefore, in a patient who has interrupted treatment with nevirapine for more than 2 weeks, nevirapine should be reintroduced with a dose escalation period of 200mg once daily for 14 days, then a 200mg twice-daily regimen (AII).
- **Discontinuation of emtricitabine, lamivudine, or tenofovir in patients with hepatitis B coinfection.** Patients with hepatitis B coinfection (hepatitis B surface antigen or HBeAg positive) and receiving one or a combination of these NRTIs may experience an exacerbation of hepatitis upon drug discontinuation [168, 169]. (See [Hepatitis B \(HBV\)/HIV Coinfection](#) section.)

# Considerations for Antiretroviral Use in Special Patient Populations

## ACUTE HIV INFECTION

(Updated January 29, 2008)

### *Panel's Recommendations:*

- *Whether treatment of acute HIV infection results in long-term virologic, immunologic, or clinical benefit is unknown; treatment should be considered optional at this time (CIII).*
- *Therapy should also be considered optional for patients in whom HIV seroconversion has occurred within the previous 6 months (CIII).*
- *If the clinician and patient elect to treat acute HIV infection with antiretroviral therapy, treatment should be implemented with the goal of suppressing plasma HIV RNA to below detectable levels (AIII).*
- *For patients with acute HIV infection in whom therapy is initiated, testing for plasma HIV RNA levels and CD4 count and toxicity monitoring should be performed as described for patients with established, chronic HIV infection (AII).*
- *If the decision is made to initiate therapy in a person with acute HIV infection, genotypic resistance testing at baseline will likely optimize virologic response; this strategy is therefore recommended (AIII). If therapy is deferred, genotypic resistance testing should still be performed, because the result may be useful in optimizing the virologic response when therapy is ultimately initiated (AIII).*
- *Since clinically significant resistance to PIs is less common than resistance to NNRTIs in treatment-naïve persons who harbor drug-resistant virus, consideration should be given to using a PI-based regimen if therapy is initiated before drug resistance test results are available (BIII).*

This section focuses on diagnosis and treatment of acute HIV-1 infection.

An estimated 40%–90% of patients acutely infected with HIV will experience symptoms of acute retroviral syndrome characterized by fever, lymphadenopathy, pharyngitis, skin rash, myalgias/artralgias, and other symptoms [308-313]. However, acute HIV infection is

often not recognized by primary care clinicians because of the similarity of the symptoms to those of influenza, infectious mononucleosis, or other illnesses. Additionally, acute infection can occur asymptomatically. [Table 25](#) provides guidance to practitioners on the recognition, diagnosis, and management of acute HIV infection.

### **Diagnosis of Acute HIV Infection**

Health care providers should maintain a high level of suspicion of acute HIV infection in patients who have a compatible clinical syndrome and who report recent high-risk behavior [314]. However, in some settings, patients may not always disclose or admit to high risk behaviors, or might not perceive their behaviors as high-risk. Thus, symptoms and signs consistent with acute retroviral syndrome should motivate consideration of this diagnosis even in the absence of reported high risk behaviors.

When acute retroviral syndrome is suspected, a plasma HIV RNA test should be used in conjunction with an HIV antibody test to diagnose acute infection (BII). Acute HIV infection is often defined by detectable HIV RNA in plasma in the setting of a negative or indeterminate HIV antibody test. A low-positive HIV RNA level (<10,000 copies/mL) may represent a false-positive test, since values in acute infection are generally very high (>100,000 copies/mL) [312, 313]. A qualitative HIV RNA test can also be used in this setting. Patients diagnosed with acute HIV infection on the basis of either a quantitative or a qualitative HIV RNA test should have confirmatory serologic testing performed at a subsequent time point (AI). ([Table 25](#))

Data from the United States and Europe demonstrate that transmitted virus may be resistant to at least one antiretroviral drug in 6%–16% of patients. If the decision is made to initiate therapy in a person with acute HIV infection, resistance testing at baseline will likely optimize virologic response; this strategy is therefore recommended (AIII). (See [Utilization of Drug Resistance Testing in Clinical Practice](#) section.) If therapy is deferred, resistance testing should still be performed because the result may be useful in optimizing the virologic response when therapy is ultimately initiated (AIII).

## Treatment for Acute HIV Infection

Clinical trials information regarding treatment of acute HIV infection is limited. Ongoing trials are addressing the question of the long-term benefit of potent treatment regimens initiated during acute infection. Potential benefits and risks of treating acute infection are as follows:

- **Potential Benefits of Treating Acute Infection.**

Preliminary data indicate that treatment of acute HIV infection with combination antiretroviral therapy has a beneficial effect on laboratory markers of disease progression [315-319]. Theoretically, early intervention could decrease the severity of acute disease; alter the initial viral setpoint, which can affect disease-progression rates; reduce the rate of viral mutation as a result of suppression of viral replication; preserve immune function; and reduce the risk for viral transmission. Additionally, although data are limited and the clinical relevance is unclear, the profound loss of gastrointestinal lymphoid tissue that occurs during the first weeks of infection may be mitigated by the early initiation of antiretroviral therapy [320, 321].

- **Potential Risks of Treating Acute HIV Infection.**

The potential disadvantages of initiating therapy include exposure to antiretroviral therapy without a known clinical benefit, which could result in drug toxicities, development of antiretroviral drug resistance, the need for continuous therapy with strict adherence, and adverse effect on quality of life.

The above risk and benefit considerations are similar to those for initiating therapy in the chronically infected asymptomatic patient. The health care provider and the patient should be fully aware that the rationale for therapy for acute HIV infection is based on theoretical considerations, and the potential benefits should be weighed against the potential risks. For these reasons, treatment of acute HIV infection should be considered optional at this time (CIII). Providers should consider enrolling patients with acute HIV infection in a clinical trial to evaluate the natural history of acute HIV and to determine the role of antiretroviral therapy in this setting. Information regarding such trials can be obtained at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or from local HIV treatment experts.

## Treatment of Recent but Nonacute HIV Infection or Infection of Undetermined Duration

Besides patients with acute HIV infection, experienced clinicians also recommend consideration of therapy for

patients in whom seroconversion has occurred within the previous 6 months (CIII). Although the initial burst of viremia among infected adults usually resolves in 2 months, rationale for treatment during the 2- to 6-month period after infection is based on the probability that virus replication in lymphoid tissue is still not maximally contained by the immune system during this time [322].

## Treatment Regimen for Acute or Recent HIV Infection

If the clinician and patient have made the decision to use antiretroviral therapy for acute or recent HIV infection, treatment should be implemented in an attempt to suppress plasma HIV RNA levels to below detectable levels (AIII). Data are insufficient to draw firm conclusions regarding specific drug recommendations to use in acute HIV infection. Potential combinations of agents should be those used in established infection (Table 6). However, since clinically significant resistance to PIs is less common than resistance to NNRTIs in treatment-naïve persons who harbor drug resistant virus, consideration should be given to using a PI-based regimen if therapy is initiated before drug resistance test results are available (BIII).

## Patient Follow-up

Testing for plasma HIV RNA levels and CD4 count and toxicity monitoring should be performed as described in [Initial Assessment and Monitoring for Therapeutic Response](#) (i.e., HIV RNA on initiation of therapy, after 2–8 weeks, and every 3–4 months thereafter) (AII).

## Duration of Therapy for Acute or Recent HIV Infection

The optimal duration of therapy for patients with acute or recent HIV infection is unknown, but ongoing clinical trials may provide relevant data regarding these concerns. Difficulties inherent in determining the optimal duration and therapy composition for acute or recent infection (and the potential need for lifelong treatment) should be considered when first counseling the patient regarding therapy.

## HIV-INFECTED ADOLESCENTS

(Updated October 29, 2004)

Older children and adolescents now make up the largest percentage of HIV-infected children cared for at

U.S. sites. The CDC estimates that at least one-half of the 40,000 yearly new HIV-infected cases in the United States are in people 13 to 24 years of age [323]. HIV-infected adolescents represent a heterogeneous group in terms of sociodemographics, mode of HIV infection, sexual and substance abuse history, clinical and immunologic status, psychosocial development, and readiness to adhere to medications. Many of these factors may influence decisions concerning when to start and what antiretroviral medications should be used.

Most adolescents have been infected during their teenage years and are in an early stage of infection, making them ideal candidates for early intervention, such as prevention counseling. A limited but increasing number of HIV-infected adolescents are long-term survivors of HIV infection acquired perinatally or through blood products as infants. Such adolescents may have a unique clinical course that differs from that of adolescents infected later in life [324].

### **Antiretroviral Therapy Considerations in Adolescents**

Adult guidelines for antiretroviral therapy are usually appropriate for postpubertal adolescents because HIV-infected adolescents who were infected sexually or through injecting drug use during adolescence follow a clinical course that is more similar to that of adults than to that of children.

Dosage for medications for HIV infection and opportunistic infections should be prescribed according to Tanner staging of puberty and not on the basis of age [325, 326]. Adolescents in early puberty (i.e., Tanner Stage I and II) should be administered doses using pediatric schedules, whereas those in late puberty (i.e., Tanner Stage V) should follow adult dosing schedules. Because puberty may be delayed in perinatally HIV-infected children [327], continued use of pediatric doses in puberty-delayed adolescents can result in medication doses that are higher than the usual adult doses. Because data are not available to predict optimal medication doses for each antiretroviral medication for this group of children, issues such as toxicity, pill or liquid volume burden, adherence, and virologic and immunologic parameters should be considered in determining when to transition from pediatric to adult doses. Youth who are in their growth spurt (i.e., Tanner Stage III in females and Tanner Stage IV in males) using adult or pediatric dosing guidelines and those adolescents whose doses have been transitioned from pediatric to adult doses should be closely monitored for medication efficacy and toxicity.

### **Adherence Concerns in Adolescents**

HIV-infected adolescents have specific adherence problems. Comprehensive systems of care are required to serve both the medical and psychosocial needs of HIV-infected adolescents, who are frequently inexperienced with health care systems. Many HIV-infected adolescents face challenges in adhering to medical regimens for reasons that include:

- denial and fear of their HIV infection;
- misinformation;
- distrust of the medical establishment;
- fear and lack of belief in the effectiveness of medications;
- low self-esteem;
- unstructured and chaotic lifestyles; and
- lack of familial and social support.

Treatment regimens for adolescents must balance the goal of prescribing a maximally potent antiretroviral regimen with realistic assessment of existing and potential support systems to facilitate adherence. Adolescents benefit from reminder systems (beepers, timers, and pill boxes) that are stylish and do not call attention to themselves. It is important to make medication adherence as user friendly and as little stigmatizing as possible for the older child or adolescent. The concrete thought processes of adolescents make it difficult for them to take medications when they are asymptomatic, particularly if the medications have side effects. Adherence to complex regimens is particularly challenging at a time of life when adolescents do not want to be different from their peers. Direct observed therapy, although considered impractical for all adolescents, might be important for selected adolescents infected with HIV [328, 329]. For a more detailed discussion on specific therapy and adherence issues for HIV-infected adolescents, see [Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection](#) [330].

Developmental issues make caring for adolescents unique. The adolescent's approach to illness is often different from that of an adult. The adolescent also faces difficulties in changing caretakers—graduating from a pediatrician to an adolescent care provider, then to an internist.

### **Special Considerations in Adolescent Females**

Gynecological care is especially difficult to provide for the HIV-infected female adolescent but is a critical part of their care. Because many adolescents with HIV



infection are sexually active, contraception and prevention of HIV transmission should be discussed with the adolescent, including the interaction of specific antiretroviral drugs on birth control pills. The potential for pregnancy may also alter choices of antiretroviral therapy. As an example, efavirenz should be used with caution in females of childbearing age and should only be prescribed after intensive counseling and education about the potential effects on the fetus, the need for close monitoring including periodic pregnancy testing, and a commitment on the part of the teen to use effective contraception. For a more detailed discussion, see [HIV-Infected Women of Reproductive Age and Pregnant Women](#) [106].

Given the lifelong infection with HIV and the need for treatment through several stages of growth and development, HIV care programs and providers need to support this appropriate transition in care for HIV-infected infants through adolescents.

## INJECTION DRUG USERS

(Updated October 29, 2004)

### ***Challenges of Treating Injection Drug Users (IDUs) Infected With HIV***

Injection drug use represents the second most common route of transmission of HIV in the United States. Although treatment of HIV disease in this population can be successful, IDUs with HIV disease present special treatment challenges. These include the existence of an array of complicating comorbid conditions, limited access to HIV care, inadequate adherence to therapy, medication side effects and toxicities, need for substance abuse treatment, and the presence of treatment-complicating drug interactions [331-333].

Underlying health problems among this population result in increased morbidity and mortality, either independent of or accentuated by HIV disease. Many of these problems are the consequence of prior poverty-related infectious disease exposures and the added effects of nonsterile needle and syringe use. These include TB, skin and soft tissue infections, recurrent bacterial pneumonia, endocarditis, hepatitis B and C, and neurologic and renal disease. Furthermore, the high prevalence of underlying mental illness in this population, antedating and/or exacerbated by substance use, results in both morbidity and difficulties in provision of clinical care and treatment [331-333]. Successful HIV therapy for IDUs often rests upon

acquiring familiarity with and providing care for these comorbid conditions.

IDUs often have decreased access to HIV care and are less likely to receive antiretroviral therapy than other populations [334, 335]. Factors associated with lack of use of antiretroviral therapy among drug users have included active drug use, younger age, female gender, suboptimal health care, not being in a drug treatment program, recent incarceration, and lack of health care provider expertise [334, 335]. The chaotic lifestyle of many drug users, the powerful pull of addictive substances, and a series of beliefs about the dangers of antiretroviral therapy among this population impact on and blunt the benefit of antiretroviral therapy and contribute to decreased adherence to antiretroviral therapy [336]. The chronic and relapsing nature of substance abuse and lack of appreciation of substance abuse as a biologic and medical disease, compounded by the high rate of coexisting mental illness, further complicates the relationship between health care workers and IDUs.

### ***Efficacy of HIV Treatment in IDUs***

Although underrepresented in clinical trials of HIV therapies, available data indicate that, when not actively using drugs, efficacy of antiretroviral therapies among IDUs is similar to other populations. Further, therapeutic failure in this population is generally the degree to which drug use results in disruption of organized daily activities, rather than drug use *per se*. Whereas many drug users can control their drug use sufficiently and over sustained periods of time to engage in care successfully, treatment of substance abuse is often a prerequisite for successful antiretroviral therapy. Close collaboration with substance abuse treatment programs and proper support and attention to the special needs of this population are often critical components of successful treatment for HIV disease. Essential to this end as well are flexible, community-based HIV care sites characterized by familiarity with, and nonjudgmental expertise in, managing the wide array of needs of substance abusers and the development and use of effective strategies for promoting medication adherence [332, 333]. Foremost among these is the provision of substance abuse treatment. In addition, other support mechanisms for adherence are of value, and the use of drug treatment and community-based outreach sites for modified directly observed therapy (DOT) has shown promise in this population [337].

## **IDU/HIV Drug Toxicities and Interactions**

IDUs are more likely to experience an increased frequency of side effects and toxicities of antiretroviral therapies. Although not systematically studied, this is likely because of the high prevalence of underlying hepatic, renal, neurologic, psychiatric, gastrointestinal, and hematologic disease among IDUs. The selection of initial and continuing antiretroviral agents in this population should be made based upon the presence of these conditions and risks.

### **Methadone and Antiretroviral Therapy**

Methadone, an orally administered long-acting opiate agonist, is the most common pharmacologic treatment for opiate addiction. Its use is associated with decreased heroin use, improved quality of life, and decreased needle sharing. Methadone exists in two racemic forms, R (active) and S (inactive). As a consequence of its opiate-induced effects on gastric emptying and metabolism by CYP isoenzymes 3A4 and 2D6, pharmacologic effects and interactions with antiretrovirals may commonly occur [338]. These may diminish the effectiveness of either or both therapies by causing opiate withdrawal, opiate overdose, or increased toxicity or decreased efficacy of antiretrovirals.

- **Methadone and NRTIs.** Most of the currently available antiretrovirals have been examined in terms of potential pharmacokinetic interactions of significance with methadone. (See [Table 22](#).) Among the NRTIs, none appears to have a clinically significant effect on methadone metabolism. Conversely, important effects of methadone on NRTIs have been well documented. Methadone is known to increase the area under the curve of zidovudine by 40% [338], with a possible increase in zidovudine-related side effects. Methadone decreases levels of stavudine and the buffered tablet didanosine formulation (no longer available) by 18% and 63%, respectively [339]. This marked reduction in didanosine levels is not observed with the EC formulation. Recent data indicate lack of significant interaction between abacavir and tenofovir and methadone.
- **Methadone and NNRTIs.** Pharmacokinetic interactions between NNRTIs and methadone are well known and clinically problematic [340]. Both efavirenz and nevirapine, potent inducers of CYP isoenzymes, have been associated with significant decreases in methadone levels. Methadone levels are decreased by 43% and 46% in those receiving efavirenz and nevirapine, respectively, with corresponding clinical opiate withdrawal. It is

necessary to inform patients and substance abuse treatment facilities of the likelihood of occurrence of this interaction if either drug is prescribed to those receiving methadone. The clinical effect is usually seen after 7 days of coadministration and is treated with increase in methadone dosage, usually at 5–10mg daily until the patient is comfortable.

Delavirdine, an inhibitor of CYP isoenzymes, increases methadone levels moderately and without clinical significance.

- **Methadone and PIs.** Limited information indicates that PI levels are generally not affected by methadone, except for amprenavir, which appears to be reduced by 30%. However, many PIs have significant effects on methadone metabolism. Saquinavir does not affect free, unbound methadone levels. However, amprenavir, nelfinavir, and lopinavir administration each results in a significant decrease in methadone levels [341, 342]. Whereas fosamprenavir may result in mild opiate withdrawal, decrease in methadone concentration from nelfinavir was not associated with opiate withdrawal. This is likely because of lack of effect on free, rather than total, methadone levels. Lopinavir/ritonavir combination has been associated with significant reductions in methadone levels and opiate withdrawal symptoms. This is because of the lopinavir, not ritonavir, component [343]. Another study indicates a lack of pharmacokinetic interaction among atazanavir and methadone [344].

### **Buprenorphine**

Buprenorphine, a partial  $\mu$ -opiate agonist, is increasingly being used for opiate abuse treatment. Its decreased risk of respiratory depression and overdose enables use in physician's offices for the treatment of opioid dependence. This flexible treatment setting could be of significant value to drug-abusing opiate-addicted HIV-infected patients requiring antiretroviral therapy, as it would enable one physician or program to provide needed medical and substance abuse services. Only limited information is currently available about interactions between buprenorphine and antiretroviral agents. In contrast to methadone, buprenorphine does not appear to raise zidovudine levels. Pilot data indicate that buprenorphine levels do not appear to be reduced and opiate withdrawal does not occur during coadministration with efavirenz.

### **Summary**

Provision of successful antiretroviral therapy for IDUs is possible. It is enhanced by supportive clinical care sites and provision of drug treatment, awareness of interactions with methadone and the increased risk of



side effects and toxicities, and the need for simple regimens to enhance medication adherence. These are important considerations in selection of regimens and provision of appropriate patient monitoring in this population. Preference should be given to antiretroviral agents with lower risk for hepatic and neuropsychiatric side effects, simple dosing schedules, and lack of interaction with methadone.

## HIV-INFECTED WOMEN OF REPRODUCTIVE AGE AND PREGNANT WOMEN

(Updated December 1, 2007)

### *Panel's Recommendations:*

- *When initiating antiretroviral therapy for women of reproductive age, the indications for initiation of therapy and the goals of treatment are the same as for other adults and adolescents (AI).*
- *Efavirenz should be avoided for the woman who desires to become pregnant or who does not use effective and consistent contraception (AIII).*
- *For the woman who is pregnant, an additional goal of therapy is prevention of mother-to-child transmission (PMTCT), with a goal of viral suppression to <1,000 copies/mL to reduce the risk of transmission of HIV to the fetus and newborn (AI).*
- *Selection of an antiretroviral combination should take into account known safety, efficacy, and pharmacokinetic data of each agent during pregnancy (AIII).*
- *Clinicians should consult the most current Public Health Service (PHS) guidelines when designing a regimen for a pregnant patient (AIII).*

This section provides a brief discussion of some unique considerations when caring for HIV-1-infected women of reproductive age and pregnant women. For a more up-to-date and in-depth discussion regarding the management of these patients, clinicians should consult the latest guidelines of the [Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States](#), which can be found in the <http://www.aidsinfo.nih.gov> Web site [106].

## **Women of Reproductive Age**

In women of reproductive age, antiretroviral regimen selection should account for the possibility of planned or unplanned pregnancy. The most vulnerable period in fetal organogenesis is early in gestation, often before pregnancy is recognized. Sexual activity, reproductive plans, and use of effective contraception should be discussed with the patient. As part of the evaluation for initiating therapy, women should be counseled about the potential teratogenic risk of efavirenz-containing regimens, should pregnancy occur. These regimens should be avoided in women who are trying to conceive or who are not using effective and consistent contraception. Various PIs and NNRTIs are known to interact with oral contraceptives, resulting in possible decreases in ethinyl estradiol or increases in estradiol or norethindrone levels. (See [Table 22](#).) These changes may decrease the effectiveness of the oral contraceptives or potentially increase risk of estrogen- or progestin-related side effects. Providers should be aware of these drug interactions and an alternative or additional contraceptive method should be considered. Amprenavir (and probably fosamprenavir) not only increases blood levels of both estrogen and progestin components, but oral contraceptives decrease amprenavir levels as well; these drugs should not be coadministered. There is minimal information about drug interactions with use of newer hormonal contraceptive methods (e.g., patch, vaginal ring). Counseling should be provided on an ongoing basis. Women who express a desire to become pregnant should be referred for preconception counseling and care, including discussion of special considerations with antiretroviral therapy use during pregnancy.

## **Pregnant Women**

Pregnancy should not preclude the use of optimal therapeutic regimens. However, because of considerations related to PMTCT and to maternal and fetal safety, timing of initiation of treatment and selection of regimens may be different from nonpregnant adults or adolescents.

## **PMTCT**

Antiretroviral therapy is recommended in all pregnant women, regardless of virologic, immunologic, or clinical parameters, for the purpose of PMTCT (AI). Reduction of HIV RNA levels to <1,000 copies/mL and use of antiretroviral therapy appear to have an independent effect on reduction of perinatal transmission [78, 79, 345].

The decision to use any antiretroviral drug during pregnancy should be made by the woman after discussion with her clinician regarding the benefits versus risks to her and her fetus. Long-term follow-up is recommended for all infants born to women who have received antiretroviral drugs during pregnancy, regardless of the infants' HIV status.

### **Regimen Considerations**

Recommendations regarding the choice of antiretroviral drugs for treatment of infected women are subject to unique considerations including:

- potential changes in pharmacokinetics, thus dosing requirements, resulting from physiologic changes associated with pregnancy;
- potential adverse effects of antiretroviral drugs on a pregnant woman;
- effect on the risk for perinatal HIV transmission; and
- potential short- and long-term effects of the antiretroviral drug on the fetus and newborn, all of which are not known for many antiretroviral drugs. (See [Table 26](#).)

Based on available data, recommendations related to drug choices have been developed by the U.S. Public Health Service Task Force and can be found in [Table 27](#).

Current pharmacokinetic studies in pregnancy, although not completed for all agents, suggest no need for dosage modification of NRTIs and nevirapine. Nelfinavir 1,250mg twice daily achieves optimal blood levels, but 750mg three times daily does not; thus, the 1,250mg twice daily dosage should be used in all pregnant women [346]. Serum concentrations for unboosted indinavir may result in lower than optimal levels during pregnancy, thus ritonavir boosting will be necessary to achieve more optimal concentrations. Preliminary data suggest lower than optimal concentration of lopinavir is seen with the currently recommended adult dose of lopinavir/ritonavir, so this agent should be used with close monitoring of virologic response [347].

Some agents may cause harm to the mother and/or the fetus, and are advised to be avoided or used with extreme caution. These agents include:

- Efavirenz-containing regimens: should be avoided in pregnancy (particularly during the first trimester) because significant teratogenic effects were seen in primate studies at drug exposures similar to those achieved during human exposure. In addition, several cases of neural tube defects have now been

reported after early human gestational exposure to efavirenz [127]

- The combination of ddI and d4T: should be avoided during pregnancy because of several reports of fatal and nonfatal but serious lactic acidosis with hepatic steatosis and/or pancreatitis after prolonged use of regimens containing these two nucleoside analogues in combination [190]. This combination should be used during pregnancy only when other NRTI drug combinations have failed or have caused unacceptable toxicity or side effects.
- Nevirapine: has been associated with a 12-fold increased risk of symptomatic hepatotoxicity in women with prenevirapine CD4 counts >250 cells/mm<sup>3</sup>. A majority of the cases occurred within the first 18 weeks of therapy. Hepatic failure and death have been reported among a small number of pregnant patients [348]. Pregnant patients on chronic nevirapine prior to pregnancy are probably at a much lower risk for this toxicity. In nevirapine-naïve pregnant women with CD4 counts >250 cells/mm<sup>3</sup>, nevirapine should not be initiated as a component of a combination regimen unless the benefit clearly outweighs the risk. If nevirapine is used, close clinical and laboratory monitoring, especially during the first 18 weeks of treatment, is strongly advised.

Clinicians who are treating HIV-infected pregnant women are strongly encouraged to report cases of prenatal exposure to antiretroviral drugs (either administered alone or in combinations) to the **Antiretroviral Pregnancy Registry (Telephone: 910-251-9087 or 1-800-258-4263)**. The registry collects observational, nonexperimental data regarding antiretroviral exposure during pregnancy for the purpose of assessing potential teratogenicity. For more information regarding selection and use of antiretroviral therapy during pregnancy, please refer to [Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States](#) [106].

Lastly, women should be counseled regarding the avoidance of breastfeeding. Continued clinical, immunologic, and virologic follow-up should be done as recommended for nonpregnant adults and adolescents.

### ***Discontinuation of Antiretroviral Therapy Postpartum***

Pregnant women who are started on antiretroviral therapy during pregnancy for the sole purpose of PMTCT and who do not meet criteria for starting treatment for their own health may choose to stop antiretroviral therapy after delivery. However, if therapy includes nevirapine, stopping all regimen components simultaneously may result in functional monotherapy because of its long half-life and subsequent increased risk for resistance. Nevirapine resistance mutations have been identified postpartum in women taking nevirapine-containing combination regimens only for PMTCT. In one study, nevirapine resistance was identified in 16% of women despite continuation of the nucleoside backbone for 5 days after stopping nevirapine [349]. Further research is needed to assess appropriate strategies for stopping nevirapine-containing combination regimens after delivery in situations when ongoing maternal treatment is not indicated.

# Antiretroviral Considerations in Patients with Coinfections

---

## HEPATITIS B (HBV)/HIV COINFECTION (Updated December 1, 2007)

It is not clear that treatment of HBV improves the course of HIV infection, nor is there evidence that treatment of HIV alters the natural history of chronic HBV. However, several liver-associated complications that are ascribed to flares in HBV activity or to toxicity of antiretroviral agents can affect the treatment of HIV in patients with HBV coinfection. These include the following:

- Emtricitabine, lamivudine, and tenofovir have activity against both HIV and HBV. Discontinuation of these drugs may potentially cause serious hepatocellular damage resulting from reactivation of HBV [342];
- Lamivudine-resistant HBV is observed in approximately 40% of patients after 2 years of lamivudine monotherapy for chronic HBV and in approximately 90% after 4 years when it is used as the only active drug for HBV in coinfecting patients [78, 79, 343, 344];
- Entecavir has activity against HIV, and its use in patients with dual infection has been associated with selection of the M184V mutation that confers resistance to lamivudine and emtricitabine [350, 351]. Therefore, entecavir should be used only with a fully suppressive antiretroviral regimen in HIV/HBV-coinfecting patients.
- Immune reconstitution can be associated with elevation in transaminases, possibly because HBV is primarily an immune-mediated disease [352]; and
- Many antiretroviral drugs can cause increases in transaminase levels. The rate and magnitude of these increases are higher with HBV coinfection [353, 354]. The etiology and consequences of these changes in liver function tests are unclear, because continuation of therapy may be accompanied by resolution of the changes. Nevertheless, some experts suspend the implicated agent(s) when the ALT is increased to 5–10 times the upper limit of normal. However, in HIV/HBV-coinfecting persons, increases in transaminase levels can herald HBeAg seroconversion, so the cause of the elevations should be investigated prior to the decision to discontinue medications. HBeAg seroconversion can be

evaluated by checking HBeAg and anti-HBe as well as HBV DNA levels.

### **Treatment Recommendations for HBV/HIV Coinfecting Patients**

- All patients with HBV should be advised to abstain from alcohol; should receive hepatitis A vaccine if found not to be immune at baseline (i.e., absence of hepatitis A total or IgG antibody); should be advised on methods to prevent HBV transmission (which do not differ from those to prevent HIV transmission); and should be evaluated for the severity of HBV infection.
- **If neither HIV nor HBV infection requires treatment:** Monitor the progression of both infections. If treatment becomes necessary for either infection, follow the guidelines listed in the scenarios below.
- **If treatment is needed for HIV but not for HBV:** The combination of tenofovir and emtricitabine or tenofovir and lamivudine should be used as the NRTI backbone of an antiretroviral regimen, which will result in treatment of both infections. Because the preferred antiretroviral regimens all contain either lamivudine or emtricitabine, it is not possible to treat only HIV infection without using a nonpreferred regimen. To avoid development of HBV-resistant mutants, none of these agents should be used as the only agent with anti-HBV activity in an antiretroviral regimen.
- **If treatment for HBV is needed:** Patients who need treatment for HBV infection should also be started on a fully suppressive antiretroviral regimen that contains NRTIs with activity against both viruses: for example, tenofovir plus either emtricitabine or lamivudine. The use of lamivudine, emtricitabine, or tenofovir as the only active anti-HBV agent should be avoided because of the risk for resistance. If tenofovir cannot be used, another agent with anti-HBV activity should be used in combination with lamivudine or emtricitabine for treatment of HBV infection. Management of HIV should be continued with a combination regimen to provide maximal suppression.
- **Treating only HBV:** In instances when HIV treatment is not an option or is not desirable, pegylated interferon-alpha may be used for the

treatment of HBV infection, as it does not lead to the emergence of HIV or HBV resistance. Adefovir dipivoxil is active against HBV but not against HIV at the 10mg dose; however, there is a theoretical risk for development of HIV resistance, as it has anti-HIV activity at higher doses and is related to tenofovir. Because of the risk for HIV drug resistance, the use of emtricitabine, lamivudine, tenofovir, or entecavir without a full combination antiretroviral regimen should be avoided.

- **Need to discontinue emtricitabine, lamivudine, or tenofovir:** Monitor clinical course with frequent liver function tests and consider the use of interferon, adefovir dipivoxil, or telbivudine to prevent flares, especially in patients with marginal hepatic reserve.

## HEPATITIS C (HCV)/HIV COINFECTION

(Updated October 29, 2004)

Long-term studies of patients with chronic HCV infection show that 2%–20% develop cirrhosis in 20 years [355]. This rate of progression increases with older age, alcoholism, and HIV infection [355-357]. A meta-analysis demonstrated that the rate of progression to cirrhosis with HCV/HIV coinfection was about threefold higher when compared with patients who are seronegative for HIV [356]. This accelerated rate is magnified in patients with low CD4 counts. Chronic HCV infection also complicates HIV treatment by the increased frequency of antiretroviral-associated hepatotoxicity [210]. Multiple studies show poor prognosis for HCV/HIV coinfection in the era of combination antiretroviral therapy. It is unclear if HCV adversely affects the rate of HIV progression [358, 359] or if this primarily reflects the impact of injection drug use (See [Injection Drug Users](#) section), which is strongly linked to HCV infection [359-361]. It is also unclear if antiretroviral therapy improves the attributable morbidity/mortality for untreated HCV.

### Assessment of HCV/HIV Coinfection

Patients with HCV/HIV coinfection should be advised to avoid or limit alcohol consumption, use appropriate precautions to prevent transmission of both viruses to others, and should be given hepatitis A and B vaccine if found susceptible. All patients with HCV, including those with HIV coinfection, should be evaluated for HCV therapy.

Standard indications for HCV therapy in the absence of HIV infection are detectable plasma HCV RNA and a liver biopsy showing bridging or portal fibrosis. ALT

levels may be elevated in association with HCV infection. However, ALT levels do not accurately reflect the severity of HIV-associated liver disease. Liver biopsy is important for HCV therapeutic decision making but is indicated only if the patient is considered a treatment candidate based on multiple other variables including severity and stability of HIV disease, other comorbidities, probability of adherence, and if there are contraindications to interferon-alpha, one of the drugs available for treatment of HCV.

Clinical trials in patients with HCV/HIV coinfection using pegylated interferon plus ribavirin for 48 weeks show sustained virologic response (SVR) rates of 60%–70% for HCV genotype 2/3 but only 15%–28% for genotype 1 [362, 363]. These data are based on experience almost exclusively in carefully selected patients with CD4 counts >200 cells/mm<sup>3</sup> [363-365].

### Treatment of HCV/HIV Coinfection

Based on these observations, treatment of HCV is recommended according to standard guidelines [366] with preference for those with higher CD4 counts (>200 cells/mm<sup>3</sup>). For some patients with lower CD4 counts, it may be preferable to initiate antiretroviral therapy and delay HCV therapy. Concurrent treatment is feasible but may be complicated by pill burden, drug toxicities, and drug interactions.

### Scenarios for Treating HCV/HIV Coinfection

Differences in HCV therapy management in the presence of HIV coinfection include:

- Ribavirin should not be given with didanosine because of the potential for drug-drug interactions leading to pancreatitis and lactic acidosis [193];
- Some NRTIs and all NNRTIs and PIs are potentially hepatotoxic so that monitoring of serum transaminase levels is particularly important [367];
- Zidovudine combined with ribavirin is associated with higher rates of anemia suggesting this combination be avoided when possible;
- Growth factors to manage interferon-associated neutropenia and ribavirin-associated anemia may be required.



## MYCOBACTERIUM TUBERCULOSIS DISEASE OR LATENT TUBERCULOSIS INFECTION WITH HIV COINFECTION

(Updated January 29, 2008)

### Panel's Recommendations:

- *The treatment of active tuberculosis (TB) disease in patients with HIV infection should follow the same principles for persons without HIV infection (AI).*
- *Presence of active TB requires immediate initiation of treatment (AI).*
- *The optimal timing of initiation of antiretroviral therapy in patients with active TB disease is not known. In antiretroviral-naïve patients, delay of antiretroviral therapy for 2 to 8 weeks after initiation of TB treatment may permit a better definition of causes of adverse drug reactions, and may reduce the risk of Immune Reconstitution Inflammatory Syndrome (IRIS or a "paradoxical reaction") once antiretroviral therapy is initiated, but delay may increase the risk of HIV-related complications and mortality, particularly in those with very low CD4 cell counts (BII).*
- *Directly observed therapy of TB treatment is strongly recommended for HIV-infected patients with active TB disease (AII).*
- *Despite pharmacokinetic drug interactions, a rifamycin should be included in regimens for patients receiving antiretroviral therapy, with dosage adjustment as necessary (AII).*
- *Where available, rifabutin is the preferred rifamycin in HIV-infected patients with active TB disease due to its lower risk of substantial interactions with antiretroviral therapy (AII).*
- *Rifampin/rifabutin-based regimens should be given at least three times weekly in HIV-infected patients with active disease and CD4 count <100 cells/mm<sup>3</sup>; twice weekly is acceptable if CD4 count >100 cells/mm<sup>3</sup> (AII).*
- *Once-weekly rifapentine is not recommended in the treatment of active TB disease in HIV-infected patients (EI).*
- *The optimal management of IRIS is unknown; TB treatment and antiretroviral therapy should be continued, along with use of non-steroidal anti-inflammatory agents for milder cases and consideration of the use of high dose corticosteroids for 1 to 4 weeks in severe cases, with the length of treatment and taper based on control of symptoms (BIII).*
- *Immune restoration as a result of antiretroviral*

*therapy may be associated with conversion from a negative to a positive tuberculin skin test (TST) or IFN- $\gamma$  release assay (IGRA) in response to M. TB-specific proteins; repeat TST or IGRA is recommended in previously TST-negative or IGRA-negative individuals after initiation of antiretroviral therapy when the CD4 cell count exceeds 200 cells/mm<sup>3</sup> (BII).*

- *HIV-infected individuals found to have latent TB infection (LTBI), defined as  $\geq 5$  mm skin test induration or positive IGRA with no prior treatment for LTBI and after appropriate evaluation to rule out active TB disease and no prior treatment of LTBI, should commence treatment with isoniazid (with pyridoxine) for 6 to 9 months (AI).*

HIV infection significantly increases the risk of progression from latent to active tuberculosis (TB) disease. In HIV-negative individuals with latent TB infection (LTBI), the lifetime risk of developing active TB disease is 5%–10%, whereas in people living with HIV with latent TB, the risk is 10% per year. [368]. The CD4 T-cell count influences both the frequency and clinical expression of active TB disease [369, 370]. Active TB also negatively affects HIV disease. It may be associated with a higher HIV viral load and more rapid progression of HIV disease [368, 369]. Important issues with respect to the use of antiretroviral therapy in patients with active TB disease are 1) the sequencing of treatments, 2) the value of directly observed therapy, 3) potential for significant pharmacokinetic drug interactions with rifamycins, 4) the additive toxicities including high rates of hepatotoxicity and neuropathy associated with drugs used for each condition, 5) development of IRIS with TB after initiation of antiretroviral therapy, 6) the effect of antiretroviral therapy on results of tuberculin skin testing, and 7) the need for integration of HIV and TB care and therapy.

**Terminology:** In this section, the terms "HIV infected with active TB disease" and "HIV/TB disease" are used synonymously to designate HIV-infected patients with active TB disease in need of TB treatment. The term "HIV/TB coinfection" may cause confusion because it can refer to either active TB or LTBI in the presence of HIV infection.

### Sequencing of Treatments

The treatment of active TB disease should follow the general principles for TB treatment in persons without HIV (AI). Below are two scenarios for sequencing the



treatment of HIV-infected patients with active TB disease:

- **Patients Currently Receiving Antiretroviral Therapy.** Patients receiving antiretroviral therapy at the time of initiation of TB treatment will require assessment of the antiretroviral therapy regimen in order to adjust the doses to permit use of the optimal TB regimen with particular attention to pharmacokinetic interactions with rifamycins (discussed below).
- **Patients Not Receiving Antiretroviral Therapy at the Time of Active TB Diagnosis.** Active pulmonary or extrapulmonary TB disease requires prompt initiation of TB treatment. However, a delay in initiation of antiretroviral therapy for 2 to 8 weeks permits easier assessment of signs and symptoms related to adverse drug reactions and may reduce the risk of IRIS. Starting antiretroviral therapy within a few days or weeks after initiating TB treatment increases the risk of IRIS compared to waiting for longer periods of time [371]. However, in patients with CD4 counts  $<200$  cells/mm<sup>3</sup>, starting antiretroviral therapy within a few days or weeks of initiating TB treatment may reduce the risk of the development of opportunistic infections (OIs) and other HIV-related complications and may improve survival [372]. The optimal timing of initiation of antiretroviral therapy after starting TB treatment is not known. While these guidelines and the OI Treatment and Prevention Guidelines from the NIH, CDC, and HIVMA/IDSA recommend a delay of antiretroviral therapy for 2 to 8 weeks (BII), the timing chosen for an individual patient depends on clinical judgment, taking into account factors such as immunologic and clinical parameters and the availability of health care.

Some experts base the timing of initiation of antiretroviral therapy in treatment naïve-patients with active TB disease on CD4 cell counts at the start of TB treatment, as shown below:

- CD4  $<100$  cells/mm<sup>3</sup>: start ART after 2 weeks
- CD4 =100–200 cells/mm<sup>3</sup>: start ART after 8 weeks
- CD4 = 200–350 cells/mm<sup>3</sup>: start ART after 8 weeks\*
- CD4  $>350$  cells/mm<sup>3</sup>: start ART after 8 to 24 weeks or after end of TB treatment\*

\* On case by case basis in clinician's judgment.

It is important to carefully monitor patients in whom initiation of antiretroviral therapy is deferred through regular clinical and CD4 cell count assessments during TB treatment in order to promptly initiate antiretroviral therapy if there is evidence of HIV

disease progression or of a drop in CD4 cell count. Individuals with CD4 cell counts  $<200$  cells/mm<sup>3</sup> should be placed on PCP prophylaxis, regardless of timing of initiation of antiretroviral therapy.

### Treatment of TB

Treatment of drug-susceptible active TB disease in HIV-infected individuals should include the standard short-course regimen outlined in treatment guidelines, which consists of isoniazid (INH), rifampin (RIF) or rifabutin (RFB), pyrazinamide (PZA), and ethambutol (EMB) or streptomycin (SM) given for 2 months, followed by INH + RIF for 4 to 7 months [373] (AI). Special attention should be given to the potential of drug-drug interactions with rifamycin as discussed below. A minimum of thrice weekly treatment with rifamycin-containing TB treatment regimens is recommended for patients with a CD4 cell count  $<100$  cells/mm<sup>3</sup> (AII). Once or twice weekly dosing has been associated with increased rates of development of rifamycin resistance in patients with advanced HIV, and once weekly rifapentine is not recommended (E1) [373-375].

### Directly Observed Therapy (DOT)

DOT of TB treatment, in a manner supportive of the patients' needs is strongly recommended for patients with HIV/TB disease (AII). In general, daily or thrice weekly DOT is recommended for the first 2 months and then three times weekly DOT for the continuation phase of 4 to 7 months (BII).

### Anti-Tuberculosis/Antiretroviral Drug Toxicities and Interactions

Almost all antiretroviral drugs are associated with the potential for hepatotoxicity. INH, RIF, and PZA may also cause drug-induced hepatitis. These first-line TB drugs should be used for treatment of active TB disease, if possible, even with coadministration of other potentially hepatotoxic drugs or in the presence of baseline liver disease (AIII). Patients receiving drugs with potential hepatotoxicity should have frequent monitoring for clinical symptoms and signs of hepatitis and laboratory monitoring for hepatotoxicity, including serum aminotransferases, bilirubin, and alkaline phosphatase.

Rifamycins are essential drugs for the treatment of active TB disease. However, they are associated with significant drug interactions with PIs, NNRTIs, maraviroc, and raltegravir, because of their effects as inducers of the hepatic cytochrome P-450 and

UGT1A1 enzymes. Despite these interactions, a rifamycin should be included in the TB treatment regimen in patients receiving antiretroviral therapy [376] (AII). Rifampin is the most potent inducer of hepatic enzymes, and results in significant decreases in exposure to ritonavir-boosted or unboosted PIs, with resultant risk of antiretroviral treatment failure. Co-administration of rifampin and nevirapine or efavirenz is associated with lower NNRTI drug exposures and greater variability in plasma NNRTI drug levels. However, recent clinical and pharmacologic data suggest that comparable virologic, immunologic, and clinical outcomes are achieved with either efavirenz [377, 378] or nevirapine [379, 380] in standard doses in combination with rifampin-containing regimens. Some experts recommend consideration of dose escalation of efavirenz in patients weighing more than 60 kg (BII). (Table 21) Rifabutin has fewer and less severe drug interactions with antiretroviral therapy drugs and is preferred in patients with HIV/TB disease when used in combination with appropriate dose adjustments, according to Table 22 [381]. In the case of an antiretroviral therapy-experienced patient in whom NNRTI-based regimens are not an option and without availability of rifabutin, consultation with an HIV expert is recommended.

### IRIS with TB: Clinical Disease

Some patients while on treatment for active TB will develop IRIS, which is characterized by findings such as fever, new or worsening lymphadenopathy, worsening of pulmonary infiltrates, and pleural effusion. These reactions may occur in the absence of HIV infection and in the absence of antiretroviral therapy, but are more common after initiation of antiretroviral therapy in patients with active TB disease as a consequence of immune reconstitution. IRIS has been reported in 8%–43% of patients with HIV/TB disease, and may contribute to the higher mortality from antiretroviral therapy in the first year of treatment. Predictors of IRIS include CD4 cell count  $<50$  cells/mm<sup>3</sup>, severe TB disease with high pathogen burden, and interval between initiation of TB and HIV treatment of less than 30 days [371, 379, 382-385]. Most IRIS in HIV/TB disease occurs within three months of the start of TB treatment. Delaying the start of antiretroviral therapy for 2 to 8 weeks may reduce the incidence and severity of IRIS, but must be weighed against the potential benefit of earlier antiretroviral therapy in improving immune function and preventing progression of HIV disease. In mild to moderate cases of IRIS, treatment of TB and HIV should be continued and nonsteroidal anti-inflammatory agents may be used to alleviate specific

symptoms (AII). In severe cases of IRIS high-dose prednisone (1mg/kg for 1 to 4 weeks followed by tapering doses, with the duration and timing of tapering based on the control of symptoms) has been associated with clinical improvement [385-387] (BIII), and additional measures such as surgical decompression may also be required.

### Immune Reconstitution with Antiretroviral Therapy: Conversion to Positive TST and/or IGRA Test

Immune reconstitution with antiretroviral therapy may result in unmasking LTBI (i.e., conversion of a previously negative TST to a positive TST or a positive interferon-gamma [IFN- $\gamma$ ] release assay [IGRA] for *M.TB*-specific proteins). A positive IGRA, similar to a positive TST, is indicative of LTBI in the absence of evidence of active TB disease [388]. Because treatment for LTBI is indicated in the absence of evidence of active TB disease, clinicians should be aware of this phenomenon. In individuals with a negative TST or IGRA and advanced HIV disease (i.e., CD4 count  $<200$  cells/mm<sup>3</sup>), TST or IGRA should be repeated after they have started antiretroviral therapy and their CD4 count has increased to above 200 cells/mm<sup>3</sup> [389] (BII).

A TST or IGRA should also be performed prior to the initiation of ART regardless of the CD4 count. Individuals found to have LTBI by IGRA or TST – defined as  $>5$  mm skin test induration without evidence of active TB disease and after appropriate evaluation for active TB disease – should commence treatment as recommended by the guidelines for treatment and prevention of OIs in HIV-infected patients. Caution should be taken regarding use of rifamycins with certain antiretroviral drugs (see above).

A more complete discussion of the use of IGRAs and the diagnosis and treatment of TB disease and LTBI in patients with HIV infection will be available in “*The Guidelines for Preventing and Treating Opportunistic Infections in HIV-Infected Adults and Adolescents – 2008: Recommendations from the NIH, the CDC, and the HIVMA/IDSA*” (in preparation).

### Integration of TB and HIV Care

Due to the complexities described above, optimal management of HIV-infected individuals with active TB disease requires close collaboration between TB and HIV clinicians, health care institutions, and public health programs.

# Prevention Counseling for the HIV-Infected Patient

(Updated October 29, 2004)

---

Prevention counseling is an essential component of management for HIV-infected persons. Each patient encounter provides an opportunity to reinforce HIV prevention messages. Therefore, each encounter should include assessment and documentation of the following:

- patient's knowledge and understanding of HIV transmission; and
- patient's HIV transmission behaviors since the last encounter with a member of the health care team.

This should be followed by a discussion of strategies to prevent transmission that might be useful to the patient. Each member of the health care team can routinely provide this counseling. Partner notification is a key component of HIV detection and prevention and should be pursued with the patient by the provider or by referral services. Behavior changes among HIV-infected persons have been observed during the era of combination antiretroviral therapy that impacts prevention, however, evidence exists that awareness of the potential benefits of antiretroviral therapy has contributed to relapse into high-risk activities. There is good evidence that the probability of HIV transmission correlates with inoculum size based on precedent in other viral infections and on the basis of the discordant couples study and studies of perinatal transmission. There is an assumption that risk of transmission is reduced with exposure by sex or needle-sharing with therapy to reduce viral load, although there are no clinical studies to support that claim and there are no viral load thresholds that could be considered safe. Further, there is the concern that this impression might lead or has led to high-risk behavior that might more than nullify any potential benefit. Lastly, HIV-infected women may engage in unprotected sex while attempting to become pregnant. Providers should discuss patient plans and desires concerning childbearing at intervals throughout care and should refer women who are interested in getting pregnant to preconception counseling and care.

The following link provides more information that providers can access to provide them with better understanding of the need for prevention and prevention counseling.

(<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5212a1.htm>) [390].

# Conclusion

---


The Panel has carefully reviewed recent results from clinical trials in HIV therapy and considered how they inform appropriate care guidelines. The Panel appreciates that HIV care is highly complex and rapidly evolving. Guidelines are never fixed and must always be individualized. Where possible, the Panel has based recommendations on the best evidence from prospective trials with defined endpoints. When such evidence does not yet exist, the panel attempted to reflect reasonable options in its conclusions.

HIV care requires, as always, partnerships and open communication. The provider can make recommendations most likely to lead to positive outcomes only if the patient's own point of view and social context are well known. Guidelines are only a starting point for medical decision making. They can identify some of the boundaries of high-quality care, but cannot substitute for sound judgment.

As further research is conducted and reported, guidelines will be modified. The Panel anticipates continued progress in the simplicity of regimens, improved potency and barrier to resistance, and reduced toxicity. The Panel hopes the guidelines are useful and is committed to their continued adjustment and improvement.

- Information included in these guidelines may not represent FDA approval or approved labeling for the particular products or indications in question. Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.

**Table 1. Rating Scheme for Clinical Practice Recommendations**  
(Updated October 29, 2004)



**Table 2. Indications for Plasma HIV RNA Testing\***  
(Updated October 29, 2004)

Clinical Indication	Information	Use
Syndrome consistent with acute HIV infection (See <a href="#">Table 25.</a> )	Establishes diagnosis when HIV antibody test is negative or indeterminate	Diagnosis <sup>†</sup>
Initial evaluation of newly diagnosed HIV infection	Baseline viral load setpoint	Use as baseline information
Every 3–4 months in patients not on therapy	Changes in viral load	Use as continued monitoring and baseline value if antiretroviral therapy is to be initiated
2–8 weeks after initiation of or change in antiretroviral therapy	Initial assessment of drug efficacy	Decision to continue or change therapy
3–4 months after start of therapy	Assessment of virologic effect of therapy	Decision to continue or change therapy
Every 3–4 months in patients on therapy	Durability of antiretroviral effect	Decision to continue or change therapy
Clinical event or significant decline in CD4 T-cells	Association with changing or stable viral load	Decision to continue, initiate, or change therapy

\* Acute illness (e.g., bacterial pneumonia, tuberculosis, herpes simplex virus, *Pneumocystis jiroveci* pneumonia), and vaccinations can cause an increase in plasma HIV RNA for 2–4 weeks; viral load testing should not be performed during this time. Plasma HIV RNA results should usually be verified with a repeat determination before starting or making changes in therapy.

† Diagnosis of HIV infection made by HIV RNA testing should be confirmed by standard methods (i.e., ELISA and Western blot testing) performed 2–4 months after the initial indeterminate or negative test.



**Table 3. Recommendations for Using Drug Resistance Assays**

(Updated December 1, 2007)

Clinical Setting/Recommendation	Rationale
<b>Drug-resistance assay recommended</b>	
<p><b>In acute HIV infection:</b> Drug resistance testing is recommended, regardless of whether treatment will be initiated immediately (<b>AIII</b>). A genotypic assay is generally preferred (<b>AIII</b>).</p> <p>If therapy is deferred, repeat resistance testing should be considered at the time ART is initiated (<b>CIII</b>).</p>	<p>If treatment is to be initiated, drug resistance testing will determine whether drug-resistant virus was transmitted and will help in the design of initial or changed (if therapy was initiated prior to test results) regimens.</p> <p>If treatment is deferred, testing still should be performed because of the potentially greater likelihood that transmitted resistance-associated mutations will be detected earlier in the course of HIV infection; results of testing may be important when treatment is eventually initiated. Repeat testing at the time ART is initiated should be considered because of the possibility that the patient may have acquired drug-resistant virus.</p>
<p><b>In chronic HIV infection:</b> Drug resistance testing is recommended at the time of entry into HIV care, regardless of whether therapy will be initiated (<b>AIII</b>). A genotypic assay is generally preferred (<b>AIII</b>).</p> <p>If therapy is deferred, repeat resistance testing should be considered at the time ART is initiated (<b>CIII</b>).</p>	<p>Transmitted HIV with baseline resistance to at least one drug may be seen in 6%–16% of patients, and suboptimal virologic responses may be seen in patients with baseline resistant mutations.</p> <p>Repeat testing at the time ART is initiated should be considered because of the possibility that the patient may have acquired drug-resistant virus.</p>
<p>With virologic failure during combination antiretroviral therapy (<b>AII</b>).</p>	<p>Testing can help determine the role of resistance in drug failure and thus maximize the number of active drugs in the new regimen, if indicated. Drug resistance testing should be performed while the patient is taking his/her antiretroviral drugs or immediately (i.e., within 4 weeks) after discontinuing therapy.</p>
<p>With suboptimal suppression of viral load after antiretroviral therapy initiation (<b>AIII</b>).</p>	<p>Testing can help determine the role of resistance and thus maximize the number of active drugs in the new regimen, if indicated.</p>
<p><b>In HIV-Infected Pregnant Women:</b> Genotypic resistance testing is recommended for all pregnant women prior to initiation of therapy (<b>AIII</b>) and for those entering pregnancy with detectable HIV RNA levels while on therapy (<b>AII</b>).</p>	<p>The goals of antiretroviral therapy in HIV-infected pregnant women are to achieve maximal viral suppression for treatment of maternal HIV infection as well as for prevention of perinatal HIV transmission. Genotypic resistance testing will assist the clinician in selecting the optimal regimen for the patient.</p>
<b>Drug resistance assay not usually recommended</b>	
<p>After discontinuation (&gt;4 weeks) of drugs (<b>DIII</b>).</p>	<p>Drug resistance mutations might become minor species in the absence of selective drug pressure, and available assays might not detect minor drug-resistant species. If testing is performed in this setting, the detection of drug resistance may be of value, but its absence does not rule out the presence of minor drug-resistant species.</p>
<p>When plasma viral load &lt;1,000 copies/mL (<b>DIII</b>).</p>	<p>Resistance assays cannot be consistently performed because of low HIV RNA levels.</p>

**Table 4a: Probability of Progressing to AIDS or Death According to CD4 Cell Count, Viral Load, and Sociodemographic Factors (Updated October 29, 2004)**

	CD4 cell count (cells/ $\mu$ L)									
	< 50		50–99		100–199		200–349		$\geq 350$	
	Viral load $\geq 5^*$	Viral load $< 5^*$	Viral load $\geq 5^*$	Viral load $< 5^*$	Viral load $\geq 5^*$	Viral load $< 5^*$	Viral load $\geq 5^*$	Viral load $< 5^*$	Viral load $\geq 5^*$	Viral load $< 5^*$
<b>CDC stage A/B and no history of IDU</b>										
Age < 50 years										
Year 1	12 (11–14)	9.5 (8.0–11)	9.2 (7.7–11)	7.0 (5.8–8.5)	6.2 (5.2–7.3)	4.7 (4.0–5.6)	2.6 (2.1–3.2)	2.0 (1.6–2.5)	2.0 (1.6–2.5)	1.5 (1.2–1.9)
Year 2	17 (15–20)	13 (11–15)	13 (11–15)	10 (8.4–12)	9.5 (8.1–11)	7.3 (6.2–8.5)	4.5 (3.7–5.4)	3.3 (2.8–4.1)	3.3 (2.7–4.0)	2.5 (2.1–3.0)
Year 3	20 (18–23)	16 (13–19)	16 (14–19)	12 (10–15)	12 (10–14)	9.3 (7.9–11)	6.1 (5.0–7.4)	4.7 (3.9–5.6)	4.4 (3.6–5.4)	3.4 (2.8–4.1)
Age $\geq 50$ years										
Year 1	17 (14–20)	13 (11–16)	12 (10–15)	9.6 (7.7–12)	8.5 (7.0–10)	6.5 (5.3–7.9)	3.6 (2.8–4.5)	2.7 (2.2–3.4)	2.8 (2.2–3.5)	2.1 (1.6–2.7)
Year 2	23 (19–27)	18 (15–21)	18 (15–21)	14 (11–17)	13 (10–15)	9.9 (8.2–12)	6.1 (5.0–7.6)	4.7 (3.8–5.8)	4.5 (3.6–5.7)	3.4 (2.8–4.3)
Year 3	27 (23–32)	21 (18–25)	22 (18–26)	17 (14–20)	16 (14–19)	13 (10–15)	8.3 (6.7–10)	6.4 (5.1–7.9)	6.0 (4.8–7.6)	4.6 (3.7–5.8)
<b>CDC stage A/B and history of IDU</b>										
Age < 50 years										
Year 1	17 (14–20)	13 (11–16)	12 (10–15)	9.5 (7.7–12)	8.4 (7.0–10)	6.5 (5.3–7.9)	3.6 (2.8–4.5)	2.7 (2.2–3.4)	2.7 (2.1–3.5)	2.1 (1.6–2.6)
Year 2	24 (21–28)	19 (16–23)	19 (16–22)	15 (12–18)	14 (12–16)	11 (8.8–13)	6.6 (5.4–8.1)	5.0 (4.1–6.1)	4.9 (3.9–6.1)	3.7 (3.0–4.6)
Year 3	30 (26–35)	24 (20–28)	24 (20–28)	19 (15–23)	18 (15–22)	14 (12–17)	9.4 (7.6–11)	7.2 (5.8–8.8)	6.8 (5.4–8.6)	5.2 (4.2–6.5)
Age $\geq 50$ years										
Year 1	22 (18–27)	17 (14–22)	17 (13–21)	13 (10–16)	11 (9.1–14)	8.8 (6.9–11)	4.9 (3.7–6.4)	3.7 (2.8–4.9)	3.8 (2.8–5.0)	2.9 (2.2–3.8)
Year 2	32 (26–38)	25 (20–31)	25 (20–31)	20 (15–25)	18 (15–23)	14 (11–18)	9.0 (7.0–11)	6.9 (5.4–8.8)	6.7 (5.1–8.7)	5.1 (3.9–6.6)
Year 3	39 (32–46)	31 (25–38)	33 (26–38)	25 (20–31)	24 (20–30)	19 (15–24)	13 (9.9–16)	9.8 (7.6–12)	9.3 (7.1–12)	7.1 (5.4–9.2)
<b>CDC stage C and no history of IDU</b>										
Age < 50 years										
Year 1	17 (15–19)	13 (11–15)	13 (11–15)	9.8 (8.1–12)	8.7 (7.2–10)	6.6 (5.5–8.1)	3.7 (2.9–4.7)	2.8 (2.2–3.5)	2.8 (2.2–3.6)	2.1 (1.7–2.7)
Year 2	23 (21–26)	18 (16–21)	18 (15–21)	14 (12–17)	13 (11–16)	10 (8.4–12)	6.3 (5.1–7.8)	4.8 (3.9–5.9)	4.6 (3.7–5.9)	3.5 (2.8–4.4)
Year 3	28 (25–31)	22 (19–25)	22 (19–26)	17 (14–21)	17 (14–20)	13 (11–15)	8.5 (6.9–11)	6.5 (5.2–8.1)	6.2 (4.9–7.9)	4.7 (3.7–6.0)
Age $\geq 50$ years										
Year 1	23 (20–26)	18 (15–21)	17 (14–20)	13 (11–16)	12 (9.7–14)	9.1 (7.3–11)	5.1 (3.9–6.5)	3.8 (3.0–5.0)	3.9 (3.0–5.1)	3.0 (2.3–3.9)
Year 2	31 (27–35)	24 (20–28)	24 (20–28)	19 (15–23)	18 (15–21)	14 (11–17)	8.6 (6.8–11)	6.6 (5.2–8.3)	6.4 (4.9–8.2)	4.9 (3.8–6.2)
Year 3	36 (32–41)	29 (24–34)	29 (25–34)	23 (19–28)	22 (18–27)	17 (14–21)	12 (9.2–15)	8.9 (7.0–11)	8.5 (6.5–11)	6.5 (5.0–8.3)
<b>CDC stage C and history of IDU</b>										
Age < 50 years										
Year 1	23 (20–26)	18 (15–21)	17 (14–21)	13 (11–16)	12 (9.5–14)	9.0 (7.2–11)	5.0 (3.9–6.5)	3.8 (2.9–5.0)	3.9 (2.9–5.1)	2.9 (2.2–3.9)
Year 2	33 (29–37)	26 (22–30)	26 (22–30)	20 (16–24)	19 (15–23)	15 (12–18)	9.2 (7.3–12)	7.0 (5.6–8.9)	6.8 (5.3–8.8)	5.2 (4.1–6.7)
Year 3	40 (35–45)	32 (27–37)	32 (27–38)	25 (21–31)	25 (22–30)	19 (16–24)	13 (10–16)	10 (7.9–13)	9.5 (7.3–12)	7.3 (5.6–9.4)
Age $\geq 50$ years										
Year 1	30 (25–36)	24 (19–29)	23 (18–28)	18 (14–23)	16 (12–20)	12 (9.5–16)	6.9 (5.1–9.2)	5.3 (3.9–7.1)	5.3 (3.9–7.2)	4.0 (3.0–5.5)
Year 2	42 (36–49)	34 (28–41)	34 (27–41)	27 (21–33)	25 (20–31)	20 (15–25)	12 (9.6–16)	9.6 (7.3–13)	9.3 (7.0–12)	7.1 (5.3–9.5)
Year 3	50 (43–58)	41 (34–49)	42 (34–50)	33 (27–41)	33 (26–40)	26 (20–32)	17 (13–23)	14 (10–18)	13 (9.6–17)	9.9 (7.4–13)

IDU=injection-drug use. \*Log copies/mL

Reprint with permission from Elsevier (The Lancet, Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. 2002 Jul 13;360(9327):119-29.)

**Table 4b. Predicted 6-month Risk of AIDS According to Age and Current CD4 Cell Count and Viral Load, Based on a Poisson Regression Model (Updated October 29, 2004)**

Viral load (copies/mL)	Predicted risk (%) at current CD4 cell count ( $\times 10^6$ cells/l) <sup>a</sup>									
	50	100	150	200	250	300	350	400	450	500
<b>Age 25 years</b>										
3,000	6.8	3.7	2.3	1.6	1.1	0.8	0.6	0.5	0.4	0.3
10,000	9.6	5.3	3.4	2.3	1.6	1.2	0.9	0.7	0.5	0.4
30,000	13.3	7.4	4.7	3.2	2.2	1.6	1.2	0.9	0.7	0.6
100,000	18.6	10.6	6.7	4.6	3.2	2.4	1.8	1.4	1.1	0.8
300,000	25.1	14.5	9.3	6.3	4.5	3.3	2.5	1.9	1.5	1.2
<b>Age 35 years</b>										
3,000	8.5	4.7	3.0	2.0	1.4	1.0	0.8	0.6	0.5	0.4
10,000	12.1	6.7	4.3	2.9	2.0	1.5	1.1	0.9	0.7	0.5
30,000	16.6	9.3	5.9	4.0	2.8	2.1	1.6	1.2	0.9	0.7
100,000	23.1	13.2	8.5	5.8	4.1	3.0	2.3	1.7	1.3	1.1
300,000	30.8	18.0	11.7	8.0	5.7	4.2	3.1	2.4	1.9	1.5
<b>Age 45 years</b>										
3,000	10.7	5.9	3.7	2.5	1.8	1.3	1.0	0.7	0.6	0.5
10,000	15.1	8.5	5.4	3.6	2.6	1.9	1.4	1.1	0.8	0.7
30,000	20.6	11.7	7.5	5.1	3.6	2.6	2.0	1.5	1.2	0.9
100,000	28.4	16.5	10.6	7.3	5.2	3.8	2.9	2.2	1.7	1.3
300,000	37.4	22.4	14.6	10.1	7.2	5.3	4.0	3.1	2.4	1.9
<b>Age 55 years</b>										
3,000	13.4	7.5	4.7	3.2	2.3	1.7	1.2	0.9	0.7	0.6
10,000	18.8	10.7	6.8	4.6	3.3	2.4	1.8	1.4	1.1	0.8
30,000	25.4	14.6	9.4	6.4	4.6	3.3	2.5	1.9	1.5	1.2
100,000	34.6	20.5	13.3	9.2	6.5	4.8	3.6	2.8	2.2	1.7
300,000	44.8	27.5	18.2	12.6	9.1	6.7	5.0	3.9	3.0	2.4

<sup>a</sup> Shading distinguishes risk: <2%, no shading; 2%–9.9%, light gray; 10%–19.9%, mid-gray;  $\geq 20\%$ , darkest gray.

Reprint with permission from Lippincott, Williams & Wilkins [Phillips A; CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. *AIDS* 2004; 18 (1):51-8].

**Table 5. Indications for Initiating Antiretroviral Therapy for the Chronically HIV-1 Infected Patient (Updated December 1, 2007)**

Clinical Condition and/or CD4 Count	Recommendations
<ul style="list-style-type: none"> <li>• History of AIDS-defining illness (AI)</li> <li>• CD4 count &lt;200 cells/mm<sup>3</sup> (AI)</li> <li>• CD4 count 200-350 cells/mm<sup>3</sup> (AII)</li> <li>• Pregnant women* (AI)</li> <li>• Persons with HIV-associated nephropathy (AI)</li> <li>• Persons coinfecting with hepatitis B virus (HBV), when HBV treatment is indicated (Treatment with fully suppressive antiviral drugs active against both HIV and HBV is recommended.) (BIII)</li> </ul>	<p style="text-align: center;">Antiretroviral therapy should be initiated.</p>
<ul style="list-style-type: none"> <li>• Patients with CD4 count &gt;350 cells/mm<sup>3</sup> who do not meet any of the specific conditions listed above</li> </ul>	<p>The optimal time to initiate therapy in asymptomatic patients with CD4 count &gt;350 cells/mm<sup>3</sup> is not well defined. Patient scenarios and comorbidities should be taken into consideration. (See box below and text regarding risks and benefits of therapy in patients with CD4 count &gt;350 cells/mm<sup>3</sup>).</p>

\* For women who do not require antiretroviral therapy for their own health, consideration can be given to discontinuing antiretroviral drugs postpartum. For more detailed discussion, please refer to the [Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women and Interventions to Reduce Perinatal HIV-1 Transmission in the United States](#) and the [HIV-Infected Women of Reproductive Age and Pregnant Women](#) section.

### Benefits and Risks of Treatment

In addition to the risks of disease progression, the decision to initiate antiretroviral therapy should also be influenced by an assessment of other potential risks and benefits associated with treatment. Potential benefits and risks of early (CD4 counts >350 cells/mm<sup>3</sup>) or deferred (CD4 count <350 cells/mm<sup>3</sup>) therapy initiation for the asymptomatic patient are outlined below.

<p><b>Potential Benefits of Early Therapy Include:</b></p> <ul style="list-style-type: none"> <li>• Maintenance of a higher CD4 count and prevention of potentially irreversible damage to the immune system</li> <li>• Decreased risk for HIV-associated complications that can sometimes occur at CD4 counts &gt;350 cells/mm<sup>3</sup>, including tuberculosis, non-Hodgkin's lymphoma, Kaposi's sarcoma, peripheral neuropathy, HPV-associated malignancies, and HIV-associated cognitive impairment</li> <li>• Decreased risk of nonopportunistic conditions, including cardiovascular disease, renal disease, liver disease, and non-AIDS-associated malignancies and infections</li> <li>• Decreased risk of HIV transmission to others, which will have positive public health implications</li> </ul> <p><b>Potential Risks of Early Therapy Include:</b></p> <ul style="list-style-type: none"> <li>• Development of treatment-related side effects and toxicities</li> <li>• Development of drug resistance because of incomplete viral suppression, resulting in loss of future treatment options</li> <li>• Less time for the patient to learn about HIV and its treatment and less time to prepare for the need for adherence to therapy</li> <li>• Increased total time on medication, with greater chance of treatment fatigue</li> <li>• Premature use of therapy before the development of more effective, less toxic, and/or better studied combinations of antiretroviral drugs</li> <li>• Transmission of drug-resistant virus in patients who do not maintain full virologic suppression</li> </ul>
---

**Table 6. Antiretroviral Components Recommended for Treatment of HIV-1 Infection in Treatment-Naïve Patients (Updated January 29, 2008)**

A combination antiretroviral regimen in treatment-naïve patients generally contains 1 NNRTI + 2 NRTIs or a single or ritonavir-boosted PI + 2 NRTIs.

Selection of a regimen for an antiretroviral-naïve patient should be individualized based on virologic efficacy, toxicities, pill burden, dosing frequency, drug-drug interaction potential, and comorbid conditions. Components listed below are designated as preferred when clinical trial data suggest optimal and durable efficacy with acceptable tolerability and ease of use. Alternative components are those that clinical trial data show efficacy but that have disadvantages, such as antiviral activity or toxicities, compared with the preferred agent. In some cases, for an individual patient, a component listed as alternative may actually be the preferred component. Clinicians initiating antiretroviral regimens in the HIV-infected pregnant patient should refer to "[Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States](http://aidsinfo.nih.gov/guidelines/)" at <http://aidsinfo.nih.gov/guidelines/>.

<b>To Construct an Antiretroviral Regimen, Select 1 Component from Column A + 1 from Column B</b>			
	<b>Column A</b> (NNRTI or PI Options – in alphabetical order)	+	<b>Column B</b> (Dual-NRTI Options)
<b>Preferred Components</b>	<b>NNRTI</b> or <b>PI</b> efavirenz <sup>1</sup> (AII)     atazanavir + ritonavir (AIII) fosamprenavir + ritonavir (2x/day) (AII) lopinavir/ritonavir <sup>2</sup> (2x/day) (AII) (coformulated)	+	<b>Preferred Components</b> <b>(alphabetical order)</b> abacavir/lamivudine <sup>3</sup> (for patients who test negative for HLAB*5701) (coformulated) (AII) <sup>6</sup> ; or tenofovir/emtricitabine <sup>3</sup> (coformulated) (AII)
<b>Alternative to Preferred Components</b>	<b>NNRTI</b> or <b>PI</b> nevirapine <sup>4</sup> (BII)     atazanavir <sup>5</sup> (BII) fosamprenavir (BII) fosamprenavir + ritonavir (1x/day) (BII) lopinavir/ritonavir (1x/day) (BII) (coformulated) <b>saquinavir + ritonavir (BII)</b>	+	<b>Alternative to Preferred Components</b> <b>(order of preference)</b> <b>zidovudine/lamivudine<sup>3</sup> (coformulated) (BII); or</b> <b>didanosine + (emtricitabine or lamivudine) (BII)</b>

<sup>1</sup> Efavirenz is not recommended for use in the first trimester of pregnancy or in sexually active women with childbearing potential who are not using effective contraception.

<sup>2</sup> The pivotal study that led to the recommendation of lopinavir/ritonavir as a preferred PI component was based on twice-daily dosing [141]. A smaller study has shown similar efficacy with once-daily dosing but also showed a higher incidence of moderate to severe diarrhea with the once-daily regimen (16% vs. 5%) [148]. In addition, once-daily dosing may be insufficient for those with viral loads >100,000 copies/mL [151].

<sup>3</sup> Emtricitabine may be used in place of lamivudine and vice versa.

<sup>4</sup> Nevirapine should not be initiated the following treatment-naïve patients: women with CD4 count >250 cells/mm<sup>3</sup> or in men with CD4 count >400 cells/mm<sup>3</sup> because of increased risk for symptomatic hepatic events in these patients.

<sup>5</sup> Atazanavir must be boosted with ritonavir if used in combination with efavirenz or tenofovir.

<sup>6</sup> Please refer to "[DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir – April 4, 2008](http://www.aidsinfo.nih.gov/guidelines/)" at <http://www.aidsinfo.nih.gov/guidelines/>.



**Table 7. Antiretroviral Components Not Recommended as Initial Therapy (Updated January 29, 2008)**

Antiretroviral drugs or components (in alphabetical order)	Reasons for not recommending as initial therapy
Abacavir/lamivudine/zidovudine (coformulated) as triple-NRTI combination regimen (DII)	<ul style="list-style-type: none"> <li>Inferior virologic efficacy</li> </ul>
Darunavir (ritonavir-boosted) (DIII)	<ul style="list-style-type: none"> <li>Insufficient data in treatment-naïve patients</li> </ul>
Delavirdine (DII)	<ul style="list-style-type: none"> <li>Inferior virologic efficacy</li> <li>Inconvenient (three times daily) dosing</li> </ul>
Didanosine + tenofovir (DII)	<ul style="list-style-type: none"> <li>High rate of early virologic failure</li> <li>Rapid selection of resistant mutations</li> <li>Potential for immunologic non-response/CD4 decline</li> </ul>
Enfuvirtide (DIII as initial regimen)	<ul style="list-style-type: none"> <li>No clinical trial experience in treatment-naïve patients</li> <li>Requires twice-daily subcutaneous injections</li> </ul>
Etravirine (DIII)	<ul style="list-style-type: none"> <li>Insufficient data in treatment-naïve patients</li> </ul>
Indinavir (unboosted) (DIII)	<ul style="list-style-type: none"> <li>Inconvenient dosing (three times daily with meal restrictions)</li> <li>Fluid requirement</li> </ul>
Indinavir (ritonavir-boosted) (DII)	<ul style="list-style-type: none"> <li>High incidence of nephrolithiasis</li> </ul>
Maraviroc (DIII)	<ul style="list-style-type: none"> <li>Insufficient data in treatment-naïve patients</li> </ul>
Nelfinavir (DII)	<ul style="list-style-type: none"> <li>Inferior virologic efficacy</li> </ul>
Raltegravir (DIII)	<ul style="list-style-type: none"> <li>Insufficient data in treatment-naïve patients</li> </ul>
Ritonavir as sole PI (DIII)	<ul style="list-style-type: none"> <li>High pill burden</li> <li>Gastrointestinal intolerance</li> </ul>
Saquinavir (unboosted) (DII)	<ul style="list-style-type: none"> <li>High pill burden</li> <li>Inferior virologic efficacy</li> </ul>
Stavudine + lamivudine (DI)	<ul style="list-style-type: none"> <li>Significant toxicities including lipoatrophy, peripheral neuropathy, and hyperlactatemia, including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis</li> </ul>
Tipranavir (ritonavir-boosted) (DII)	<ul style="list-style-type: none"> <li>Inferior virologic efficacy</li> </ul>

**Table 8. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time**  
(Updated January 29, 2008)

	Rationale	Exception
<b>Antiretroviral Regimens Not Recommended</b>		
<b>Monotherapy with NRTI (EII)</b>	<ul style="list-style-type: none"> <li>• Rapid development of resistance</li> <li>• Inferior antiretroviral activity when compared with combination with three or more antiretrovirals</li> </ul>	<ul style="list-style-type: none"> <li>• No exception (see footnote below regarding the pregnant patient)</li> </ul>
<b>Dual-NRTI regimens (EII)</b>	<ul style="list-style-type: none"> <li>• Rapid development of resistance</li> <li>• Inferior antiretroviral activity when compared with combination with three or more antiretrovirals</li> </ul>	<ul style="list-style-type: none"> <li>• No exception (see footnotes below regarding the pregnant patient and post-exposure prophylaxis)</li> </ul>
<b>Triple-NRTI regimens (EII) except for abacavir/zidovudine/lamivudine or possibly tenofovir + zidovudine/lamivudine</b>	<ul style="list-style-type: none"> <li>• High rate of early virologic nonresponse seen when triple NRTI combinations including ABC/TDF/3TC or TDF/ddI/3TC were used as initial regimen in treatment-naïve patients</li> <li>• Other 3-NRTI regimens have not been evaluated</li> </ul>	<ul style="list-style-type: none"> <li>• Abacavir/zidovudine/lamivudine (CII); and possibly tenofovir + zidovudine/lamivudine (DII) in selected patients where other combinations are not desirable</li> </ul>
<b>Antiretroviral Components Not Recommended as Part of Antiretroviral Regimen</b>		
<b>Atazanavir + indinavir (EIII)</b>	<ul style="list-style-type: none"> <li>• Potential additive hyperbilirubinemia</li> </ul>	<ul style="list-style-type: none"> <li>• No exception</li> </ul>
<b>Didanosine + stavudine (EIII)</b>	<ul style="list-style-type: none"> <li>• High incidence of toxicities: peripheral neuropathy, pancreatitis, and hyperlactatemia</li> <li>• Reports of serious, even fatal, cases of lactic acidosis with hepatic steatosis with or without pancreatitis in pregnant women*</li> </ul>	<ul style="list-style-type: none"> <li>• When no other antiretroviral options are available and potential benefits outweigh the risks (DIII) (see footnote below regarding the pregnant patient)</li> </ul>
<b>2-NNRTI combination (EII)</b>	<ul style="list-style-type: none"> <li>• When EFV combined with NVP, higher incidence of clinical adverse events seen when compared to either EFV- or NVP-based regimen</li> <li>• Both EFV and NVP may induce metabolism and may lead to reductions in ETR exposure – thus should not be used in combination</li> </ul>	<ul style="list-style-type: none"> <li>• No exception</li> </ul>
<b>Efavirenz in first trimester of pregnancy or in women with significant child-bearing potential (EIII)</b>	<ul style="list-style-type: none"> <li>• Teratogenic in nonhuman primates</li> </ul>	<ul style="list-style-type: none"> <li>• When no other antiretroviral options are available and potential benefits outweigh the risks (DIII) (see footnote below regarding the pregnant patient)</li> </ul>
<b>Emtricitabine + lamivudine (EIII)</b>	<ul style="list-style-type: none"> <li>• Similar resistance profile</li> <li>• No potential benefit</li> </ul>	<ul style="list-style-type: none"> <li>• No exception</li> </ul>
<b>Stavudine + zidovudine (EII)</b>	<ul style="list-style-type: none"> <li>• Antagonistic effect on HIV-1</li> </ul>	<ul style="list-style-type: none"> <li>• No exception</li> </ul>
<b>Unboosted darunavir, saquinavir, or tipranavir (EII)</b>	<ul style="list-style-type: none"> <li>• Inadequate bioavailability</li> <li>• Virologic efficacy of these unboosted PIs has not been proven</li> </ul>	<ul style="list-style-type: none"> <li>• No exception</li> </ul>

• When constructing an antiretroviral regimen for an HIV-infected pregnant woman, please consult “Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States” in <http://www.aidsinfo.nih.gov/guidelines/>.

• When considering an antiretroviral regimen to use in post-exposure prophylaxis, please consult “Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis” in *CDC MMWR Recommendations and Reports*, September 30, 2005/54 (RR 09); 1–17 and “Management of Possible Sexual, Injection-Drug-Use, or Other Non-occupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy” in *CDC MMWR Recommendations and Reports*, January 21, 2005/54 (RR 02); 1–19.

**Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (Updated January 29, 2008)**

Page 1 of 2

ARV Class	ARV Agent(s)	Advantages	Disadvantages
NNRTIs (in alphabetical order)		<p><b>NNRTI Class Advantages:</b></p> <ul style="list-style-type: none"> <li>• Save PI options for future use</li> <li>• Long half-lives</li> <li>• Less metabolic toxicity (hyperlipidemia, insulin resistance) than with some PIs</li> </ul>	<p><b>NNRTI Class Disadvantages:</b></p> <ul style="list-style-type: none"> <li>• Low genetic barrier to resistance (single mutation confers resistance): greater risk for resistance with failure or treatment interruption</li> <li>• Cross resistance among approved NNRTIs</li> <li>• Skin rash</li> <li>• Potential for CYP450 drug interactions (See <a href="#">Tables 20–22b</a>)</li> <li>• Transmitted resistance to NNRTIs more common than resistance to PIs</li> </ul>
	<b>Efavirenz (EFV)</b>	<ul style="list-style-type: none"> <li>• Antiretroviral activity equivalent or superior to all comparators to date</li> <li>• Low pill burden; once-daily dosing</li> <li>• Fixed-dose combination with tenofovir + emtricitabine</li> </ul>	<ul style="list-style-type: none"> <li>• Neuropsychiatric side effects</li> <li>• Teratogenic in nonhuman primates, contraindicated in first trimester of pregnancy; avoid use in women with pregnancy potential</li> <li>• Lower CD4 cell count response than with LPV/r</li> </ul>
	<b>Nevirapine (NVP)</b>	<ul style="list-style-type: none"> <li>• No food effect</li> <li>• Less lipid effects than EFV</li> </ul>	<ul style="list-style-type: none"> <li>• Higher incidence of rash than with other NNRTIs, including rare but serious hypersensitivity reactions (Stevens-Johnson syndrome or toxic epidermal necrolysis)</li> <li>• Higher incidence of hepatotoxicity than with other NNRTIs, including serious and even fatal cases of hepatic necrosis</li> <li>• Treatment-naïve, female patients and treatment-naïve patients with high pre-NVP CD4 counts (&gt;250 cells/mm<sup>3</sup> females, &gt;400 cells/mm<sup>3</sup> males) are at higher risk for symptomatic hepatic events. NVP not recommended in these patients unless benefit clearly outweighs risk</li> <li>• Less clinical trial data than with EFV</li> </ul>
PIs (in alphabetical order)		<p><b>PI Class Advantage:</b></p> <ul style="list-style-type: none"> <li>• Save NNRTI for future use</li> <li>• Higher genetic barrier to resistance</li> <li>• PI resistance uncommon with failure (boosted PIs)</li> </ul>	<p><b>PI Class Disadvantages:</b></p> <ul style="list-style-type: none"> <li>• Metabolic complications (fat accumulation, dyslipidemia, insulin resistance)</li> <li>• Gastrointestinal side effects</li> <li>• Liver toxicity (especially with chronic hepatitis B or C)</li> <li>• CYP3A4 inhibitors &amp; substrates: potential for drug interactions (more pronounced w/ RTV-based regimens) (See <a href="#">Tables 20–22b</a>)</li> <li>• PR interval prolongation: generally inconsequential unless combined with another drug with similar effect</li> </ul>
	<b>Atazanavir (unboosted) (ATV)</b>	<ul style="list-style-type: none"> <li>• Less adverse effect on lipids than other PIs</li> <li>• Once-daily dosing</li> <li>• Low pill burden (two pills per day)</li> <li>• Good GI tolerability</li> </ul>	<ul style="list-style-type: none"> <li>• Indirect hyperbilirubinemia sometimes leading to jaundice or scleral icterus</li> <li>• Nephrolithiasis</li> <li>• PR interval prolongation: generally inconsequential unless combined with another drug with similar effect</li> <li>• Reduced drug exposure when used with TDF and EFV: need addition of RTV (ATV 300mg QD + RTV 100mg QD)</li> <li>• Absorption depends on food and low gastric pH; should not be used with proton pump inhibitors; separate doses with antacid or H2 blockers</li> </ul>
	<b>Atazanavir/ritonavir (ATV/r)</b>	<ul style="list-style-type: none"> <li>• RTV-boosting: higher trough ATV concentration and greater antiviral effect</li> <li>• Once-daily dosing</li> <li>• Low pill burden (two pills per day)</li> <li>• Low risk for PI resistance with failure</li> </ul>	<ul style="list-style-type: none"> <li>• Similar and potentially more side effects than unboosted atazanavir</li> <li>• Potentially more adverse effect on lipids than unboosted ATV</li> <li>• More hyperbilirubinemia and jaundice than unboosted ATV</li> <li>• Most efficacy <b>data in treatment-experienced patients</b></li> <li>• Absorption depends on food and low gastric pH; separate doses with antacid or H2 blockers</li> <li>• <b>In treatment-naïve patients only – can use with proton pump inhibitor in a dose no higher than omeprazole 20mg once daily taken approximately 12 hours prior to ritonavir-boosted ATV</b></li> </ul>
	<b>Fosamprenavir (unboosted) (FPV)</b>	<ul style="list-style-type: none"> <li>• No food effect</li> </ul>	<ul style="list-style-type: none"> <li>• Skin rash</li> <li>• Potential for PI resistance with failure, including selection of mutations resistance to darunavir</li> <li>• Gastrointestinal intolerance (higher incidence with once-daily than with twice-daily dosing)</li> <li>• Metabolic toxicity (dyslipidemia, insulin resistance)</li> </ul>

**Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (Updated January 29, 2008)**

Page 2 of 2

ARV Class	ARV Agent(s)	Advantages	Disadvantages
PIs (cont'd, in alphabetical order)	Fosamprenavir/ritonavir (FPV/r)	<ul style="list-style-type: none"> <li>Twice-daily dosing resulted in efficacy comparable to LPV/r</li> <li>RTV-boosting: higher trough FPV concentration and greater antiviral effect</li> <li>Once-daily dosing possible</li> <li>No food effect</li> <li>Low risk for PI resistance with failure</li> </ul>	<ul style="list-style-type: none"> <li>Skin rash</li> <li>Once-daily dosing results in lower FPV concentrations than twice-daily dosing</li> <li>Metabolic toxicity (dyslipidemia, insulin resistance)</li> </ul>
	Lopinavir/ritonavir (LPV/r)	<ul style="list-style-type: none"> <li>Coformulated as Kaletra®</li> <li>Potential for once-daily dosing in treatment-naïve patients</li> <li>No food restriction with oral tablet formulation</li> <li>Recommended PI in pregnant women</li> <li>Greater CD4 T-cell count increase than with EFV-based regimens</li> <li>Low risk for PI resistance with failure</li> </ul>	<ul style="list-style-type: none"> <li>Gastrointestinal intolerance (higher incidence with once-daily than twice-daily dosing)</li> <li>Metabolic toxicity (dyslipidemia, insulin resistance)</li> <li>Preliminary data: lower drug exposure in pregnant women</li> <li>Once-daily dosing: lower trough concentration than BID and greater failure rates in patients with viral load &gt;100,000 copies/mL</li> </ul>
	Saquinavir + ritonavir (SQV/r)	<ul style="list-style-type: none"> <li>Data from GEMINI study show efficacy similar to LPV/r</li> <li>Alternative PI in pregnant women</li> </ul>	<ul style="list-style-type: none"> <li>Gastrointestinal intolerance</li> <li>Higher pill burden than for other PI regimens (6/day)</li> </ul>
Dual NRTIs		<ul style="list-style-type: none"> <li>Established backbone of combination antiretroviral therapy</li> </ul>	<ul style="list-style-type: none"> <li>Rare but serious cases of lactic acidosis with hepatic steatosis reported (d4T&gt;ddI=ZDV&gt;TDF=ABC=3TC=FTC)</li> </ul>
Dual-NRTI pairs (in alphabetical order)	Abacavir + lamivudine (ABC + 3TC)	<ul style="list-style-type: none"> <li>Non-inferior to ZDV+ 3TC with regard to virologic responses</li> <li>Better CD4 T-cell count response than with ZDV/3TC</li> <li>Once-daily dosing</li> <li>Coformulation (Epizicom®)</li> <li>No food effect</li> <li>No cumulative TAM-mediated resistance</li> </ul>	<ul style="list-style-type: none"> <li>Potential for abacavir systemic hypersensitivity reaction in patients with HLA-B*5701</li> </ul>
	Didanosine + lamivudine (ddI + 3TC) or Didanosine + emtricitabine (ddI + FTC)	<ul style="list-style-type: none"> <li>Once-daily dosing</li> <li>No cumulative TAM-mediated resistance</li> </ul>	<ul style="list-style-type: none"> <li>Didanosine: peripheral neuropathy, pancreatitis</li> <li>Food effect: needs to be taken on an empty stomach</li> <li>Requires dosing separation from most PIs</li> <li>Increase in toxicities when used with ribavirin, tenofovir, stavudine, or hydroxyurea</li> <li>Lack of comparative data with other standard dual-NRTI combinations</li> </ul>
	Tenofovir/emtricitabine (or lamivudine) (TDF/FTC or 3TC)	<ul style="list-style-type: none"> <li>Good virologic response when used with efavirenz; superior to AZT/3TC + EFV</li> <li>Once-daily dosing</li> <li>No food effect</li> <li>Coformulated as Truvada™ (TDF/FTC) and Atripla™ (EFV/TDF/FTC)</li> <li>No cumulative TAM-mediated resistance</li> <li>TDF/FTC: less M184V than AZT/3TC, less K65R than TDF + 3TC</li> </ul>	<ul style="list-style-type: none"> <li>Tenofovir: potential for renal impairment</li> <li>Interactions with: <ol style="list-style-type: none"> <li>ATV: TDF reduces ATV levels; need to add low dose RTV</li> <li>ddI: TDF increases ddI level; need to reduce ddI dose (combination not recommended)</li> </ol> </li> </ul>
	Zidovudine + lamivudine (ZDV + 3TC)	<ul style="list-style-type: none"> <li>Extensive experience</li> <li>Coformulated as Combivir®</li> <li>No food effect (though better tolerated with food)</li> <li>Gradual accumulation of resistance: early failure associated with M184V only</li> </ul>	<ul style="list-style-type: none"> <li>Bone marrow suppression, especially anemia, with ZDV</li> <li>Gastrointestinal intolerance</li> <li>Mitochondrial toxicity, including lipoatrophy, lactic acidosis, hepatic steatosis</li> <li>Inferior to TDF/FTC in combination with EFV</li> <li>Less CD4 T-cell response compared with ABC/3TC</li> <li>Greater selection of M184V than with TDF/FTC</li> </ul>
	Emtricitabine (in place of lamivudine)	<ul style="list-style-type: none"> <li>Longer half-life than lamivudine</li> <li>Once-daily dosing</li> <li>Coformulation with TDF (Truvada™) and with EFV/TDF (Atripla™)</li> <li>TDF/FTC: less M184V than AZT/3TC, less K65R than TDF + 3TC</li> </ul>	<ul style="list-style-type: none"> <li>Hyperpigmentation/skin discoloration</li> </ul>

**Table 10. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

(Updated December 1, 2007)

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Intracellular half-life	Elimination	Adverse Events
<b>Abacavir (ABC)</b> <b>ZIAGEN</b> <b>TRIZIVIR - w/ ZDV+3TC</b> <b>EPZICOM - w/ 3TC</b>	<b>ZIAGEN</b> 300mg tablets or 20mg/mL oral solution <b>TRIZIVIR-ABC</b> 300mg + ZDV 300mg + 3TC 150mg <b>EPZICOM-ABC</b> 600mg + 3TC 300mg	300mg two times/day; or 600mg once daily; or as TRIZIVIR- 1 tablet two times/day EPZICOM- 1 tablet once daily	Take without regard to meals; Alcohol increases abacavir levels 41%; abacavir has no effect on alcohol	83%	1.5 hours	12–26 hours	Metabolized by alcohol dehydrogenase and glucuronyl transferase. Renal excretion of metabolites 82% TRIZIVIR & EPZICOM not for patients with CrCl < 50 mL/min	Hypersensitivity reaction that can be fatal, symptoms may include fever, rash, nausea, vomiting, malaise or fatigue, loss of appetite, respiratory symptoms such as sore throat, cough, shortness of breath
<b>Didanosine (ddI)</b> <b>VIDEX EC, Generic didanosine enteric coated (dose same as VIDEX EC)</b>	<b>VIDEX EC</b> 125, 200, 250, or 400mg  Buffered tablets (non-EC) are no longer available.	<b>Body weight <math>\geq</math> 60kg:</b> 400mg once daily EC capsule <b>with TDF:</b> 250mg/day <b><math>\leq</math> 60 kg:</b> 250mg daily EC capsule <b>with TDF:</b> 200mg/day	Levels decrease 55%; Take 1/2 hour before or 2 hours after meal	30–40%	1.5 hours	>20 hours	Renal excretion 50%  Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> )	Pancreatitis; peripheral neuropathy; nausea  Lactic acidosis with hepatic steatosis is a rare but potentially life-threatening toxicity associated with use of NRTIs.
<b>Emtricitabine (FTC)</b> <b>EMTRIVA</b>  Also available as : <b>ATRIPLA - w/ EFV &amp; TDF</b> <b>TRUVADA - w/ TDF</b>	<b>EMTRIVA-</b> 200mg hard gelatin capsule and 10mg/mL oral solution  <b>ATRIPLA - EFV</b> 600mg + FTC 200mg + TDF 300mg  <b>TRUVADA - FTC</b> 200mg + TDF 300mg	<b>EMTRIVA -</b> 200mg capsule once daily or 240mg (24 mL) oral solution once daily <b>ATRIPLA -</b> One tablet once daily  <b>TRUVADA -</b> One tablet once daily	Take without regard to meals	93%	10 hours	>20 hours	Renal excretion Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> ) <b>ATRIPLA -</b> not for patients with CrCl < 50 mL/min <b>TRUVADA -</b> not for patients with CrCl < 30 mL/min	Minimal toxicity; lactic acidosis with hepatic steatosis (rare but potentially life-threatening toxicity with use of NRTIs.) Hyper-pigmentation/skin discoloration
<b>Lamivudine (3TC)</b> <b>EPIVIR</b>  <b>COMBIVIR- w/ ZDV</b>  <b>EPZICOM - w/ ABC</b>  <b>TRIZIVIR- w/ ZDV+ABC</b>	<b>EPIVIR</b> 150mg and 300mg tablets or 10mg/mL oral solution  <b>COMBIVIR-</b> 3TC 150mg + ZDV 300mg  <b>EPZICOM -</b> 3TC 300mg + ABC 600mg  <b>TRIZIVIR -</b> 3TC 150mg + ZDV 300mg + ABC 300mg	<b>EPIVIR</b> 150mg two times/day; or 300mg daily  <b>COMBIVIR -</b> 1 tablet two times/day  <b>EPZICOM -</b> 1 tablet once daily  <b>TRIZIVIR -</b> 1 tablet two times/day	Take without regard to meals	86%	5–7 hours	18–22 hours	Renal excretion  Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> ) COMBIVIR, TRIZIVIR & EPZICOM not for patients with CrCl < 50 mL/min	Minimal toxicity; lactic acidosis with hepatic steatosis (rare but potentially life-threatening toxicity with use of NRTIs)



**Table 10. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**  
(Updated December 1, 2007)

Page 2 of 2

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Intracellular half-life	Elimination	Adverse Events
<b>Stavudine (d4T)</b> <b>ZERIT</b>	<b>ZERIT</b> 15, 20, 30, 40mg capsules or 1mg/mL for oral solution	Body weight <u>&gt;60 kg</u> : 40mg two times/day;  Body weight <u>≤60 kg</u> : 30mg two times/day	Take without regard to meals	86%	1.0 hour	7.5 hours	Renal excretion 50%  Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> )	<ul style="list-style-type: none"> <li>Peripheral neuropathy;</li> <li>Lipodystrophy</li> <li>Pancreatitis</li> <li>Lactic acidosis with hepatic steatosis-higher incidence than w/ other NRTIs</li> <li>Hyperlipidemia</li> <li>Rapidly progressive ascending neuromuscular weakness (rare)</li> </ul>
<b>Tenofovir Disoproxil Fumarate (TDF)</b> <b>VIREAD</b>  Also Available as : <b>ATRIPLA</b> - w/ EFV + FTC <b>TRUVADA</b> - w/ FTC	<b>VIREAD</b> 300mg tablet  <b>ATRIPLA</b> - EFV 600mg + FTC 200mg + TDF 300mg  <b>TRUVADA</b> - TDF 300mg + FTC 200mg	<b>VIREAD</b> 1 tablet once daily  <b>ATRIPLA</b> - One tablet once daily  <b>TRUVADA</b> 1 tablet once daily	Take without regard to meals	25% in fasting state; 39% with high-fat meal	17 hours	>60 hours	Renal excretion  Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> )  <b>ATRIPLA</b> - not for patients with CrCl <50 mL/min <b>TRUVADA</b> - not for patients with CrCl < 30 mL/min	<ul style="list-style-type: none"> <li>Asthenia, headache, diarrhea, nausea, vomiting, and flatulence; renal insufficiency;</li> <li>Lactic acidosis with hepatic steatosis (rare but potentially life-threatening toxicity with use of NRTIs)</li> </ul>
<b>Zidovudine (AZT, ZDV)</b> <b>RETROVIR</b>  <b>COMBIVIR</b> - w/ 3TC  <b>TRIZIVIR</b> - w/ 3TC+ABC	<b>RETROVIR</b> 100mg capsules, 300mg tablets, 10mg/mL intravenous solution, 10mg/mL oral solution  <b>COMBIVIR</b> 3TC 150mg + ZDV 300mg  <b>TRIZIVIR</b> -3TC 150mg + ZDV 300mg + ABC 300mg	<b>RETROVIR</b> 300mg two times/day or 200mg three times/ day  <b>COMBIVIR or TRIZIVIR</b> - 1 tablet two times/day	Take without regard to meals	60%	1.1 hours	7 hours	Metabolized to AZT glucuronide (GAZT). Renal excretion of GAZT Dosage adjustment in renal insufficiency (See <a href="#">Table 16</a> )  <b>COMBIVIR</b> & <b>TRIZIVIR</b> - not for patients with CrCl < 50 mL/min	<ul style="list-style-type: none"> <li>Bone marrow suppression: macrocytic anemia or neutropenia;</li> <li>Gastrointestinal intolerance, headache, insomnia, asthenia;</li> <li>Lactic acidosis with hepatic steatosis (rare but potentially life-threatening toxicity associated with use of NRTIs).</li> </ul>

**Table 11. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**  
(Updated **January 29, 2008**)

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Elimination	Adverse Events
<b>Delavirdine (DLV)/ RESCRIPTOR</b>	100mg tablets or 200mg tablets	400mg 3 times/day; four 100mg tablets can be dispersed in ≥3 oz. of water to produce slurry; 200mg tablets should be taken as intact tablets; separate dose from antacids by 1 hour	Take without regard to meals	85%	5.8 hours	Metabolized by cytochrome P450 (3A inhibitor); 51% excreted in urine (<5% unchanged); 44% in feces	<ul style="list-style-type: none"> <li>• Rash*;</li> <li>• Increased transaminase levels;</li> <li>• Headaches</li> </ul>
<b>Efavirenz (EFV)/ SUSTIVA</b>  Also available as <b>ATRIPLA</b> - with FTC + TDF	50, 100, 200mg capsules or 600mg tablets <b>ATRIPLA</b> - EFV 600mg + FTC 200mg + TDF 300mg	600mg daily on an empty stomach, at or before bedtime	High-fat/high-caloric meals increase peak plasma concentrations of capsules by 39% and tablets by 79%; take on an empty stomach	Data not available	40–55 hours	Metabolized by cytochrome P450 (3A mixed inducer/ inhibitor);  No dosage adjustment in renal insufficiency if EFV is used alone;  <b>ATRIPLA</b> - not for patients with CrCl <50 mL/min	<ul style="list-style-type: none"> <li>• Rash*;</li> <li>• Central nervous system symptoms;†</li> <li>• Increased transaminase levels;</li> <li>• False-positive cannabinoid test;</li> <li>• Teratogenic in monkeys‡</li> </ul>
<b>Etravirine (ETR)/ INTELENCE</b>	<b>100mg tablets</b>	<b>200mg twice daily following a meal</b>	<b>Take following a meal.</b>  <b>Fasting conditions reduce drug exposure by approximately 50%</b>	<b>Unknown</b>	<b>41 ± 20 hours</b>	<b>Metabolized by cytochrome P450 (3A4, 2C9, and 2C19 substrate, 3A4 inducer, 2C9 and 2C19 inhibitor)</b>	<ul style="list-style-type: none"> <li>• <b>Rash*</b></li> <li>• <b>Nausea</b></li> </ul>
<b>Nevirapine (NVP)/ VIRAMUNE</b>	200mg tablets or 50mg/5 mL oral suspension	200mg daily for 14 days; thereafter, 200mg by mouth two times/day	Take without regard to meals	> 90%	25–30 hours	Metabolized by cytochrome P450 (3A inducer); 80% excreted in urine (glucuronidated metabolites; <5% unchanged); 10% in feces	<ul style="list-style-type: none"> <li>• Rash including Stevens-Johnson syndrome*</li> <li>• Symptomatic hepatitis, including fatal hepatic necrosis, have been reported‡</li> </ul>

\* During clinical trials, NNRTI was discontinued because of rash among 7% of patients taking nevirapine, 4.3% of patients taking delavirdine, 1.7% of patients taking efavirenz, and 2% of patients taking etravirine. Rare cases of Stevens-Johnson syndrome have been reported with the use of all four NNRTIs, the highest incidence seen with nevirapine use.

† Adverse events can include dizziness, somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, and euphoria. Overall frequency of any of these symptoms associated with use of efavirenz was 52%, as compared with 26% among controls subjects; 2.6% of those persons on efavirenz discontinued the drug because of these symptoms; symptoms usually subside spontaneously after 2–4 weeks.

‡ Symptomatic, sometimes serious, and even fatal hepatic events (accompanied by rash in approximately 50% of cases) occur with significantly higher frequency in treatment-naive female patients with prenevirapine CD4 counts >250 cells/mm<sup>3</sup> or in treatment-naive male patients with prenevirapine CD4 counts >400 cells/mm<sup>3</sup>. Nevirapine should not be initiated in these patients unless the benefit clearly outweighs the risk. This toxicity has not been observed when nevirapine is given as single doses to mothers or infants for prevention of mother-to-child HIV transmission.

**Table 12. Characteristics of Protease Inhibitors (PIs)**  
(Updated **January 29, 2008**)

Page 1 of 3

Generic Name/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio- availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Atazanavir (ATV)/ REYATAZ</b>	100, 150, 200mg capsules	400mg once daily  <u>If taken with efavirenz or tenofovir:</u> RTV 100mg + ATV 300mg once daily	Administration with food increases bioavailability  Take with food; avoid taking with antacids	Not determined	7 hours	Cytochrome P450 3A4 inhibitor and substrate  Dosage adjustment in hepatic insufficiency recommended (See <a href="#">Table 16</a> )	Room temperature (up to 25°C or 77°F)	<ul style="list-style-type: none"> <li>● Indirect hyperbilirubinemia</li> <li>● Prolonged PR interval— 1<sup>st</sup> degree symptomatic AV block in some pts</li> <li>● Use with caution in pts with underlying conduction defects or on concomitant medications that can cause PR prolongation</li> <li>● Hyperglycemia</li> <li>● Fat maldistribution</li> <li>● Possible increased bleeding episodes in pts with hemophilia</li> <li>● <b>Nephrolithiasis</b></li> </ul>
<b>Darunavir (DRV)/ PREZISTA</b>	300mg tablet	(DRV 600mg + RTV 100mg) twice daily	Food ↑ Cmax & AUC by 30% - should be administered with food	<u>Absolute bioavailability:</u> DRV alone – 37%; w/ RTV – 82%;	15 hours (when combined with RTV)	Cytochrome P450 3A4 inhibitor and substrate	Room temperature (up to 25°C or 77°F)	<ul style="list-style-type: none"> <li>● Skin rash (7%) – DRV has a sulfonamide moiety; Stevens-Johnson syndrome &amp; erythema multiforme have been reported.</li> <li>● <b>Hepatotoxicity</b></li> <li>● Diarrhea, nausea</li> <li>● Headache</li> <li>● Hyperlipidemia</li> <li>● Transaminase elevation</li> <li>● Hyperglycemia</li> <li>● Fat maldistribution</li> <li>● Possible increased bleeding episodes in pts with hemophilia</li> </ul>
<b>Fosamprenavir (FPV)/ LEXIVA</b>	700mg tablet Oral suspension: 50mg/mL	<u>ARV-naïve patients:</u> <ul style="list-style-type: none"> <li>● FPV 1,400mg BID or</li> <li>● (FPV 1,400mg + RTV 200mg) QD or</li> <li>● (FPV 700mg + RTV 100mg) BID</li> <li>● (FPV 1,400mg + RTV 100mg) QD</li> </ul> <u>PI-experienced pts (QD not recommended):</u> <ul style="list-style-type: none"> <li>● (FPV 700mg + RTV 100mg) BID</li> </ul> <u>Coadministration w/ EFV (FPV boosted only):</u> <ul style="list-style-type: none"> <li>● (FPV 700mg + RTV 100mg) BID or</li> <li>● (FPV 1,400mg + RTV 300mg) QD</li> </ul>	No significant change in amprenavir pharmacokinetics in fed or fasting state	Not established	7.7 hours (amprenavir)	Amprenavir is a cytochrome P450 3A4 inhibitor, inducer, and substrate  Dosage adjustment in hepatic insufficiency recommended (See <a href="#">Table 16</a> )	Room temperature (up to 25°C or 77°F)	<ul style="list-style-type: none"> <li>● Skin rash (19%)</li> <li>● Diarrhea, nausea, vomiting</li> <li>● Headache</li> <li>● Hyperlipidemia</li> <li>● Transaminase elevation</li> <li>● Hyperglycemia</li> <li>● Fat maldistribution</li> <li>● Possible increased bleeding episodes in patients with hemophilia</li> </ul>
<b>Indinavir/ CRIXIVAN</b>	200, 333, 400mg capsules	800mg every 8 hours;  <u>With RTV:</u> (IDV 800mg + RTV 100 or 200mg) every 12 hours	<u>Unboosted IDV:</u> Levels decrease by 77%  Take 1 hour before or 2 hours after meals; may take with skim milk or low-fat meal  <u>RTV-boosted IDV:</u> Take with or without food	65%	1.5–2 hours	Cytochrome P450  3A4 inhibitor (less than ritonavir)  Dosage adjustment in hepatic insufficiency recommended (See <a href="#">Table 16</a> )	Room temperature  15°–30°C (59°–86°F), protect from moisture	<ul style="list-style-type: none"> <li>● Nephrolithiasis</li> <li>● GI intolerance, nausea</li> <li>● Indirect hyperbilirubinemia</li> <li>● Hyperlipidemia</li> <li>● Headache, asthenia, blurred vision, dizziness, rash, metallic taste, thrombocytopenia, alopecia, and hemolytic anemia</li> <li>● Hyperglycemia</li> <li>● Fat maldistribution</li> <li>● Possible increased bleeding episodes in pts with hemophilia</li> </ul>

**Table 12. Characteristics of Protease Inhibitors (PIs)**  
(Updated **January 29, 2008**)

Page 2 of 3

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Lopinavir + Ritonavir (LPV/r)/ KALETRA</b>	Each tablet contains LPV 200mg + RTV 50mg Oral solution: Each 5 mL contains LPV 400mg + RTV 100mg  Note: Oral solution contains 42% alcohol	LPV 400mg + RTV 100mg (2 tablets or 5 mL) twice daily or LPV 800mg + RTV 200mg (4 tablets or 10mL) once daily (Note: once-daily dosing only recommended for treatment-naïve pts; not for patients receiving EFV, NVP, FPV, or NFV)  <u>With EFV or NVP:</u> For treatment-experienced pts: LPV 600mg + RTV 150mg (3 oral tablets) twice daily or LPV 533 mg + RTV 133 mg (6.7 mL oral solution) twice daily with food	Oral tablet -No food effect; take with or without food  Oral solution - Moderately fatty meal ↑ LPV AUC & C <sub>min</sub> by 80% & 54%, respectively; take with food	Not determined in humans	5–6 hours	Cytochrome P450 (3A4 inhibitor and substrate)	Oral tablet is stable at room temperature  Oral solution is stable at 2°–8°C until date on label; is stable when stored at room temperature (up to 25°C or 77°F) for 2 months	<ul style="list-style-type: none"> <li>• GI intolerance, nausea, vomiting, diarrhea (higher incidence with once-daily than twice-daily dosing)</li> <li>• Asthenia</li> <li>• Hyperlipidemia (esp. hypertriglyceridemia)</li> <li>• Elevated serum transaminases</li> <li>• Hyperglycemia</li> <li>• Fat maldistribution</li> <li>• Possible increased bleeding episodes in patients with hemophilia</li> </ul>
<b>Nelfinavir (NFV)/ VIRACEPT</b>	250mg tablets or 625 mg tablets  50mg/g oral powder	1,250mg two times/day or 750mg three times/day	Levels increase 2–3 fold  Take with meal or snack	20%–80%	3.5–5 hours	Cytochrome P450 3A4 inhibitor and substrate	Room temperature  15°–30°C (59°–86°F)	<ul style="list-style-type: none"> <li>• Diarrhea</li> <li>• Hyperlipidemia</li> <li>• Hyperglycemia</li> <li>• Fat maldistribution</li> <li>• Possible increased bleeding episodes among patients with hemophilia</li> <li>• Serum transaminase elevation</li> </ul>
<b>Ritonavir (RTV)/ NORVIR</b>	100mg capsules or 600mg/7.5 mL solution	600mg every 12 hours (when ritonavir is used as sole PI)  As pharmacokinetic booster for other PIs – 100mg – 400mg per day in 1–2 divided doses	Levels increase 15%  Take with food if possible; this may improve tolerability	Not determined	3–5 hours	Cytochrome P450 (3A4 > 2D6) substrate; Potent 3A4, 2D6 inhibitor	Refrigerate capsules  Capsules can be left at room temperature (up to 25°C or 77°F) for ≤30 days;  Oral solution should NOT be refrigerated	<ul style="list-style-type: none"> <li>• GI intolerance, nausea, vomiting, diarrhea</li> <li>• Paresthesias – circumoral and extremities</li> <li>• Hyperlipidemia, esp. hypertriglyceridemia</li> <li>• Hepatitis</li> <li>• Asthenia</li> <li>• Taste perversion</li> <li>• Hyperglycemia</li> <li>• Fat maldistribution</li> <li>• Possible increased bleeding episodes in patients with hemophilia</li> </ul>
<b>Saquinavir tablets and hard gel capsules (SQV)/ INVIRASE</b>	200mg hard gel capsules, 500mg tablets	(SQV 1,000mg + RTV 100mg) PO BID	Take within 2 hours of a meal when taken with RTV	4% erratic (when taken as sole PI)	1–2 hours	Cytochrome P450 (3A4 inhibitor and substrate)	Room temperature  15°–30°C (59°–86°F)	<ul style="list-style-type: none"> <li>• GI intolerance, nausea and diarrhea</li> <li>• Headache</li> <li>• Elevated transaminase enzymes</li> <li>• Hyperlipidemia</li> <li>• Hyperglycemia</li> <li>• Fat maldistribution</li> <li>• Possible increased bleeding episodes in patients with hemophilia</li> </ul>

\* Dose escalation for Ritonavir when used as sole PI: Days 1 and 2: 300mg two times; Days 3–5: 400mg two times; Days 6–13: 500mg two times; Day 14: 600mg two times/day.

**Table 12. Characteristics of Protease Inhibitors (PIs)**  
(Updated **January 29, 2008**)

Page 3 of 3

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Tipranavir (TPV)/ APTIVUS</b>	250mg capsules	500mg twice daily with ritonavir 200mg twice daily  Unboosted tipranavir is <u>not</u> recommended	Take both TPV & RTV with food.  Bio-availability increased with high- fat meal	Not determined	6 hours after single dose of TPV/ RTV	TPV – Cytochrome P450 (3A4 inducer and substrate)  Net effect when combined with RTV – CYP 3A4 inhibitor and CYP 2D6 inhibitor	Refrigerated capsules are stable until date on label; if stored at room temperature (up to 25°C or 77°F) – must be used within 60 days	<ul style="list-style-type: none"> <li>• Hepatotoxicity – clinical hepatitis including hepatic decompensation has been reported, monitor closely, esp. in patients with underlying liver diseases</li> <li>• Skin rash – TPV has a sulfonamide moiety, use with caution in patients with known sulfonamide allergy</li> <li>• Rare cases of fatal and nonfatal intracranial hemorrhages have been reported. Most patients had underlying comorbidity such as brain lesion, head trauma, recent neurosurgery, coagulopathy, hypertension, alcoholism, or on medication with increase risk for bleeding</li> <li>• Hyperlipidemia (esp. hypertriglyceridemia)</li> <li>• Hyperglycemia</li> <li>• Fat maldistribution</li> <li>• Possible increased bleeding episodes in patients with hemophilia</li> </ul>



**Table 13. Characteristics of Fusion Inhibitors (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Enfuvirtide (T20)/ FUZEON</b>	<ul style="list-style-type: none"> <li>Injectable – in lyophilized powder</li> <li>Each vial contains 108 mg of enfuvirtide, reconstitute with 1.1 mL of Sterile Water for injection for delivery of approximately 90mg/1 mL</li> </ul>	90mg (1 mL) subcutaneously (SC) two times/day	Not applicable	Not applicable	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	<p>Store at room temperature (up to 25°C or 77°F)</p> <p>Reconstituted solution should be stored under refrigeration at 2°C–8°C (36°F–46°F) and used within 24 hours</p>	<ul style="list-style-type: none"> <li>Local injection site reactions – almost 100% of patients (pain, erythema, induration, nodules and cysts, pruritus, ecchymosis)</li> <li>Increased bacterial pneumonia</li> <li>Hypersensitivity reaction (&lt;1%) - symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases; rechallenge is not recommended</li> </ul>

**Table 14. Characteristics of CCR5 Antagonists (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Maraviroc (MVC)/ SELZENTRY</b>	150mg and 300mg tablets	<ul style="list-style-type: none"> <li><b>150mg twice daily</b> when given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except tipranavir/ritonavir)</li> <li><b>300mg twice daily</b> when given with NRTIs, enfuvirtide, tipranavir/ritonavir, nevirapine, and other drugs that are not strong CYP3A inhibitors</li> <li><b>600mg twice daily</b> when given with CYP3A inducers, including efavirenz, rifampin, etc. (without a CYP3A inhibitor)</li> </ul>	No food effect; take with or without food	23% for 100mg dose and 33% (predicted) for 300mg	14–18 hrs	Cytochrome P450 (CYP3A substrate)	Room temperature	Abdominal pain, cough, dizziness, musculoskeletal symptoms, pyrexia, rash, upper respiratory tract infections, hepatotoxicity, orthostatic hypotension.

**Table 15. Characteristics of Integrase Inhibitors (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Raltegravir (RAL)/ ISENTRESS</b>	400mg tablets	40mg twice daily	Take with or without food	Not established	≈ 9 hrs	UGT1A1-mediated glucuronidation	Room temperature	Nausea, headache, diarrhea, pyrexia, CPK elevation

**Table 16. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency**Page 1 of 2 (Updated **January 29, 2008**)

Antiretrovirals	Daily Dose	Dosing in Renal Insufficiency	Dosing in Hepatic Impairment
<b>Nucleoside Reverse Transcriptase Inhibitors</b> – Note: Use of fixed-dose combination NRTI (+/- NNRTI) of: ATRIPLA, COMBIVIR, TRIZIVIR, EPZICOM – not recommended in patients with CrCl <50 mL/min; use of TRUVADA – not recommended in patients with CrCl <30 mL/min			
Abacavir* (ZIAGEN)	300mg PO BID	No need for dosage adjustment	No dosage recommendation
Didanosine (VIDEX)	>60 kg 400mg PO QD  <60 kg 250mg QD	<b>Dose</b> <b>CrCl (mL/min)</b> >60 kg <60 kg 30-59 200mg 125 mg 10-29 125 mg 100mg < 10 125 mg 75 mg CAPD or HD patients: use same dose as CrCl < 10 ml/min	No dosage recommendation
Emtricitabine (EMTRIVA)	200mg oral capsule PO QD or 240mg (24mL) oral solution PO QD	<b>CrCl</b> <b>capsule</b> <b>solution</b> 30-49 200mg q48h 120mg q24h 15-29 200mg q72h 80mg q24h <15 200mg q96h 60mg q24h or HD*	No dosage recommendation
Lamivudine* (EPIVIR)	300mg PO QD or 150mg PO BID	<b>CrCl (mL/min)</b> <b>Dose</b> 30-49 150mg QD 15-29 150mg x 1, then 100mg QD 5-14 150mg x 1, then 50mg QD <5 50mg x 1, then 25 mg QD or HD*	No dosage recommendation
Stavudine (ZERIT)	>60 kg 40mg PO BID <60 kg 30mg PO BID	<b>Dose</b> <b>CrCl (mL/min)</b> >60 kg <60 kg 26-50 20mg q12h 15 mg q12h 10-25 20mg q24h 15 mg q24h or HD*	No dosage recommendation
Tenofovir (VIREAD)	300mg PO QD	<b>CrCl (mL/min)</b> <b>Dose</b> 30-49 300mg q48h 10-29 300mg twice weekly ESRD 300mg q7d or HD*	No dosage recommendation
Tenofovir + Emtricitabine (TRUVADA)	1 tablet PO QD	<b>CrCl (mL/min)</b> <b>Dose</b> 30-49 tablet q48h <30 not recommended	No dosage recommendation
Zidovudine* (RETROVIR)	300mg PO BID	“Severe” renal impairment or HD*: 100mg TID or 300mg QD	No dosage recommendation
<b>Non-Nucleoside Reverse Transcriptase Inhibitors</b>			
Delavirdine (RESCRIPTOR)	400mg PO TID	No dosage adjustment necessary	No recommendation; use with caution in patients with hepatic impairment
Efavirenz (SUSTIVA) Efavirenz/tenofovir/ emtricitabine (ATRIPLA)	600mg PO QD One tablet PO QD	No dosage adjustment necessary Atripla™ - not recommended if CrCl <50 ml/min	No recommendation; use with caution in patients with hepatic impairment
Etravirine (INTELENCE)	200mg PO BID following a meal	No dosage adjustment necessary	No dosage adjustment for Child-Pugh Class A or B. Have not been evaluated in patients with Child-Pugh Class C.
Nevirapine (VIRAMUNE)	200mg PO BID	No dosage adjustment necessary	No data available; avoid use in patients with moderate to severe hepatic impairment

HD\* = dose after dialysis on dialysis days, HD = hemodialysis, CAPD = chronic ambulatory peritoneal dialysis, ESRD = End Stage Renal Disease

**Table 16. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency**

Page 2 of 2 (Updated January 29, 2008)

Antiretrovirals	Daily Dose	Dosing in Renal Insufficiency	Dosing in Hepatic Impairment
<b>Protease Inhibitors</b>			
Atazanavir (REYATAZ)	400mg PO QD	No dosage adjustment for patients with renal dysfunction not requiring hemodialysis Treatment-naïve patients on hemodialysis: ATV 300mg + RTV 100mg once daily Treatment-experienced patients on hemodialysis: ATV- or RTV-boosted ATV not recommended	<b>Child-Pugh Score</b> 7-9      Dose: 300mg QD >9      Dose: not recommended
Darunavir (PREZISTA, DRV)	(DRV 600mg + RTV 100mg) PO BID	No dosage adjustment necessary	No dosage adjustment in patients with mild to moderate hepatic impairment. DRV is not recommended in patients with severe hepatic impairment
Fosamprenavir (LEXIVA)	1,400mg PO BID	No dosage adjustment necessary	<b>Child-Pugh Score</b> 5-8      Dose: 700mg BID 9-12      Dose: not recommended ritonavir boosting should not be used in patients with hepatic impairment
Indinavir (CRIXIVAN)	800mg PO q8h	No dosage adjustment necessary	Mild to moderate hepatic insufficiency because of cirrhosis: 600mg q8h
Lopinavir/ritonavir (KALETRA)	400/100mg PO BID or 800/200mg PO QD (QD only for tx-naïve pats)	No dosage adjustment necessary	No dosage recommendation; use with caution in patients with hepatic impairment
Nelfinavir (VIRACEPT)	1,250mg PO BID	No dosage adjustment necessary	No dosage recommendation; use with caution in patients with hepatic impairment
Ritonavir (NORVIR)	600mg PO BID	No dosage adjustment necessary	No dosage adjustment in mild hepatic impairment; no data for moderate to severe impairment, use with caution
Saquinavir (INVIRASE)	1,000mg with RTV 100mg PO BID	No dosage adjustment necessary	No dosage recommendation; use with caution in patients with hepatic impairment
Tipranavir (APTIVUS)	500mg PO BID with ritonavir 200mg PO BID	No dosage adjustment necessary	No dosage recommendation; use with caution in patients with hepatic impairment; TPV/RTV is contraindicated in pts with moderate to severe (Child-Pugh Class B & C) hepatic insufficiency
<b>Fusion Inhibitors</b>			
Enfuvirtide (FUZEON)	90mg SQ q12h	No dosage adjustment necessary	No dosage recommendation
<b>CCR5 Antagonists</b>			
Maraviroc (SELZENTRY)	The recommended dose differs based on concomitant medications because of drug interactions. See Table 14 for detailed dosing information.	No dosage recommendation; use with caution. Patients with CrCL <50 mL/min should receive MVC and CYP3A inhibitor only if potential benefit outweigh the risk.	No dosage recommendations. Concentrations will likely be increased in patients with hepatic impairment.
<b>Integrase Inhibitors</b>			
Raltegravir (ISENRESS)	400mg twice daily	No dosage adjustment.	No dosage adjustment.

**Creatinine Clearance calculation:**

Male:  $(140 - \text{age in yr}) \times \text{weight (kg)} / 72 \times \text{S.Cr.}$       Female:  $(140 - \text{age in yr}) \times \text{weight (kg)} \times 0.85 / 72 \times \text{S.Cr.}$

**Child-Pugh Score**

Component	Score Given		
	1	2	3
Encephalopathy*	None	Grade 1-2	Grade 3-4
Ascites	None	Mild or controlled by diuretics	Moderate or refractory despite diuretics
Albumin	>3.5 g/dl	2.8 to 3.5 g/dl	<2.8 g/dl
Total Bilirubin	<2 mg/dL (<34 μ mol/L)	2 to 3 mg/dL (34 μ mol/L to 50 μ mol/L)	>3 mg/dL (>50 μ mol/L)
OR Modified Total Bilirubin**	<4 mg/dL	4-7 mg/dL	>7 mg/dL
Prothrombin time (sec prolonged) OR INR	<4  <1.7	4-6  1.7-2.3	>6  >2.3

\* NB: Encephalopathy Grades - Grade 1: Mild confusion, anxiety, restlessness, fine tremor, slowed coordination; Grade 2: Drowsiness, disorientation, asterixis; Grade 3: Somnolent but rousable, marked confusion, incomprehensible speech, incontinence, hyperventilation; Grade 4: Coma, decerebrate posturing, flaccidity

\*\* Modified Total Bilirubin used to score patients who have Gilbert's syndrome or who are taking indinavir

**Child-Pugh Classification** - Child-Pugh Class A = score 5-6; Class B = score 7-9; Class C = score >9

**Table 17. Strategies to Improve Adherence to Antiretroviral Therapy (Updated October 29, 2004)**

- Establish readiness to start therapy
- Provide education on medication dosing
- Review potential side effects
- Anticipate and treat side effects
- Utilize educational aids including pictures, pillboxes, and calendars
- Engage family, friends
- Simplify regimens, dosing, and food requirements
- Utilize team approach with nurses, pharmacists, and peer counselors
- Provide accessible, trusting health care team

**Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations**

Page 1 of 6 (Updated **January 29, 2008**)

**18a. Potentially Life-Threatening and Serious Adverse Events**

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>POTENTIALLY LIFE-THREATENING ADVERSE EFFECTS (In alphabetical order)</b>						
<b>Acute hepatic failure</b>	NVP	<p><u>Onset:</u> Greatest risk within first few weeks of therapy; can occur through 18 weeks</p> <p><u>Symptoms:</u> Abrupt onset of flu-like symptoms (nausea, vomiting, myalgia, fatigue), abdominal pain, jaundice, or fever with or without skin rash; may progress to fulminant hepatic failure with encephalopathy</p> <p>Approximately 1/2 of the cases have accompanying skin rash</p> <p>Some may present as part of DRESS syndrome (drug rash with eosinophilia and systemic symptoms)</p>	<p><u>Symptomatic hepatic events:</u></p> <ul style="list-style-type: none"> <li>• 4% overall (2.5%–11% from different trials)</li> <li>• In women - 11% in those w/ pre-NVP CD4 &gt;250 cells/mm<sup>3</sup> vs. 0.9% w/ CD4 &lt;250 cells/mm<sup>3</sup></li> <li>• In men - 6.3% w/ pre-NVP CD4 &gt;400 cells/mm<sup>3</sup> vs. 2.3% w/ CD4 &lt;400 cells/mm<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Treatment-naïve patients with higher CD4 count at initiation (&gt;250 cells/mm<sup>3</sup> in women &amp; &gt;400 cells/mm<sup>3</sup> in men)</li> <li>• Female gender (including pregnant women)</li> <li>• HIV (-) individuals when NVP is used for post-exposure prophylaxis</li> <li>• High NVP concentration</li> </ul>	<ul style="list-style-type: none"> <li>• Avoid initiation of NVP in women w/ CD4 &gt;250 cells/mm<sup>3</sup> or men w/ CD4 &gt;400 cells/mm<sup>3</sup> unless the benefit clearly outweighs the risk</li> <li>• Counsel patients re: signs &amp; symptoms of hepatitis; stop NVP &amp; seek medical attention if signs &amp; symptoms of hepatitis, severe skin rash, or hypersensitivity reactions appear</li> <li>• Monitoring of ALT &amp; AST (every 2 weeks x first month, then monthly x 3 months, then every 3 months)</li> <li>• Obtain AST &amp; ALT in patients with rash</li> <li>• 2-week dose escalation may reduce incidence of hepatic events</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue ARV including nevirapine (caution should be taken in discontinuation of 3TC, FTC, or TDF in HBV-coinfected patients)</li> <li>• Discontinue all other hepatotoxic agents if possible</li> <li>• Rule out other causes of hepatitis</li> <li>• Aggressive supportive care as indicated</li> </ul> <p><b>Note:</b> Hepatic injury may progress despite treatment discontinuation. Careful monitoring should continue until symptom resolution.</p> <p><b>Do not rechallenge patient with NVP</b></p> <p>The safety of other NNRTIs (EFV, <b>ETR</b>, or DLV) in patients who experienced significant hepatic event from NVP is unknown – use with caution.</p>
<b>Lactic acidosis/hepatic steatosis +/- pancreatitis (severe mitochondrial toxicities)</b>	NRTIs, esp. d4T, ddI, ZDV	<p><u>Onset:</u> months after initiation of NRTIs</p> <p><u>Symptoms:</u></p> <ul style="list-style-type: none"> <li>• Insidious onset with nonspecific gastrointestinal prodrome (nausea, anorexia, abdominal pain, vomiting), weight loss, and fatigue;</li> <li>• Subsequent symptoms may be rapidly progressive with tachycardia, tachypnea, hyperventilation, jaundice, muscular weakness, mental status changes, or respiratory distress</li> <li>• Some may present with multi-organ failure (hepatic failure, acute pancreatitis, encephalopathy, and respiratory failure)</li> </ul> <p><u>Laboratory findings:</u></p> <ul style="list-style-type: none"> <li>• Increased lactate (often &gt;5 mmole)</li> <li>• Low arterial pH (some as low as &lt;7.0)</li> <li>• Low serum bicarbonate</li> <li>• Increased anion gap</li> <li>• Elevated serum transaminases, prothrombin time, bilirubin</li> <li>• Low serum albumin</li> <li>• Increase serum amylase &amp; lipase in patients with pancreatitis</li> <li>• Histologic findings of the liver – microvesicular or macrovesicular steatosis</li> </ul>	<p>Rare</p> <p>One estimate 0.85 cases per 1,000 patient-years</p> <p>Mortality up to 50% in some case series, (esp. in patients with serum lactate &gt;10 mmole)</p>	<ul style="list-style-type: none"> <li>• d4T + ddI</li> <li>• d4T, ZDV, ddI use (d4T most frequently implicated)</li> <li>• Long duration of NRTI use</li> <li>• Female gender</li> <li>• Obesity</li> <li>• Pregnancy (esp. with d4T+ddI)</li> <li>• ddI + hydroxyurea or ribavirin</li> <li>• High baseline body mass index</li> </ul>	<ul style="list-style-type: none"> <li>• Routine monitoring of lactic acid is not recommended</li> <li>• Consider obtaining lactate levels in patients with low serum bicarbonate or high anion gap and with complaints consistent with lactic acidosis</li> <li>• Appropriate phlebotomy technique for obtaining lactate level should be employed</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARVs if this syndrome is highly suspected (diagnosis is established by clinical correlations, drug history, and lactate level)</li> <li>• Symptomatic support with fluid hydration</li> <li>• Some patients may require IV bicarbonate infusion, hemodialysis or hemofiltration, parenteral nutrition or mechanical ventilation</li> <li>• IV thiamine and/or riboflavin – resulted in rapid resolution of hyperlactatemia in some case reports</li> </ul> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• Interpretation of high lactate level should be done in the context of clinical findings</li> <li>• The implication of asymptomatic hyperlactatemia is unknown at this point</li> </ul> <p><b>ARV treatment options:</b></p> <ul style="list-style-type: none"> <li>• Use NRTIs with less propensity of mitochondrial toxicities – (e.g., ABC, TDF, 3TC, FTC) – should not be introduced until lactate returns to normal</li> <li>• Recommend close monitoring of serum <b>bicarbonate or</b> lactate after restarting NRTIs</li> <li>• Consider NRTI-sparing regimens</li> </ul>



**Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations**

Page 2 of 6 (Updated **January 29, 2008**)

**18a. Potentially Life-Threatening and Serious Adverse Events** (continued)

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>POTENTIALLY LIFE-THREATENING ADVERSE EFFECTS (In alphabetical order)</b>						
<b>Hypersensitivity reaction (HSR)</b>	ABC	<p><u>Onset of 1<sup>st</sup> reaction:</u> median onset – 9 days; approximately 90% within 1<sup>st</sup> 6 weeks</p> <p><u>Onset of rechallenge reactions:</u> within hours of rechallenge dose</p> <p><u>Symptoms:</u> acute onset of symptoms (in descending frequency): high fever, diffuse skin rash, malaise, nausea, headache, myalgia, chills, diarrhea, vomiting, abdominal pain, dyspnea, arthralgia, respiratory symptoms (pharyngitis, dyspnea/tachypnea)</p> <p><i>With continuation of ABC, symptoms may worsen to include:</i> hypotension, respiratory distress, vascular collapse</p> <p><i>Rechallenge reactions:</i> generally greater intensity than 1<sup>st</sup> reaction, can mimic anaphylaxis</p>	Clinically suspected ≈ 8% in clinical trial (2%–9%); 5% in retrospective analysis; <b>significantly reduced with pre-treatment HLA screening</b>	<ul style="list-style-type: none"> <li>•HLA-B*5701, HLA-DR7, HLA-DQ3 (from Australian data)</li> <li>•Higher incidence of grade 3 or 4 HSR with 600mg once-daily dose than 300mg twice-daily dose in one study (5% vs. 2%)</li> </ul>	<ul style="list-style-type: none"> <li>•<b>HLA B*5701 screening prior to initiation of ABC</b></li> <li>•<b>Those patients tested (+) for HLA B*5701 should be labelled as allergic to abacavir in medical records</b></li> <li>•Educate patients about potential signs and symptoms of HSR and need for reporting of symptoms promptly</li> <li>•Wallet card with warning information for patients</li> </ul>	<ul style="list-style-type: none"> <li>•Discontinue ABC and other ARVs</li> <li>•Rule out other causes of symptoms (e.g., intercurrent illnesses such as viral syndromes, and other causes of skin rash, etc.)</li> <li>•Most signs and symptoms resolve 48 hours after discontinuation of ABC</li> </ul> <p><i>More severe cases:</i></p> <ul style="list-style-type: none"> <li>•Symptomatic support – antipyretic, fluid resuscitation, pressure support (if necessary)</li> </ul> <p><b>Do not rechallenge patients with ABC after suspected HSR</b></p>
<b>Lactic acidosis/ Rapidly progressive ascending neuromuscular weakness</b>	Most frequently implicated ARV: d4T	<p><u>Onset:</u> months after initiation of ARV; then dramatic motor weakness occurring within days to weeks</p> <p><u>Symptoms:</u> very rapidly progressive ascending demyelinating polyneuropathy, may mimic Guillain-Barré syndrome; some patients may develop respiratory paralysis requiring mechanical ventilation; resulted in deaths in some patients</p> <p><u>Laboratory findings may include:</u></p> <ul style="list-style-type: none"> <li>•Low arterial pH</li> <li>•Increased lactate</li> <li>•Low serum bicarbonate</li> <li>•Increased anion gap</li> <li>•Markedly increased creatine phosphokinase</li> </ul>	Rare	<ul style="list-style-type: none"> <li>•Prolonged d4T use (found in 61 of 69 [88%] cases in one report)</li> </ul>	<ul style="list-style-type: none"> <li>•Early recognition and discontinuation of ARVs may avoid further progression</li> </ul>	<ul style="list-style-type: none"> <li>•Discontinuation of ARVs</li> <li>•Supportive care, including mechanical ventilation if needed (as in cases of lactic acidosis listed previously)</li> <li>•Other measures attempted with variable success: plasmapheresis, high-dose corticosteroid, intravenous immunoglobulin, carnitine, acetylcarnitine</li> <li>•Recovery often takes months – ranging from complete recovery to substantial residual deficits</li> <li>•Symptoms may be irreversible in some patients</li> </ul> <p><b>Do not rechallenge patient with offending agent</b></p>
<b>Stevens-Johnson syndrome (SJS)/ Toxic epidermal necrosis (TEN)</b>	NVP > EFV, DLV, <b>ETR</b>  Also reported with: APV, FPV, ABC, DRV, ZDV, ddI, IDV, LPV/r, ATV	<p><u>Onset:</u> first few days to weeks after initiation of therapy</p> <p><u>Symptoms:</u> <i>Cutaneous involvement:</i></p> <ul style="list-style-type: none"> <li>•Skin eruption with mucosal ulcerations (may involve orolingival mucosa, conjunctiva, anogenital area)</li> <li>•Can rapidly evolve with blister or bullae formation</li> <li>•May eventually evolve to epidermal detachment and/or necrosis</li> <li>•<b>For NVP, may occur with hepatic toxicity</b></li> </ul> <p><i>Systemic Symptoms:</i> fever, tachycardia, malaise, myalgia, arthralgia</p> <p><i>Complications:</i> ↓ oral intake → fluid depletion; bacterial or fungal superinfection; multiorgan failure</p>	NVP: 0.3%–1% DLV & EFV: 0.1%, <b>ETR &lt;0.1%</b>  1–2 case reports for ABC, FPV, ddI, ZDV, IDV, LPV/r, ATV, DRV	<ul style="list-style-type: none"> <li>•NVP: Female, Black, Asian, Hispanic</li> </ul>	<ul style="list-style-type: none"> <li>•<b>For NVP:</b> 2-week lead in period with 200mg once daily, then escalate to 200mg twice daily</li> <li>•Educate patients to report symptoms as soon as they appear</li> <li>•Avoid use of corticosteroid during NVP dose escalation – may increase incidence of rash</li> </ul>	<ul style="list-style-type: none"> <li>•Discontinue all ARVs and any other possible agent(s) (e.g., cotrimoxazole) <u>Aggressive symptomatic support may include:</u></li> <li>•Intensive care support</li> <li>•Aggressive local wound care (e.g., in a burn unit)</li> <li>•Intravenous hydration</li> <li>•Parenteral nutrition, if necessary</li> <li>•Pain management</li> <li>•Antipyretics</li> <li>•Empiric broad-spectrum antimicrobial therapy if superinfection is suspected</li> </ul> <p><u>Controversial management strategies:</u></p> <ul style="list-style-type: none"> <li>•Corticosteroid</li> <li>•Intravenous immunoglobulin</li> </ul> <p><b>Do not rechallenge patient with offending agent</b></p> <ul style="list-style-type: none"> <li>• It is unknown whether patients who experienced SJS while on one NNRTI are more susceptible to SJS from another NNRTI – most experts would suggest avoiding use of this class unless no other options are available</li> </ul>

**Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations**

Page 3 of 6 (Updated **January 29, 2008**)

**18a. Potentially Life-Threatening and Serious Adverse Events** (continued)

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>POTENTIALLY SERIOUS ADVERSE EFFECTS (in alphabetical order)</b>						
<b>Bleeding events</b>	TPV/r: reports of intracranial hemorrhage (ICH)  PIs: ↑ bleeding in hemophiliac patients	<u>Median time to ICH event:</u> 525 days on TPV/r therapy  <u>Hemophiliac patients:</u> ↑ spontaneous bleeding tendency – in joints, muscles, soft tissues, and hematuria	In 2006, 13 cases of ICH reported, w/ TPV/r use, including 8 fatalities  <u>For hemophilia:</u> frequency unknown	<u>For ICH:</u> •Patients with CNS lesions, head trauma, recent neurosurgery, coagulopathy, hypertension, alcohol abuse, or receiving anticoagulant or anti-platelet agents <u>For hemophiliac patients:</u> •PI use	<u>For ICH:</u> •Avoid use of TPV/r in patients at risk for ICH <u>For hemophiliac patients:</u> •Consider using NNRTI-based regimen •Monitor for spontaneous bleeding	<u>For ICH:</u> •Discontinue TPV/r – manage ICH with supportive care <u>For hemophiliac patients:</u> •May require increased use of Factor VIII products
<b>Bone marrow suppression</b>	ZDV	<u>Onset:</u> few weeks to months  <u>Laboratory abnormalities:</u> •Anemia •Neutropenia  <u>Symptoms:</u> fatigue because of anemia; potential for increase of bacterial infections because of neutropenia	Severe Anemia (Hgb < 7 g/dL): 1.1%–4%  Severe Neutropenia (ANC <500 cells/mm <sup>3</sup> ): 1.8%–8%	•Advanced HIV •High dose •Pre-existing anemia or neutropenia •Concomitant use of bone marrow suppressants (such as cotrimoxazole, ribavirin, ganciclovir, etc.)	•Avoid use in patients at risk •Avoid other bone marrow suppressants if possible •Monitor CBC with differential at least every three months (more frequently in patients at risk)	•Switch to another NRTI if there is an alternative option; •Discontinue concomitant bone marrow suppressant if there is an alternative option; otherwise: <u>For neutropenia:</u> •Identify and treat other causes •Consider treatment with filgrastim <u>For anemia:</u> •Identify and treat other causes of anemia (if present) •Blood transfusion if indicated •Consider erythropoietin therapy
<b>Hepatotoxicity (clinical hepatitis or asymptomatic serum transaminase elevation)</b>	All NNRTIs; All PIs; <b>Most</b> NRTIs; <b>Maraviroc</b>	<u>Onset:</u> NNRTI: for NVP – 2/3 within 1 <sup>st</sup> 12 weeks NRTI: over months to years PI: generally after weeks to months <u>Symptoms/Findings:</u> <b>NNRTI:</b> •Asymptomatic to non-specific symptoms such as anorexia, weight loss, or fatigue. Approximately ½ of patients with NVP-associated symptomatic hepatic events present with skin rash. <b>NRTI:</b> •ZDV, ddI, d4T: may cause hepatotoxicity associated with lactic acidosis with microvesicular or macrovesicular hepatic steatosis because of mitochondrial toxicity •3TC, FTC, or TDF: HBV-coinfected patients may develop severe hepatic flare when these drugs are withdrawn or when resistance develops. <b>PI:</b> •Clinical hepatitis & hepatic decompensation have been reported with TPV/RTV & DRV/RTV, but also other PIs to varying degrees. Underlying liver disease increases risk. •Generally asymptomatic, some with anorexia, weight loss, jaundice, etc.	Varies with the different agents	•Hepatitis B or C coinfection •Alcoholism •Concomitant hepatotoxic drugs •Elevated ALT &/or AST at baseline •For NVP-associated hepatic events – female w/ pre-NVP CD <sub>4</sub> >250cells/mm <sup>3</sup> or male w/ pre-NVP CD <sub>4</sub> >400cells/mm <sup>3</sup>	•NVP: monitor liver-associated enzymes at baseline, 2 & 4 weeks, then monthly for 1 <sup>st</sup> 3 months; then every 3 months •TPV/RTV: contraindicated in patients with moderate to severe hepatic insufficiency; for other patients follow “frequently” during treatment •Other agents: monitor liver-associated enzymes at least every 3–4 months or more frequently in patients at risk	•Rule out other causes of hepatotoxicity – alcoholism, viral hepatitis, chronic HBV w/ 3TC, FTC, or TDF withdrawal, or HBV resistance, etc. <u>For symptomatic patients:</u> •Discontinue all ARVs (with caution in patients with chronic HBV infection treated w/ 3TC, FTC, and/or TDF) and other potential hepatotoxic agents •After symptoms subside & serum transaminases returned to normal, construct a new ARV regimen without the potential offending agent(s) <u>For asymptomatic patients:</u> •If ALT >5–10x ULN, some may consider discontinuing ARVs, others may continue therapy with close monitoring •After serum transaminases return to normal, construct a new ARV regimen without the potential offending agent(s)  <b>Note:</b> Please refer to information regarding NVP-associated symptomatic hepatic events & NRTI-associated lactic acidosis with hepatic steatosis in this table

**Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations**Page 4 of 6 (Updated **January 29, 2008**)**18a. Potentially Life-Threatening and Serious Adverse Events** (continued)

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>POTENTIALLY SERIOUS ADVERSE EFFECTS (in alphabetical order)</b>						
<b>Nephrolithiasis/ urolithiasis/ crystalluria</b>	IDV: most frequent; <b>Reports with atazanavir</b>	<u>Onset:</u> any time after beginning of therapy – especially at times of reduced fluid intake  <u>Laboratory abnormalities:</u> pyuria, hematuria, crystalluria; rarely – rise in serum creatinine & acute renal failure  <u>Symptoms:</u> flank pain and/or abdominal pain (can be severe), dysuria, frequency	12.4% of nephrolithiasis reported in clinical trials (4.7%–34.4% in different trials)	<ul style="list-style-type: none"> <li>•History of nephrolithiasis</li> <li>•Patients unable to maintain adequate fluid intake</li> <li>•High peak IDV concentration</li> <li>•↑ duration of exposure</li> </ul>	<ul style="list-style-type: none"> <li>•Drink at least 1.5–2 liters of non-caffeinated fluid (preferably water) per day</li> <li>•Increase fluid intake at first sign of darkened urine</li> <li>•Monitor urinalysis and serum creatinine every 3–6 months</li> </ul>	<ul style="list-style-type: none"> <li>•Increase hydration</li> <li>•Pain control</li> <li>•May consider switching to alternative agent or therapeutic drug monitoring if treatment option is limited</li> <li>•Stent placement may be required</li> </ul>
<b>Nephrotoxicity</b>	IDV, TDF	<u>Onset:</u> IDV: months after therapy TDF: weeks to months after therapy  <u>Laboratory and other findings:</u> IDV: ↑ serum creatinine, pyuria; hydronephrosis or renal atrophy TDF: ↑ serum creatinine, proteinuria, hypophosphatemia, glycosuria, hypokalemia, non-anion gap metabolic acidosis  <u>Symptoms:</u> IDV: asymptomatic; rarely develop to end stage renal disease TDF: asymptomatic to signs of nephrogenic diabetes insipidus, Fanconi syndrome	Severe toxicity is rare	<ul style="list-style-type: none"> <li>•History of renal disease</li> <li>•Concomitant use of nephrotoxic drugs</li> </ul>	<ul style="list-style-type: none"> <li>•Avoid use of other nephrotoxic drugs</li> <li>•Adequate hydration if on IDV therapy</li> <li>•Monitor serum creatinine, urinalysis, serum potassium and phosphorus in patients at risk</li> </ul>	<ul style="list-style-type: none"> <li>•Stop offending agent, generally reversible</li> <li>•Supportive care</li> <li>•Electrolyte replacement as indicated</li> </ul>
<b>Pancreatitis</b>	ddI alone; ddI + d4T; ddI + hydroxyurea (HU), ribavirin (RBV), or TDF	<u>Onset:</u> usually weeks to months  <u>Laboratory abnormalities:</u> increased serum amylase and lipase  <u>Symptoms:</u> postprandial abdominal pain, nausea, vomiting	ddI alone: 1%–7%  ddI with HU: ↑ by 4–5 fold  ddI with RBV, d4T, or TDF: ↑ frequency	<ul style="list-style-type: none"> <li>•High intracellular and/or serum ddI concentrations</li> <li>•History of pancreatitis</li> <li>•Alcoholism</li> <li>•Hypertriglyceridemia</li> <li>•Concomitant use of ddI with d4T, HU, or RBV</li> <li>•Use of ddI + TDF without ddI dose reduction</li> </ul>	<ul style="list-style-type: none"> <li>•ddI should not be used in patients with history of pancreatitis</li> <li>•Avoid concomitant use of ddI with d4T, TDF, HU, or RBV</li> <li>•<b>Reduce ddI dose when used with TDF</b></li> <li>•Monitoring of amylase/lipase in asymptomatic patients is generally not recommended</li> </ul>	<ul style="list-style-type: none"> <li>•Discontinue offending agent(s)</li> <li>•Symptomatic management of pancreatitis: bowel rest, IV hydration, pain control, then gradual resumption of oral intake</li> <li>•Parenteral nutrition may be necessary in patients with recurrent symptoms upon resumption of oral intake</li> </ul>

**Table 18. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations**

Page 5 of 6 (Updated January 29, 2008)

**18b. Adverse Events With Potential Long-Term Complications** (in alphabetical order)

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>Cardiovascular effects</b>	Possibly PIs and other ARVs with unfavorable effects on lipids (e.g. EFV, d4T)	<u>Onset:</u> months to years after beginning of therapy  <u>Presentation:</u> premature coronary artery disease	3–6 per 1,000 patient-years	Other risk factors for cardiovascular disease such as smoking, age, hyperlipidemia, hypertension, diabetes mellitus, family history of premature coronary artery disease, and personal history of coronary artery disease	<ul style="list-style-type: none"> <li>Assess each patient's cardiac risk factors</li> <li>Consider non-PI based regimen</li> <li>Monitor &amp; identify patients with hyperlipidemia or hyperglycemia</li> <li>Counseling for life style modification: smoking cessation, diet, and exercise</li> </ul>	<ul style="list-style-type: none"> <li>Early diagnosis, prevention, and pharmacologic management of other cardiovascular risk factors such as hyperlipidemia, hypertension, and insulin resistance/diabetes mellitus</li> <li>Assess cardiac risk factors</li> <li>Lifestyle modifications: diet, exercise, and/or smoking cessation</li> <li>Switch to agents with less propensity for increasing cardiovascular risk factors, i.e., NNRTI- or ATV-based regimen &amp; avoid d4T use</li> </ul>
<b>Hyperlipidemia</b>	All PIs (except unboosted ATV); d4T; EFV (to a lesser extent)	<u>Onset:</u> weeks to months after beginning of therapy  <u>Presentation:</u> <u>All PIs except ATV:</u> ↑ in LDL & total cholesterol (TC) & triglyceride (TG), ↓ in HDL <u>LPV/r &amp; RTV:</u> disproportionate ↑ in TG  <u>d4T:</u> mostly ↑ in TG; may also have ↑ in LDL & total cholesterol (TC)  <u>EFV or NVP:</u> ↑ in HDL, slight ↑ TG	Varies with different agents <u>Swiss Cohort:</u> ↑TC & TG – 1.7–2.3x higher in patients receiving (non-ATV) PI	<ul style="list-style-type: none"> <li>Underlying hyperlipidemia</li> <li>Risk based on ARV therapy</li> <li>PI: LPV/r &amp; RTV - boosted PIs &gt; NFV &amp; APV &gt; IDV &gt; ATV;</li> <li>NNRTI: EFV more common than NVP</li> <li>NRTI: d4T most common</li> </ul>	<ul style="list-style-type: none"> <li>Use non-PI, non-d4T based regimen</li> <li>Use ATV-based regimen</li> <li>Fasting lipid profile at baseline, 3–6 months after starting new regimen, then annually or more frequently if indicated (in high-risk patients, or patients with abnormal baseline levels)</li> </ul>	<ul style="list-style-type: none"> <li>Follow HIVMA/ACTG guidelines for management [391]</li> <li>Assess cardiac risk factor</li> <li>Lifestyle modification: diet, exercise, and/or smoking cessation</li> <li>Switching to agents with less propensity for causing hyperlipidemia</li> </ul> <p><u>Pharmacologic Management:</u></p> <ul style="list-style-type: none"> <li>↑ total cholesterol, LDL, TG 200–500mg/dL: “statins” – pravastatin or atorvastatin (See <a href="#">Tables 20 &amp; 21</a> for drug interaction information)</li> <li>TG &gt;500mg/dL: gemfibrozil or micronized fenofibrate</li> </ul>
<b>Insulin resistance/ Diabetes mellitus</b>	All PIs	<u>Onset:</u> weeks to months after beginning of therapy  <u>Presentation:</u> Polyuria, polydipsia, polyphagia, fatigue, weakness; exacerbation of hyperglycemia in patients with underlying diabetes	Up to 3%–5% of patients developed diabetes in some series	<ul style="list-style-type: none"> <li>Underlying hyperglycemia, family history of diabetes mellitus</li> </ul>	<ul style="list-style-type: none"> <li>Use PI-sparing regimens</li> <li>Fasting blood glucose 1–3 months after starting new regimen, then at least every 3–6 months</li> </ul>	<ul style="list-style-type: none"> <li>Diet and exercise</li> <li>Consider switching to an NNRTI-based regimen</li> <li>Metformin</li> <li>“Glitazones”</li> <li>Sulfonylurea</li> <li>Insulin</li> </ul>
<b>Osteonecrosis</b>	All PIs	<u>Clinical Presentation (generally similar to non-HIV population):</u> <ul style="list-style-type: none"> <li>Insidious in onset, with subtle symptoms of mild to moderate periarticular pain</li> <li>85% of the cases involving one or both femoral heads, but other bones may also be affected</li> <li>Pain may be triggered by weight bearing or movement</li> </ul>	Reported incidence on the rise <u>Symptomatic osteonecrosis:</u> 0.08%–1.33%; <u>Asymptomatic osteonecrosis:</u> 4% from MRI reports	<ul style="list-style-type: none"> <li>Diabetes</li> <li>Prior steroid use</li> <li>Old age</li> <li>Alcohol use</li> <li>Hyperlipidemia</li> <li>Role of ARVs and osteonecrosis – still controversial</li> </ul>	<ul style="list-style-type: none"> <li>Risk reduction (e.g., limit steroid and alcohol use)</li> <li>Asymptomatic cases w/ &lt;15% bony head involvement – follow with MRI every 3–6 months x 1 yr, then every 6 months x 1 yr, then annually – to assess for disease progression</li> </ul>	<p><u>Conservative management:</u></p> <ul style="list-style-type: none"> <li>↓ weight bearing on affected joint;</li> <li>Remove or reduce risk factors</li> <li>Analgesics as needed</li> </ul> <p><u>Surgical Intervention:</u></p> <ul style="list-style-type: none"> <li>Core decompression +/- bone grafting – for early stages of disease</li> <li>For more severe and debilitating disease – total joint arthroplasty</li> </ul>

**Table 18. Antiretroviral Therapy Associated Adverse Effects and Management Recommendations**Page 6 of 6 (Updated **January 29, 2008**)**18c. Adverse Effects Compromising Quality of Life and/or With Potential Impact on Medication Adherence** (in alphabetical order)

Adverse effects	Causative ARVs	Onset/clinical manifestation	Estimated frequency	Risk Factors	Prevention/monitoring	Management
<b>Central nervous system effects</b>	EFV	<u>Onset:</u> begin with first few doses <u>Symptoms:</u> may include one or more of the following: drowsiness, somnolence, insomnia, abnormal dreams, dizziness, impaired concentration & attention span, depression, hallucination; exacerbation of psychiatric disorders; psychosis; suicidal ideation  Most symptoms subside or diminish after 2–4 weeks	>50% of patients may have some symptoms	<ul style="list-style-type: none"> <li>•Pre-existing or unstable psychiatric illnesses</li> <li>•Use of concomitant drugs with CNS effects</li> <li>•Rates in African-Americans may be higher due to genetic predisposition of slower clearance</li> </ul>	<ul style="list-style-type: none"> <li>•Take at bedtime or 2–3 hours before bedtime</li> <li>•Take on an empty stomach to reduce drug concentration &amp; CNS effects</li> <li>•Warn patients regarding restriction of risky activities – such as operating heavy machinery during the 1<sup>st</sup> 2–4 weeks of therapy</li> </ul>	<ul style="list-style-type: none"> <li>•Symptoms usually diminish or disappear after 2–4 weeks</li> <li>•May consider discontinuing therapy if symptoms persist and cause significant impairment in daily function or exacerbation of psychiatric illness</li> </ul>
<b>Fat maldistribution</b>	PIs, thymidine analogs – d4T > ZDV	<u>Onset:</u> gradual - months after initiation of therapy <u>Symptoms:</u> <ul style="list-style-type: none"> <li>•Lipoatrophy – peripheral fat loss manifested as facial thinning, thinning of extremities and buttocks (d4T)</li> <li>•Increase in abdominal girth, breast size, and dorsocervical fat pad (buffalo hump)</li> </ul>	High – exact frequency uncertain; increases with duration on offending agents	<ul style="list-style-type: none"> <li>•Lipoatrophy – low baseline body mass index</li> </ul>	<ul style="list-style-type: none"> <li>•Lipoatrophy: avoid thymidine nucleosides or switch from ZDV or d4T to abacavir or tenofovir</li> </ul>	<ul style="list-style-type: none"> <li>•Switching to other agents – may slow or halt progression; however, may not reverse effects</li> <li>•Injectable poly-L-lactic acid for treatment of facial lipoatrophy</li> </ul>
<b>Injection site reactions</b>	Enfuvirtide	<u>Onset:</u> Within first few doses  <u>Symptoms:</u> pain, pruritus, erythema, ecchymosis, warmth, nodules, rarely injection site infection	98%	<ul style="list-style-type: none"> <li>•All patients</li> </ul>	<ul style="list-style-type: none"> <li>•Educate patients regarding use of sterile technique, ensure solution at room temperature before injection, rotate injection sites, avoid injection into sites with little subcutaneous fat or sites of existing or previous reactions</li> </ul>	<ul style="list-style-type: none"> <li>•Massaging area after injection may reduce pain</li> <li>•Wear loose clothing – especially around the injection site areas or areas of previous reactions</li> <li>•Rarely, warm compact or analgesics may be necessary</li> </ul>
<b>Peripheral neuropathy</b>	ddI, d4T, ddC	<u>Onset:</u> weeks to months after initiation of therapy (may be sooner in patients with pre-existing neuropathy) <u>Symptoms:</u> <ul style="list-style-type: none"> <li>•Begins with numbness &amp; paresthesia of toes and feet</li> <li>•May progress to painful neuropathy of feet and calf</li> <li>•Upper extremities less frequently involved</li> <li>•Can be debilitating for some patients</li> <li>•May be irreversible despite discontinuation of offending agent(s)</li> </ul>	ddI: 12%–34% in clinical trials  d4T: 52% in monotherapy trial  ddC: 22%–35% in clinical trials  Incidence increases with prolonged exposure	<ul style="list-style-type: none"> <li>•Pre-existing peripheral neuropathy;</li> <li>•Combined use of these NRTIs or concomitant use of other drugs that may cause neuropathy</li> <li>•Advanced HIV disease</li> <li>•High dose or concomitant use of drugs that may increase ddI intracellular activities (e.g., HU or RBV)</li> </ul>	<ul style="list-style-type: none"> <li>•Avoid using these agents in patients at risk – if possible</li> <li>•Avoid combined use of these agents</li> <li>•Patient query at each encounter</li> </ul>	<ul style="list-style-type: none"> <li>•May consider discontinuing offending agent before pain becomes disabling – may halt further progression, but symptoms may be irreversible</li> </ul> <u>Pharmacological management (with variable successes):</u> <ul style="list-style-type: none"> <li>•Gabapentin (most experience), tricyclic antidepressants, lamotrigine, oxycarbamazepine (potential for CYP interactions), topiramate, tramadol</li> <li>•Narcotic analgesics</li> <li>•Capsaicin cream</li> <li>•Topical lidocaine</li> </ul>

**Table 19. HIV-Related Drugs With Overlapping Toxicities (Updated December 1, 2007)**

Bone Marrow Suppression	Peripheral Neuropathy	Pancreatitis	Nephrotoxicity	Hepato-toxicity	Rash	Diarrhea	Ocular Effects
Amphotericin B	Didanosine	Cotrimoxazole	Acyclovir (IV, high dose)	Azithromycin	Abacavir	Atovaquone	Cidofovir
Cidofovir	Isoniazid	Didanosine	Adefovir	Clarithromycin	Atazanavir	Clindamycin	Didanosine
Cotrimoxazole	Linezolid	Lamivudine (children)	Aminoglycosides	Delavirdine	Atovaquone	Darunavir	Ethambutol
Cytotoxic Chemotherapy	Stavudine	Pentamidine	Amphotericin B	Efavirenz	Cotrimoxazole	Fos-amprenavir	Linezolid
Dapsone		Ritonavir	Cidofovir	Fluconazole	Dapsone	Lopinavir/ritonavir	Rifabutin
Flucytosine		Stavudine	Foscarnet	Isoniazid	Darunavir		Voriconazole
Ganciclovir			Indinavir	Itraconazole	Delavirdine	Nelfinavir	
Hydroxyurea			Pentamidine	Ketoconazole	Efavirenz	Ritonavir	
Interferon- $\alpha$			Tenofovir	Maraviroc	<b>Etravirine</b>	Tipranavir	
Linezolid				Nevirapine	Fosamprenavir		
Peginterferon- $\alpha$				<b>NRTIs (hepatic steatosis)</b>	Maraviroc		
Primaquine				PIs (esp. Tipranavir)	Nevirapine		
Pyrimethamine				Rifabutin	Sulfadiazine		
Ribavirin				Rifampin	Tipranavir		
Rifabutin				Voriconazole	Voriconazole		
Sulfadiazine							
Trimetrexate							
Valganciclovir							
Zidovudine							



**Table 20. Adverse Drug Reactions and Related “Black Box Warnings” in Product Labeling for Antiretroviral Agents (Updated January 29, 2008)**

Page 1 of 2

Below is a list of antiretroviral drugs with “black box warnings” in their current product labels.

The Food and Drug Administration can require that warnings regarding special problems associated with a prescription drug, including those that might lead to death or serious injury, be placed in a prominently displayed box, commonly known as a “black box.” Please note that other serious toxicities associated with antiretroviral agents are not listed in this table.

Antiretroviral Drug	Pertinent Black Box Warning Information
<b>Abacavir</b> (ZIAGEN <sup>®</sup> , or as combination products in EPZICOM and TRIZIVIR)	<ul style="list-style-type: none"> <li>• Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir:             <ul style="list-style-type: none"> <li>– This is a multi-organ clinical syndrome, characterized by two or more groups of the following signs or symptoms including (1) fever, (2) rash, (3) gastrointestinal (e.g., nausea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory symptoms (including dyspnea, cough, or pharyngitis).</li> <li>– Abacavir should be discontinued as soon as hypersensitivity reaction is suspected.</li> <li>– Any product containing abacavir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible – because more severe symptoms can occur within hours after restarting abacavir and may include life-threatening hypotension and death.</li> </ul> </li> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</li> </ul>
<b>Didanosine</b> (VIDEX-EC)	<ul style="list-style-type: none"> <li>• Fatal and nonfatal pancreatitis have occurred with didanosine alone or in combination with other antiretroviral agents.             <ul style="list-style-type: none"> <li>– Didanosine should be withheld if pancreatitis is suspected.</li> <li>– Didanosine should be discontinued if pancreatitis is confirmed.</li> </ul> </li> <li>• Fatal lactic acidosis has been reported among pregnant women who received a combination of didanosine and stavudine with other antiretroviral combinations.             <ul style="list-style-type: none"> <li>– Didanosine and stavudine combination should only be used during pregnancy if the potential benefit clearly outweighs the potential risks.</li> </ul> </li> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</li> </ul>
<b>Emtricitabine</b> (EMTRIVA); or in combination product with tenofovir DF (TRUVADA) or with tenofovir DF and efavirenz (ATRIPLA)	<ul style="list-style-type: none"> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals.</li> <li>• Emtricitabine is not indicated for the treatment of hepatitis B infection (HBV); the safety and efficacy have not been established in patients with HIV/HBV coinfection.</li> <li>• Severe acute exacerbations of hepatitis B have been reported in patients who discontinued emtricitabine – hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation of tenofovir in HIV/HBV coinfecting patients.</li> <li>• If appropriate, initiation of anti-HBV therapy may be warranted after discontinuation of tenofovir.</li> </ul>
<b>Lamivudine</b> (EPIVIR), or in combination products COMBIVIR, EPZICOM, and TRIZIVIR)	<ul style="list-style-type: none"> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</li> <li>• EpiVir tablets and oral solution (used to treat HIV infection) contain a higher dose of lamivudine than EpiVir-HBV tablets and oral solution (used to treat chronic hepatitis B). <b>Patients with HIV infection should receive only dosage and formulations appropriate for treatment of HIV.</b></li> <li>• Severe acute exacerbations of hepatitis B infection have been reported in HBV/HIV coinfecting patients upon discontinuation of lamivudine-containing products. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation of lamivudine in patients with HIV/HBV coinfection.</li> <li>• If appropriate, initiation of anti-hepatitis B therapy may be warranted.</li> </ul>

**Table 20. Adverse Drug Reactions and Related “Black Box Warnings” in Product Labeling for Antiretroviral Agents (Updated January 29, 2008)**

Page 2 of 2

Antiretroviral Drug	Pertinent Black Box Warning Information
<b>Maraviroc</b> (SELZENTRY)	<ul style="list-style-type: none"> <li>• Hepatotoxicity has been reported with maraviroc and may be preceded by evidence of a systemic allergic reaction (e.g., pruritic rash, eosinophilia, or elevated IgE).</li> <li>• Immediately evaluate patients with signs or symptoms of hepatitis or allergic reaction.</li> </ul>
<b>Nevirapine</b> (VIRAMUNE)	<ul style="list-style-type: none"> <li>• Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure, has been reported. Patients may present with nonspecific prodromes of hepatitis and progress to hepatic failure.</li> <li>• Women with CD4 counts &gt;250 cells/mm<sup>3</sup>, including pregnant women receiving chronic treatment for HIV infection, are at considerably higher risk of hepatotoxicities.</li> <li>• Severe, life-threatening, and even fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction have occurred with nevirapine treatment.</li> <li>• Patients should be monitored intensively during the first 18 weeks of nevirapine therapy to detect potentially life-threatening hepatotoxicity or skin reactions.</li> <li>• A 14-day lead-in period with nevirapine 200mg daily must be followed strictly.</li> <li>• Nevirapine should not be restarted after severe hepatic, skin, or hypersensitivity reactions.</li> </ul>
<b>Ritonavir</b> (NORVIR)	<ul style="list-style-type: none"> <li>• Coadministration of ritonavir with certain non-sedating antihistamines, sedative hypnotics, antiarrhythmics, or ergot alkaloids may result in potentially serious or life-threatening adverse events because of possible effects of ritonavir on hepatic metabolism of certain drugs.</li> </ul>
<b>Stavudine</b> (Zerit <sup>®</sup> )	<ul style="list-style-type: none"> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</li> <li>• Fatal lactic acidosis has been reported among pregnant women who received a combination of stavudine and didanosine with other antiretroviral combinations.</li> <li>• The stavudine and didanosine combination should only be used during pregnancy if the potential benefit clearly outweighs the potential risks.</li> <li>• Fatal and nonfatal pancreatitis have occurred when stavudine was part of a combination regimen with didanosine with or without hydroxyurea.</li> </ul>
<b>Tenofovir</b> (VIREAD); or in combination product with emtricitabine (TRUVADA) or with efavirenz and emtricitabine (ATRIPLA)	<ul style="list-style-type: none"> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.</li> <li>• Tenofovir is not indicated for the treatment of chronic hepatitis B (HBV) infection; safety and efficacy in patients with HIV/HBV coinfection have not been established.</li> <li>• Severe acute exacerbations of hepatitis B have been reported in patients who discontinued tenofovir – hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation of tenofovir in HIV/HBV-coinfected patients.</li> <li>• If appropriate, initiation of anti-HBV therapy may be warranted after discontinuation of tenofovir.</li> </ul>
<b>Tipranavir</b> (APTIVUS)	<ul style="list-style-type: none"> <li>• Tipranavir coadministered with ritonavir 200mg twice daily has been associated with reports of both fatal and nonfatal intracranial hemorrhage.</li> <li>• Tipranavir coadministered with ritonavir 200mg twice daily has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C coinfection, as these patients have an increased risk of hepatotoxicity.</li> </ul>
<b>Zidovudine</b> (RETROVIR), or in combination products COMBIVIR and TRIZIVIR	<ul style="list-style-type: none"> <li>• Zidovudine can be associated with hematologic toxicities, including granulocytopenia and severe anemia, including among advanced HIV patients.</li> <li>• Prolonged zidovudine use has been associated with symptomatic myopathy.</li> <li>• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</li> </ul>

**Table 21. Drugs That Should Not Be Used With PI, NNRTI, or CCR5 Antagonist Antiretrovirals**  
(Updated **January 29, 2008**)

Drug Category <sup>#</sup>	Calcium channel blocker	Cardiac	Lipid Lowering Agents	Anti-Mycobacterial <sup>‡</sup>	Anti-histamine <sup>§</sup>	Gastro-intestinal drugs <sup>¶</sup>	Neuro-leptic	Psychotropic	Ergot Alkaloids (vasoconstrictor)	Herbs	Other
Atazanavir	Bepiridil	(none)	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	dihydroergotamine (D.H.E. 45) ergotamine <sup>†</sup> (various forms) ergonovine methylergonovine	St. John's wort	fluticasone indinavir irinotecan
Darunavir/ ritonavir	(none)	(none)	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	carbamazepine phenobarbital phenytoin fluticasone <sup>⊗</sup>
Fosamprenavir	Bepiridil	(none)	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	Delavirdine fluticasone oral contraceptives
Indinavir	(none)	amiodarone	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	Atazanavir
Lopinavir/ Ritonavir	(none)	flecainide propafenone	simvastatin lovastatin	rifampin <sup>‡</sup> rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	fluticasone <sup>⊗</sup>
Nelfinavir	(none)	(none)	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	
Ritonavir	Bepiridil	amiodarone flecainide propafenone quinidine	simvastatin lovastatin	rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	voriconazole (with RTV ≥ 400mg BID) fluticasone <sup>⊗</sup> alfuzosin
Saquinavir/ ritonavir	(none)	(none)	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort garlic supplements	fluticasone
Tipranavir/ ritonavir	Bepiridil	amiodarone flecainide propafenone quinidine	simvastatin lovastatin	rifampin rifapentine	astemizole terfenadine	cisapride	pimozide	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	fluticasone <sup>⊗</sup>
Delavirdine	(none)	(none)	simvastatin lovastatin	rifampin rifapentine <sup>‡</sup> rifabutin	astemizole terfenadine	cisapride H2 blockers proton pump inhibitors	(none)	alprazolam midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	amprenavir fosamprenavir carbamazepine phenobarbital phenytoin
Efavirenz	(none)	(none)	(none)	rifapentine <sup>‡</sup>	astemizole terfenadine	cisapride	(none)	midazolam <sup>Σ</sup> triazolam	as above	St. John's wort	voriconazole
Etravirine	(none)	(none)	(none)	rifampin rifapentine <sup>‡</sup>	(none)	(none)	(none)	(none)	(none)	St. John's wort	Unboosted PI, ritonavir-boosted atazanavir, fosamprenavir, or tipranavir, other NNRTIs, Carbamazepine, phenobarbital, phenytoin
Nevirapine	(none)	(none)	(none)	rifampin rifapentine <sup>‡</sup>	(none)	(none)	(none)	(none)	(none)	St. John's wort	
Maraviroc	•	•	•	rifampin rifapentine <sup>‡</sup>	•	•	•	•	•	St. John's wort	•

# Certain listed drugs are contraindicated based on theoretical considerations. Thus, drugs with narrow therapeutic indices and suspected metabolic involvement with P450-3A, 2D6, or unknown pathways are included in this table. Actual interactions may or may not occur among patients.

‡ HIV patients treated with rifapentine have a higher rate of TB relapse than those treated with other rifamycin-based regimens; an alternative agent is recommended.

‡ In one small study, higher doses of RTV (additional 300mg BID) or a double dose of LPV/RTV offset rifampin-inducing activity of LPV. Of note, 28% of subjects discontinued because of increases in LFTs. The safety of this combination is still under evaluation. Further studies are needed.

Σ Midazolam can be used with caution as a single dose and given in a monitored situation for procedural sedation.

† This is likely a class effect.

∂ Astemizole and terfenadine are not marketed in the United States. The manufacturer of cisapride has a limited-access protocol for patients meeting specific clinical eligibility criteria.

⊗ Concomitant use of fluticasone and ritonavir results in significantly reduced serum cortisol concentrations. Coadministration of fluticasone and ritonavir or any ritonavir-boosted PI regimen is not recommended unless potential benefit outweighs risk of systemic corticosteroid side effects. Fluticasone should be used with caution and alternatives considered if given with an unboosted PI regimen.

**Suggested Alternatives:**

**Cerivastatin (no longer marketed in the United States), simvastatin, lovastatin:** Pravastatin and fluvastatin have the least potential for drug-drug interactions (except for pravastatin with darunavir/ritonavir, see [Table 22a](#)); atorvastatin should be used with caution, using the lowest possible starting dose and monitor closely; no pharmacokinetic data or safety data are available for coadministration of rosuvastatin with the antiretroviral agents.

**Rifabutin:** clarithromycin, azithromycin (MAI prophylaxis); clarithromycin, azithromycin, ethambutol (MAI treatment)

**Astemizole, terfenadine (no longer marketed in the United States):** desloratadine, loratadine, fexofenadine, cetirizine

**Midazolam, triazolam:** temazepam, lorazepam

**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**

Page 1 of 6

(Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>		
<b>Drugs Affected</b>	<b>Atazanavir (ATV)</b>	<b>Fosamprenavir (FPV)</b>
<b>ANTIFUNGALS</b>		
<b>Itraconazole</b>	No data, but potential for bi-directional inhibition between itraconazole and PIs, monitor for toxicities.	No data, but potential for bi-directional inhibition between itraconazole and PIs, monitor for toxicities. Dose: Dose adjustment for patients receiving >400mg/day may be needed.
<b>Ketoconazole</b>	Unboosted: No dosage adjustment necessary. RTV boosted: See RTV recommendations.	No data, but presumably similar interaction as seen with APV with an increase in both APV and ketoconazole levels (APV ↑ 31%; ketoconazole ↑ 44%). Dose: Consider ketoconazole dose reduction if dose is >400mg/day. If FPV/r: Use with caution; do not exceed 200mg ketoconazole daily.
<b>Voriconazole</b>	RTV boosted: No data, but potential for bi-directional inhibition between voriconazole and PIs exists; monitor for toxicities. See RTV recommendations if boosted with RTV.	No data, but potential for bi-directional inhibition between voriconazole and PIs; monitor for toxicities. See RTV recommendations if boosted with RTV.
<b>ANTI-MYCOBACTERIALS</b>		
<b>Clarithromycin</b>	Levels: clarithromycin AUC ↑ 94% and may cause QTc prolongation. Clarithromycin active metabolite concentrations are significantly reduced. Dose: ↓ clarithromycin dose by 50%. Consider alternative therapy.	Presumably similar interaction and recommendation as APV. Levels: APV AUC ↑ 18%. No change in clarithromycin AUC. No dose adjustment.
<b>Rifabutin</b>	Levels: Rifabutin AUC ↑ 2.5-fold Dose: ↓ rifabutin dose to 150mg QOD or 3x/week <sup>‡</sup>	Rifabutin 150mg QOD + FPV 700/100mg BID, rifabutin unchanged. No data on FPV level. Dose: No change in FPV dose; decrease rifabutin to 150mg QD or 300mg 3x/week <sup>‡</sup> . If RTV-boosted FPV, reduce rifabutin dose to 150mg QOD or 3x/week <sup>‡</sup> .
<b>Rifampin</b>	Should not be coadministered.	A substantial decrease in APV AUC (≈ ↓ 82%) is expected based on the interaction with APV. Should not be coadministered.
<b>HORMONAL CONTRACEPTIVES</b>		
	Levels: Ethinyl estradiol AUC ↑ 48%, norethindrone AUC ↑ 110% Dose: use lowest effective dose or alternative methods.	An increase in ethinyl estradiol and norethindrone levels occurred with APV, and APV levels ↓ 20%. Do not coadminister; alternative methods of contraception are recommended.
<b>LIPID-LOWERING AGENTS</b>		
<b>Atorvastatin</b>	Atorvastatin levels have potential for large increase. Use lowest possible starting dose of atorvastatin with careful monitoring.	Atorvastatin AUC ↑ 150% - use lowest possible starting dose of atorvastatin with careful monitoring.
<b>Pravastatin</b>	No data.	No data.
<b>Simvastatin Lovastatin</b>	Levels: Potential for large increase in statin levels. Avoid concomitant use.	Levels: Potential for large increase in statin levels. Avoid concomitant use
<b>ANTICONVULSANTS</b>		
<b>Carbamazepine Phenobarbital Phenytoin</b>	Unknown, but may decrease ATV levels substantially. Monitor anticonvulsant level and virologic response. Consider using alternative anticonvulsant or monitoring ATV level and boosting with RTV if necessary.	Unknown, but may decrease APV levels substantially. Monitor anticonvulsant levels and virologic response, or consider alternative anticonvulsant. Consider monitoring APV levels and boosting with RTV if necessary.
<b>Methadone</b>	No change in methadone or ATV levels.	With APV, R-methadone levels ↓ 13%, and APV C <sub>min</sub> ↓ 25%. The interaction with FPV is presumed to be similar. Monitor and titrate methadone if needed.

<sup>‡</sup> Rifabutin: At least 3x/week is recommended if CD4 cell count is <100/mm<sup>3</sup>

**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**

Page 2 of 6

(Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>		
<b>Drugs Affected</b>	<b>Atazanavir (ATV)</b>	<b>Fosamprenavir (FPV)</b>
<b>ERECTILE DYSFUNCTION AGENTS</b>		
<b>Sildenafil</b>	Sildenafil levels have potential for increase. Start with reduced dose of 25mg every 48 hours and monitor for adverse effects.	Sildenafil AUC ↑ 2- to 11-fold with APV. Use cautiously. Start with reduced dose of 25mg every 48 hours and monitor for adverse effects.
<b>Tadalafil</b>	Concomitant administration will result in substantial increase in tadalafil AUC and half-life (normal=17.5h). Start with a 5mg dose, and do not exceed a single dose of 10mg every 72 hours.	No data, but concomitant administration will result in substantial increase in tadalafil AUC and half-life (normal = 17.5 h). Start with a 5 mgdose, and do not exceed a single dose of 10mg every 72 hours.
<b>Vardenafil</b>	No data, but vardenafil AUC may be substantially increased. Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 24 hours. Do not exceed 2.5mg in 72 hours if administered with RTV.	No data, but vardenafil AUC may be substantially increased. Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 24 hours. Do not exceed 2.5mg in 72 hours if administered with RTV.
<b>MISCELLANEOUS</b>	<p><b>Diltiazem:</b> AUC ↑ 125%, ↓ diltiazem dose by 50%; ECG monitoring is recommended.</p> <p><b>Other calcium channel blockers:</b> caution is warranted; dose titration should be considered; ECG monitoring is recommended.</p> <p><b>Irinotecan:</b> ATV inhibits UGT and may interfere with irinotecan metabolism; avoid concomitant use.</p> <p><b>H<sub>2</sub>-receptor antagonists:</b></p> <ul style="list-style-type: none"> <li>• Not recommended with unboosted ATV.</li> <li>• H<sub>2</sub>-receptor antagonist dose should not exceed a 40mg dose equivalent of famotidine BID. ATV 300mg + RTV 100mg should be administered simultaneously with, and/or &gt;10 hours after the H<sub>2</sub>-receptor antagonist.</li> <li>• In treatment experienced patients, if TDF is used with H<sub>2</sub>-receptor antagonists, ATV 400mg + RTV 100mg should be used.</li> </ul> <p><b>Proton-Pump Inhibitors (PPI):</b></p> <ul style="list-style-type: none"> <li>• PPIs are not recommended for patients receiving unboosted ATV or in treatment-experienced patients.</li> <li>• For treatment-naïve patients, PPI dose not exceeding a 20mg dose equivalent of omeprazole may be taken approximately 12 hours prior to ATV 300mg + RTV 100mg.</li> </ul> <p><b>Antacids and buffered medications:</b> Reduced ATV concentrations are expected with simultaneous administration; give ATV 2 hrs before or 1 hr after these medications.</p>	<p><b>H<sub>2</sub> Blockers:</b> Coadministration of ranitidine with FPV decreases (↓) APV AUC 30%; C<sub>min</sub> unchanged. Separate administration if coadministration is necessary. Monitor closely for desired virologic response. Consider boosting with RTV.</p> <p><b>Proton-Pump Inhibitors:</b> No effect of esomeprazole 20mg on APV AUC, C<sub>max</sub>, or C<sub>min</sub>, regardless of whether FPV was given with or without ritonavir.</p>

**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**

Page 3 of 6

(Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>			
<b>Drugs Affected</b>	<b>Darunavir + Ritonavir (DRV/RTV)<sup>†</sup></b>	<b>Indinavir (IDV)</b>	<b>Lopinavir + Ritonavir (LPV/r)</b>
<b>ANTIFUNGALS</b>			
<b>Itraconazole</b>	Level: No data. Dose: Use with caution; do not exceed 200mg itraconazole daily.	Level: IDV 600mg Q8H given with itraconazole 200mg BID: AUC similar to IDV 800mg Q8H. Dose: IDV 600mg Q8H; Itraconazole: Do not exceed 200mg BID.	Levels: Itraconazole $\uparrow$ when administered with LPV/r. Dose: Itraconazole – consider not exceeding 200mg/day, or monitor level and toxicity.
<b>Ketoconazole</b>	Levels: DRV AUC $\uparrow$ 42%. Azole AUC $\uparrow$ 3-fold. Dose: Use with caution; do not exceed 200mg ketoconazole QD.	Levels: IDV $\uparrow$ 68%. Dose: IDV 600mg Q8H.	Levels: LPV AUC $\downarrow$ 13%. Azole $\uparrow$ 3-fold. Dose: Use with caution; do not exceed 200mg ketoconazole daily.
<b>Voriconazole</b>	Levels: No data with DRV/r. Voriconazole AUC $\downarrow$ 39% with RTV 100mg BID; coadministration not recommended unless benefit outweighs risk.	Levels: No significant changes in AUC of azole or IDV (healthy subjects). See RTV recommendations if boosted with RTV. Dose: Standard.	Voriconazole AUC $\downarrow$ 39% with RTV 100mg BID; Coadministration is not recommended unless the benefit outweighs the risk.
<b>ANTI-MYCOBACTERIALS</b>			
<b>Clarithromycin</b>	Levels: Clarithromycin AUC $\uparrow$ 57%. DRV: No significant effect. Dose: Adjust clarithromycin dose for moderate & severe renal impairment.	Levels: Clarithromycin $\uparrow$ 53%. No dose adjustment.	Levels: $\uparrow$ Clarithromycin AUC 77%. Dose: Adjust clarithromycin dose for moderate and severe renal impairment.
<b>Rifabutin</b>	Levels: No data Dose: Decrease rifabutin to 150mg QOD.	Levels: IDV $\downarrow$ 32%. Rifabutin $\uparrow$ 2X. Dose: $\downarrow$ rif to 150mg/d or 300mg 3x/week. <sup>‡</sup> IDV 1,000mg Q8H. If RTV boosted, rif 150mg QOD or 3x/week <sup>‡</sup> continue current dose of boosted IDV.	Levels: Rifabutin AUC $\uparrow$ 3-fold. 25-O-desacetyl metabolite $\uparrow$ 47.5-fold. Dose: Decrease rifabutin dose to 150mg QOD or 3x/week <sup>‡</sup> ; LPV/r: Standard.
<b>Rifampin</b>	Levels: No data, but a significant decrease in DRV concs is expected. <b>Should not be coadministered.</b>	Levels: IDV (unboosted) $\downarrow$ 89%; IDV (boosted) $\downarrow$ 87%; <b>Should not be coadministered.</b>	Levels: LPV AUC $\downarrow$ 75%. <sup>*</sup> <b>Should not be coadministered.</b>
<b>HORMONAL CONTRACEPTIVES</b>			
	Levels: Potential for $\downarrow$ ethinyl estradiol from RTV. Use alternative or additional method with DRV/r.	Levels: Norethindrone $\uparrow$ 26%. Ethinylestradiol $\uparrow$ 24%. No dose adjustment.	Levels: Ethinyl estradiol $\downarrow$ 42%. Use alternative or additional method.
<b>LIPID-LOWERING AGENTS</b>			
<b>Atorvastatin</b>	Statin exposure from 10mg QD with DRV/r gives similar exposure to 40mg QD alone. Use lowest possible statin starting dose w/careful monitoring.	Levels: Potential for increase in atorvastatin levels. Use lowest possible starting dose of atorvastatin with careful monitoring.	Atorvastatin AUC $\uparrow$ 5.88-fold. Use lowest possible starting dose of atorvastatin with careful monitoring.
<b>Pravastatin</b>	Levels: Mean $\uparrow$ in statin AUC was 81% with DRV/r. However, statin AUC increased by up to 5-fold in some subjects. Start at lowest dose and titrate up, monitor for toxicities.	No data.	Pravastatin AUC $\uparrow$ 33%; no dosage adjustment necessary.
<b>Simvastatin Lovastatin</b>	Levels: Potential for large increase in statin levels. Avoid concomitant use.	Levels: Potential for large increase in statin levels. Avoid concomitant use.	Levels: Potential for large increase in statin levels. Avoid concomitant use.
<b>ANTICONVULSANTS</b>			
<b>Carbamazepine Phenytoin</b>	Coadministration is expected to result in significant decrease in DRV concentrations. Avoid concomitant use.	Carbamazepine markedly $\downarrow$ IDV AUC. Consider alternative anticonvulsant, RTV boosting, and/or monitoring IDV level.	Many possible interactions: carbamazepine: $\uparrow$ levels when co-administered with RTV. Use with caution. Monitor anticonvulsant levels. Phenytoin: $\downarrow$ levels of LPV, RTV, and of phenytoin when given together. Avoid concomitant use or monitor LPV level.
<b>Methadone</b>	Levels: No data with DRV/r. However, RTV is a known inducer of methadone metabolism. Monitor closely; increase methadone as clinically indicated.	No change in methadone levels.	Methadone AUC $\downarrow$ 53%. Opiate withdrawal may occur. Monitor and titrate dose if needed. May require $\uparrow$ methadone dose.
<b>ERECTILE DYSFUNCTION AGENTS</b>			
<b>Sildenafil</b>	Sildenafil AUC from a 25 mg single dose given w/ DRV/r was similar to 100mg given alone. Do not exceed 25 mg q48h; monitor for adverse effects.	Sildenafil AUC $\uparrow$ 3-fold. Use cautiously. Start with reduced dose of 25 mg every 48 hours and monitor for adverse effects.	Sildenafil AUC $\uparrow$ 11-fold in combination with RTV. Do not exceed 25mg every 48 hours.
<b>Tadalafil</b>	No data, but concomitant administration is expected to result in substantial increase in tadalafil AUC and half-life (normal = 17.5h). Do not exceed a single dose of 10mg in 72h.	Concomitant administration will result in substantial increase in tadalafil AUC & half-life (normal=17.5h). Start with 5mg dose; do not exceed a single dose of 10mg q72h.	Tadalafil AUC $\uparrow$ 124% when coadministered with RTV. Do not exceed a single dose of 10mg every 72 hours.
<b>Vardenafil</b>	No data, but a substantial increase in vardenafil AUC is expected. Do not exceed a single dose of 2.5 mg in 72 hours.	Vardenafil AUC $\uparrow$ 16-fold. IDV (unboosted) AUC $\downarrow$ 30%. Dose: Consider sildenafil instead of vardenafil if IDV unboosted. Do not exceed vardenafil 2.5mg in 72h if administered w/RTV.	No data, but vardenafil AUC may be substantially increased. Do not exceed a single 2.5mg dose in 72 hours.
<b>Miscellaneous</b>	Paroxetine and Sertraline AUC's $\downarrow$ 39% and 49%, respectively. Patients initiated on DRV/r should be monitored closely for antidepressant response. Carefully titrate SSRI dose based on clinical assessment. DRV levels unchanged when DRV/r is administered with omeprazole or ranitidine.	Grapefruit juice $\downarrow$ IDV levels by 26%. Vitamin C $\geq$ 1 gram/day $\downarrow$ IDV AUC by 14% and C <sub>min</sub> by 32%. Amlodipine: Amlodipine AUC $\uparrow$ 90% when coadministered with IDV/RTV. No change in IDV/RTV levels. Monitor closely.	LPV/r levels unchanged when tablets are given with omeprazole or ranitidine.

<sup>†</sup> Darunavir interaction studies were conducted with RTV 100mg BID and mostly with darunavir doses of 300–400mg BID instead of the FDA approved dose of DRV 600mg BID

<sup>‡</sup> Rifabutin: At least 3x/week is recommended if CD4 cell count is <100/mm<sup>3</sup>.

<sup>\*</sup> In one small study, higher doses of RTV (an additional 300mg BID) or a double dose of LPV/RTV offset rifampin-inducing activity of LPV. Of note, 28% of subjects discontinued treatment because of increases in LFTs. The safety of this combination is still under evaluation. Further studies are needed.



**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**

Page 4 of 6

(Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>		
<b>Drugs Affected</b>	<b>Nelfinavir (NFV)</b>	<b>Ritonavir* (RTV)</b>
<b>ANTIFUNGALS</b>		
<b>Itraconazole</b>	No data, but potential for bi-directional inhibition between itraconazole and PIs; monitor for toxicities.	No data, but potential for bi-directional inhibition between itraconazole and RTV; monitor for toxicities. Dose: Dose adjustment for patients receiving >400mg itraconazole may be needed, or consider monitoring itraconazole level.
<b>Ketoconazole</b>	No dose adjustment necessary.	Levels: ketoconazole ↑ 3X. Dose: Use with caution; do not exceed 200mg ketoconazole daily.
<b>Voriconazole</b>	No data, but potential for bi-directional inhibition between voriconazole and PIs exists; monitor for toxicities.	Levels: voriconazole AUC ↓ 82% when coadministered with 400mg BID of RTV, and concomitant therapy of voriconazole with RTV 400mg BID or higher is contraindicated. Voriconazole AUC ↓ 39% with RTV 100mg BID; administration of voriconazole and RTV 100mg is not recommended unless benefit outweighs risk.
<b>ANTI-MYCOBACTERIALS</b>		
<b>Clarithromycin</b>	No data.	Levels: Clarithromycin ↑ 77%. Dose: Adjust clarithromycin dose for moderate and severe renal impairment.
<b>Rifabutin</b>	Levels: NFV ↓ 32% if 750mg Q8H dose given; no change if 1,250mg Q12H dose used. Rifabutin ↑ 2X. Dose: ↓ rifabutin to 150mg QD or 300mg 3x/wk. <sup>g</sup> NFV 1,250mg BID.	Levels: Rifabutin ↑ 4X. Dose: ↓ rifabutin to 150mg QOD or dose 3x/week. <sup>g</sup> RTV: Maintain current dose.
<b>Rifampin</b>	Levels: NFV ↓ 82%. <b>Should not be coadministered.</b>	Levels: RTV ↓ 35%. Increased liver toxicity possible. Coadministration may lead to loss of virologic response if RTV sole PI. Alternative antimycobacterial agents, such as rifabutin, should be considered. <b>Should not be coadministered.</b>
<b>HORMONAL CONTRACEPTIVES</b>		
	Levels: Norethindrone ↓ 18%. Ethinyl estradiol ↓ 47%. Use alternative or additional method.	Levels: Ethinyl estradiol ↓ 40%. Use alternative or additional method.
<b>LIPID-LOWERING AGENTS</b>		
<b>Atorvastatin</b>	Atorvastatin AUC ↑ 74%. Use lowest possible starting dose of atorvastatin with careful monitoring.	Levels: 450% ↑ when administered with SQV/RTV combination. Use lowest possible starting dose of atorvastatin with careful monitoring.
<b>Pravastatin</b>	No data.	Levels: 50% ↓ when administered with SQV/RTV combination. Dose: Pravastatin dosage adjustment based on lipid response.
<b>Simvastatin Lovastatin</b>	Simvastatin AUC ↑ 505%. Potential for large increase in lovastatin AUC. Avoid concomitant use.	Levels: Potential for large increase in statin levels. Avoid concomitant use.
<b>ANTICONVULSANTS</b>		
<b>Carbamazepine Phenobarbital Phenytoin</b>	Unknown, but may decrease NFV levels substantially. Monitor anticonvulsant levels and virologic response. Consider alternative anticonvulsant or NFV levels.	Carbamazepine: ↑ serum levels when coadministered with RTV. Use with caution. Monitor anticonvulsant levels.
<b>METHADONE</b>	NFV may decrease methadone levels, but opiate withdrawal rarely occurs. Monitor and titrate dose if needed. May require ↑ methadone dose.	Methadone ↓ 37%. Monitor and titrate dose if needed. May require ↑ methadone dose.
<b>ERECTILE DYSFUNCTION AGENTS</b>		
<b>Sildenafil</b>	Sildenafil AUC ↑ 2- to 11-fold. Use cautiously. Start with reduced dose of 25mg every 48 hours; monitor for adverse effects.	Sildenafil AUC ↑ 11-fold. Use cautiously. Start with reduced dose of 25 mg every 48 hours and monitor for adverse effects.
<b>Tadalafil</b>	Concomitant administration will result in substantial increase in tadalafil AUC and half-life (normal = 17.5 h). Start with a 5mg dose, and do not exceed a single dose of 10mg every 72 hours.	Tadalafil AUC ↑ 124%. Start with a 5mg dose, and do not exceed a single dose of 10mg every 72 hours.
<b>Vardenafil</b>	No data, but vardenafil AUC may be substantially increased. Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 24 hours. Do not exceed 2.5mg in 72 hours if administered with RTV.	Vardenafil AUC ↑ 49-fold. RTV AUC ↓ 20%. Dose: Vardenafil: Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 72 hours. RTV: Maintain current dose.
<b>Miscellaneous</b>		Many possible interactions. <u>Desipramine</u> ↑ 145%; reduce dose. <u>Trazodone</u> AUC ↑ 2.4-fold when given with RTV 200mg BID. Use lowest dose of trazodone and monitor for CNS and CV adverse effects. <u>Theophylline</u> ↓ 47%; monitor theophylline levels. RTV 100mg BID significantly increases systemic exposure of inhaled (oral or nasal) fluticasone and may predispose patients to systemic corticosteroid effects. Coadministration not recommended unless benefit of fluticasone outweighs the risk.

\* Drugs for which plasma concentrations may be decreased by coadministration with ritonavir: anticoagulants (warfarin), anticonvulsants (phenytoin, divaproex, lamotrigine), antiparasitics (atovaquone).

<sup>g</sup> Rifabutin: At least 3x/week is recommended if CD4 cell count is <100/mm<sup>3</sup>.

**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**

Page 5 of 6

(Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>			
<b>Drugs Affected</b>	<b>Saquinavir<sup>†</sup> (SQV)</b>	<b>Tipranavir + Ritonavir (TPV/RTV)</b>	<b>Maraviroc (MVC)</b>
<b>ANTIFUNGALS</b>			
<b>Itraconazole</b>	Bi-directional interaction between itraconazole & SQV has been observed. Dose: Not established, but decreased itraconazole dosage may be warranted. Consider therapeutic drug monitoring for itraconazole.	No data. Use with caution; do not exceed 200mg itraconazole daily.	Possible increase in maraviroc concentration. Dose: 150mg BID.
<b>Ketoconazole</b>	Levels: SQV ↑ 3X. Dose: No dosage adjustment necessary.	No data. Use with caution; do not exceed 200mg ketoconazole daily.	Levels: MVC AUC ↑ 5x. Dose: 150mg BID.
<b>Voriconazole</b>	No data, but potential for bi-directional inhibition between voriconazole and PIs, monitor for toxicities	Potential for bi-directional inhibition between voriconazole and PIs exists. Voriconazole AUC ↓ 39% with RTV 100mg BID; interaction between TPV and voriconazole unknown. Coadministration is not recommended unless the benefit outweighs the risk.	No data, monitor for toxicities.
<b>ANTI-MYCOBACTERIALS</b>			
<b>Clarithromycin</b>	Levels: Clarithromycin ↑ 45%. SQV ↑ 177%. Dose: No dose adjustment.	Levels: TPV ↑ 66%, Clarithromycin ↑ 19%, 14-hydroxy-clarithromycin metabolite ↓ 97%. Dose: No adjustment for patients with normal renal function; reduce clarithromycin dose by 50% for CrCl 30–60 mL/min; reduce clarithromycin dose by 75% for CrCl <30 mL/min.	Possible increase in maraviroc concentration. Dose: 150mg BID.
<b>Rifampin</b>	Levels: SQV ↓ 84%. Marked elevation of transaminases was seen in a pharmacokinetic study, where healthy volunteers received a combination of rifampin 600mg QD + RTV/SQV 100/1,000mg BID. This combination should not be used.	No data; should not be coadministered.	Levels: MVC AUC ↓ 64%. Dose: 600mg BID or use rifabutin instead of rifampin.
<b>Rifabutin</b>	Levels: SQV ↓ 40%. Dose: Rifabutin 150mg QOD or 3x/week. <sup>‡</sup>	Levels: Rifabutin AUC ↑ 2.9-fold. 25-O-desacetyl metabolite ↑ 20.7-fold. Dose: Decrease rifabutin dose to 150mg QOD or 3x/week. <sup>‡</sup> Single-dose study, thus the effect of multiple doses of rifabutin on TPV/r PK was not assessed.	No data, potential for induction of MVC metabolism. If used without a strong CYP3A inducer or inhibitor: 300mg BID. Monitor for virologic response. If used with a strong CYP3A inhibitor: 150mg BID.
<b>HORMONAL CONTRACEPTIVES</b>			
	No data.	Levels: Ethinyl estradiol Cmax and AUC ↓ ~ 50%. <sup>‡</sup> Use alternative or additional method. Women on estrogen may have increased risk of nonserious rash. Used as hormone replacement therapy, monitor clinically for signs of estrogen deficiency.	No significant interaction, safe to use in combination.
<b>LIPID-LOWERING AGENTS</b>			
<b>Atorvastatin</b>	Levels: 450% ↑ when administered with SQV/RTV combination. Use lowest possible starting dose of atorvastatin with careful monitoring.	Levels: Atorvastatin AUC ↑ 9-fold. Dose: Use lowest possible starting dose of atorvastatin with careful monitoring.	No data, potentially safe to use in combination.
<b>Pravastatin</b>	Levels: 50% ↓ when administered with SQV/RTV combination. No dose adjustment needed. Dose: Pravastatin dosage adjustment based on lipid response.	No data.	No data, potentially safe to use in combination.
<b>Simvastatin Lovastatin</b>	Levels: Potential for large increase in statin levels. Avoid concomitant use.	Potential for large increase in statin levels. Avoid concomitant use.	No data, potentially safe to use in combination.
<b>ANTICONVULSANTS</b>			
<b>Carbamazepine Phenobarbital Phenytoin</b>	Unknown, but may markedly ↓ SQV levels. Consider alternative anticonvulsant. Monitor anticonvulsant levels and consider monitoring SQV level.	No data. Consider alternative anticonvulsant. Monitor anticonvulsant levels and consider obtaining TPV level.	Possible decrease in maraviroc concentration Dose: 600mg BID or use alternative antiepileptic agent.
<b>Methadone</b>	Methadone AUC ↓ 19% when coadministered with SQV/RTV 1,000/100mg BID. Dose: No adjustment for this PI regimen, but monitor and titrate to methadone response as necessary.	No data. Dosage of methadone may need to be increased when coadministered with TPV/r.	No data, potentially safe to use in combination.

<sup>‡</sup> Study conducted with TPV/r dose(s) other than FDA-approved dose of 500/200mg BID.<sup>†</sup> Some drug interaction studies were conducted with Invirase<sup>®</sup> soft gel capsule.

**Table 22a. Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc**Page 6 of 6 (Updated **January 29, 2008**)

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>			
<b>Drugs Affected</b>	<b>Saquinavir<sup>†</sup> (SQV)</b>	<b>Tipranavir + Ritonavir (TPV/RTV)</b>	<b>Maraviroc (MVC)</b>
<b>ERECTILE DYSFUNCTION AGENTS</b>			
<b>Sildenafil</b>	Sildenafil AUC ↑ 2-fold. Use a 25mg starting dose of sildenafil.	No data. Starting dose should not exceed 25 mg sildenafil within 48 hours.	No data, potentially safe to use in combination.
<b>Tadalafil</b>	Concomitant administration will result in substantial increase in tadalafil AUC and half-life (normal = 17.5 h). Start with a 5mg dose, and do not exceed a single dose of 10mg every 72 hours.	No data. Starting dose should not exceed 10mg tadalafil every 72 hours.	No data, potentially safe to use in combination.
<b>Vardenafil</b>	No data, but vardenafil AUC may be substantially increased. Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 24 hours. Do not exceed a single 2.5mg dose in 72 hours if administered with RTV.	No data. Starting dose should not exceed 2.5mg vardenafil every 72 hours.	No data, potentially safe to use in combination.
<b>Miscellaneous</b>	Grapefruit juice ↑ SQV levels. Dexamethasone ↓ SQV levels.	<u>Abacavir</u> ↓ 35%–44%. <sup>a</sup> Appropriate doses for the combination of ABC and TPV/r have not been established. <u>Zidovudine</u> ↓ 31%–43%. Appropriate doses for the combination of ZDV and TPV/r have not been established. <u>Loperamide</u> ↓ 51%. <sup>a</sup> TPV C <sub>min</sub> ↓ 26% with loperamide. <u>Antacids</u> ↓ TPV ~30%, TPV should be administered 2 hrs before or 1 hr after these medications. <u>Fluconazole</u> : Doses >200mg/day are not recommended to be given with TPV. TPV capsules contain alcohol. Avoid use of disulfiram and metronidazole.	No data.

<sup>a</sup> Study conducted with TPV/r dose(s) other than FDA-approved dose of 500/200mg BID.<sup>†</sup> Some drug interaction studies were conducted with Invirase<sup>®</sup> soft gel capsule.

**Table 22b. Drug Interactions Among Antiretrovirals and Other Drugs: NNRTIs (Updated January 29, 2008)**

Page 1 of 2

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>				
<b>Drugs Affected</b>	<b>Delavirdine (DLV)</b>	<b>Efavirenz (EFV)</b>	<b>Etravirine (ETR)</b>	<b>Nevirapine (NVP)</b>
<b>ANTIFUNGALS</b>				
<b>Fluconazole</b>	No clinically significant changes in DLV or fluconazole concentrations.	No clinically significant changes in EFV or fluconazole concentrations.	↑ ETR, ↔ fluconazole Dose: standard	Levels: NVP: Cmax, AUC, and Cmin ↑ 100%. Fluconazole: No change. Risk of hepatotoxicity may ↑ with this combination. If coadministered, monitor NVP toxicity.
<b>Itraconazole</b>			↑ ETR, ↓ itraconazole Dose adjustments for itraconazole may be necessary depending on other coadministered drugs, monitor itraconazole level.	
<b>Ketoconazole</b>	DLV: Cmin ↑ 50%. Ketoconazole: No data. Dose: Standard.	No data.	↑ ETR, ↓ ketoconazole Dose adjustments for ketoconazole may be necessary depending on other coadministered drugs.	Levels: Keto ↓ 63%. NVP ↑ 15%–30%. Dose: Not recommended.
<b>Posaconazole</b>			↑ ETR, ↔ posaconazole Dose: standard	
<b>Voriconazole</b>	Metabolism of voriconazole may be inhibited by DLV. Voriconazole may inhibit NNRTI metabolism. Frequently monitor for NNRTI toxicity and antifungal outcome.	Levels: EFV ↑ 44%. Voriconazole ↓ 77%. This combination is not recommended.	↑ ETR, ↑ voriconazole Dose adjustments for voriconazole may be necessary depending on other coadministered drugs, consider monitoring voriconazole level	Metabolism of voriconazole may be induced by NVP. Voriconazole may inhibit NNRTI metabolism. Carefully monitor for NNRTI toxicity and antifungal outcome.
<b>ANTI-MYCOBACTERIALS</b>				
<b>Clarithromycin</b>	Levels: Clarithromycin ↑ 100%. DLV ↑ 44%. Adjust dosage for renal failure.	Levels: Clarithromycin ↓ 39%. Monitor for efficacy or use alternative agent.	↑ ETR AUC 42%, ↓ clarithromycin AUC 39%, Cmin 53%, ↑ 14-OH-clarithromycin AUC 21% Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC	Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy or use alternative agent.
<b>Rifabutin</b>	Levels: DLV ↓ 80%. Rifabutin ↑ 100%. Not recommended.	Levels: EFV unchanged. Rif ↓ 35%. Dose: ↑ rifabutin dose to 450–600mg QD or 600mg 3x/week.* EFV: Standard.	↓ ETR AUC 37% and Cmin 35%, ↓ rifabutin AUC 17% Cmin 24%, ↓ 25-O-desacetyl-rifabutin AUC 17% Cmin 22% Rifabutin dose of 300 mg daily if ETR is NOT coadministered with a RTV boosted PI If ETR is coadministered with DRV/RTV or SQV/RTV, and rifabutin is needed, consider alternative antiretroviral agent to ETR	Levels: NVP ↓ 16%. No dose adjustment.*
<b>Rifampin/ Rifapentine</b>	Levels: DLV ↓ 96%. Contraindicated.	Levels: EFV ↓ 25%. Dose: Maintain EFV dose at 600mg QD in patients weighing <60 kg or consider ↑ EFV to 800mg QD.	Potential for significant ↓ ETR Do not coadminister ETR with rifampin or rifapentine	Levels: NVP ↓ 20%–58%. Virologic consequences are uncertain; the potential for additive hepatotoxicity exists. If used, coadministration should be done with careful monitoring of virologic responses and toxicities.
<b>HORMONAL CONTRACEPTIVES</b>				
	Levels of ethinyl estradiol may increase. Clinical significance is unknown.	Levels: Ethinyl estradiol ↑ 37%. No data on other component. Use alternative or additional methods.	↑ ethinylestradiol AUC 22%, ↔ Norethindrone Dose: standard	Levels: Ethinyl estradiol ↓ approx 20%. Use alternative or additional methods.

\* These recommendations apply to regimens that do not include PIs, which can substantially increase rifabutin levels.

**Table 22b. Drug Interactions Among Antiretrovirals and Other Drugs: NNRTIs (Updated January 29, 2008)**

Page 2 of 2

<b>Drug Interactions Requiring Dose Modifications or Cautious Use</b>				
<b>Drugs Affected</b>	<b>Delavirdine (DLV)</b>	<b>Efavirenz (EFV)</b>	<b>Etravirine (ETR)</b>	<b>Nevirapine (NVP)</b>
<b>LIPID-LOWERING AGENTS</b>				
<b>Atorvastatin</b>	Potential for inhibition of atorvastatin metabolism. Use lowest possible dose and monitor for toxicity.	Levels: Atorvastatin AUC ↓ 43%; EFV unchanged. Dose: Adjust atorvastatin dose according to lipid responses, not to exceed the maximum recommended dose.	↔ ETR, ↓ atorvastatin AUC 37%, ↑ 2-OH-atorvastatin AUC 27% Cmax 76% Dose: standard; adjust atorvastatin dose based on response	No data.
<b>Fluvastatin</b>			↔ ETR, ↑ fluvastatin Dose adjustments for these HMG-CoA reductase inhibitors may be necessary	
<b>Pravastatin Rosuvastatin</b>	No data.	No data.	↔ ETR, ↔ pravastatin, ↔ rosuvastatin Dose: standard	No data.
<b>Simvastatin Lovastatin</b>	Levels: Potential for large increase in statin levels. Avoid concomitant use.	Levels: Simvastatin AUC ↓ by 58%; EFV unchanged. Dose: Adjust simvastatin dose according to lipid responses, not to exceed the maximum recommended dose.	↔ ETR, ↓ lovastatin, ↓ simvastatin Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. If used with ritonavir-boosted PI, simvastatin and lovastatin should be avoided.	No data.
<b>ANTICONVULSANTS</b>				
<b>Carbamazepine Phenobarbital Phenytoin</b>	Levels: DLV Cmin ↓ 90% when coadministered with phenytoin, phenobarbital, or carbamazepine. Contraindicated.	Use with caution. CBZ and EFV AUCs ↓ 27% and 36%, respectively, when combined. One case report showed low EFV concs with phenytoin. Monitor anticonvulsant and EFV levels. If possible, use alternative anticonvulsant.	Potential for ↓ ETR & Anticonvulsant concentrations Do not coadminister ETR with carbamazepine, phenobarbital or phenytoin. Consider alternative anticonvulsants.	
<b>Methadone</b>	Levels: DLV unchanged; no data on methadone levels but potential for increased levels. Monitor for methadone toxicity; may require a dose reduction.	Levels: Methadone ↓ 60%. Opiate withdrawal common; increased methadone dose often necessary. Titrate methadone dose to effect.	↔ ETR, ↔ methadone Dose: standard; however, monitor for methadone withdrawal symptoms and adjust methadone as needed	Levels: NVP unchanged. Methadone ↓ significantly. Opiate withdrawal common when this combination is used; increased methadone dose often necessary. Titrate methadone dose to effect.
<b>Miscellaneous</b>	May increase levels of dapsone, warfarin, and quinidine. <b>Sildenafil:</b> Potential for increased concentrations and adverse effects. Use cautiously. Start with reduced dose of 25mg every 48 hours and monitor for adverse effects. <b>Vardenafil:</b> No data, but vardenafil AUC may be substantially increased. Start with a 2.5mg dose and do not exceed a single 2.5mg dose in 24 hours. <b>Tadalafil:</b> No data, but concomitant administration will likely result in substantial increase in tadalafil AUC and half-life (normal = 17.5 h). Start with a 5mg dose and do not exceed a single dose of 10mg every 72 hours. Coadministration of fluoxetine increases DLV Cmin 50%.	Monitor warfarin when used concomitantly.	↓ antiarrhythmics Dose: use with caution with antiarrhythmics concentration monitoring if available ↑ warfarin, Monitor INR ↑ diazepam - a decrease in diazepam may be needed dexamethasone (systemic) ↓ ETR Use with caution or alternative corticosteroid particularly for long term use ↓ cyclosporine, sirolimus, tacrolimus – monitor immunosuppressant levels ↓ sildenafil AUC 57% Dose: standard, may need to alter sildenafil dose based on clinical effect	No data.

**Table 22c. Drug Interactions Among Antiretrovirals and Other Drugs: NRTIs (Updated October 10, 2006)**

Drug Interactions Requiring Dose Modifications or Cautious Use				
Drugs Affected	Didanosine (ddI)	Stavudine (d4T)	Tenofovir (TDF)	Zidovudine (ZDV)
<b>Atazanavir (ATV)</b>	Levels: Simultaneous EC ddi + ATV (with food): ↓ AUC of ddi 34%. ATV no change. Administer separately; ATV should be taken with food and ddi-EC on an empty stomach.	No data.	ATV 400mg + TDF 300mg - Levels: ATV AUC ↓ 25% and Cmin ↓ 40%. TDF AUC ↑ 24%. Avoid concomitant use without RTV. ATV + RTV 300/100mg QD + TDF 300mg QD - Levels: ATV AUC ↓ 25% and Cmin ↓ 23%; ATV Cmin higher with RTV than without. TDF AUC ↑ 30%; monitor for toxicities. Dose: ATV + RTV 300/100mg QD coadministered with TDF 300mg QD.	ZDV: No change in AUC but 30% ↓ in Cmin. Significance unknown.
<b>Cidofovir, Ganciclovir, Valganciclovir</b>	Buffered ddi + ganciclovir (GCV): ddi AUC ↑ 50%–111%; GCV AUC ↓ 21% when ddi administered 2 hours prior to oral GCV; no change in IV GCV concentrations. Appropriate doses for the combination of ddi and GCV have not been established.	No data.	Serum concentration of these drugs and/or tenofovir may be increased. Monitor for dose-related toxicities.	Ganciclovir + ZDV: No significant changes in levels for either drug. Potential increase in hematologic toxicities.
<b>Darunavir (DRV)</b>	No data.	No data.	Levels: Tenofovir AUC ↑ 22%, Cmax ↑ 24% and Cmin ↑ 37%. Clinical significance unknown; monitor for tenofovir toxicity.	No data.
<b>Didanosine</b>	•	Peripheral neuropathy, lactic acidosis, and pancreatitis seen with this combination; should be avoided unless potential benefit far outweighs potential risks.	Levels: ddi EC AUC ↑ by 48%–60%, Cmax ↑ by 48%–64% For patients >60 kg, 250mg/day of ddi EC is recommended; for patients <60 kg, 200mg EC ddi is recommended; the ddi doses apply to patients with creatinine clearance >60 mL/min. Monitor for ddi-associated toxicities.	No significant interactions.
<b>Indinavir (IDV)</b>	EC ddi can be taken together with IDV.	No significant PK interaction.	Levels: IDV Cmax ↑ 14%. Dose: Standard.	No significant PK interaction.
<b>Lopinavir/ritonavir (LPV/r)</b>	No data.	No data.	LPV/r 400/100mg AUC ↓ 15%; TDF AUC ↑ 34%; clinical significance of interaction is unknown; monitor for tenofovir toxicities.	No data.
<b>Methadone</b>	Levels: EC ddi unchanged. Dose: No change EC ddi.	Levels: d4T ↓ 27%; methadone unchanged. Dose: No dose adjustment.	No change in methadone or TDF levels.	ZDV AUC ↑ 43%. Monitor for ZDV-related adverse effects.
<b>Ribavirin</b>	Coadministration not recommended. Ribavirin increases the intracellular levels of the active metabolite of ddi and may cause serious toxicities.	No data.	Level: Ribavirin unchanged; no data on TDF level.	Ribavirin inhibits phosphorylation of ZDV; this combination should be avoided if possible, or closely monitor virologic response.
<b>Tipranavir/ ritonavir</b>	Levels: EC ddi ↓ 10%. <sup>a</sup> TPV Cmin ↓ 34% with EC ddi. <sup>a</sup> Dose: EC ddi and TPV/r should be separated by at least 2 hours.	No significant PK interaction.	TPV AUC and Cmin ↓ 9%–18% and 12%–21%, respectively <sup>a</sup> ; clinical significance is unknown.	Levels: ZDV AUC and Cmax ↓ 31%–42% and 46%–51%, respectively. <sup>a</sup> Appropriate doses for the combination of ZDV and TPV/r have not been established.

<sup>a</sup> Study conducted with TPV/r dose(s) other than FDA-approved dose of 500/200mg BID.



Table 23a. Drug Effects on Concentration of PIs (Updated October 10, 2006)

Drug Affected	Fosamprenavir	Atazanavir	Lopinavir/Ritonavir	Nelfinavir	Ritonavir	Saquinavir*	Tipranavir
<b>Protease Inhibitors</b>							
<b>Darunavir (DRV)</b>	No data.	<u>Levels:</u> ATV concentrations from ATV 300mg QD when administered with DRV/r were similar to ATV/r 300/100mg QD. DRV was unchanged. <u>Dose:</u> Administer ATV 300mg QD with DRV/r for exposure similar to ATV/r 300/100mg QD.	<u>Levels:</u> DRV AUC and Cmin ↓ 53% and 65%, respectively. LPV AUC and Cmin ↑ 37% and 72%, respectively. <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>	No data.	<u>Levels:</u> 14-fold ↑ in DRV exposure in combination with RTV 100mg BID. <u>Dose:</u> DRV should only be used in combination with RTV 100mg BID to achieve sufficient DRV exposure.	<u>Levels:</u> DRV AUC and Cmin ↓ 26% and 42%, respectively. SQV exposure similar to when administered with RTV 1,000/100mg BID. ‡ <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>	No data.
<b>Fosamprenavir (FPV)</b>	•	<u>Levels:</u> With FPV/ATV 1,400/400 QD, ATV AUC & Cmin ↓ 33% and 57%, resp. FPV AUC and Cmin ↑ 78% and 283%, respectively. With FPV/r 700/100mg BID + ATV 300mg QD, ATV AUC and Cmax ↓ 22% and 24%, resp; FPV unchanged. <u>Dose:</u> Insufficient data for dose recommendation.	<u>Levels:</u> With coadministration of FPV 700mg BID and LPV/r capsules 400/100mg BID, FPV Cmin ↓ 64% and LPV Cmin ↓ 53%. An increased rate of adverse events was seen with coadministration. <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>	•	<u>Levels:</u> FPV AUC and Cmin ↑ 100% and 400%, respectively, with 200mg RTV. <u>Dose:</u> FPV 1,400mg + RTV 200mg QD; or FPV 700mg + RTV 100mg BID.	<u>Levels:</u> APV AUC ↓ 32%. <u>Dose:</u> Insufficient data for dose recommendation	<u>Levels:</u> APV AUC and Cmin ↓ 44% and 55%, respectively, when given as APV/r 600/100 BID with TPV/r. No data with FPV, but a ↓ in AUC is expected. <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>
<b>Indinavir (IDV)</b>	<u>Levels:</u> APV AUC ↑ 33%. <u>Dose:</u> Not established.	Coadministration of these agents is not recommended because of potential for additive hyperbilirubinemia.	<u>Levels:</u> IDV AUC and Cmin ↑. <u>Dose:</u> IDV 600mg BID.	<u>Levels:</u> IDV ↑ 50%; NFV ↑ 80%. <u>Dose:</u> Limited data for IDV 1,200mg BID + NFV 1,250mg BID.	<u>Levels:</u> IDV ↑ 2–5 times. <u>Dose:</u> IDV/RTV 400/400mg, 800/100mg, or 800/200mg BID Caution: Renal events may ↑ with ↑ IDV concentrations.	<u>Levels:</u> IDV-No effect. SQV ↑ 4-7 times. † <u>Dose:</u> Insufficient data.	No data. <b>Should not be coadministered, as doses are not established.</b>
<b>Lopinavir/Ritonavir (LPV/r)</b>	•	<u>Levels:</u> With ATV 300 QD + LPV/r 400/100 BID, ATV Cmin ↑ 45%; ATV AUC and Cmax were unchanged. LPV PK similar to historic data.	•	•	Additional ritonavir is generally not recommended.	•	<u>Levels:</u> LPV AUC and Cmin ↓ 55% & 70%, respectively. <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>
<b>Nelfinavir (NFV)</b>	<u>Levels:</u> APV AUC ↑ 1.5-fold. <u>Dose:</u> Insufficient data.	•	<u>Levels:</u> With LPV capsules, LPV ↓ 27%; NFV ↑ 25%. <u>Dose:</u> No data with LPV/r tablets. No dosing recommendation.	•	•	•	No data. <b>Should not be coadministered, as doses are not established.</b>
<b>Ritonavir (RTV)</b>	•	<u>Levels:</u> ATV AUC ↑ 238%. <u>Dose:</u> ATV 300mg QD + RTV 100mg QD.	Lopinavir is coformulated with ritonavir as Kaletra®.  Additional ritonavir is generally not recommended.	<u>Levels:</u> RTV - No effect. NFV ↑ 1.5 times. <u>Dose:</u> not established	•	<u>Levels:</u> RTV no effect SQV ↑ 20 times. †‡ <u>Dose:</u> 1,000/100mg SQV hgc/RTV BID or 400/400mg BID.	<u>Levels:</u> TPV AUC ↑ 11-fold.
<b>Saquinavir (SQV)</b>	<u>Levels:</u> APV AUC ↓ 32%. <u>Dose:</u> Insufficient data.	<u>Levels:</u> SQV AUC ↑ 60% with SQV/ATV/RTV 1,600/300/100 QD, compared with SQV/RTV 1,600/100 QD. <u>Dose:</u> No dose recommendations can be made.	<u>Levels:</u> SQV <sup>†</sup> AUC and Cmin ↑ <u>Dose:</u> SQV 1,000mg BID; LPV/r standard.	<u>Levels:</u> SQV ↑ 3–5 times; NFV ↑ 20%. †	•	•	<u>Levels:</u> SQV AUC and Cmin ↓ 76% and 82%, respectively, when given as SQV/r 600/100 BID with TPV/r. <u>Dose:</u> <b>Should not be coadministered, as doses are not established.</b>

\* Several drug interaction studies have been completed with saquinavir given as Invirase or Fortovase.

† Study conducted with Fortovase.

‡ Study conducted with Invirase.

Table 23b. Drug Effects on Concentration of NNRTIs and Maraviroc (Updated January 29, 2008)

Drug Affected	Delavirdine	Efavirenz	Etravirine	Nevirapine	Maraviroc
<b>Fosamprenavir (FPV)</b>	Levels: Presumably, similar PK effects as APV: APV AUC ↑ 130%, and DLV AUC ↓ 61%. Dose: Coadministration not recommended.	Levels: APV Cmin ↓ 36% (when dosed at 1,400mg QD with 200mg RTV). Dose: FPV 1,400mg + RTV 300mg QD; or FPV 700mg + RTV 100mg BID.	Levels: APV AUC ↑ 69%, Cmin ↑ 77% Dose: Do not coadminister with boosted or unboosted FPV	No data.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID
<b>Atazanavir (ATV)</b>	No data.	Levels: With unboosted ATV, ATV AUC ↓ 74%. EFV no change. Dose: ATV 300 + RTV 100mg QD with food - ATV concentrations similar to unboosted ATV; if desired ATV concentrations not achieved with ATV/r 300/100mg, may need to increase the dose of ATV/r - insufficient information for specific recommendation. EFV dose - standard.	Levels: With unboosted ATV, ETR AUC, Cmax and Cmin ↑ 50%, 47% and 58%, respectively ATV AUC ↓ 17%, Cmin ↓ 47% With ATV/RTV, ETR AUC, Cmax and Cmin ↑ approx 30% ATV AUC ↓ 14% Cmin ↓ 38% Dose: Should not be coadministered with unboosted ATV or ATV/RTV	No data. A decrease in ATV levels is expected. Coadministration is not recommended. Effect of NVP on ritonavir-boosted ATV combination unknown; if used, consider monitoring ATV level.	Levels: With unboosted ATV, MVC AUC ↑ 3.6x. With ATV/r, MVC AUC ↑ 5x. Dose: With unboosted ATV or ATV/r, 150mg BID.
<b>Darunavir (DRV)</b>	No data.	Levels: DRV AUC and Cmin ↓ 13% and 31%, respectively. EFV AUC and Cmin ↑ 21% and 17%, respectively. Dose: Clinical significance unknown. Use standard doses and monitor closely. Consider monitoring levels.	Levels: ETR AUC ↓ 37% Cmin ↓ 49% DRV no change Dose: Standard for ETR and DRV. Despite decrease in ETR, safety and efficacy established with this combination	Levels: NVP AUC and Cmin ↑ 27% and 47%, respectively. DRV unchanged.† Dose: Standard.	Levels: With DRV/r, MVC AUC ↑ 4x. Dose: 150mg BID.
<b>Delavirdine (DLV)</b>	•	•	•	•	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
<b>Efavirenz (EFV)</b>	•	•	Potential for ↓ ETR concentration, Do not coadminister	•	Levels: MVC AUC ↓ 45%. Dose: 600mg BID.
<b>EFV + LPV/r or SQV/r</b>	•	•	•	•	Levels: MVC AUC ↑ 2.5–5x. Dose: 150mg BID.
<b>Etravirine (ETR)</b>	•	•	•	•	Levels: MVC AUC ↓ 53%, Cmax ↓ 60% Dose: 600mg BID
<b>ETR + DRV/r</b>	•	•	•	•	Levels: MVC AUC ↑ 210%, Cmax ↑ 77% Dose: 150mg BID
<b>Indinavir (IDV)</b>	Levels: IDV ↑ >40%; DLV - No effect. Dose: IDV 600mg q8h. DLV standard.	Levels: IDV ↓ 31%. Dose: IDV 1,000mg q8h; consider IDV/RTV. EFV standard.	Dose: No data. Do not coadminister	Levels: IDV ↓ 28%; NVP no effect. Dose: IDV 1,000mg q8h, or consider IDV/RTV. NVP standard.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
<b>Lopinavir/Ritonavir (LPV/r)</b>	Levels: LPV levels expected to increase. Dose: Insufficient data.	Levels: With LPV/r tablets 600/150mg BID + EFV 600mg QD, LPV Cmin and AUC ↑ 35% and 36%, respectively. No formal study of LPV/r tablets 400/100mg BID + EFV. EFV no change. Dose: LPV/r tablets 600/150mg BID, when used in with EFV in tx-experienced patients. EFV dose - standard.	Levels: ETR AUC ↑ 17% Cmin ↑ 23% LPV AUC ↓ 20%, Cmin ↓ 8% Dose: standard for ETR and LPV/RTV The amount of safety data at ↑ ETR exposures is limited, therefore, use caution	Levels: With LPV/r capsules, LPV Cmin dec. 55%. Dose: LPV/r tablets 600/150mg BID, when used in combination with NVP in tx-experienced patients. NVP standard.	Levels: MVC AUC ↑ 4x. Dose: 150mg BID.
<b>Nelfinavir (NFV)</b>	Levels: NFV ↑ 2 times. DLV ↓ 50%. Dose: No data.	Levels: NFV ↑ 20%. Dose: Standard.	Dose: no data. Do not coadminister	Levels: NFV ↑ 10%. NVP no effect. Dose: Standard.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
<b>Nevirapine (NVP)</b>	No data.	Levels: NVP-no effect. EFV AUC ↓ 22%.	Potential for ↓ ETR concentration, Do not coadminister	•	Levels: No significant change. Dose: 300mg BID if use without PI 150mg BID – if used with PI (except TPV/r).
<b>Ritonavir (RTV)</b>	Levels: RTV ↑ 70%. DLV no effect. Dose: Appropriate doses not established.	Levels: RTV ↑ 18%. EFV ↑ 21%. Dose: Standard.	Dose: No data. Do not coadminister ETR and RTV 600mg	Levels: RTV ↓ 11%. NVP no effect. Dose: Standard.	Levels: With RTV 100 mg BID, MVC AUC ↑ 2.6x. Dose: 150mg BID.
<b>Saquinavir (SQV)</b>	Levels: SQV <sup>†</sup> ↑ 5 times; DLV no effect. Dose: SQV/RTV 1,000mg/100mg BID.	Levels: SQV <sup>‡</sup> ↓ 62%. EFV ↓ 12%. SQV is not recommended as sole PI when EFV is used. Dose: SQV/RTV 1000mg/100mg BID.	Level: ETR AUC ↓ 33% Cmin ↓ 29% SQV unchanged Dose: SQV/RTV 1000/100mg BID. ETR reduced exposures similar to ETR reduced exposures with DRV/RTV; therefore no dose adjustment	Levels: SQV ↓ 25%. NVP no effect. Dose: SQV/RTV 1,000mg/100mg BID.	Levels: With SQV/r, MVC AUC ↑ 9.8x. Dose: 150mg BID.
<b>Tipranavir (TPV)</b>	No data.	Levels: With TPV/r 500/100mg BID, TPV AUC and Cmin ↓ 31% and 42%, respectively. EFV unchanged. With TPV/r 750/200mg BID, TPV PK unchanged. Dose: No dose adjustments necessary.	Level: ETR AUC ↓ 76% Cmin ↓ 82% TPV AUC ↑ 18% Cmin ↑ 24% Dose: Do not coadminister	Levels: No data on the effect of NVP on TPV/r PK. NVP PK unchanged. <sup>a</sup>	Levels: With TPV/r, no significant change. Dose: 300mg BID.

‡ Study conducted with Invirase. † Based on between-study comparison. <sup>a</sup> Study conducted with TPV/r dose(s) other than FDA-approved dose of 500/200mg BID.

**Table 24. Suggested Minimum Target Trough Concentrations for Persons With Wild-Type HIV-1**  
 [283-285, 287] (Updated October 6, 2005)

Drug	Concentration (ng/mL)
Amprenavir (AGENERASE) or Fosamprenavir (LEXIVA)	400 (measured as amprenavir concentration)
Atazanavir (REYATAZ)	150
Indinavir (CRIXIVAN)	100
Lopinavir/ritonavir (KALETRA)	1,000
Nelfinavir (VIRACEPT) <sup>a</sup>	800
Ritonavir (NORVIR) <sup>b</sup>	2100
Saquinavir (INVIRASE)	100–250
Efavirenz (SUSTIVA)	1,000

- a. Measurable active (M8) metabolite.  
 b. Ritonavir given as a single PI.

**Table 25. Identifying, diagnosing, and managing acute HIV-1 infection (Updated January 29, 2008)**

- **Suspecting acute HIV infection:** Signs or symptoms of acute HIV infection with recent (within 2-6 weeks) high HIV risk exposure\*
  - Signs/symptoms/laboratory findings may include but are not limited to one or more of the following: fever, lymphadenopathy, skin rash, myalgia/arthralgia, headache, diarrhea, oral ulcers, leucopenia, thrombocytopenia, transaminase elevation
  - High risk exposures include sexual contact with a person infected with HIV or at risk for HIV, sharing of injection drug use paraphernalia, or contact of potentially infectious blood with mucous membranes or breaks in skin\*
  
- **Differential diagnosis:** EBV- and non-EBV (e.g., CMV)-related infectious mononucleosis syndromes, influenza, viral hepatitis, streptococcal infection, syphilis
  
- **Evaluation/diagnosis of acute/primary HIV infection**
  - HIV antibody EIA (rapid test if available)
    - Reactive EIA must be followed by Western blot
    - Negative EIA or reactive EIA with negative or indeterminate Western blot should be followed by a virologic test\*\*
  - Positive virologic test in this setting is consistent with acute HIV infection
  - Positive quantitative or qualitative HIV RNA test should be confirmed with subsequent documentation of seroconversion
  
- **Patient management:**
  - Treatment of acute HIV infection is considered optional. **(CIII)**
  - Enrollment in clinical trial should be considered.

\* In some settings, behaviors conducive to acquisition of HIV infection might not be ascertained, or might not be perceived as “high-risk” by the health care provider or the patient or both. Thus, symptoms and signs consistent with acute retroviral syndrome should motivate consideration of this diagnosis even in the absence of reported high risk behaviors.

\*\* p24 antigen or HIV RNA assay. P24 antigen is less sensitive but more specific than HIV RNA tests; HIV RNA tests are generally preferred. HIV RNA tests include quantitative bDNA or RT-PCR, or qualitative transcription-mediated amplification (APTIMA, GenProbe).

**Table 26. Preclinical and Clinical Data Relevant to the Use of Antiretrovirals in Pregnancy**

(Updated December 1, 2007)

(See [Safety and Toxicity of Individual Antiretroviral Drugs in Pregnancy](#) for more detail on drugs. Table adopted from [Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.](#))

Antiretroviral drug	FDA pregnancy category †	Placental passage (newborn: mother drug ratio)	Long-term animal carcinogenicity studies	Animal teratogen studies
<b>Nucleoside and nucleotide analogue reverse transcriptase inhibitors</b>				
Abacavir (Ziagen, ABC)	C	Yes (rats)	Positive (malignant and nonmalignant tumors of liver, thyroid in female rats, and preputial and clitoral gland of mice and rats)	Positive (rodent anasarca and skeletal malformations at 1,000mg/kg (35x human exposure) during organogenesis; not seen in rabbits)
Didanosine (Videx, ddI)	B	Yes (human) [0.5]	Negative (no tumors, lifetime rodent study)	Negative
Emtricitabine (Emtriva, FTC)	B	Yes (mice and rabbits) [0.4–0.5]	Negative (no tumors, lifetime rodent study)	Negative
Lamivudine (EpiVir, 3TC)	C	Yes (human) [~1.0]	Negative (no tumors, lifetime rodent study)	Negative
Stavudine (Zerit, d4T)	C	Yes (rhesus monkey) [0.76]	Positive (mice and rats, at very high dose exposure, liver and bladder tumors)	Negative (but sternal bone calcium decreases in rodents)
Tenofovir DF (Viread)	B	Yes (human) [0.95–0.99]	Positive (hepatic adenomas in female mice at high doses)	Negative (osteomalacia when given to juvenile animals at high doses)
Zidovudine* (Retrovir, AZT, ZDV)	C	Yes (human) [0.85]	Positive (rodent, noninvasive vaginal epithelial tumors)	Positive (rodent-near lethal dose)
<b>Non-nucleoside reverse transcriptase inhibitors</b>				
Delavirdine (Rescriptor)	C	Unknown	Positive (hepatocellular adenomas and carcinomas in male and female mice but not rats, bladder tumors in male mice)	Positive (rodent-ventricular septal defect)
Efavirenz (Sustiva)	D	Yes (cynomologus monkey, rat, rabbit) [~1.0]	Positive (hepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas in female but not male mice)	Positive (cynomologus monkey- anencephaly, anophthalmia, microphthalmia)
Nevirapine (Viramune)	B	Yes (human) [~1.0]	Positive (hepatocellular adenomas and carcinomas in mice and rats)	Negative
<b>Protease inhibitors</b>				
Amprenavir (Agenerase)*	C	Minimal/variable (human)	Positive (hepatocellular adenomas and carcinomas in male mice and rats)	Negative (but deficient ossification and thymic elongation in rats and rabbits)
Atazanavir	B	Minimal/variable (human)	Positive (hepatocellular adenomas in female mice)	Negative
Darunavir (Prezista)	B	Unknown	Not completed	Negative
Fosamprenavir (Lexiva)	C	Unknown	Positive (benign and malignant liver tumors in male rodents)	Negative (deficient ossification with amprenavir but not fosamprenavir)
Indinavir (Crixivan)	C	Minimal (human)	Positive (thyroid adenomas in male rats at highest dose)	Negative (but extra ribs in rodents)
Lopinavir/Ritonavir (Kaletra)	C	Yes (human) [0.20 +/- 0.13]	Positive (hepatocellular adenomas and carcinomas in mice and rats)	Negative (but delayed skeletal ossification and increase in skeletal variations in rats at maternally toxic doses)
Nelfinavir (Viracept)	B	Minimal/variable (human)	Positive (thyroid follicular adenomas and carcinomas in rats)	Negative
Ritonavir (Norvir)	B	Minimal (human)	Positive (liver adenomas and carcinomas in male mice)	Negative (but cryptorchidism in rodents)
Saquinavir (Fortovase)	B	Minimal (human)	Negative	Negative
Tipranavir (Aptivus)	C	Unknown	In progress	Negative (decreased ossification and pup weights in rats at maternally toxic doses)
<b>Fusion inhibitors</b>				
Enfuvirtide (Fuzeon)	B	Unknown	Not done	Negative
<b>CCR5 antagonists</b>				
Maraviroc (Selzentry)	B	Unknown	Negative	Negative

\*No longer available in the United States.

† Food and Drug Administration Pregnancy Categories:

A - Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and no evidence exists of risk during later trimesters).

B - Animal reproduction studies fail to demonstrate a risk to the fetus, and adequate but well-controlled studies of pregnant women have not been conducted.

C - Safety in human pregnancy has not been determined; animal studies are either positive for fetal risk or have not been conducted, and the drug should not be used unless the potential benefit outweighs the potential risk to the fetus.

D - Positive evidence of human fetal risk that is based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the use of the drug among pregnant women might be acceptable despite its potential risks.

X - Studies among animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly outweighs any possible benefit.

**Table 27. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy**  
(Updated December 1, 2007)

Page 1 of 4

(See also "[Safety and Toxicity of Individual Antiretroviral Drugs in Pregnancy](#)" for additional toxicity data. Table adopted from "[Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States](#)". Please see this document for detailed guidelines on treatment options.)

Antiretroviral Drug	Pharmacokinetics in Pregnancy	Concerns in Pregnancy	Rationale for Recommended Use in Pregnancy
<b>NRTIs/ NtRTIs</b>		See text for discussion of potential maternal and infant mitochondrial toxicity.	NRTIs are recommended for use as part of combination regimens, usually including two NRTIs with either an NNRTI or one or more PIs. Use of single or dual NRTIs alone is not recommended for treatment of HIV infection (ZDV alone may be considered for prophylaxis of perinatal transmission in pregnant women with HIV RNA <1,000 copies/mL).
<b>Recommended agents</b>			
Zidovudine*	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated [392]	No evidence of human teratogenicity [128]. Well-tolerated, short-term safety demonstrated for mother and infant.	Preferred NRTI for use in combination antiretroviral regimens in pregnancy based on efficacy studies and extensive experience; should be included in regimen unless significant toxicity or stavudine use.
Lamivudine*	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated [393]	No evidence of human teratogenicity [128]. Well-tolerated, short-term safety demonstrated for mother and infant.	Because of extensive experience with lamivudine in pregnancy in combination with zidovudine, lamivudine plus zidovudine is the recommended dual NRTI backbone for pregnant women.
<b>Alternate agents</b>			
Didanosine	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated [394].	Cases of lactic acidosis, some fatal, have been reported in pregnant women receiving didanosine and stavudine together [395, 396].	Alternate NRTI for dual nucleoside backbone of combination regimens. Didanosine should be used with stavudine only if no other alternatives are available.
Emtricitabine†	No pharmacokinetic studies in human pregnancy.	No studies in human pregnancy.	Alternate NRTI for dual nucleoside backbone of combination regimens.
Stavudine	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated [397].	No evidence of human teratogenicity [128]. Cases of lactic acidosis, some fatal, have been reported in pregnant women receiving didanosine and stavudine together [395, 396].	Alternate NRTI for dual nucleoside backbone of combination regimens. Stavudine should be used with didanosine only if no other alternatives are available. Do not use with zidovudine due to potential for antagonism.
Abacavir*	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated.	Hypersensitivity reactions occur in ~5%–8% of nonpregnant persons; a much smaller percentage are fatal and are usually associated with rechallenge. Rate in pregnancy unknown. Patient should be educated regarding symptoms of hypersensitivity reaction.	Alternate NRTI for dual nucleoside backbone of combination regimens. See footnote regarding use in triple NRTI regimen.‡
<b>Insufficient data to recommend use</b>			
Tenofovir†	Limited studies in human pregnancy; data indicate AUC lower in third trimester than postpartum but trough levels similar. Phase I study in late pregnancy in progress.	Studies in monkeys show decreased fetal growth and reduction in fetal bone porosity within 2 months of starting maternal therapy [398]. Clinical studies in humans (particularly children) show bone demineralization with chronic use; clinical significance unknown [260, 399]. Significant placental passage in humans (cord:maternal blood ratio ~1.0).	Because of lack of data on use in human pregnancy and concern regarding potential fetal bone effects, tenofovir should be used as a component of a maternal combination regimen only after careful consideration of alternatives.
<b>Not recommended</b>			
Zalcitabine (no longer available in the United States.)	No studies in human pregnancy.	Rodent studies indicate potential for teratogenicity and developmental toxicity.	Given lack of data and concerns regarding teratogenicity in animals, not recommended for use in human pregnancy unless alternatives are not available.



**Table 27. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy (Updated December 1, 2007)**

Page 2 of 4

Antiretroviral Drug	Pharmacokinetics in Pregnancy	Concerns in Pregnancy	Rationale for Recommended Use in Pregnancy
<b>NNRTIs</b>			
Hypersensitivity reactions, including hepatic toxicity, and rash more common in women, unclear if increased in pregnancy			
NNRTIs are recommended for use in combination regimens with 2 NRTI drugs.			
<b>Recommended agents</b>			
Nevirapine	Pharmacokinetics not significantly altered in pregnancy; no change in dose indicated [400, 401].	No evidence of human teratogenicity [128]. Increased risk of symptomatic, often rash-associated, and potentially fatal liver toxicity among women with CD4 counts >250/mm <sup>3</sup> when first initiating therapy [129, 184]; unclear if pregnancy increases risk.	Nevirapine should be initiated in pregnant women with CD4 counts >250 cells/mm <sup>3</sup> only if benefit clearly outweighs risk, due to the increased risk of potentially life-threatening hepatotoxicity in women with high CD4 counts. Women who enter pregnancy on nevirapine regimens and are tolerating them well may continue therapy, regardless of CD4 count.
<b>Not recommended</b>			
Efavirenz†	No studies in human pregnancy.	FDA Pregnancy Class D; significant malformations (anencephaly, anophthalmia, cleft palate) were observed in 3 (15%) of 20 infants born to cynomolgus monkeys receiving efavirenz during the first trimester at a dose giving plasma levels comparable to systemic human therapeutic exposure; there are three case reports of neural tube defects in humans after first trimester exposure [127, 128, 402], relative risk unclear.	Use of efavirenz should be avoided in the first trimester, and women of childbearing potential must be counseled regarding risks and avoidance of pregnancy. Because of the known failure rates of contraception, alternate regimens should be strongly considered in women of childbearing potential. Use after the second trimester of pregnancy can be considered if other alternatives are not available and if adequate contraception can be assured postpartum.
Delavirdine	No pharmacokinetic studies in human pregnancy.	Rodent studies indicate potential for carcinogenicity and teratogenicity (see <a href="#">Table 26</a> ).	Given lack of data and concerns regarding teratogenicity in animals, not recommended for use in human pregnancy unless alternatives are not available.
<b>Protease inhibitors</b>			
Hyperglycemia, new onset or exacerbation of diabetes mellitus, and diabetic ketoacidosis reported with PI use; unclear if pregnancy increases risk. Conflicting data regarding preterm delivery in women receiving PIs (see text).			
<b>Recommended agents</b>			
Lopinavir/ritonavir	Pharmacokinetic studies of standard dose of lopinavir/ritonavir capsules (3 capsules twice daily) during 3 <sup>rd</sup> trimester indicated levels were significantly lower than during postpartum period and in nonpregnant adults [347]; an increased dose of 4 capsules of lopinavir/ritonavir twice daily starting in the 3 <sup>rd</sup> trimester resulted in adequate lopinavir exposure [403]; by 2 weeks postpartum, standard dosing was again appropriate. Pharmacokinetic studies of the new lopinavir/ritonavir tablet formulation are under way, but data are not yet available.	No evidence of human teratogenicity [128]. Well-tolerated, short-term safety demonstrated in Phase I/II studies.	The capsule formulation is no longer available. Pharmacokinetic studies of the new tablet formulation are under way, but there are currently insufficient data to make a definitive recommendation regarding dosing in pregnancy. Some experts would administer standard dosing (2 tablets twice daily) throughout pregnancy and monitor virologic response and lopinavir drug levels, if available. Other experts, extrapolating from the capsule formulation pharmacokinetic data, would increase the dose of the tablet formulation during the 3 <sup>rd</sup> trimester (from 2 tablets to 3 tablets twice daily), returning to standard dosing postpartum. Once daily lopinavir/ritonavir dosing is not recommended during pregnancy because there are no data to address whether drug levels are adequate with such administration.

**Table 27. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy (Updated December 1, 2007)**

Page 3 of 4

Antiretroviral Drug	Pharmacokinetics in Pregnancy	Concerns in Pregnancy	Rationale for Recommended Use in Pregnancy
<b>Alternate agents</b>			
Indinavir	Two studies including 18 women receiving indinavir 800mg three times daily showed markedly lower levels during pregnancy compared to postpartum, although suppression of HIV RNA was seen [404, 405]	Theoretical concern re: increased indirect bilirubin levels, which may exacerbate physiologic hyperbilirubinemia in the neonate, but minimal placental passage. Use of unboosted indinavir during pregnancy is not recommended.	Alternate PI to consider if unable to use nelfinavir or saquinavir-HGC/ritonavir, but would need to give indinavir as ritonavir-boosted regimen. Optimal dosing for the combination of indinavir/ritonavir in pregnancy is unknown.
Ritonavir	Phase I/II study in pregnancy showed lower levels during pregnancy compared to postpartum [406]	Limited experience at full dose in human pregnancy; has been used as low-dose ritonavir boosting with other PIs.	Given low levels in pregnant women when used alone, recommended for use in combination with second PI as low-dose ritonavir “boost” to increase levels of second PI.
Saquinavir-hard gel capsule [HGC] (Invirase®)/ritonavir	Pharmacokinetic studies of saquinavir-soft gel capsules (SGC) indicated that inadequate drug levels were observed in pregnant women given 1,200mg of saquinavir-SGC as a sole PI three times daily [407, 408], but adequate levels were achieved when 800mg saquinavir-SGC boosted with ritonavir 100mg was given twice daily [409]. However, saquinavir-SGC are no longer produced. Limited pharmacokinetic data on saquinavir-hard gel capsule (HGC), and the new 500mg tablet formulation, suggest that 1,000mg saquinavir-HGC/100mg ritonavir given twice daily achieves adequate saquinavir drug levels in pregnant women [410].	Well-tolerated, short-term safety demonstrated for mother and infant for both saquinavir-SGC and -HGC in combination with low-dose ritonavir.	Saquinavir-SGC are no longer available. There are only limited pharmacokinetic data on saquinavir-HGC and the new tablet formulation in pregnancy. Ritonavir-boosted saquinavir-HGC or saquinavir tablets are alternative PIs for combination regimens in pregnancy, and are alternative initial antiretroviral recommendations for nonpregnant adults.
<b>Insufficient data to recommend use</b>			
Amprenavir ( <i>no longer available in the United States.</i> )	Limited studies in human pregnancy.	Oral solution contraindicated in pregnant women because of high levels of propylene glycol, which may not be adequately metabolized during pregnancy.	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use of capsules during pregnancy.
Atazanavir	Limited studies in small number of pregnant women atazanavir (N=33) and atazanavir-ritonavir (N=9) suggest standard dosing achieves adequate drug levels [411, 412].	Theoretical concern re: increased indirect bilirubin levels, which may exacerbate physiologic hyperbilirubinemia in the neonate, although transplacental passage is very low and likely to be variable (10%).	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.
Darunavir	No pharmacokinetic studies in human pregnancy.	No experience in human pregnancy.	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.
Fosamprenavir	No pharmacokinetic studies in human pregnancy.	Limited experience in human pregnancy.	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.
Tipranavir	No pharmacokinetic studies in human pregnancy.	No experience in human pregnancy.	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.

**Table 27. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy (Updated December 1, 2007)**

Page 4 of 4

Antiretroviral Drug	Pharmacokinetics in Pregnancy	Concerns in Pregnancy	Rationale for Recommended Use in Pregnancy
<b>Not Recommended</b>			
Nelfinavir	Adequate drug levels are achieved in pregnant women with nelfinavir 1,250mg given twice daily although levels are variable in late pregnancy [346, 413]. In a similar study of pregnant women in their second and third trimester dosed at 1,250mg given twice daily, women in the third trimester had lower concentration of nelfinavir than women in their second trimester [414]. In a study of the new 625mg tablet formulation dosed at 1,250mg twice daily, lower AUC and peak levels were observed during the third trimester of pregnancy than postpartum [415].		
<b>Fusion Inhibitors</b>			
<b>Insufficient data to recommend use</b>			
Enfuvirtide	No pharmacokinetic studies in human pregnancy.	Minimal data in human pregnancy [416].	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.
<b>CCR5 Antagonists</b>			
<b>Insufficient data to recommend use</b>			
Maraviroc	No pharmacokinetic studies in human pregnancy.	No experience in human pregnancy.	Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.



HGC = hard gel capsule; NRTI = nucleoside reverse transcriptase inhibitor; NtRTI = nucleotide reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; SGC = soft gel capsule.

\* Zidovudine and lamivudine are included as a fixed-dose combination in Combivir®; zidovudine, lamivudine, and abacavir are included as a fixed-dose combination in Trizivir®.

† Emtricitabine and tenofovir are included as a fixed-dose combination in Truvada®; emtricitabine, tenofovir, and efavirenz are included as a fixed-dose combination in Atripla™.

# Triple NRTI regimens including abacavir have been less potent virologically compared to PI-based HAART regimens. Triple NRTI regimens should be used only when an NNRTI- or PI-based HAART regimen cannot be used (e.g., due to significant drug interactions). A study evaluating use of zidovudine/lamivudine/abacavir among pregnant women with HIV RNA <55,000 copies/mL as a class-sparing regimen is in development.

**Figure A: Prognosis According to CD4 Cell Count and Viral Load in the Pre-HAART and HAART Eras (Updated October 29, 2004)**



Reprint with permission from Elsevier (The Lancet, Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. 2002 Jul 13;360(9327):119-29.)

## References

1. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. *N Engl J Med*, 1996. 334(11):701-6.
2. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. *J Acquir Immune Defic Syndr*, 2000. 24(2):106-14.
3. Hecht FM, Wilson IB, Wu AW, et al. Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. *Ann Intern Med*, 1999. 131(2):136-43.
4. Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. *AIDS*, 1998. 12(4):417-24.
5. Kitahata MM, Van Rompaey SE, Dillingham PW, et al. Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. *J Gen Intern Med*, 2003. 18(2):95-103.
6. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. *Antivir Ther*, 2003. 8(5):471-8.
7. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis*, 2004. 39(5):609-29.
8. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. *Arch Intern Med*, 2003. 163(18):2187-95.
9. Flandre P, Costagliola D. On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients. *AIDS*, 2006. 20(16):2118-20.
10. Vercauteren J, Vandamme AM. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. *Antiviral Res*, 2006. 71(2-3):335-42.
11. Gianotti N, Mondino V, Rossi MC, et al. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. *Clin Infect Dis*, 2006. 42(10):1470-80.
12. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. *Clin Infect Dis*, 2005. 40(12):1828-36.
13. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. *AIDS*, 2002. 16(2):209-18.
14. Lanier ER, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. *Antivir Ther*, 2004. 9(1):37-45.
15. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. *J Infect Dis*, 2004. 189(5):837-46.
16. Flandre P, Chappey C, Marcelin AG, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. *J Infect Dis*, 2007. 195(3):392-8.
17. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. *AIDS*, 2007. 21(2):179-85.
18. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. *AIDS*, 2006. 20(6):847-53.
19. Verhofstede C, Wanzele FV, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. *AIDS*, 1999. 13(18):2541-6.
20. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. *AIDS*, 2000. 14(18):2857-67.
21. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. *AIDS*, 1999. 13(18):F123-7.
22. Benson CA, Vaida F, Havlir DV, et al. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. *J Infect Dis*, 2006. 194(9):1309-18.

23. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med*, 2002. 347(6):385-94.
24. Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. *AIDS Res Hum Retroviruses*, 2007. 23(8):988-95.
25. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes—a 96-week analysis. *J Acquir Immune Defic Syndr*, 2006. 43(5):535-40.
26. Kuritzkes DR, Lalama CM, Ribaldo HJ, et al. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naïve HIV-1-Infected Subjects. *J Infect Dis*, 2008. [Epub ahead of print].
27. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1-infected persons in 10 US cities. *J Infect Dis*, 2004. 189(12):2174-80.
28. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. *J Infect Dis*, 2005. 192(6):958-66.
29. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. *BMJ*, 2005. 331(7529):1368.
30. Bennett D, McCormick L, Kline R, et al. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Feb 22-25, 2005; Boston, MA. Abstract 674.
31. Wheeler W, Mahle K, Bodnar U, et al. Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 648.
32. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. *HIV Clin Trials*, 2007. 8(1):1-8.
33. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. *J Infect Dis*, 2007. 196(3):356-60.
34. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naïve patients: implications for routine resistance screening before initiation of antiretroviral therapy. *Clin Infect Dis*, 2005. 40(3):468-74.
35. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. *JAMA*, 2004. 292(2):180-9.
36. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. *N Engl J Med*, 2004. 351(3):229-40.
37. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. *AIDS*, 2006. 20(1):21-8.
38. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost-effectiveness analysis. *Clin Infect Dis*, 2005. 41(9):1316-23.
39. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). *AIDS*, 2002. 16(3):369-79.
40. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. *Lancet*, 1999. 353(9171):2195-9.
41. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beinr Community Programs for Clinical Research on AIDS. *AIDS*, 2000. 14(9):F83-93.
42. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. *AIDS*, 2002. 16(4):579-88.
43. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. *AIDS*, 2002. 16(5):727-36.
44. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). *Antivir Ther*, 2003. 8(5):427-34.



- [45.](#) Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. *Clin Infect Dis*, 2004. 38(5):723-30.
- [46.](#) Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. *JAMA*, 2000. 283(2):229-34.
- [47.](#) Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). *JAMA*, 2000. 283(2):205-211.
- [48.](#) Machouf N, Thomas R, Nguyen VK, et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. *J Med Virol*, 2006. 78(5):608-13.
- [49.](#) Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B\*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet*, 2002. 359(9308):727-32.
- [50.](#) Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet*, 2002. 359(9312):1121-2.
- [51.](#) Phillips EJ, Sullivan JR, Knowles SR, et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. *AIDS*, 2002. 16(16):2223-5.
52. Phillips E, Rauch A, Nolan D, et al. Pharmacogenetics and clinical characteristics of patch test confirmed patients with abacavir hypersensitivity. *Rev Antivir Ther*, 2006. 3:57.
- [53.](#) Mallal S, Phillips E, Carosi G, et al. HLA-B\*5701 screening for hypersensitivity to abacavir. *N Engl J Med*, 2008. 358(6):568-79.
54. Saag M, Balu R, Brachman P, et al. High sensitivity of HLA-B\*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity. 4<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEAB305.
- [55.](#) Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. *AIDS Res Hum Retroviruses*, 2004. 20(1):111-26.
- [56.](#) Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. *Nat Med*, 2005. 11(11):1170-2.
- [57.](#) Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1--infected individuals. *J Exp Med*, 1997. 185(4):621-8.
- [58.](#) Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. *Ann Intern Med*, 1993. 118(9):681-8.
- [59.](#) Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. *J Infect Dis*, 2006. 194(7):926-30.
60. Hunt PW, Martin JN, Sinclair E, et al. Drug-resistant phenotype is associated with decreased in vivo T-cell activation independent of changes in viral replication among patients discontinuing antiretroviral therapy. *Antiviral Ther*, 2003. 8:S82.
- [61.](#) Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. *Clin Infect Dis*, 2007. 44(4):591-5.
- [62.](#) Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. *Antimicrob Agents Chemother*, 2007. 51(2):566-75.
- [63.](#) Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. *J Virol*, 2001. 75(1):251-9.
- [64.](#) Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. *J Virol*, 2006. 80(10):4909-20.
65. Reeves JD, Han D, Wrin T, et al. Enhancements to the Trofile HIV Coreceptor Tropism Assay enable reliable detection of CXCR4-using subpopulations at less than 1%. 47<sup>th</sup> International Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007, Chicago, IL. Abstract # H-1026.
- [66.](#) de Jong JJ, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. *J Virol*, 1992. 66(2):757-65.
- [67.](#) Jensen MA, Coetzer M, van 't Wout AB, et al. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. *J Virol*, 2006. 80(10):4698-704.

- [68.](#) Sander O, Sing T, Sommer I, et al. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. *PLoS Comput Biol*, 2007. 3(3):e58.
- [69.](#) Brumme ZL, Dong WW, Yip B, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. *AIDS*, 2004. 18(4):F1-9.
- [70.](#) Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4<sup>(+)</sup> T cells during primary HIV-1 infection. *Proc Natl Acad Sci USA*, 1998. 95(15):8869-73.
- [71.](#) Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci USA*, 1997. 94(24):13193-7.
- [72.](#) Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science*, 1997. 278(5341):1295-300.
- [73.](#) Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science*, 1997. 278(5341):1291-5.
- [74.](#) Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4<sup>+</sup> T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med*, 1999. 5(5):512-7.
- [75.](#) Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. *Lancet*, 1998. 352(9142):1725-30.
- [76.](#) Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*, 1998. 338(13):853-60.
- [77.](#) Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. *J Infect Dis*, 1999. 179(3):717-20.
- [78.](#) Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. *N Engl J Med*, 1999. 341(6):385-93.
- [79.](#) Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. *N Engl J Med*, 1999. 341(6):394-402.
- [80.](#) Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*, 1996. 272(5265):1167-70.
- [81.](#) Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. *JAMA*, 2006. 296(12):1498-506.
- [82.](#) O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4<sup>+</sup> lymphocyte counts and the risk of progression to AIDS. *N Engl J Med*, 1996. 334(7):426-31.
- [83.](#) Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. *AIDS*, 1999. 13(14):1873-80.
- [84.](#) Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. *AIDS*, 2001. 15(6):735-46.
- [85.](#) Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. *J Acquir Immune Defic Syndr*, 2005. 39(2):195-8.
- [86.](#) Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. *AIDS*, 2004. 18(1):81-8.
- [87.](#) Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4<sup>+</sup> lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*, 1997. 126(12):946-54.
- [88.](#) Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*, 2002. 360(9327):119-29.
- [89.](#) Phillips A, CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. *AIDS*, 2004. 18(1):51-8.
- [90.](#) Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. *Lancet*, 2007. 370(9585):407-13.
- [91.](#) Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm<sup>3</sup> or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm<sup>3</sup> or greater. *J Acquir Immune Defic Syndr*, 2007. 45(2):183-92.
- [92.](#) Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. *N Engl J Med*, 1997. 337(11):725-33.

- 93.** Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med*, 1997. 337(11):734-9.
- 94.** Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. *JAMA*, 2001. 286(20):2568-77.
- 95.** Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. *Ann Intern Med*, 2003. 138(8):620-6.
- 96.** May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. *AIDS*, 2007. 21(9):1185-97.
- 97.** Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med*, 2006. 166(15):1632-41.
- 98.** Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 cell count. *AIDS*, 2007. 21(13):1717-21.
- 99.** Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. *AIDS*, 2006. 20(5):741-9.
- 100.** Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr*, 2006. 43(1):27-34.
- 101.** Lau B, Gange SJ and Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm<sup>3</sup>. *J Acquir Immune Defic Syndr*, 2007. 44(2):179-87.
102. D'Arminio Monforte A, Abrams D, et al HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS-defining malignancies: Results from the D:A:D study. In: Program and Abstracts: 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 84.
- 103.** Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med*, 2006. 355(22):2283-96.
- 104.** Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. *AIDS*, 2007. 21(14):1957-63.
105. Emery S for the SMART Study Group and INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy (ART) at baseline in SMART: A rationale for a trial to examine early treatment of HIV disease. 4<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WePeB018.
- 106.** US Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and Interventions to reduce perinatal HIV-1 transmission in the United States. Rockville, MD: HIV/AIDS Treatment Information Service. Available at <http://AIDSinfo.nih.gov>.
- 107.** Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. *Nephrol Dial Transplant*, 2006. 21(10):2809-13.
- 108.** Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. *J Am Soc Nephrol*, 2005. 16(8):2412-20.
- 109.** Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. *Clin Infect Dis*, 2007. 44(3):441-6.
- 110.** Mellors JW, Margolick JB, Phair JP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. *JAMA*, 2007. 297(21):2349-50.
- 111.** Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. *J Acquir Immune Defic Syndr*, 2002. 31(Suppl 3):S123-7.
- 112.** Gulick RM, Ribaldo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. *JAMA*, 2006. 296(7):769-81.
- 113.** Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*, 2004. 292(2):191-201.
- 114.** Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *N Engl J Med*, 1999. 341(25):1865-73.

115. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract THLB0204.
- [116.](#) Squires K, Lazzarin A, Gatell JM, et al. Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. *J Acquir Immune Defic Syndr*, 2004. 36(5):1011-9.
- [117.](#) Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med*, 2003. 349(24):2293-303.
- [118.](#) Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. *Lancet*, 1998. 351(9102):543-9.
119. Haubrich RH, Riddler S, DiRienzo G, et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract #38.
- [120.](#) Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin Infect Dis*, 2003. 37(1):113-28.
- [121.](#) Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. *Antimicrob Agents Chemother*, 2004. 48(12):4680-6.
- [122.](#) Gulick RM, Ribaud HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. *N Engl J Med*, 2004. 350(18):1850-61.
- [123.](#) Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naïve subjects. *J Infect Dis*, 2005. 192(11):1921-30.
- [124.](#) van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. *Lancet*, 2004. 363(9417):1253-63.
- [125.](#) Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naïve individuals. *HIV Clin Trials*, 2002. 3(3):186-94.
126. Sustiva ( Prescribing Information, Bristol Myers Squibb). August 2004.
- [127.](#) Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. *AIDS*, 2002. 16(2):299-300.
- [128.](#) Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989 - 31 January 2007. Wilmington, NC: Registry Coordinating Center; 2007. Available at: <http://www.APRegistry.com>.
- [129.](#) Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. *J Acquir Immune Defic Syndr*, 2004. 35(5):538-9.
- [130.](#) Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. *J Infect Dis*, 2005. 191(6):825-9.
131. Dear Health Care Professional Letter. "Clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE® (nevirapine)", Boehringer Ingelheim, February 2004.
- [132.](#) Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. *Antimicrob Agents & Chemother*, 2002. 46(12):3907-16.
- [133.](#) Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. *J Infect Dis*, 2003. 188(5):635-42.
- [134.](#) Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. *Antivir Ther*, 2005. 10(6):735-43.
- [135.](#) Malan D, Krantz E, Wirtz D, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. *J Acquir Immune Defic Syndr*, 2008. 47(2):161-7.
- [136.](#) Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. *AIDS*, 2006. 20(5):711-8.
- [137.](#) Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. *AIDS*, 2007. 21(9):1215-8.



- [138.](#) van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. *AIDS*, 2003. 17(7):987-99.
- [139.](#) Pulido F, Baril JG, Staszewski S, et al. Long-term efficacy and safety of fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r) over 96 weeks. 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract H-361.
- [140.](#) Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet*, 2006. 368(9534):476-82.
- [141.](#) Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med*, 2002. 346(26):2039-46.
- [142.](#) Murphy RL, daSilva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. *HIV Clin Trials*, 2008. 9(1):1-10.
- [143.](#) Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. *J Acquir Immune Defic Syndr*, 2003. 32(1):18-29.
- [144.](#) Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. *AIDS*, 2003. 17(18):2603-14.
- [145.](#) Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. *J Acquir Immune Defic Syndr*, 2004. 35(1):22-32.
- [146.](#) Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients. *AIDS*, 2004. 18(11):1529-37.
- [147.](#) Ruane PJ, Lubner AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. *Antimicrob Agents Chemother*, 2007. 51(2):560-5.
- [148.](#) Johnson MA, Gathe JC Jr, Podzamczek D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. *J Acquir Immune Defic Syndr*, 2006. 43(2):153-60.
- [149.](#) Molina JM, Podzadecki TJ, Johnson MA, et al. A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks. *AIDS Res Hum Retroviruses*, 2007. 23(12):1505-14.
- [150.](#) Mildvan D, Tierney C, Gross R, et al. Randomized comparison in treatment-naïve patients of once-daily vs. twice-daily lopinavir/ritonavir-based ART and comparison of once-daily self-administered vs. directly observed therapy. 14<sup>th</sup> Conference on Retrovirus and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 138.
- [151.](#) Clumeck N, Lunzen JV, Chiliade P, et al. ARTEMIS – efficacy and safety of lopinavir (BiD vs QD) and darunavir (QD) in antiretroviral-naïve patients. 11<sup>th</sup> European AIDS Conference; 2007; Madrid. Abstract LBPS 7/5.
- [152.](#) Boffito M, Else L, Back D, et al. Pharmacokinetics (PK) of atazanavir/ritonavir (ATV/r) once daily (OD) and lopinavir/ritonavir (LPV/r) twice daily (BD) and OD over 72 hours following drug intake cessation. 11<sup>th</sup> European AIDS Conference; 2007; Madrid. Abstract LBPS 7/4.
- [153.](#) Walmsley S, Ruxrungtham K, Slim J, et al. Saquinavir/r (SQV/r) BiD versus lopinavir/r (LPV/r) BiD, plus emtricitabine/tenofovir (FTC/TDF) QD as initial therapy in HIV-1 infected patients: the GEMINI study. 11<sup>th</sup> European AIDS Conference; 2007; Madrid. Abstract PS1/4.
- [154.](#) Ait-Khaled M, Stone C, Amphlett G, et al.; CNA3002 International Study Team. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. *AIDS*, 2002. 16(12):1686-9.
- [155.](#) DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. *Clin Infect Dis*, 2004. 39(7):1038-46.
- [156.](#) Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *N Engl J Med*. 2006. 354(3):251-60. *N Engl J Med*, 2006. 354(3):251-60.
- [157.](#) Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. *J Acquir Immune Defic Syndr*, 2008. 47(1):74-8.

- 158.** Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. *Clin Infect Dis*, 2006. 42(2):283-90.
- 159.** Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. *Clin Infect Dis*, 2003. 36(8):1070-3.
- 160.** Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. *Clin Infect Dis*, 2005. 40(8):1194-8.
- 161.** Moore R, Keruly J, Gallant J. Tenofovir and renal dysfunction in clinical practice. 14<sup>th</sup> Conference on Retrovirus and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 832.
- 162.** Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. *J Acquir Immune Defic Syndr*, 2006. 43(3):278-83.
- 163.** Kiser JJ, Carten ML, Aquilante CL, et al. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-Infected Patients. *Clin Pharmacol Ther*, 2008. 83(2):265-72.
- 164.** Staszewski S, Keiser P, Montaner JS, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: A randomized equivalence trial. *JAMA*, 2001. 285(9):1155-63.
- 165.** Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). *Curr Med Res Opin*, 2004. 20(7):1103-14.
- 166.** Podzamczar D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the Combine Study). *Antiviral Ther*, 2002. 7(2):81-90.
- 167.** Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. *Clin Infect Dis*, 2004. 39(1):129-32.
- 168.** Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. *Clin Infect Dis*, 1999. 28(5):1032-5.
- 169.** Sellier P, Clevenbergh P, Mazon MC, et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. *Scand J Infect Dis*, 2004. 36(6-7):533-5.
- 170.** Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 2004; San Francisco, CA.
- 171.** Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS4001 (CLASS) preliminary 48 week results. XIV International AIDS Conference; July 2002; Barcelona, Spain. Abstract TuOrB1189.
- 172.** Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. *AIDS*, 2003. 17(14):2045-52.
- 173.** Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. *J Acquir Immune Defic Syndr*, 2006. 43(3):284-92.
- 174.** Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naïve patients: effect of sex and ethnicity. *HIV Med*, 2006. 7(2):85-98.
- 175.** DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. *AIDS*, 2006. 20(10):1391-9.
- 176.** Moyle G, Higgs C, Teague A, et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. *Antivir Ther*, 2006. 11(1):73-8.
- 177.** DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir vs lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at Week 48: ARTEMIS. 47<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract H-718b.
- 178.** Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. *J Acquir Immune Defic Syndr*, 2006. 43(5):509-15.



- 179.** Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. *J Acquir Immune Defic Syndr*, 2007. 46(2):125-33.
180. Saag M, Ive P, Heere J, et al. A multicenter, randomized, double blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naïve subjects infected with R5 HIV: week 48 results of the MERIT study. 4<sup>th</sup> IAS Conference on HIV pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney. Abstract MOPEB016.
- 181.** Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patients. *AIDS*, 2008. 22(3):385-93.
- 182.** Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. *JAMA*, 2006. 296(7):806-14.
- 183.** Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. *J Infect Dis*, 1999. 180(3):659-65.
- 184.** Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. *Clin Infect Dis*, 2004. 38(Suppl 2):S80-9.
- 185.** denBrinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. *AIDS*, 2000. 14(18):2895-902.
- 186.** Saves M, Raffi F, Clevenbergh P, et al. and the APROCO Study Group. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother*, 2000. 44(12):3451-5.
- 187.** Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. *AIDS*, 2000. 14(3):273-8.
- 188.** Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis*, 2001. 33(11):1931-7.
- 189.** Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. *Clin Infect Dis*, 2001. 33(11):1914-21.
190. Food and Drug Administration. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women. Rockville, MD: U.S. Department of Health and Human Services; Jan 5, 2001. Talk Paper T01-02.
191. **Intelence (Package Insert, Tibotec, Inc.). January 2008.**
192. Bethell R, Adams J, DeMuys J, et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Feb 8-11, 2004; San Francisco, California. Abstract 138.
- 193.** Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. *Antimicrob Agents Chemother*, 1997. 41(6):1231-6.
- 194.** Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. *J Infect Dis*, 2000. 182(1):321-5.
- 195.** Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. *J Antimicrob Chemother*, 2004. 53(5):696-9.
- 196.** Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. *Clin Infect Dis*, 2003. 37(8):1112-8.
- 197.** Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? *AIDS*, 2003. 17(5):711-20.
- 198.** Cheever L. Forum for Collaborative HIV Research. What do we know about adherence levels in different populations? Adherence to HIV therapy: Building a bridge to success. Available at <http://www.gwhealthpolicy.org>. Washington, D.C. 1999.10.
- 199.** Greenberg RN. Overview of patient compliance with medication dosing: a literature review. *Clin Ther*, 1984. 6(5):592-9.
- 200.** Crespo-Fierro M. Compliance/adherence and care management in HIV disease. *J Assoc Nurses AIDS Care*, 1997. 8(4):43-54.
- 201.** Williams A, Friedland G. Adherence, compliance, and HAART. *AIDS Clin Care*, 1997. 9(7):51-54, 58.

- [202.](#) Fowler ME. Recognizing the phenomenon of readiness: Concept analysis and case study. *J Assoc Nurses AIDS Care*, 1998. 9(3):72-6.
- [203.](#) CDC. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR*, 1998. 47(RR-5):1-41.
- [204.](#) McPherson-Baker S, Malow RM, Penedo F, et al. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. *AIDS Care*, 2000. 12(4):399-404.
- [205.](#) O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. *J Acquir Immune Defic Syndr*, 2003. 34(4):407-14.
- [206.](#) Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. *Lancet*, 2001. 358(9290):1322-7.
- [207.](#) Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. *Clin Infect Dis*, 2001. 32(1):124-9.
- [208.](#) Fagot JP, Mockenhaupt M, Bouwes-Bavinck J-N, for the EuroSCAR study group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *AIDS*, 2001. 15(14):1843-8.
- [209.](#) Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. *AIDS*, 2002. 16(10):1341-9.
- [210.](#) Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA*, 2000. 283(1):74-80.
- [211.](#) Cepeda JA, Wilks D. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection. *AIDS*, 2000. 14(3):332-3.
- [212.](#) Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. *Lancet*, 2001. 357(9252):280-1.
- [213.](#) Guyader D, Poinsignon Y, Cano Y, Saout L. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. *J Hepatol*, 2002. 37(2):289-91.
- [214.](#) Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. *Clin Infect Dis*, 2004. 38(8):e79-80.
- [215.](#) Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. *N Engl J Med*, 2001. 344(13):984-96.
- [216.](#) Acosta EP. Pharmacokinetic enhancement of protease inhibitors. *J Acquir Immune Defic Syndr*, 2002. 29(Suppl 1):S11-8.
- [217.](#) Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. *Antimicrob Agents Chemother*, 1997. 41(3):654-60.
- [218.](#) Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. *Arch Intern Med*, 2002. 162(9):985-92.
- [219.](#) Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. *Clin Infect Dis*, 2002. 35(9):1106-12.
- [220.](#) Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med*, 2003. 167(4):603-62.
- [221.](#) Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. *AIDS*, 2001. 15(11):1379-88.
- [222.](#) Zala C, Salomon H, Ochoa C, et al. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. *J Acquir Immune Defic Syndr*, 2002. 29(4):368-73.
- [223.](#) Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. *Ann Intern Med*, 1990. 113(2):111-7.
- [224.](#) Jung D, Griffy K, Dorr A, et al. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. *J Clin Pharmacol*, 1998. 38(11):1057-62.
- [225.](#) Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. *J Clin Pharmacol*, 2005. 45(12):1360-7.
226. Dear Health Care Provider letter. Important new pharmacokinetic data for REYATAZ® (atazanavir sulfate) in combination with Viread® (tenofovir disoproxil fumarate). Bristol-Myers Squibb Company, August 8, 2003.
- [227.](#) Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother*, 2004. 48(6):2091-6.

- [228.](#) Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. *AIDS*, 2003. 17(16):2345-9.
- [229.](#) Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. *AIDS*, 2004. 18(5):775-9.
- [230.](#) d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. *AIDS*, 2000. 14(5):499-507.
- [231.](#) Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. *AIDS*, 2001. 15(2):185-94.
- [232.](#) Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. *AIDS*, 1998. 12(11):F117-22.
- [233.](#) Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. *Lancet*, 2001. 358(9295):1760-5.
- [234.](#) Ghani AC, Ferguson NM, Fraser C, et al. Viral replication under combination antiretroviral therapy: a comparison of four different regimens. *J Acquir Immune Defic Syndr*, 2002. 30(2):167-76.
- [235.](#) Maggiolo F, Migliorino M, Pirali A, et al. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. *J Acquir Immune Defic Syndr*, 2000. 25(1):36-43.
- [236.](#) Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. *J Virol*, 2002. 76(21):11104-12.
- [237.](#) Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. *JAMA*, 2005. 293(7):817-29.
- [238.](#) Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. *AIDS*, 2002. 16(14):1967-9.
- [239.](#) Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. *JAMA*, 2001. 286(2):171-9.
- [240.](#) Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. *N Engl J Med*, 2001. 345(6):398-407.
- [241.](#) Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. *N Engl J Med*, 2003. 348(22):2186-95.
- [242.](#) Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. *N Engl J Med*, 2003. 348(22):2175-85.
- [243.](#) Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. *Lancet*, 2007. 369(9568):1169-78.
244. Nelson M, Fäkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104aLB.
245. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104bLB.
246. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 105aLB.
247. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007; Los Angeles, CA. Abstract 105bLB.
- [248.](#) Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. *Lancet*, 2006. 368(9534):466-75.

- [249.](#) Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. *J Infect Dis*, 2000. 182(5):1375-84.
- [250.](#) Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. *JAMA*, 2002. 288(2):169-80.
- [251.](#) Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. *AIDS*, 1999. 13(7):797-804.
- [252.](#) Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med*, 2001. 344(7):472-80.
- [253.](#) Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. *N Engl J Med*, 2003. 349(9):837-46.
254. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV01: 24-week results of a phase 2b exploratory trial. 16<sup>th</sup> International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract ThLB0215.
- [255.](#) Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. *Lancet*, 2007. 370(9581):39-48.
- [256.](#) Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. *Lancet*, 2007. 370(9581):29-38.
- [257.](#) Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. *AIDS*, 2007. 21(10):1293-9.
- [258.](#) Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. *J Infect Dis*, 2007. 196(2):304-12.
- [259.](#) Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevrimat) against human immunodeficiency virus infection. *Antimicrob Agents Chemother*, 2007. 51(10):3574-81.
- [260.](#) Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. *AIDS*, 2002. 16(9):1257-63.
- [261.](#) Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet*, 2004. 364(9428):51-62.
- [262.](#) Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. *JAIDS*, 2004. 37(1):1147-54.
- [263.](#) Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. *AIDS*, 2001. 15(11):1369-77.
- [264.](#) Garcia F, De Lazzari E, Plana M, et al. Long-Term CD4<sup>+</sup> T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4<sup>+</sup> T-Cell Count. *J Acquir Immune Defic Syndr*, 2004. 36(2):702-13.
- [265.](#) Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. *J Acquir Immune Defic Syndr*, 2001. 27(2):168-75.
- [266.](#) Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. *AIDS*, 2006. 20(8):1141-50.
- [267.](#) Loutfy MR, Walmsley SL, Mullin CM, et al. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. *J Infect Dis*, 2005. 192(8):1407-11.
- [268.](#) Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. *AIDS*, 2006. 20(3):371-7.
269. Baker J, Peng G, Rapkin J, et al. HIV-related Immune Suppression after ART Predicts Risk of Nonopportunistic Diseases: Results from the FIRST Study. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 37.



- [270.](#) Huttner AC, Kaufmann GR, Battegay M, et al. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. *AIDS*, 2007. 21(8):939-46.
- [271.](#) Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4<sup>+</sup> T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. *AIDS*, 2005. 19(6):569-75.
- [272.](#) Lacombe K, Pacanowski J, Meynard JL, et al. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. *AIDS*, 2005. 19(10):1107-8.
- [273.](#) Negredo E, Bonjoch A, Paredes R, et al. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. *Clin Infect Dis*, 2005. 41(6):901-5.
274. Hammer S, Bassett R, Fischl M, et al for the ACTG 372A Study Team. Randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with plasma HIV RNA < 500 copies/mL. 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 56.
- [275.](#) Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with  $\leq 250$ /microL CD4 T cells and undetectable plasma virus load. *J Infect Dis*, 1999. 180(1):56-60.
- [276.](#) Katlama C, Carcelain G, Duvivier C, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. *AIDS*, 2002. 16(15):2027-34.
- [277.](#) DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. *Ann Intern Med*, 2000. 133(6):447-54.
- [278.](#) Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. *Clin Infect Dis*, 2004. 38(8):1159-66.
- [279.](#) Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. *Lancet*, 1999. 353(9156):863-8.
- [280.](#) Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. *Ann Intern Med*, 2002. 133(6):401-10.
- [281.](#) Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. *AIDS*, 2002. 16(2):201-7.
- [282.](#) Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. *Clin Pharmacol Ther*, 1988. 43(4):345-53.
- [283.](#) Acosta EP, Gerber JG; Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. *AIDS Res Hum Retroviruses*, 2002. 18(12):825-34.
- [284.](#) Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. *AIDS*, 2002. 16(Suppl 1):S5-37.
- [285.](#) Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. *Curr Opin Infect Dis*, 2002. 15(1):17-22.
- [286.](#) Van Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. *Ther Drug Monit*, 2002. 24(3):323-31.
- [287.](#) Optimizing TDM in HIV clinical care. (May 20, 2003. <http://www.hivpharmacology.com>).
- [288.](#) Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. *J Infect Dis*, 2003. 188(7):977-85.
- [289.](#) Ghosn J, Wirlden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. *AIDS*, 2005. 19(15):1643-7.
- [290.](#) Jaafar A, Massip P, Sandres-Saune K, et al. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4<sup>+</sup> T lymphocyte count. *J Med Virol*, 2004. 74(1):8-15.
- [291.](#) Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. *Clin Infect Dis*, 2008. 46(2):296-304.
- [292.](#) Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. *Lancet*, 2006. 9527(367):1981-9.
- [293.](#) DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. *AIDS*, 2008. 22(2):237-47.
- [294.](#) Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. *HIV Med*, 2007. 8(2):96-104.
- [295.](#) Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. *AIDS*, 2004. 18(3):439-46.

- 296.** Cardillo PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. *Clin Infect Dis*, 2005. 40(4):594-600.
- 297.** Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. *J Acquir Immune Defic Syndr*, 2005. 39(5):523-9.
- 298.** Pogány K, van Valkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm<sup>3</sup>: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). *J Acquir Immune Defic Syndr*, 2007. 44(4):395-400.
- 299.** Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. *J Infect Dis*, 2007. 195(10):1426-36.
- 300.** Weber R, Friis-Møller N, Sabin C, et al. HIV and non-HIV-related deaths and their relationship to immunodeficiency: the D:A:D Study. 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Feb 22-25, 2005; Boston, MA. Abstract 595.
- 301.** Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). *AIDS*, 2006. 20(5):719-23.
- 302.** Cressey TR, Jourdain G, Lallemand MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. *J Acquir Immune Defic Syndr*, 2005. 38(3):283-8.
- 303.** Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. *Clin Infect Dis*, 2006. 42(3):401-7.
- 304.** Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS*, 2004. 18(18):2391-400.
- 305.** McIntyre JA, Martinson N, Gray GE. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. 3<sup>rd</sup> International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract TuFo0204.
- 306.** Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. *Lancet*, 2007. 370(9600):1698-705.
- 307.** Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. *Lancet*, 2007. 370(9600):1668-70.
- 308.** Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. *AIDS*, 1991. 5(1):1-14.
- 309.** Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. *J Infect Dis*, 1993. 168(6):1490-501.
- 310.** Kinloch-De Loes S, de Saussure P, Saurat JH, et al. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases. *Clin Infect Dis*, 1993. 17(1):59-65.
- 311.** Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. *Ann Intern Med*, 1996. 125(4):257-64.
- 312.** Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. *Ann Intern Med*, 2001. 134(1):25-9.
- 313.** Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. *AIDS*, 2002. 16(8):1119-29.
- 314.** Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*, 2006. 55(RR-14):1-17.
- 315.** Hoen B, Dumon B, Harzic M, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial. *J Infect Dis*, 1999. 180(4):1342-6.
- 316.** Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. *J Infect Dis*, 1997. 175(5):1051-5.
- 317.** Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. *AIDS*, 1999. 13(7):791-6.
- 318.** Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. *J Infect Dis*, 2000. 181(1):121-31.



- 319.** Smith DE, Walker BD, Cooper DA, et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? *AIDS*, 2004. 18(5):709-18.
- 320.** Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. *J Exp Med*, 2004. 200(6):761-70.
- 321.** Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. *J Virol*, 2003. 77(21):11708-17.
- 322.** Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. *Nat Med*, 1998. 4(3):341-5.
- 323.** Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States by race, ethnicity, 1998 - 2002. HIV/AIDS Surveillance Supplement Report 10 (No. 1).
- 324.** Grubman S, Gross E, Lerner-Weiss N, et al. Older children and adolescents living with perinatally acquired human immunodeficiency virus infection. *Pediatrics*, 1995. 95(5):657-63.
- 325.** Pharmacokinetics and pharmacodynamics in adolescents. January 20-21, 1994. Proceedings. *J Adolesc Health*, 1994. 15(8):605-78.
326. el-Sadar W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7. (AHCPR Publication No. 94-0572). Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994.
- 327.** Buchacz K, Rogol AD, Lindsey JC, et al. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. *J Acquir Immune Defic Syndr*, 2003. 33(1):56-65.
- 328.** Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. *AIDS Care*, 2001. 13(1):27-40.
- 329.** Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to HAART: a pilot program of modified directly observed therapy. *AIDS Read*, 2001. 11(6):317-9, 324-8.
- 330.** Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection. <http://aidsinfo.nih.gov>.
- 331.** Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. *Clin Infect Dis*, 1995. 20(6):1467-79.
- 332.** O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. *N Engl J Med*, 1994. 331(7):450-9.
333. Friedland GH. HIV Disease in Substance Abusers: Treatment Issues in Sande MA, and Volberding P, eds., *The Medical Management of AIDS*, 6<sup>th</sup> Ed., (Philadelphia, WB Saunders Company, 1999).
- 334.** Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. *JAMA*, 1998. 280(6):547-9.
- 335.** Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. *JAMA*, 1998. 280(6):544-6.
- 336.** Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. *J Acquir Immune Defic Syndr*, 2001. 28(1):47-58.
- 337.** Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. *Clin Infect Dis*, 2004. 38(Suppl 5):S376-87.
- 338.** Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. *Mt Sinai J Med*, 2000. 67(5-6):429-36.
- 339.** Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. *J Acquir Immune Defic Syndr*, 2000. 24(3):241-8.
- 340.** Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. *Clin Infect Dis*, 2001. 33(9):1595-7.
- 341.** Bart PA, Rizzardini PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. *Ther Drug Monit*, 2001. 23(5):553-5.
- 342.** McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. *Am J Addict*, 2004. 13(2):163-80.
- 343.** McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. *Clin Infect Dis*, 2003. 37(4):476-82.
- 344.** Friedland G, Andrews L, Schreiber T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. *AIDS*, 2005. 19(15):1635-41.

- [345.](#) Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. *J Infect Dis*, 2001. 183(4):539-45.
346. Bryson Y, Stek A, Mirochnick M, et al. Pharmacokinetics, Antiviral activity and safety of nelfinavir (NFV) in combination with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2. 9<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA. Abstract 795-W.
- [347.](#) Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. *AIDS*, 2006. 20(15):1931-9.
- [348.](#) Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. *J Acquir Immune Defic Syndr*, 2004. 36(3):772-6.
- [349.](#) Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. *AIDS*, 2005. 19(1):63-7.
- [350.](#) McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. *N Engl J Med*, 2007. 356(25):2614-21.
351. Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. *AIDS*, 2007. 21(17):2365-6.
- [352.](#) Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. *J Infect Dis*, 2005. 191(7):1169-79.
- [353.](#) Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. *Hepatology*, 2002. 35(1):182-9.
- [354.](#) Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. *Clin Infect Dis*, 2004. 38(Suppl 2):S90-7.
- [355.](#) Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. *MMWR Recomm Rep.*, 2004. 53(RR-15):1-112. Erratum in: *MMWR Morb Mortal Wkly Rep*. 2005 Apr 1;54(12):311.
- [356.](#) Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis*, 2001. 33(4):562-9.
- [357.](#) Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology*, 1999. 30(4):1054-8.
- [358.](#) Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. *Hepatology*, 1994. 20(5):1152-5.
- [359.](#) Sabin CA, Telfer P, Phillips AN, et al. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. *J Infect Dis*, 1997. 175(1):164-8.
- [360.](#) Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. *Lancet*, 2003. 362(9387):877-8.
- [361.](#) Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*, 2003. 33(3):365-72.
- [362.](#) Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. *Ann Intern Med*, 2003. 138(3):197-207.
- [363.](#) Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. *Hepatology*, 2001. 34(5):1035-40.
- [364.](#) Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfecting persons. *N Engl J Med*, 2004. 351(5):451-9.
- [365.](#) Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*, 2004. 351(5):438-50.
- [366.](#) Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. *Hepatology*, 2004. 39(4):1147-71.
- [367.](#) Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. *Clin Infect Dis*, 2003. 7(2):475-99.
- [368.](#) Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am J Respir Crit Care Med*, 1995. 151(1):129-35.
- [369.](#) Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. *Am Rev Respir Dis*, 1993. 148(5):1292-7.

- 370.** Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beinr Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). *Clin Infect Dis*, 1997. 25(2):242-6.
- 371.** French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. *Curr HIV/AIDS Rep*, 2007. 4(1):16-21.
- 372.** Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. *J Acquir Immune Defic Syndr*, 2007. 44(2):229-34.
- 373.** Centers for Disease Control and Prevention. Treatment of Tuberculosis. *MMWR*, 2003. 52(RR11):1-77.
- 374.** Centers for Disease Control and Prevention. Notice to Readers: Acquired Rifampin Resistance in Persons with Advanced HIV Disease Being Treated for Active Tuberculosis with Intermittent Rifampin-Based Regimens. *MMWR*, 2002. 51(10):214-5.
- 375.** Vernon A, Burman W, Benator D, et al. Acquired rifampin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. *Lancet*, 1999. 353(9167):1843-7.
- 376.** Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. *AIDS*, 2002. 16(1):75-83.
- 377.** Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. *J Antimicrob Chemother*, 2006. 58(6):1299-302.
- 378.** Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C in African patients coinfecting with either *Mycobacterium tuberculosis* or human herpesvirus-8. *J Infect Dis*, 2005. 191(3):324-32.
- 379.** Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. *J Infect Dis*, 2006. 53(6):357-63.
- 380.** Avinhingsanon A, Monsuthi W, Kantipong P, et al. Pharmacokinetics and 12 weeks efficacy of nevirapine 600 mg per day in HIV infected patients with active TB receiving rifampin: A multicenter study. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, CA. Abstract 576.
- 381.** Centers for Disease Control and Prevention. Notice to readers: Updated guidelines for the use of rifampin for the treatment of tuberculosis among HIV infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. *MMWR*, 2004. 53(2):37.
- 382.** French MA, Price P and Stone SF. Immune restoration disease after antiretroviral therapy. *AIDS*, 2004. 18(12):1615-21.
- 383.** Colebunders R, John L, Huyst V, et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. *Int J Tuberc Lung Dis*, 2006. 10(9):946-53.
- 384.** Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. *Antivir Ther*, 2005. 10(3):417-22.
- 385.** Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. *AIDS*, 2007. 21(3):335-41.
- 386.** Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. *Arch Intern Med*, 2002. 162(1):97-9.
- 387.** Wendel KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. *Chest*, 2001. 120(1):193-7.
- 388.** Menzies D, Pai M and Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med*, 2007. 146(5):340-54.
- 389.** Girardi E, Palmieri F, Zaccarelli M, et al. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. *AIDS*, 2002. 16(14):1976-9.
- 390.** Centers for Disease Control and Prevention. Incorporating HIV Prevention into the Medical Care of Persons Living with HIV. *MMWR*, 2003. 52(RR12):1-24.
- 391.** Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *Clin Infect Dis*, 2003. 37(5):613-27.
- 392.** O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. *Am J Obstet Gynecol*, 1993. 168(5):1510-6.

- [393.](#) Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. *J Infect Dis*, 1998. 178(5):1327-33.
- [394.](#) Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. *J Infect Dis*, 1999. 180(5):1536-41.
- [395.](#) Bristol-Myers Squibb Company. Healthcare Provider Important Drug Warning Letter. 28 September 2001.
- [396.](#) Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. *Sex Transm Inf*, 2002. 78(1):58-9.
- [397.](#) Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. *J Infect Dis*, 2004. 190(12):2167-74.
- [398.](#) Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (*Macaca mulatta*). *J Acquir Immune Defic Syndr*, 2002. 29(3):207-20.
- [399.](#) Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics*, 2006. 118(3):e711-8.
400. Aweeka F, Lizak P, Frenkel L, et al. Steady state nevirapine pharmacokinetics during 2nd and 3rd trimester pregnancy and postpartum: PACTG 1022. 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 932.
- [401.](#) Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. *Pediatr Infect Dis J*, 2001. 20(8):803-5.
- [402.](#) De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. *Arch Intern Med*, 2002. 162(3):355.
403. Mirchonick M, Stek A, Capparelli E, et al. Lopinavir exposure with a higher dose during the 3rd trimester of pregnancy. 13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, Colorado. Abstract 710.
- [404.](#) Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. *Antimicrob Agents Chemother*, 2007. 51(2):783-6.
- [405.](#) Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women [letter]. *AIDS*, 2000. 14(8):1061-2.
406. Scott GB, Rodman JH, Scott WA, et al. Pharmacokinetic and virologic response to ritonavir (RTV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-10-infected pregnant women and their infants. 9<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA. Abstract 794-W.
- [407.](#) Acosta EP, Bardeguet A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. *Antimicrob Agents Chemother*, 2004. 48(2):430-6.
- [408.](#) Zorrilla CD, Van Dyke R, Bardeguet A, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. *Antimicrob Agents Chemother*, 2007. 51(6):2208-10.
- [409.](#) Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. *HIV Clin Trials*, 2001. 2(6):460-5.
410. Burger D, Eggink A, van der ende I, et al. The pharmacokinetics of saquinavir in the new tablet formulation + ritonavir (1000/100 mg twice daily) in HIV-1-infected pregnant women. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 741.
411. Ripamonti D, Cattaneo D, Airoldi M, et al. Atazanavir-based HAART in pregnancy. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 742.
412. Natha M, Hay P, Taylor G, et al. Atazanavir use in pregnancy: a report of 33 cases. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 750.
413. Aweeka F, Tierney C, Stek A, et al. ACTG 5153s: pharmacokinetic exposure and virological response in HIV-1-infected pregnant women treated with PI. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 739.
- [414.](#) Villani P, Florida M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. *Br J Clin Pharmacol*, 2006. 62(3):309-15.
415. Read J, Best B, Stek A, et al. Nelfinavir pharmacokinetics (625-mg tablets) during the third trimester of pregnancy and postpartum. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 740.
- [416.](#) Meyohas MC, Lacombe K, Carbonne B, et al. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. *AIDS*, 2004. 18(14):1966-8.



## Appendix A: Financial Disclosure for Members of the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (A Working Group of OARAC) – February 2007

[Note: The Financial Disclosure for Panel Members will be updated after February 2008. The new disclosure listing will be posted on the <http://aidsinfo.nih.gov> Web site.]

Name	Panel Status*	Company	Relationship
Jean R. Anderson	M	Abbott Laboratories Glaxo Smith Kline Pfizer	<ul style="list-style-type: none"> <li>• Speakers Bureau</li> <li>• Speakers Bureau</li> <li>• Advisory Board; Grant recipient; Speakers Bureau; Stock Holder</li> </ul>
A. Cornelius Baker	M	Gilead Sciences Glaxo Smith Kline	<ul style="list-style-type: none"> <li>• Travel support for international AIDS conference and company presentation</li> <li>• Honoraria</li> </ul>
John G. Bartlett	C	Abbott Laboratories Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Pfizer Tibotec	<ul style="list-style-type: none"> <li>• Advisory Board; Honoraria</li> <li>• Advisory Board</li> <li>• Grant recipient</li> <li>• Advisory Board</li> <li>• Advisory Board</li> <li>• DSMB Member</li> </ul>
Victoria Cargill-Swiren	M	None	N/A
Charles Carpenter	M	Bristol Myers Squibb	<ul style="list-style-type: none"> <li>• Consultant</li> </ul>
Laura W. Cheever	M	None	N/A
Judith Currier	M	Abbott Laboratories Achillon Pharmaceuticals Boehringer-Ingelheim Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Merck Schering Plough Theratechnologies Tibotec Vertex	<ul style="list-style-type: none"> <li>• Advisory Board; Grant recipient</li> <li>• DSMB Member</li> <li>• Advisory Board (2005)</li> <li>• Advisory Board</li> <li>• Advisory Board, DSMB member</li> <li>• Advisory Board; Grant recipient</li> <li>• Advisory Board; Grant recipient</li> <li>• Grant Recipient</li> <li>• Grant Recipient</li> <li>• Advisory Board; Grant recipient; Consultant</li> <li>• Grant Recipient</li> </ul>
Paul Dalton	M	Napo Pfizer Tibotec	<ul style="list-style-type: none"> <li>• Advisory Board</li> <li>• Advisory Board</li> <li>• Consultant</li> </ul>
Steven G. Deeks	M	Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Monogram Pfizer Roche Tibotec Trimeris	<ul style="list-style-type: none"> <li>• Consultant</li> <li>• Honoraria</li> <li>• Consultant</li> <li>• Consultant</li> <li>• DSMB Member</li> <li>• Grant recipient; Consultant</li> <li>• Consultant</li> <li>• Consultant</li> </ul>
Carlos del Rio	M	Abbott Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Merck & Co. Pfizer Tibotec	<ul style="list-style-type: none"> <li>• Honoraria</li> <li>• Consultant</li> <li>• Research support</li> <li>• Research support</li> <li>• Research support</li> <li>• Research support</li> <li>• Research support</li> </ul>
Wafaa El-Sadr	M	None	N/A

Name	Panel Status*	Company	Relationship
Courtney V. Fletcher	M	Bristol Myers Squibb Glaxo Smith Kline Tibotec	<ul style="list-style-type: none"> <li>• Ad-hoc advisory board</li> <li>• Ad-hoc advisory board</li> <li>• Ad-hoc advisory board</li> </ul>
Joel E. Gallant	M	Abbott Laboratories Boehringer-Ingelheim Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Merck Monogram Biosciences Panacos Pfizer Roche Tibotec	<ul style="list-style-type: none"> <li>• Honoraria</li> <li>• Grant recipient</li> <li>• Advisory Board</li> <li>• Advisory Board; Grant recipient; Honoraria</li> <li>• Advisory Board; Grant recipient</li> <li>• Advisory Board; Grant recipient</li> <li>• Advisory Board</li> <li>• Advisory Board</li> <li>• Advisory Board; Grant recipient</li> <li>• Grant recipient; Honoraria</li> <li>• Advisory Board; Grant recipient</li> </ul>
Eric P. Goosby	M	Abbott Pharmaceuticals Chevron Corporation Gilead Sciences Pfizer Pharmaceuticals	<ul style="list-style-type: none"> <li>• Grant recipient</li> <li>• Grant recipient</li> <li>• Grant recipient; Speakers Bureau; Consultant</li> <li>• Grant recipient</li> </ul>
Roy M. Gulick	M	Abbott Laboratories Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Merck Monogram Panacos Pfizer Roche-Trimeris Schering-Plough Tibotec	<ul style="list-style-type: none"> <li>• Consultant</li> <li>• Consultant</li> <li>• Grant recipient; Consultant</li> <li>• Consultant</li> <li>• Grant recipient</li> <li>• Honoraria; Consultant</li> <li>• Grant recipient</li> <li>• Grant recipient; Consultant</li> <li>• Consultant</li> <li>• Grant recipient; Consultant</li> <li>• Grant recipient; Consultant</li> </ul>
Mark Harrington	M	None	N/A
W. Keith Henry	M	Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline  Pfizer Roche Serono Theratechnologies	<ul style="list-style-type: none"> <li>• Research Support; Speakers Bureau; Honoraria; Consultant</li> <li>• Speakers Bureau; Honoraria; Consultant</li> <li>• Research Support; Advisory Board; Speakers Bureau; Honoraria; Consultant</li> <li>• Research Support; Honoraria</li> <li>• Speakers Bureau; Honoraria</li> <li>• Research Support</li> <li>• Research Support</li> </ul>
Martin S. Hirsch	M	Merck Schering Plough Tibotec	<ul style="list-style-type: none"> <li>• DSMB member</li> <li>• Consultant</li> <li>• Consultant</li> </ul>
Morris Jackson	M	Abbott Laboratories Glaxo Smith Kline	<ul style="list-style-type: none"> <li>• National Advocate Summit</li> <li>• Summer Summit 2004</li> </ul>
Wilbert Jordan	M	Abbott Laboratories Bristol Myers Squibb Gilead Sciences Glaxo Smith Kline Pfizer Roche Serono Tibotec	<ul style="list-style-type: none"> <li>• Advisory Board; Grant recipient; Speakers Bureau; Honoraria</li> <li>• Advisory Board; Speakers Bureau; Honoraria; Consultant</li> <li>• Advisory Board; Grant recipient; Speakers Bureau; Honoraria</li> <li>• Advisory Board; Grant recipient; Speakers Bureau; Honoraria</li> <li>• Grant recipient; Speakers Bureau; Honoraria</li> <li>• Speakers Bureau; Honoraria</li> <li>• Advisory Board; Speakers Bureau; Honoraria</li> </ul>
Jonathan E. Kaplan	M	None	N/A
H. Clifford Lane	C	Novartis	<ul style="list-style-type: none"> <li>• NIH patent on aldesleukin licensed to Novartis; CRADA with Novartis</li> </ul>



